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1. Introduction 
Modern nanomedicine is divided into viral, lipoid and polymeric gene- and drug-carrier 
systems.[1] Herein, viral systems generally suffer from high production costs and upscaling 
difficulties.[2] Lipoid carriers, such as liposomes or lipoplexes, can be produced more cost-
efficiently, however, their storage is challenging.[2] Polymer-based carriers require the 
utilization of tailored, and biodegradable or biocompatible polymers. During the last years, 
the utilization of poly(2-oxazoline)s (P(Ox)s) in terms of biomedical applications has 
increased significantly.[3-4]  
The synthesis of P(Ox)s via the cationic ring-opening polymerization (CROP) was first 
developed in the 1960s by four independent research groups.[5-8] The living CROP is divided 
into three steps: (i) Initiation, (ii) propagation, and (iii) termination.[9] The initiator commonly 
consists of a labile leaving group, such as a halide, tosylate or triflate, which is bound to a 
partially positive charged carbon atom.[10] During the initiation, the free electron pair of the 
nitrogen atom reacts with that carbon atom by a nucleophilic attack. Subsequently, the 
positively charged oxazolinium ion can be attacked by another monomer, leading to a 
controlled and living chain growth during the propagation. The reaction can be terminated by 
the addition of a nucleophile. 
 
Scheme 1.1. Schematic representation of the living CROP of 2-oxazolines consisting of (i) initiation, (ii) 
propagation, and (iii) termination as well as examples for functional groups that can be introduced on the α-
position (red), ω-position (blue) or in the side-chain (green). 
A crucial drawback of the synthesis of P(Ox)s, however, were the rather long reaction times 
of up to weeks, which could be significantly shortened to several minutes by the utilization of 
the microwave technique.[11] Since then, many functionalization strategies have been 
established successfully, resulting in functional P(Ox)s.[10, 12] By choosing functional 
initiators, the introduction of single modifications, such as alkynes,[13] amines[14] or carboxylic 
acids[15-16] at the α-position of the polymer is possible. Furthermore, appropriate end-
functionalization allows the introduction of azides,[17-18] hydroxyl groups,[15, 19-20] amino 
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groups,[21-23] or large hydrophobic ω-end-groups.[20, 24-26] In addition, the utilization of 2-
substituted monomers can be used for the introduction of multiple (distinct) functionalities 
into the polymer chain.[10, 27] Common examples for functional side-chains are alkynes,[28-30] 
azides,[31-33] thiols,[34] carboxylic acids,[35-36] alkenyls,[37-38] aldehydes,[39] and amino 
groups.[40-41] These numerous modification opportunities enable the preparation of tailored 
polymers with adjustable properties. The resulting polymers are pseudopeptides, which are 
biotolerable with respect to their type and amount of functional groups, making P(Ox)s 
promising candidates for biomedical applications. For this reason, Chapter 2 will provide an 
overview of the state of the art of P(Ox)s with respect to approaches regarding self-assembly, 
in vitro and in vivo experiments as well as the first clinical trial. 
In order to correctly evaluate the effects of an applied macromolecular structure on the 
properties regarding self-assembly as well as drug- or gene-delivery, it is important to 
evaluate the reactivity ratios of different monomers utilized for the preparation of copolymers. 
Numerous publications already discussed the effect of the counter-ion of the initiator on the 
polymerization kinetics.[42-45] Furthermore, the effect of the substituent in 2-position was 
investigated.[46-48] Copolymerization of different 2-oxazolines resulted in random,[9, 49] 
gradient[27, 50-51] or quasi block copolymers.[52-53] Herein, differences within the copolymer 
composition can for instance be caused by length of the alkyl chain in 2-position.[9, 49] In 
Chapter 3, two amino functionalized monomers are compared directly: (i) 2-(4-((tert-
Butoxycarbonyl)amino)butyl)-2-oxazoline (BocOx), which is already known from 
literature[41] and (ii) tert-butyl 2-iminooxazolidine-3-carboxylate (BocOI), which was newly 
synthesized within this thesis.[54] Herein, the synthesis routes of both monomers are shortly 
compared. Afterwards, polymerization kinetics of BocOI and 2-ethyl-2-oxazoline (EtOx), BocOx 
and EtOx as well as BocOx and 2-methyl-2-oxazoline (MeOx) are conducted to gain an overview 
of the reactivity ratios of the different monomers during copolymerization. Since the 
polymerization of BocOI and the assumed mechanism have been unknown up to this point, a 
series of BocOI homopolymers and copolymers with EtOx are synthesized and deprotected to 
yield polymers consisting of poly(urea) and P(Ox). All resulting polymers and tert-
butyloxycarbonyl (Boc) protected precursors are characterized and compared regarding their 
properties. Furthermore, BocOx containing statistic and block copolymers are synthesized and 
characterized. Hereby the acidic deprotection of BocOx containing copolymers yielding 2-(4-
aminobutyl)-2-oxazoline (AmOx) groups will be shown. 
As already mentioned, possible applications of P(Ox)s are positioned in biomedical 
applications, such as drug or gene delivery.[3-4] Herein, the utilization of P(Ox)s is versatile, 
ranging from nano- and microparticles,[50] as well as nanocapsules[55] to crosslinked networks 
such as hydrogels,[41] surface coatings[56] or nanogels.[51, 57] Herein, the assembly of 
amphiphilic block copolymers has been described.[53, 58-60] Chapter 4 deals with P(Ox) 
containing nanostructures. Firstly, the utilization of water-soluble P(Ox)s for the stabilization 
of hydrophobic nanoparticles consisting of poly(lactide-co-glycolide) (PLGA) during 
preparation, purification and lyophilization, aiming an all-in-one system to replace common 
particle stabilizers, i.e. poly(vinyl alcohol), Pluronic F127, glucose, saccharose and trehalose. 
Furthermore, amphiphilic block copolymers consisting of P(Ox)s were self- and co-assembled 
in water as well as characterized regarding their pH responsiveness. In addition to that, AmOx 
containing block copolymers are self-assembled in chloroform and reversibly core cross-
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linked using glutaraldehyde (GA) to form imines. Additionally the covalent attachment of 6-
amino-fluorescein (6AF) and doxorubicin (DOX) to the resulting nanogels will be shown. 
In addition to the synthesis and assembly of P(Ox)s, their application in biomedical sciences 
has been widely explored during the last decade.[3-4] Herein, the application of cationic P(Ox)s 
in terms of gene delivery represents one interesting field of research.[38, 61-62] Chapter 5 
describes the utilization of AmOx containing copolymers for gene transfection. Hereby, 
copolymers containing either EtOx (random), MeOx (gradient) or 2-nonyl-2-oxazoline 
(NonOx, block) representing the comonomer are compared regarding their cyto- and 
hemocompatibility, cellular uptake as well as transfection efficiency. A further possible 
application for functional P(Ox)s is the delivery of conjugated drugs, e.g. proteins or small 
molecules. Hereby, the most important issue concerns the activity of the active 
pharmaceutical ingredient (API). For this reason, Chapter 6 describes the preparation of two 
different P(Ox) drug conjugates, i.e. the P(Ox)ylation of interleukin-4 (IL-4) to water soluble 
P(Ox)s using biorthogonal copper catalyzed click chemistry (CuAAC) and the conjugation of 
doxorubicin (DOX) to AmOx containing nanogels via Schiff-base chemistry.  
The aim of this thesis is to push forward the potential of 2-oxazolines in terms of synthesis, 
self-assembly and biomedical utilization. Hereby, the synthesis of two different monomers, 
namely BocOx and BocOI will be presented. Homo- and copolymerization kinetics with 
EtOx, respectively MeOx will provide an overview of the monomer distribution within the 
polymers, which is important for further implementations of the polymers in terms of self-
assembly as well as gene- and drug-delivery. Furthermore, the contribution of different P(Ox) 
regarding the preparation of colloidal nanostructures will be shown. Herein, P(Ox) 
homopolymers will be utilized as surfactants and cryoprotectants for the stabilization of 
nanoparticles. It will be demonstrated that different P(Ox) block copolymers can be utilized to 
form distinct nanostructures, suitable for gene-and drug delivery applications. In addition to 
that, the usage of cationic, pH responsive nanostructures with respect to gene-delivery will be 
conducted. Herein, nanostructures will be compared to water soluble cationic random and 
gradient copolymers. Furthermore, the contribution of P(Ox) to successful and targeted drug 
delivery will be shown. This thesis contributes to the knowledge of P(Ox) in a wide range, 
covering not only the synthesis, however, also the preparation and characterization self-
assembled structures and their biomedical potential. 
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2. Poly(2-oxazoline)s in biomedical applications 
Parts of this chapter have been published in: P6) M. N. Leiske1, M. Hartlieb2, A. Traeger3, U. 
S. Schubert4, Evolution of poly(2-oxazoline)s from in vitro and in vivo studies to clinical 
trials, submitted. 
During the last decades, a large range of functionalized P(Ox)s has been reported.[10, 27] Due to 
their preparation route via the CROP, it is possible to introduce different substituents that are 
feasible for biomedical applications on defined positions along the macromolecule (Scheme 
2.1).[4] α- or ω-end-groups can be achieved by the utilization of functional initiators or 
terminating agents to introduce single functionalities. With respect to biomedical applications, 
these might be useful for the covalent attachment of targeting ligands or fluorescent dyes as 
well as the conjugations of single proteins or drugs. Furthermore, the opportunity of side 
chain functionalization by the utilization of 2-substituted monomers represents an important 
advantage in comparison to other polymers, e.g. poly(ethylene glycol) (PEG). Depending on 
their reactivity ratios, monomers that are copolymerized can form random or gradient 
copolymers.[27, 50-51] Thereby, functional units, such as carboxylic acids, amino groups or 
alkynes can be used for post-polymerization functionalization,[36, 38] polyplex formation[38, 61, 
63]
 or multiple active pharmaceutical ingredient (API) conjugation.[28, 35, 64] Additionally, by 
using the sequential monomer addition block copolymers can be prepared.[57, 65-66] 
 
Scheme 2.1. Schematic representation of P(Ox)s and their possibilities of modification useful for biomedical 
implementations. 
Depending on the monomer hydrophilicity, (water) solubility can be adjusted, and the 
formation of polymersomes, particles, micelles or vesicles can be induced.[50] Consequently, 
the versatility of P(Ox)s does not halt the level of chemical functionality, however, allows the 
formation of nano- and microassemblies (Scheme 2.2),[50, 57, 67] which can heavily influence 
the interaction of polymer therapeutics and biological systems. Hereby, the nanoscopic phase 
separation can be used for encapsulation of drugs or dyes[22, 65] by either absorption of small 
molecules into the hydrophobic phase (encapsulation)[21] or the attachment to functional 
subunits of the polymer (conjugation).[28, 35] 
2. Poly(2-oxazoline)s in biomedical applications 
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Scheme 2.2. Schematic representation of different assembled P(Ox) structures: (i) Nanocapsules,[55] (ii) 
micelles,[21] (iii) nanogels,[51] (iv) hydrogels,[51] and (v) surface coatings.[68]  
Herein, the hydrohphilic poly(2-ethyl-2-oxazoline) (P(EtOx)) or poly(2-methyl-2-oxazoline) 
(P(MeOx)) shell induces a shielding towards unspecific interactions with biological matter 
and prevents undesired protein interactions comparable to PEG.[24-25, 69-70] Furthermore, the 
preparation of cross-linked materials, such as nanogels,[51, 57] capsules,[55] and hydrogels[41, 51] 
is possible by either covalent or physical interactions.[51] In general, these materials are 
utilized, e.g. for drug delivery,[35] gene purification[56] or as nano reaction compartment.[71]  
 
2.1. In vitro elucidation of the potential of P(Ox)s for biomedical applications 
In order to evaluate the potential of P(Ox)s for biomedical applications, in vitro investigations 
(i.e. cell tests) are indespensable. Hereby, the initial experiments mainly cover the elucidation 
of the cytocompatibility, respectively cell viability as well as the hemocompatibility, i.e. 
erythrocyte aggregation and hemolysis experiments (Scheme 2.3). Herein, P(EtOx) and 
P(MeOx) of varios molar masses did not cause any cytotoxycity, erythrocyte aggregation or 
hemoglobin release in short-term experiments.[72-73] Long-term experiments revealed a slight 
decrease of the cell viability dependent on the molar masss of the polymers and the incubation 
time.[72-73] In addition to that, experiments showed an increase of the cytotoxicity of P(EtOx) 
in dependence on the degree of hydrolysis.[74] However, investigations on the hydrolysis of 
P(EtOx) under physiological conditions have shown that a degree of hydrolysis above 10% is 
unlikely.[75] Furthermore, P(Ox) micelles with a poly(lactic acid) (PLA) or poly(2-butyl-2-
oxazoline) core were determined to be non-toxic.[67, 76]  
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Scheme 2.3. Possibilities of in vitro studies in terms of biochemical polymer or carrier systems: (i) Cell viability 
determination by cytotoxicity, hemoglobin release or cell aggregation measurements, (ii) comparison of the 
uptake efficiency of drugs, polymers and carrier systems as well as (iii) utilization of different cell lines for the 
determination of cell specificity. 
In addition to biocompatibility, applications regarding drug or gene delivery require a 
moderate cellular uptake and an efficient release of the API or the genetic material within the 
cellular compartment. In general, the cellular uptake of carriers with P(EtOx) was determined 
to be slower than the pure drugs[14, 16, 66, 77] This finding might be advantageous in terms of 
blood circulation times and pharmacokinetics. Furthermore, cell specificity of carriers can be 
increased by the utilization of special targeting units.[14-15] 
 
2.2. In vivo biocompatibility and therapeutic efficiency of P(Ox)s 
According to standardized in vitro assays, P(EtOx) and P(MeOx) are generally cyto- and 
hemocompatible, i.e. they do not induce cytotoxicity, hemolytic activity or cell aggregation 
up to concentrations of 10 mg mL-1. However, these preliminary experiments can only 
provide a first impression about the biocompatibility and the therapeutic efficiency. In vivo, 
several attributes of drugs can be altered by using polymers, e.g. their solubility. Many drugs 
are not (well) water soluble. Conjugation to or encapsulation into water-soluble polymeric 
delivery systems that can be solubilized or suspended in water is a common way to resolve 
this issue.[21-22] P(EtOx) and P(MeOx) themselves were elucidated to have comparable 
characteristics like PEG in terms of the prevention of phagocytosis, unwanted protein 
interaction and renal excretion.[25] The significantly higher hydrodynamic volume of the 
polymer drug conjugates consequently leads to a reduction of the blood clearance and a 
following increase of the blood circulation time.[66] Therefore, the encountering of various 
different tissue and cell types expressing different receptors and markers is possible by 
equipping polymer carriers with targeting ligands to enhance the cell specificity.[14] 
Considering these results, P(Ox)s can fulfill all requirements for successful drug and gene 
delivery systems. For this reason, the current focus of research mainly covers in vivo 
experiments regarding blood circulation times, organ specificity and therapeutic efficiency 
(Scheme 2.4). 
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Scheme 2.4. Favorable attributes of polymeric nanocarriers for drug delivery: (i) Long blood circulation times, 
and (ii) tissue specificity, i.e. targeted cellular uptake 
The biodistribution and blood clearance of different polymers was already investigated by 
utilizing radioactive labeling using various tracer elements, such as 67Ga,[24] 125I,[25, 78] 89Zr,[69-
70]
 
18F,[70] or 111In.[79-80] Hereby, measurements of tissue related radioactivity enabled the 
determination of organ accumulations and blood circulations times. Herein, the blood 
circulation times were found to be dependent on the molar mass of the polymers, which might 
be useful in terms of application.[78] Furthermore, it is important to mention that the label 
itself can also have an influence on the biodistribution of the elucidated polymers.[70] Hence, 
89Zr-labeled P(EtOx)50 revealed an increased uptake into kidneys, liver and heart after 1 h and 
4 h, while 18F labeled P(EtOx) showed an increased uptake into kidneys directly after 
injection. Consequently, it was shown that even small end groups, such as 89Zr- or 19F-labels, 
have a tremendous effect on the performance of a polymeric carrier in vivo and have to be 
considered carefully. 
Due to the fact that PEG is predominantly used as a stealth polymer, water soluble P(Ox)s are 
often compared with PEG.[24-25, 70, 80] Hereby, any observed differences between PEG and 
P(EtOx) decrease with an increasing molar mass of the polymers.[81] Overall, the polymers 
revealed a similar behavior for comparable molar masses. 
Since, P(Ox)s were demonstrated to be biocompatible and the blood clearance rate as well as 
the biodistribution of P(Ox)s and PEG are similar, they are ideal candidates for the utilization 
as drug carriers; adjustment of molar mass of the polymers and the choice of monomers can 
influence the blood circulation time as well as organ accumulations. 
Consequently, short blood circulation times and unspecific cellular uptake of drugs might be 
prevented by covalent conjugation to biocompatible, shielding polymers such as P(EtOx) and 
P(MeOx).[28, 66, 79] Herein, the conjugation of granulocyte stimulating factor g to P(EtOx) with 
varying molar mass leads to higher efficiencies when using polymers with a higher degree of 
polymerization (DP).[79] Furthermore, the conjugation of multiple API units was demostrated 
using rotigotine.[28] Herein, the drug was attached to the polymer by using biorthogonal 
copper catalyzed click chemistry (CuAAC). Moreover, a labile ester linker between the drug 
and the polymer was used to ensure efficient drug release in acidic cellular compartments. In 
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vivo investigations revealed steady plasma drug concentrations over several days and, 
consequently, reduced unwanted side-effects such as dyskinesia.[64]  
In particular in terms of cancer therapy, the enhanced blood circulation times might be 
advantageous to ensure an efficient delivery of the cytostatic agent into the tumor cells, e.g. 
by exploiting the EPR effect. Hereby, conjugation via azide cleavable hydrazone linker,[16, 35] 
the encapsulation into P(Ox) based micelles,[14-16, 19, 76-77, 82] or liposomes[26, 83] leads to an 
enhanced solubility[67] of the cytostatic agents as well as longer blood circulation times[22, 83] 
and higher therapeutic efficiencies[14-15, 21, 67, 76] while expressing a high biocompatibility.[22, 77] 
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3. Synthesis and polymerization of functional 2-oxazolines 
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The synthesis of P(Ox)s via CROP facilitates the synthesis of functional homo- and 
copolymers with a tailored structure. Within this chapter, the synthesis and polymerization 
route of the Boc protected 2-oxazoline 2-(4-((tert-butoxycarbonyl(amino)butyl)-2-oxazoline 
(BocOx), which is known from literature, will be compared with the newly synthesized tert-
butyl 2-iminooxazolidine-3-carboxylate (BocOI). Since the polymerization kinetic of a monomer is 
for instance dependent on the substituent in 2-position, kinetic investigations on the polymerization 
rate constant (kp) are indispensable. Furthermore, the copolymerization of different monomers can 
result in random, gradient or quasi block copolymers, depending on the reactivity ratios of the used 
monomers. For this reason, detailed kinetic investigations on the homopolymerization of the newly 
synthesized BocOI as well as on the copolymerization of BocOI and EtOx will be performed. In 
order to obtain information about the monomer distribution within water soluble cationic P(Ox) 
copolymers, the copolymerization of BocOx and EtOx as well as BocOx and MeOx will also be 
investigated. On the basis of the resulting kp values, a series of functional homo- and copolymers 
will be synthesized and characterized. 
 
3.1. Monomer synthesis and polymerization mechanism 
During the last decade, amino functionalized P(Ox)s have been widely explored. While post-
polymerization functionalization represents an effective method to introduce primary,[35, 38, 62, 
84-85]
 secondary,[38] or tertiary amino moieties,[38, 85] suitable protection groups like the acid 
labile tert-butyloxycarbonyl (Boc) protection group enable the possibility of a polymerization 
of amino functionalized 2-oxazoline monomers.[40-41, 61] M. Hartlieb et al. synthesized the Boc 
protected 2-oxazoline BocOx in a three step synthesis approach (Figure 3.1A).[41] In the first 
reaction step (a), the amino group of 5-aminovaleric acid is protected using di-tert-butyl 
dicarbonate (DiBoc). Subsequently, the carboxylic acid can be activated by the addition of 
ethyl chloroformate to facilitate the reaction with 2-chloroethylamine (b). Finally, the ring 
closure can be conducted under basic conditions (c) to obtain BocOx (3), which is suitable for 
the CROP.  
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Figure 3.1. Comparison of the synthesis of BocOx (3) and BocOI (5). A: Three step BocOx (3) synthesis. a) 
DiBoc, dioxane/water, NaOH, RT; b) ethyl chloroformate, 2-chloroethylamine hydrochloride, NEt3, DMF, RT; 
c) DMF, K2CO3 60 °C. B: Single step BocOI (5) synthesis. a) DiBoc, dioxane/water, NaOH, RT. C: Molecular 
structure of 5 derived by X-ray crystal structure analysis; H-atoms are excluded. 
By variation of the spacer length between the oxazoline ring and the substituent in 2-position, 
it is assumable that the monomer- and, consequently, the polymer characteristics can be 
altered. A shorter spacer might affect the solubility as well as the biocompatibility or cellular 
uptake of the resulting polymers. For this reason, it was aimed to compare the properties of 2-
amino-oxazoline and 2-(4-aminobutyl)-2-oxazoline) containing polymers. 
2-Amino-2-oxazoline hydrochloride can be obtained commercially. As this substance does 
not have an alkyl spacer between the heterocycle and the functional amino group, this 
molecule is denoted by its imine-amine tautomerism in solution. Previous investigations 
already ascertained that in solution mainly the amino form is present.[86] By the utilization of 
discrete Fourier transform (DFT) calculations, the electronegativity of the nitrogen atoms 
based on the π-bond lengths could be determined (endo N: –0.317; exo N: –0.272).[87] 
Consequently, BocOI (5) can be synthesized directly from 2-amino-2-oxazoline 
(Figure 3.1B). As the tautomeric equilibrium cannot be shifted completely to 2-amino-2-
oxazoline, the yield of the accomplished Boc protection reaction was determined to be ~70%. 
The crude product could be purified by recrystallization from cyclohexanes and the x-ray 
crystal structure analysis of a single crystal proved the identity of BocOI (5, Figure 3.1C). The 
purity of the final product was proven by 1H-NMR, proving the by-product being less than 
10% after purification (Figure 3.2A). HR-ESI MS measurements showed product peaks and 
verified the lability of the Boc protection group by the appearance of the dominant signal at 
m/z = 131.0 Da (M – Boc + H+) (Figure 3.2B). 
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Figure 3.2. Characterization data of BocOI (5). A: 1H-NMR (300 MHz, CDCl3) and B: HR-ESI MS. 
It was aimed to polymerize BocOI (5) by the utilization of a cationic initiator, such as methyl 
p-toluenesulfonate (MeTos), which is commonly used for the CROP of 2-oxazolines. The 
CROP of 1,3-oxazolidine-2-thione was already described previously, suggesting the 
possibility to polymerize BocOI (5) with the aid of MeTos.[88] Scheme 3.1 shows the 
postulated mechanism of the controlled polymerization of BocOI (5). During the initiation 
step (a), the free electron of the monomer’s exo nitrogen attacks the methyl group of the 
initiator in a nucleophilic way. Subsequently, intramolecular electron shifts lead to a partial 
positive charge on the carbon atom in 5-position, which can be attacked by another monomer 
(propagation, b). The chain growth can be terminated by the addition of a nucleophile (c), e.g. 
water. The resulting polymeric structure is a poly(urea) derivative with one Boc protected 
nitrogen in the polymer backbone. Consequently, the CROP of BocOI (5) might facilitate the 
preparation of poly(urea) in a controlled manner instead of the commonly used 
polymerization described by O. Bayer in the 1940s.[89] 
 
Scheme 3.1. Schematic representation of the postulated mechanism of the CROP of BocOI (5) initiated with 
MeTos. a) Initiation; b) propagation; c) termination. 
 
3.2. Polymerization kinetics 
Within this sub-chapter the polymerization kinetics of BocOI (5) will be shown. Furthermore, 
the copolymerization kinetics of BocOI (5) and EtOx, BocOx (3) and EtOx, as well as BocOx 
(3) and MeOx) will be discussed. 
As already described in Chapter 1, P(Ox)s can be synthesized via CROP. In general, kinetic 
investigations are necessary to determine the linearity of the monomer consumption during 
the polymerization process. By the performance of homopolymerizations kinetics, it is 
possible to determine the controllability as well as the polymerization speed, respectively the 
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reaction rate constant (kp). The kp of the monomer under the investigated conditions could be 
calculated by the assumption that ln[�]బln[�]� = ݂ሺ�ሻ complies with �௘௙௙, eventuating equations 
(3.1) and (3.2). ln �଴ − ln �� = �௘௙௙ ∙ �         (3.1) �௘௙௙ = �௣[�]           (3.2) 
Within copolymerization reactions, monomers with different kp values can form different 
copolymers, i.e. random,[9, 49] gradient[27, 50-51] or quasi block copolymers,[52-53] as depicted in 
Chapter 1. In order to obtain a further insight on the monomer distribution within the polymer 
chain, detailed kinetic investigations on the copolymerization of different monomers are 
indispensable. Herein, reactivity ratios for copolymerization of the monomer pairs are 
calculated at four different monomer ratios at 30% conversion of the monomer with the 
higher reaction constant as determined using least-linear least square fitting (equation 
(3.3)).[90-91] 
 �ଵ = ሺ�భ−ଵሻ௙భమ+௙భሺ�భ+�మ−ଶሻ௙భమ+ଶሺଵ−�మሻ௙భ+�మ         (3.3) 
F1: instantaneous mole fraction, f1: monomer fraction of monomer 1, f2: monomer fraction of 
monomer 2, r1: reactivity ratio of monomer 1, r2: reactivity ratio of monomer 2 
Homopolymerization kinetics of EtOx,[11] MeOx[48] and BocOx[41] are already known from 
literature. Consequently, within this sub-chapter, only the homopolymerizations kinetics of 
BocOI (5) will be presented. For the purpose of accomplishing a copolymerization of 2-
oxazolines and oxazolidine imines, time-dependent kinetics on the copolymerization of 
BocOI (5) and EtOx were conducted. As BocOx, respectively AmOx, containing cationic 
polymers were aimed to be used for gene-delivery applications (Chapter 5), the 
copolymerization with a non-ionic water soluble monomer is indispensable to enhance its 
biocompatibility. For this reason, copolymerization kinetics of BocOx (3) and EtOx as well as 
the more reactive MeOx and BocOx (3) were performed.  
Initial kinetics were conducted on the homopolymerization of BocOI (5). Due to the fact that 
a copolymerization with 2-oxazolines, i.e. EtOx, was planned, preliminary experiments were 
conducted at 140 °C, being a well applicable temperature for the polymerization of EtOx 
considering the reaction speed and the dispersity of the resulting polymers.[11] Unfortunately, 
keff in dependence on the polymerization time was not linear under the investigated 
conditions. It was suggested that the monomer suffers from thermal deprotection at high 
reaction temperatures as already known from literature for other examples.[92] Furthermore, it 
is quite likely that a non-protected 2-imino-1,3-oxazolidine monomer can still be polymerized 
by using a CROP, when referring to A. Nagai et al.. Herein, 1,3-oxazolidine-2-thione was 
polymerized utilizing methyl trifluoromethanesulfonate without any protection groups for the 
endo N.[88] It might be presumed that the 2-imino-1,3-oxazolidine is significantly more 
reactive than BocOI (5), because of a lack in steric hindrance, leading to the lack in linearity 
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of the conversion in dependence on the time caused by slow initiation speeds compared to the 
propagation. A. Nagai et al. therefore polymerized 1,3-oxazolidine-2-thione at low 
temperatures of 30 to 40 °C. Unfortunately, by using such low reaction temperatures, the 
polymerization rate constant of 2-oxazolines is very low, leading to reaction times of several 
days or weeks.[11] For this reason, the polymerization temperature was lowered to 100 °C, also 
reducing the side-reactions caused by the high reactivity of BocOI (5), however, still being 
applicable for a copolymerization with 2-oxazolines. Time-dependent polymerization kinetics 
resulted in a nearly linear dependency of keff on the polymerization time (Figure 3.3A). With 
respect to size-exclusion chromatography (SEC) measurements (Figure 3.3B), side-reactions 
were only present at high molar masses, or monomer conversions above 80%. The positive 
deviation of the molar mass might be attributed to chain coupling reactions, also known for 
P(Ox)s.[93]  
Figure 3.3. Kinetik studies of BocOI (5, [M/I] = 60) in CH2Cl2 at 100 °C initiated with MeTos. A: Time-
dependent polymerization kinetics calculated by the monomer conversion obtained from gas chromatography 
(GC) analytics. B: Molar mass and dispersity in dependence on the monomer conversion. C: SEC traces (CHCl3-
i-PrOH-NEt3, PS-calibrated) of the reaction mixture after distinct polymerization times. 
Nevertheless, the polymerization kinetics was determined to follow pseudo first-order under 
the given conditions and the kp value of BocOI (5) was determined to be 97.6 L mol-1 s-1. For 
comparison, also a kinetic study of EtOx was conducted by using the same conditions as for 
BocOI (5), resulting in a kp value of 4.6 L mol-1 s-1, being 20 times lower than BocOI (5). 
This large difference within the determined reaction constants might lead to the formation of 
quasi block copolymers by one-pot copolymerization.  
In order to obtain a further insight on the monomer distribution within the polymer chain, 
detailed kinetic investigations on the copolymerization of BocOI (5) and EtOx are 
indispensable. For this reason, copolymerization experiments were conducted using 20, 40, 60 
or 80% BocOI (5) within the monomer feed. Figure 3.4 shows exemplary logarithmic plots of 
the copolymerization of 20% BocOI (5) with 80% EtOx (Figure 3.4A).  
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Figure 3.4. Exemplary ln plots of the time-dependent polymerization kinetics of A: EtOx (80%) and BocOI (5, 
20%) performed in dichloromethane at 100 °C with [M]/[I] = 100 and MeTos as initiator; B: MeOx (80%) and 
BocOx (3, 20%) performed in acetonitrile at 140 °C with [M]/[I] = 150 and methyl tosylate as initiator; C: EtOx 
(80%) and BocOx (3, 20%) performed in acetonitrile at 140 °C with [M]/[I] = 150 and methyl tosylate as 
initiator. 
Herein, the copolymerization of EtOx (kp = 5.2 ± 1.4 L mol-1 s-1, r = 0.000 ± 0.002) and 
BocOI (5, kp = 58.0 ± 5.6 L mol-1 s-1, r = 28.72 ± 10.00) presumably produces quasi block 
copolymers. To illustrate this fact, the fractions of the monomer with a lower reaction 
constant were plotted against the total polymer length (Figure 3.5D). During the synthesis of 
P(BocOIn-co-EtOxm) most of the BocOI (5) is consumed prior the incorporation of EtOx into 
the polymer chain, independent on the utilized monomer ratios, verifying a very narrow 
gradient area within the polymer chain. Consequently, the synthesis of quasi block 
copolymers can be achieved in a one-pot copolymerization. A similar behavior was already 
reported for the copolymerization of 2-phenyl-2-oxazoline and MeOx.[52] 
In order to obtain information about the monomer distribution within water-soluble cationic 
copolymers, also the copolymerization kinetics of BocOx (3) and EtOx, respectively MeOx 
were conducted utilizing the same monomer ratios as BocOI (5) and EtOx. Figure 3.4 shows 
exemplary logarithmic plots of the copolymerization of 20% BocOx (3) with 80% MeOx 
(Figure 3.4B), or EtOx (Figure 3.4C). Within the investigated monomer ratios and reaction 
conditions, the reactivity ratios of EtOx (kp = 47.2 ± 11.0 L mol-1 s-1, r = 0.98 ± 0.06) and 
BocOx (3, kp = 44.0 ± 13.3 L mol-1 s-1, r = 1.02 ± 0.06) are nearly similar, suggesting the 
formation of random copolymers as already preliminary reported by M. Hartlieb et al..[41] 
Moreover, it was previously demonstrated that the kp value of MeOx is increased compared to 
EtOx.[27] For this reason, our results on an increased reactivity of MeOx (kp = 75.4 ± 2.8 
L mol-1 s-1, r = 1.50 ± 0.16) in relation to BocOx (3, kp = 50.7 ± 4.0 L mol-1 s-1, r = 0.67 ± 
0.08) comply with the literature and suggest the formation of gradient copolymers.  
Copolymers consisting of monomers with similar reactivity ratios such as P(EtOxn-co-
BocOxm) exhibit a linear increase of the fraction of the monomers (Figure 3.5F), whereas the 
increase in the instantaneous mole fraction in a gradient copolymer (P(MeOxn-co-BocOxm) is 
more exponential (Figure 3.5E). 
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Figure 3.5. A to C: Schematic representation of the polymerization conditions and the proposed polymeric 
structures of different copolymers synthesized in a one-pot reaction. A: cyan: EtOx, red: BocOx; B: green: 
MeOx, red. BocOx; C: cyan: EtOx; orange: BocOI. D to F: Monomer distribution calculated from the kinetic 
plots of the copolymerization. The symbols show the experimental values, the lines show the non-linear 
Boltzmann fitting of the values. D: Copolymerization of EtOx and BocOx (3) performed in acetonitrile at 140 °C 
with [M]/[I] = 150 and MeTos as initiator. E: Copolymerization of MeOx and BocOx (3) performed in 
acetonitrile at 140 °C with [M]/[I] = 150 and MeTos as initiator. F: Copolymerization of EtOx and BocOI (5) 
performed in dichloromethane at 100 °C with [M]/[I] = 100 and MeTos as initiator. 
As shown in Figure 3.5, the results of the kinetic investigations facilitate the synthesis of 
water-soluble BocOx (3), respectively AmOx, containing copolymers with either a random or 
a gradient monomer distribution by choosing either EtOx or MeOx as a suitable comonomer 
for polymerization. Furthermore, the copolymerization of BocOI (5) and EtOx is achievable 
by CROP and results in quasi block copolymers. In the following paragraphs, a series of 
different homo- and copolymers will be synthesized, characterized and compared. 
 
3.3. Synthesis of polymers containing P(Ox) and poly(urea) 
This sub-chapter will provide an overview about different homo- and copolymers synthesized 
using CROP. Firstly, a series of poly(urea) containing homo- and copolymers as well as their 
characterization will be presented. Then, the preparation of BocOx containing random, 
gradient and block copolymers will be explained. Finally, Fluorescent labeling of the block 
copolymers will be shown. Homopolymers that are utilized for nanoparticle stabilization 
(Chapter 4.1) or drug delivery (Chapter 6) within this thesis were prepared according to 
literature procedures[17, 48] and are, consequently, not part of the following sub-chapter. 
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After obtaining the polymerization kinetics of BocOI, four Boc protected homopolymers with 
varying DP from 25 to 100 (P01 to P04) were synthesized and characterized accordingly 
using 1H-NMR, SEC, differential scanning calorimetry (DSC) and thermogravimetric analysis 
(TGA) measurements (Table 3.1). Thereby, 1H-, 13C-, 1H correlation spectroscopy (COSY) 
and 1H-13C heteronuclear single quantum coherence (HSQC) NMR measurements were 
performed to confirm the predicted polymeric structure (Figure 3.6).  
 
Figure 3.6. Characterization of P(BocOI)54 (P02). A: 1H-1H-COSY NMR spectrum (300 MHz, CDCl3) and B: 
HSCQ NMR spectrum (300 MHz, CDCl3). 
In the 1H-NMR spectrum, two signals (δ = 3.5 and 3.9 ppm) could be allocated to the 
backbone of the polymer, indicating different substituents on the nitrogen atoms in the 
backbone, namely the proton and the Boc protection group. Furthermore, the signal at δ = 
8.8 ppm is typical for the proton of an amide group. 1H-COSY NMR measurements were 
correlated the neighboring of protons. A coupling of the signal at δ = 3.5 ppm with the signals 
at δ = 3.9 and 8.8 ppm suggests the structure of the proposed poly(urea). Furthermore, the DP 
of the polymers could be determined by evaluation of 1H-NMR by comparison of the 
aromatic MeTos protons at δ = 7.15 and 7.67 ppm with the backbone protons at δ = 3.5 ppm. 
The DP of the homopolymers was determined to be 19, 54, 73 and 112, respectively 
(Table 3.1).  
Table 3.1. Characterization data for P(BocOI)n (P01 to P04). a 1H-NMR (300 MHz) in CDCl3. bSEC in CHCl3-i-
PrOH-NEt3 (PS-cal.). 
ID Composition [M]/[I] NMRa SECb 
 
  BocOI conversion 
[%] 
DP Mn 
[kg mol-1] 
Mn 
[kg mol-1] 
Ð 
P01 P(BocOI)19 25 91.9 19 3.5 3.8 1.18 
P02 P(BocOI)54 50 86.9 54 10.3 4.3 1.22 
P03 P(BocOI)73 75 85.0 73 13.6 4.4 1.31 
P04 P(BocOI)112 100 87.2 112 20.9 4.2 1.20 
SEC measurements were conducted to gain information about the uniformity of the polymers 
(Table 3.1). Hereby, polymers with a narrow dispersity (Ð ≤1.3) were obtained. Furthermore, 
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even though different DPs were calculated using 1H-NMR, die molar masses regarding SEC 
measurements did not vary significantly. This might be caused by column interactions of the 
polymers, which were not obtained during kinetic studies. A possible explanation for the 
different results might be attributed to the differences in the molar mass of the polymers P01 
to P04 (min. 3.5 kDa) compared to the kinetic studies (max. 2.7 kDa).  
Based on the data of the kinetic investigations, copolymers consisting of BocOI and EtOx are 
found to be block-like. This might be advantageous, e.g. in terms of self-assembly properties 
(Chapter 4.2), and, consequently, also a series of copolymers consisting of BocOI and EtOx 
was synthesized (Table 3.2). Hereby, the DP of the copolymers was kept constant, while the 
monomer ratios were varied from 20 to 80% BocOI (Table 3.2). The polymers were 
characterized using 1H-NMR and SEC measurements (Figure 3.7). 1H-NMR measurements 
showed that all copolymers revealed a similar DP of around 100 and varying BocOI contents. 
The dispersity of the polymers was determined to be Ð < 1.4. 
Table 3.2. Characterization data for P(BocOIn-co-EtOxm) (P05 to P08) and P(EtOx)116 (P09). a 1H-NMR 
(300 MHz) in CDCl3. bSEC in CHCl3-i-PrOH-NEt3 (PS-cal.). 
ID Composition NMRa SECb 
 
 DP BocOI 
[mol%] 
Mn 
[kg mol-1] 
Mn 
[kg mol-1] 
Ð 
P05 P(BocOI16-co-EtOx84) 95 16 11.3 6.1 1.27 
P06 P(BocOI36-co-EtOx64) 96 36 13.0 5.3 1.36 
P07 P(BocOI52-co-EtOx48) 100 52 14.4 5.9 1.34 
P08 P(BocOI84-co-EtOx16) 100 84 17.2 7.4 1.26 
P09 P(EtOx)116 116 0 11.5 6.8 1.16 
Boc protected urea containing copolymers could be deprotected using trifluoroacetic acid 
(TFA, Scheme 3.2), resulting in either poly(urea) homopolymers (Scheme 3.2A) or block like 
copolymers from P(EtOx) and P(OI) (Scheme 3.2B). Due to the fact that the deprotected 
copolymers were not soluble in any suitable solvent, further analytics, such as mass 
spectrometry (MS) or SEC were not possible. However, NMR measurements in deuterated 
TFA could be conducted to verify the successful deprotection of the polymers.  
Scheme 3.2. Schematic representation of the performed deprotection reactions of A: P(BocOI)n to P(OI)n as well 
as B: P(BocOIn-co-EtOxm) to P(OIn-co-EtOxm) utilizing TFA as deprotection agent. 
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Figure 3.7. A: SEC traces (CHCl3-i-PrOH-NEt3, PS-cal.) of P05 to P09. B: 1H-NMR (300 MHz, CDCl3) of P06. 
Additionally, DSC and TGA measurements of all deprotected polymers as well as the Boc 
protected precursors were performed and the results were compared with P(EtOx)166 (P09) 
(Table 3.3). Regarding the TGA measurements (Figure 3.8), Boc protected homopolymers 
(P01 to P04) revealed a slight increase of the Td from 155 to 170 °C in dependence on the 
molar mass. Furthermore, a partial decomposition of up to 50% mass loss could be observed, 
possibly caused by a thermal deprotection of the polymers.[94] A second Td could be observed 
around 200 °C, which is also determined to be the Td of the deprotected homopolymers P10 
to P13. Furthermore, after deprotection no significant dependence of the Td on the molar mass 
could be observed (Table 3.3). This might be caused by intra- and intermolecular stabilization 
of the polymers due to hydrogen bond formation during heating process. The increased Td of 
the deprotected homopolymers compared to Boc protected homopolymers might also be 
explained by this phenomenon. In terms of the Boc protected copolymers P05 to P08, no 
apparent relation between the Td and the BocOI content within the polymers could be 
observed (Table 3.3). The sharp decrease in mass above a heating temperature of 200 °C may 
be related to thermal deprotection (Figure 3.8A).  
 
Figure 3.8. TGA of the A: Boc protected polymers P01 and P05 to P09 and B: deprotected polymers P04 and 
P14 to P17 as well as P09. 
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Further decomposition of copolymers follows the Td of P(BocOI) and P(EtOx) with respect to 
the monomer ratios. The degradation temperatures of deprotected copolymers (P14 to P17) 
are comparable to the homopolymers (P01 to P04) revealing no significant trend at a mass 
loss of 5%, while further degradation also follows P(OI) or P(EtOx) with respect to the 
monomer ratios (Table 3.3, Figure 3.8B). DSC measurements were performed to obtain 
information about a possible glass transition temperature (Tg) of the polymers. The Boc 
protected homopolymers P01 to P03 revealed a Tg of 65 to 70 °C independent on the molar 
mass of the polymers. However, the reason why the Tg of P04 (98 °C) was significantly 
increased compared to the other Boc protected homopolymers is not understood yet. 
Deprotected homopolymers (P10 to P13) show a distinct lower Tg of 0 to 10 °C. The sharp 
decrease of the Tg after deprotection of the homopolymers might be caused by inter- and 
intramolecular interactions of the poly(urea) structure. The Tg of the Boc protected 
copolymers (P05 to P08) was determined to be 50 to 55 °C independent on the incorporated 
monomer ratios. In contrast, after deprotection, the influence of the urea amount within the 
copolymers (P14 to P17) is significant. The Tg of P(EtOx)116 (P09) was determined to be 
62.7 °C, similar to the deprotected copolymer containing 80% EtOx (P14, Tg = 65.8 °C). The 
Tg decreases down to –5 °C for the copolymer containing 20% EtOx (P17), which is distinctly 
lower than P(EtOx)116 (P09) or the deprotected homopolymers (P10 to P13).  
Table 3.3. Characterization data for all synthesized polymers and Boc protected precursors as determined by the 
utilization of TGA and DSC measurements. The 2nd heating cycle was used for the determination of the Tg. 
ID Pre Composition NMRa DSC TGA 
 
  DP BocOI 
[mol%] 
Mn 
[kg mol-1] 
Tg 
[°C] 
Td 
[°C] 
P01 - P(BocOI)19 19 100 3.5 69.6 154.3 
P02 - P(BocOI)54 54 100 10.3 66.2 164.5 
P03 - P(BocOI)73 73 100 13.6 68.9 167.6 
P04 - P(BocOI)112 112 100 20.9 97.9 170.2 
P05 - P(BocOI16-co-EtOx84) 95 18 11.3 53.2 89.2 
P06 - P(BocOI36-co-EtOx64) 96 27 13.0 51.5 155.6 
P07 - P(BocOI52-co-EtOx48) 100 47 14.4 56.7 120.0 
P08 - P(BocOI84-co-EtOx16) 100 76 17.2 54.2 168.7 
P09 - P(EtOx)116 116 0 11.5 62.7 353.1 
P10 P01 P(OI)19 19 100 1.6 0.8 175.1 
P11 P02 P(OI)54 54 100 4.7 - 218.2 
P12 P03 P(OI)73 73 100 6.3 7.6 136.3 
P13 P04 P(OI)112 112 100 9.6 2.4 179.5 
P14 P05 P(OI16-co-EtOx84) 95 18 9.7 65.8 203.3 
P15 P06 P(OI36-co-EtOx64) 96 27 9.4 10.6 136.1 
P16 P07 P(OI52-co-EtOx48) 100 47 9.2 5.9 137.3 
P17 P08 P(OI84-co-EtOx16) 100 76 8.8 -4.9 168.1 
Possibly, this phenomenon is caused by a homogeneous mixture of both blocks in bulk. 
Furthermore, a probable explanation could be attributed to the decrease of the Tg of P(EtOx) 
with decreasing block length.[95]Besides copolymerization of P(Ox)s with BocOI, the 
synthesis of functionalized P(Ox)s is of significant interest since they can be utilized for post-
polymerization functionalization reactions, self-assembly processes as well as drug and gene 
delivery applications. 
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It was aimed to obtain biocompatible cationic polymers which are suitable for gene 
transfection (Chapter 5) or drug delivery applications (Chapter 6). For this reason, the amino 
functionalized monomer BocOx (3) was copolymerized with either EtOx, which forms 
randomly distributed copolymers (Scheme 3.3A) or MeOx in order to obtain gradient 
copolymers (Scheme 3.3B) as determined by kinetic investigations (Chapter 3.2). By the 
synthesis via CROP, also the synthesis of block copolymers via sequential monomer addition 
is facilitated (Scheme 3.3C). After purification of the Boc protected polymer precursors, 
acidic deprotection using TFA and subsequent ion exchange leads to AmOx containing 
copolymers with a different monomer distribution. It is assumed that in aqueous solution, the 
cationic charges in MeOx containing copolymers are more concentrated due to their gradient 
monomer distribution, while they are randomly distributed within the whole polymer chain in 
EtOx containing copolymers. 
 
Scheme 3.3. Synthesis route of cationic copolymers. A and B: Copolymers synthesized via one-pot 
polymerization of 2-oxazolines and acidic deprotection. A: P(MeOxn-grad-AmOxm). B: P(EtOxn-r-AmOxm). a) 
Polymerization initiated using MeTos performed in acetonitrile at 140 °C. b) i. TFA, RT, overnight; ii. 
Amberlyst A21, methanol, RT, overnight. C: P(EtOxn-b-AmOxm) synthesized via sequential monomer addition. 
a) Polymerization of EtOx block initiated using MeTos performed in acetonitrile at 140 °C. b) Polymerization of 
BocOx block in acetonitrile at 140 °C. c) i. TFA, RT, overnight; ii. Amberlyst A21, methanol, RT, overnight. 
Green: MeOx. Cyan: EtOx. Red: BocOx/AmOx. 
Herein, the synthesis of the Boc protected precursors and the AmOx containing cationic 
copolymers is exemplarily described for polymers containing 20% BocOx (P18 and P20), 
respectively AmOx (P19 and P21). The precursors as well as the final copolymers could be 
characterized using 1H-NMR (Table 3.4, Figure 3.9) and SEC measurements (Table 3.4).  
By means of 1H-NMR measurements of Boc protected precursors (Figure 3.9, bottom 
spectra), the DP of the polymers and, consequently, the median molar mass could be 
determined. Hereby, the integrals of the tosylate initiator are compared with the backbone 
peaks of the polymers (δ = 3.4 ppm). More important, also the amount of BocOx within the 
polymer could be determined by comparing the integrals of a peak, which is specific for one 
monomer, e.g. the MeOx side chain at δ = 2.1 ppm (Figure 3.9B) and the polymer backbone 
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peak at δ = 3.4 ppm. Furthermore, the success of the deprotection reaction could be verified 
by the disappearance of the referring peak at δ = 1.4 ppm (Figure 3.9, top spectra). 
Table 3.4. Key properties of the synthesized P(Ox)s determined by either 1H-NMR spectroscopy (300 MHz) in 
aCDCl3, bCD3OD or cD2O; dcalculated from Boc protected precursor; ecalculated from deprotected copolymer. 
fSEC in DMAc + 0.21% LiCl, PS-cal.; gSEC in 0.3% TFA + 0.1 M NaCl, P2VP-cal.; hSEC (CHCl3-i-PrOH-NEt3 
(94:2:4), PS-cal.)  
ID Pre Composition NMR SEC 
 
  DP mol% 
MeOx/ 
EtOx 
mol% 
BocOx/ 
AmOx 
Mn 
[kg mol-1] 
Mn 
[kg mol-1] 
Ð 
P18 - P(EtOx150-r-BocOx33) 183a 82e 18e 22.8 19.1f 1.16f 
P19 P18 P(EtOx150-r-AmOx33) 183b,d 82 18 19.6 8.0g 1.41g 
P20 - P(MeOx130-grad-BocOx31) 161a 81e 19e 18.6 15.2f 1.33f 
P21 P20 P(MeOx130-grad-AmOx31) 161b,d 81 19 15.5 7.0g 1.48g 
P22 - P(EtOx)98 98 100 - 10.0 5.7h 1.05h 
P23 P222 P(EtOx98-b-BocOx32) 130a 75a 25a 17.5a 8.2h 1.07h 
P24 P23 P(EtOx98-b-AmOx32) 130c 75c 25c 14.2c 13.8f 1.11f 
P25 P24 P(EtOx98-b-[AmOx31-stat-
FOx1]) 
130c 75c 25c 15.3c 14.1f 1.12f 
SEC measurements were conducted to gain information about the polymer dispersity after 
preparation (Table 3.4). The Boc protected polymers exhibited a dispersity of Ð ≤ 1.33, being 
well-suited for further experiments. Furthermore, measurements on an aqueous SEC provided 
information about the stability of the polymers during acidic deprotection. No degradation of 
the polymer backbone could be observed. 
In addition to random and gradient block copolymers, also the preparation of tailored block 
copolymers, suitable for self-assembly and core cross-linking (Chapter 4.2) by CROP is 
enabled using the sequential monomer addition technique (Table 3.4). In order to prepare 
micelles, a water soluble block copolymer consisting of EtOx and BocOx was synthesized 
and deprotected (P24). 
Figure 3.9. 1H NMR (300 MHz) spectra of A: P(EtOx150-stat-BocOx33) (P18, CDCl3) and P(EtOx150-stat-
AmOx33) (P19, D2O), as well as B: P(MeOx130-grad-BocOx31) (P20, CDCl3) and P(MeOx130-grad-AmOx31) 
(P21), D2O. 
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The DP of the polymer blocks could be determined using 1H-NMR (Table 3.4). Furthermore, 
the block-like chain growth was verified using SEC measurements (Figure 3.10A), revealing 
a clear shift to lower elution volumes after addition of the second monomer to the reaction 
mixture.  
 
Figure 3.10. A: SEC traces (CHCl3-i-PrOH-NEt3 (94:2:4), PS-cal.) of preparation of P(EtOx98-b-BocOx32) (P23) 
via the sequential monomer additon. B: SEC traces (DMAc + 0.21% LiCl, PS-cal.) of the Alexafluor 660 
labeling P(EtOx98-b-AmOx32) (P24) yielding P(EtOx98-b-[AmOx31-stat-FOx1]) (P25). 
Additionally, by SEC measurements, the dispersity of the polymers was determined to be 
narrow (Ð < 1.1) (Table 3.6). After acidic deprotection, P(EtOx98-b-AmOx32) (P24) was 
labeled with Alexafluor 660-NHS ester to obtain P(EtOx98-b-[AmOx31-stat-FOx1]) (P25). The 
success of the fluorescent labeling as well as the absence of unbound dye or polymer 
degradation was verified using SEC measurements. Looking at P24, after labeling, the RI as 
well as the UV/Vis trace of the labeled polymer (P25) is shifted to higher elution volumes 
(Figure 3.10B). Since the traces are still narrow and monomodal, a degradation of the polymer 
is unlikely. The Alexafluor-600 functionality rather altered the column interaction of the 
polymer.  
Within this chapter, the synthesis of BocOx and BocOI was presented (Chapter 3.1). 
Furthermore, kinetic investigations on the homopolymerizations of BocOI as well as its 
copolymerization with EtOx, resulting in quasi block copolymers, was demonstrated. In 
addition to kinetic studies of these two monomers, also the copolymerization of BocOx and 
EtOx, as well as BocOx and MeOx was evaluated, revealing random and gradient copolymers 
(Chapter 3.2). Based on the kinetic investigations, a series of poly(urea) and P(Ox) containing 
homo and copolymers was synthesized and characterized (Chapter 3.3). Within the following 
chapter, the contribution of water-soluble P(Ox) homopolymers in terms of nanoparticle 
production will be discussed. Furthermore, the self-assembly of block copolymers will be 
presented. 
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4. P(Ox) containing nanostructures 
Parts of this chapter have been published in: P1) M. N. Leiske, M. Hartlieb, F. H. Sobotta, R. 
M. Paulus, H. Görls, P. Bellstedt, U. S. Schubert, Polym. Chem. 2016, 7, 4924-4936. P2) M. 
N. Leiske, A.-K. Trützschler, S. Armoneit, P. Sungur, S. Hoeppener, M. Lehmann, A. 
Traeger, U. S. Schubert, J. Mater. Chem. B. 2017, 5, 9102-9113. P3) M. N. Leiske, F. H. 
Sobotta, F. Richter. S. Hoeppener, J. C. Brendel, A. Traeger, U. S. Schubert, 
Biomacromolecules 2018, 19, 748-760. P4) D. Hoelzer‡, M. N. Leiske‡, M. Hartlieb, T. Bus, 
D. Pretzel, S. Hoeppener, K. Kempe, R. Thierbach, U. S. Schubert, Oncotarget 2018, in press. 
P8) M. Hartlieb‡, T. Bus‡, J. Kübel, D. Pretzel, S. Hoeppener, M. N. Leiske, K. Kempe, B. 
Dietzek, U. S. Schubert, Bioconjugate Chem. 2017, 28, 1229-1235. ‡Equal contribution of 
both authors. 
This chapter is dedicated to the utilization of P(Ox) based homopolymers and copolymers in 
the production of colloidal nanostructures. While the first part of the work focuses on the use 
of P(Ox) as cryoprotectant and its usage in the stabilization of polymeric nanoparticles, the 
second sub chapter describes the self-assembly of P(Ox) block copolymers. Here, amphiphilic 
block copolymers were self- and co-assembled in water in order to form mixed micelles. 
Furthermore, hydrophilic P(Ox) block copolymers were assembled in chloroform to obtain 
nanostructures with a cationic core. These nanostructures were cross-linked to obtain 
nanogels.  
 
4.1. P(Ox) mediated nanoparticle stabilization 
Nanomedicine represents one promising approach for the curing of various diseases, which 
require targeted drug uptake to lower unwanted side-effects.[1] The design and preparation of 
potent and safe drug carriers play a pivotal role in pharmaceutical, biomedical and chemical 
research, since nanocarriers offer possibilities of cell and organ specificity, e.g. by the 
introduction of targeting ligands. Furthermore, a minimization of side-effects can be achieved 
by the encapsulation and protection of the active pharmaceutical ingredient (API). Herein, 
water-insoluble polyesters, i.e. the Food and Drug Administration (FDA) approved 
poly(lactic-co-glycolic acid) (PLGA), are already used in numerous preclinical trials.[96] 
However, major obstacles regarding the utilization of nanoparticles are caused by their 
preparation,[97-99] purification or storage, respectively lyophilization.[100] In particular, the 
encapsulation of hydrophilic drugs is problematic, since it requires the emulsification method 
for nanoparticle preparation, and, consequently, the utilization of emulsifiers or 
surfactants.[101-102] Poly(vinyl alcohol) (Mowiol 8-88, PVA) and Pluronic F127 represent two 
important macromolecules, which are commonly used for nanoparticle stabilization during 
preparation,[101-102] while lyophilization is usually conducted using glucose, saccharose or 
trehalose as a cryo-protectant.[100-101, 103] In order to reduce the amount of substances being 
used for nanoparticle, an all-in-one system being suitable for the stabilization of hydrophobic 
nanoparticles during preparation, purification and lyophilization is envisioned.  
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The utilization of P(EtOx) or P(MeOx) could be beneficial, in particular in terms of elongated 
blood circulation times of nanoparticles, assuming that the surfactant is (partially) 
incorporated into the polymer shell during emulsification. The possibility to dissolve P(EtOx) 
and P(MeOx) in water as well as in various organic solvents[27] makes them ideal candidates 
for investigations on their properties regarding nanoparticle stabilization. For this reason, a 
small library of water-soluble homopolymers (Table 4.1) consisting of either P(EtOx)n or 
P(MeOx)n was synthesized accordingly to literature procedures.[48] The polymers were 
characterized utilizing 1H-NMR to obtain information about the DP, which was determined to 
be 25, 60, 100 or 200 in case of both utilized monomers. Furthermore, SEC measurements 
were conducted to gain information about the polymer dispersity. With exception of P35 (Ɖ = 
1.38), all polymers revealed a narrow dispersity (Ɖ ≤ 1.2).  
Table 4.1. Key properties of the synthesized P(Ox)s determined by a 1H-NMR (300 MHz, CDCl3) and bSEC 
(DMAc, 0.21% LiCl, PS-cal.). cSEC (CHCl3-i-PrOH-NEt3 (94:2:4), PS-cal.). 
ID Pre Composition NMRa SECb 
 
  DP Mn 
[kg mol-1] 
Mn 
[kg mol-1] 
Ð 
P26 - P(EtOx)25 25 2.5 6.3 1.09 
P27 - P(EtOx)61 61 6.0 12.2 
7.0c 
1.09 
1.15c 
P28 - P(EtOx)107 107 10.7 19.1 1.16 
P29 - P(EtOx)184 184 18.4 25.3 1.21 
P30 P27 P(EtOx)61-NH2 61 6.0 3.5c 1.14c 
P31 P30 P(EtOx)61-Rhodamine B 61 6.0 4.2c 1.13c 
P32 - P(MeOx)25 25 2.1 5.3 1.09 
P33 - P(MeOx)57 57 4.8 6.3 1.14 
P34 - P(MeOx)98 98 8.3 18.0 1.19 
P35 - P(MeOx)211 211 17.9 30.1 1.38 
P36 - P(MeOx)57-NH2 57 4.8 12.9 1.07 
P37 P36 P(MeOx)57-Rhodamine B 57 4.8 13.0 1.09 
In order to visualize the P(Ox)s by confocal laser scanning microscopy (CLSM) 
measurements, homopolymers with a DP of 60 (P27 and P33) were fluorescently labeled with 
rhodamine B. Two different approaches were used: (i) P(EtOx)61 (P27) was reacted with 
ethylene diamine to obtain an ω-terminal amino functionality (P30) that can be used for 
labeling with rhodamine B sulfur chloride (P31). (ii) An amino ω-terminated P(MeOx)57 was 
synthesized by quenching of the polymerization with ethylene diamine (P36) and, 
subsequently, reacted with rhodamine B sulfur chloride (P37). SEC measurements of all 
polymers (Figure 4.1) were conducted to prove the attachment of the dye to the polymer as 
well as the polymer stability and successful purification from excessive dye.  
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Figure 4.1. A: SEC traces (CHCl3-i-PrOH-NEt3 (94:2:4), PS-cal.) of the rhodamine B labeling of P(EtOx)61 
(P27). B: SEC traces (DMAc + 0.21% LiCl, PS-cal.) of the rhodamine B labeling of P(MeOx)57 (P36).  
For this purpose, the absorption of the labeled polymers at λ = 540 to 550 nm, which is 
corresponding to the rhodamine B label, was measured in addition to the RI. The traces of 
P36 and P37 perfectly overlap (Figure 4.1B), indicating successful polymer labeling. Looking 
at P(EtOx)61 (P27), after labeling, the RI as well as the UV/Vis trace of the labeled polymer 
(P30) is shifted to higher elution volumes (Figure 4.1A). Since the traces are still narrow and 
monomodal, a degradation of the polymer is improbable. More likely, the rhodamine B ω-
functionality altered the column interaction of the polymer on the chloroform based SEC. The 
labeling efficiencies of the polymers were not determined, as it was not of importance for the 
planned application as nanoparticle stabilizers. For this reason, both labeling strategies were 
defined to be of equal success. 
After the polymer preparation, P(Ox)s were investigated regarding their ability for 
nanoparticle stabilization during the preparation of nanoparticles. Hereby, initial experiments 
were used for the comparison of P(EtOx)61 (P27) and PVA, respectively Pluronic F127, at 
different concentrations. More precisely, aqueous solutions of different concentrations, i.e. 3, 
5 and 10 wt%, of P(EtOx)61 (P27) were prepared and utilized as stabilizer during 
emulsification. Nanoparticle characteristics were evaluated using dynamic light scattering 
(DLS) measurements and compared to nanoparticles produced with PVA or Pluronic F127 
(Figure 4.2B). PVA and Pluronic F127 are already stabilizing the emulsion satisfyingly at a 
concentration of 3wt% resulting in small nanoparticles (d < 150 nm) with a narrow 
polydispersity index (PDI) lower than 0.2. By using P27, much higher surfactant 
concentrations are required to obtain nanoparticles (d ≈ 200 nm) with a comparable low PDI 
below 0.2. While Pluronic F127 as an amphiphilic ABA triblock copolymer with a 
hydrophobic inner block represents a classical emulsifier being able to intrinsically form 
micelles in aqueous solution,[104] PVA and P27 do not have this segregation of blocks with 
different hydrophobicity. One possible explanation for the success of the homopolymers for 
nanoparticle stabilization might be attributed to their dynamic viscosity (Figure 4.2C). 
Aqueous PVA solutions of 3 wt% have a dynamic viscosity of 4.5 mPa s, while it is 2.5 mPa s 
for a 10 wt% solution of P27. For this reason, it is assumed that the dynamic viscosity of the 
polymer solution represents an important factor for the success of a polymer solution in terms 
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of nanoparticle stabilization. Another important factor might be the increased solubility of 
P27 in water and organic solvents. This phenomenon is also known from PVA, which 
represents a very good emulsifier. With respect to PVA, the stabilization of the interphase 
between water and the organic droplet is achieved by a different solution behavior of the 
hydrophobic polymer backbone and the hydrophilic hydroxyl groups within the polymer side-
chains.[105] In the case of P(Ox)s similar characteristics are determined, leading to an 
enhanced stabilization of the interphase and, consequently, a good stabilization of the 
emulsion (Figure 4.2A). 
 
Figure 4.2. A: Schematic representation of the nanoparticle preparation via the nanoemulsion technique. A 
hydrophobic drug and the polymer are dissolved in a not water miscible organic solvent and water is added. 
Surfactants are added and the solution is emulsified by sonication. After evaporation of the organic solvent, 
nanoparticles are obtained. Magnification of the nanoparticle-aqueous phase boundary layer is presented, 
showing the potential behavior of polymer surfactants in the nanoemulsion process. B: Properties of PLGA 
nanoparticles prepared via the nanoemulsion technique (water and ethyl acetate), using different surfactants as 
determined by DLS measurements (n = 3, 5 measurements each). Hashes represent the position of non-
investigated concentrations. C: Dynamic viscosity of aqueous surfactant solutions in dependence in the polymer 
concentrations. 
After these prelimary investigations, further experiments concentrating on differences in the 
side-chain hydrophobicity and the DP of the utilized polymers were conducted. Hereby, 
P(EtOx)n (P26 to P29) and P(MeOx)n (P32 to P35) were used in a concentration of 10 wt% 
within the aqueous layer during emulsification. The resulting nanoparticles were characterized 
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by the mean of DLS measurements in terms of their size and PDI value (Figure 4.3A). P(Ox)s 
surfactants with a DP of 25 (P26 and P32) did not lead to defined nanoparticles, however, 
large aggregates. P(Ox) with a DP of 60, 100 or 200 independent on the repeating unit were of 
equal quality in terms of size and PDI of the resulting nanoparticles. As it was assumed that 
the dynamic viscosity of the aqueous solution is an important factor for successful 
nanoparticle stabilization, this parameter was determined for all aqueous P(Ox) solutions 
(10 wt%) (Figure 4.3B). 
 
Figure 4.3. A: Characteristics of PLGA nanoparticles produced via the nanoemulsion technique (water and ethyl 
acetate) using different P(Ox)s as surfactants. The P(Ox) concentration during emulsification was 10 wt%. The 
samples were diluted 1:10 with ultra-pure water after emulsification. Z-average and PDI were determined using 
DLS measurements. B: Dynamic viscosity of P(Ox) (P26 to P29 and P32 to P35) solutions with different DP. 
As already known from other water soluble polymers, the dynamic viscosity of the solutions 
is dependent on the DP of the utilized polymers. P(Ox)s with a DP of 25 (P26 and P32) 
exhibit a dynamic viscosity of ~2 mPa s, increasing in dependence on the DP of the polymers. 
Hereby, no significant differences caused by the polymer repeating unit are observable. In 
addition to the dynamic viscosity of the polymer solution, also the polymer length might 
influence the stabilization of the emulsion, due to a weaker stabilization of the interphase by 
shorter polymer chains.  
After successful investigations of the particle stabilization during preparation, lyophilization 
experiments were conducted to test whether hydrophilic P(Ox)s can also be used as suitable 
cryoprotectants. Since the surfactant experiments revealed no significant advantages of 
P(Ox)s of a DP of 100 or 200 compared to DP 60, initial lyophilization experiments were 
performed using P(EtOx)61 (P27) in comparison to the commonly utilized sugars trehalose, 
saccharose and glucose.[100-101, 103] 
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Figure 4.4. A: Schematic representation of the lyophilization and resuspension of polymeric nanoparticles using 
P(Ox)s as suitable particle stabilizers (cryoprotectants). B: Properties of the lyophilized PLGA nanoparticles 
using different cryoprotectants at various concentrations. Diameter size ratios of the z-average and PDI ratios 
were determined by DLS investigations (n = 3, 5 measurements each). Ratios were calculated using equation 
(4.1) and (4.2). 
Here, PLGA nanoparticles were prepared via the nanoprecipitation technique without any 
particle stabilizers. After evaporation of the organic water miscible solvent (acetone), size and 
PDI of the nanoparticles were determined by DLS measurements. Subsequently, a specific 
amount of a cryoprotectant was added to the nanoparticle suspension and lyophilization was 
conducted (Figure 4.4A). Then, the nanoparticles were resuspended in water and 
characterized by DLS. Z-average ratios (Figure 4.4B) as well as PDI ratios (Figure 4.4C) were 
calculated using equations (4.1) and (4.2). � − ��݁��݃݁ ����� =  ௭−��௘��௚௘ �௙�௘� �௬௢௣ℎ���௭���௢௡௭−��௘��௚௘ �௙�௘� ௣�௘௣�����௢௡      (4.1) ��� ����� =  ��� �௙�௘� �௬௢௣ℎ���௭���௢௡��� �௙�௘� ௣�௘௣�����௢௡         (4.2) 
Herein, size and PDI ratios of a value of 1 are favorable, indicating no significant changes 
regarding the nanoparticle characteristics. At very high concentrations of 10 wt% saccharose 
revealed the best performance (size ratio = 1.0; PDI ratio = 1.8), while Glucose (size ratio = 
1.0; PDI ratio = 2.1) and trehalose (size ratio = 1.4, PDI ratio = 2.7) are slightly more 
unfavorable than saccharose. Possible ranges of P27 utilized as a cryoprotectant are 0.1 to 
5 wt%, i.e. 0.5 wt% was determined to be an ideal polymer concentration with regard to the 
nanoparticle characteristics (size ratio = 1.2; PDI ratio = 2.0). The slight increase in size can 
be attributed to the polymers that assemble on the nanoparticle surface and, consequently 
enlarge the hydrodynamic diameter. Hence, at this certain, low cryoprotectant concentration, 
P33 is superior to the investigated sugars. Furthermore, sugars are required in 20-fold 
concentration to achieve comparable results. 
After that, the library of water soluble P(EtOx)n (P26 to P29) and P(MeOx)n (P32 to P35) 
was investigated in terms of cryoprotectant applications (Figure 4.5). Herein, the tested 
polymers revealed similar results as in the surfactant experiments. P(Ox)s with a DP of 25 
(P26 and P32) were determined not to be suitable as a cryoprotectant (PDI ratio > 3), while 
P(Ox)s with a DP of 60 (P27 and P33), 100 (P28 and P34) or 200 (P29 and P35) showed 
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similar results (size ratio ≈ 1; PDI ratio ≤ 2). For this reason, P27 and P33 were used for 
further investigations. 
 
Figure 4.5. Z-average (columns) and PDI (dots) ratios of PLGA nanoparticles prepared by the nanoprecipitation 
technique (water and acetone) using 0.3 wt% P(Ox). The particles were lyophilized without further purification 
and the ratios were calculated by using equation (4.1) and (4.2) (n = 3, 5 measurements each). 
After successful investigations of P(Ox)s in terms of their suitability to act as surfactants 
during nanoparticle preparation or cryoprotectants during lyophilization, they were examined 
regarding their influence on successful nanoparticle purification. For this reason, PLGA 
nanoparticles were produced via nanoprecipitation (water and acetone) by using an 0.3 wt% 
solution of either P27 or P33 as the aqueous phase. After evaporation of the organic solvent, 
the size (d = 190 nm) and PDI (<0.1) of the resulting nanoparticles was determined using 
DLS measurements. Subsequently, the nanoparticles were purified by either centrifugation, 
which is important to separate the nanoparticles from small dissolved molecules, or syringe 
filtration, which can be used to purify nanoparticles from larger aggregates. Prior to 
lyophilization nanoparticles were resuspended in either water or a 0.5 wt% P(Ox)s solution. 
DLS measurements of the lyophilized P(Ox)s provided information about their uniformity, 
while cryoTEM measurements were utilized to visualize the particle morphology (Figure 4.6). 
 
Figure 4.6. Influence of various purification techniques on the size distribution and morphology of PLGA 
nanoparticles that were prepared by nanoprecipitation, determined by DLS (columns, n = 3, 5 measurements 
each) and cryoTEM measurements. 
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With regard to the analytical results, syringe filtration represents a suitable purification 
method for PLGA nanoparticles prepared using P(Ox)s as particle stabilizers, resulting in 
small nanoparticles (d ≈ 200 nm; PDI < 0.1). According to cryoTEM measurements, the 
resulting nanoparticles were well-defined and only few aggregates could be detected.  
By using centrifugation as a purification method for polymeric nanoparticles, strong forces 
are exerted to the particles. Furthermore, it is possible that the water soluble P(Ox)s are 
separated from the nanoparticles during the centrifugation process. To test this possibility, the 
supernatant of the centrifuged nanoparticles was discarded and they were resuspended in 
either water or a 0.5 wt% P(Ox)s solution. DLS measurements of nanoparticles resuspended 
in water revealed strong aggregation, proving the assumption of a separation of the surfactant 
and the particle. However, a resuspension in a 0.5 wt% P(Ox)s solution resulted in narrow 
disperse, well-defined nanoparticles.  
To further prove this assumption, the rhodamine B labeled P(Ox)s P31 and P37 were used in 
a similar centrifugation experiment to determine the residual amount of P(Ox) within the 
nanoparticle suspension. The nanoparticles were characterized by DLS and UV/vis 
measurements (Figure 4.7A). Hereby, the amount of P(Ox) in solution was determined by the 
utilization of a Rhodamine B calibration. Nanoparticles that were resuspended in a 0.5 wt% 
P(Ox) solution contained a 10-fold amount of P(Ox) compared to the nanoparticles, 
resuspended in water. This low amount of stabilizer led to nanoparticle aggregation, while 
nanoparticles that were resuspended in a P(Ox) solution are still well-defined. To further 
illustrate the interaction of the surfactant with the hydrophobic nanoparticles, microparticles 
were produced using the rhodamine B labeled P(MeOx)57 (P37) as surfactant. The 
microparticles were characterized using CLSM measurements (Figure 4.7B), showing a clear 
fluorescent corona and, hence, verifying the assumption of a strong interaction of the P(Ox) 
surfactant with the nanoparticle surface. 
 
Figure 4.7. Characteristics of the PLGA nanoparticles prepared by nanoprecipitation (water and acetone) using 
rhodamine B labeled P(EtOx)61 as the surfactant. A: Z-average and PDI values were determined via DLS 
measurements. aCalculated from UV/Vis absorption measurements at λEx = 630 nm. n. a.: not available because 
of particle aggregation. B: CLSM (λEx = 514 nm, λEm = 531 to 704 nm) of PLGA microparticles prepared by 
microemulsion (water and dichloromethane) using P(MeOx)57-Rhodamine B (P37) as surfactant. 
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Within this study, it could be shown that water soluble P(Ox)s, i.e. P(EtOx) and P(MeOx) are 
utilizable for the stabilization of hydrophobic PLGA nanoparticles. Furthermore, the 
stabilization of poly(methacrylate) based nanoparticles could be demonstrated (data not 
shown). Hereby, a minimum DP of 60 was necessary to obtain reproducible and satisfying 
results during preparation, purification and lyophilization. Hence, an all in one system usable 
for further applications could be invented.  
 
4.2. Self-assembly of P(Ox) block copolymers 
In addition to P(Ox) mediated nanoparticle stabilization, the self-assembly of different block 
copolymers was investigated. Hence, this subchapter is dedicated to the preparation of 
polymer colloids consisting of different block copolymers. The resulting nanostructures can 
be utilized to facilitate the transport of genetic material (Chapter 5) or APIs (Chapter 6).  
Firstly, poly(urea) containing quasi block copolymers were assembled in water. Herein, 
polymers with 28 wt% poly(urea) were found to form very uniform nanostructures 
accordingly to DLS measurements (d = 297 ±8 nm; PDI = 0.020 ± 0.015; Figure 4.8A). Cryo 
transmission electron-microscopy (cryoTEM) measurements were conducted to confirm the 
results obtained by DLS (Figure 4.8A), revealing brush-like spherical structures 
(Figure 4.8B). It is assumable that the investigated polymers form strong hydrogen bonds in 
water and, for that reason, self-assemble. However, due to lack of accessible functionalities, 
the prepared nanostructures could not be used for the complexation of genetic material or the 
conjugation of an API and were, consequently, not further elucidated within this thesis.  
 
Figure 4.8. Self-assembly of quasi block copolymers consisting of poly(urea) and (PEtOx) (P(OI46-co-EtOx117)). 
A: cryoTEM image. B: Schematic representation of hydrogen bond stabilized nanostructures. 
Furthermore, cationic P(Ox) nanostructures were prepared by self- and co-assembly of AmOx 
and EtOx containing amphiphilic block copolymers. The utilization of these nanostructures as 
polymeric vectors for the transfection of cells will be further discussed in Chapter 5. For the 
successful complexation of genetic material and polymers, cationic charges are indispensable. 
However, they are also known to force membrane disruption.[106] In fact, a shielding of the 
cationic charges, e.g. by EtOx, can reduce membrane disruption by shielding of the cationic 
charges.[107] For this reason, pH responsive system, in which the cationic charges are shielded 
at a physiological pH value of 7.4, while they stretch after protonation at lower 
endolysosomal pH values of 5 to trigger the endosomal release, was aimed. In order to access 
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functional P(Ox) based nanostructures, two different block copolymers with NonOx 
representing the hydrophobic block were synthesized. Herein, the hydrophilic block of the 
macromolecules consisted of either AmOx (P39), which allows polyplex formation of the 
resulting nanostructure, or EtOx (P38) to mediate stealth effect and enhanced 
cytocompatibility. Block copolymers were prepared and deprotected accordingly to 
copolymer synthesis described in Chapter 3.3. The polymers were characterized using 1H-
NMR for determination of the block ratios as well as using SEC to gain insight about the 
dispersity (Table 4.2). In both polymers, the DP of NonOx was kept similar, leading to 
different weight ratios of the hydrophobic and the hydrophilic block. P(EtOx155-b-NonOx76 
(P38) consisted 55 wt% NonOx, leading to a favorable assembly into worm-like structures,[60] 
while the cationic block copolymer P(NonOx52-b-AmOx184 (P39) contained 28 wt% NonOx, 
favorably leading to spherical micelles during the assembly process.  
Table 4.2. Key properties of the synthesized polymers. aSEC (eluent: DMAc, 0.21% LiCl; PS-standard); b 1H-
NMR (300 MHz). cCalculated from Boc-protected precursor polymer). eSEC (eluent: 0.1 M NaCl(aq) + 0.3% 
TFA; P2VP-standard). 
ID Composition NMR SEC 
 
 
 DP Wt% 
(EtOx/AmOx) 
Wt% 
(NonOx) 
Mn 
[kg mol-1] 
Mn 
[kg mol-1] 
Ð 
P38 P(EtOx155-b-NonOx76) 231 45 55 30.4 38.3 1.14 
P39 P(NonOx52-b-AmOx184) 236c 72c 28c 36.4 24.3 1.26 
In order to obtain polymeric micelles which express high transfection efficiencies in 
combination with an enhanced cytocompatibility, mixed micelles were prepared. For the 
preparation of the nanostructures, the polymers were mixed in different ratios prior to 
assembly to obtain nanostructures with 0, 20, 40, 60, 80 or 100% of the cationic polymer 
(P39) within the shell. Final nanostructures were prepared in 0.9 wt% NaCl representing 
physiological salt concentrations. 
Preliminary characterization of the nanostructures was conducted by means of DLS 
measurements to obtain information about the size and uniformity of the micelles 
(Figure 4.9A). Interestingly, all nanostructures containing at least 20 wt% P38 are 
significantly larger (d = 80 to 100 nm) than the nanostructures consisting of 100 wt% P39 (d 
= 60 nm). Furthermore, the PDI of the micelles was also shown to be dependent on the ratio 
of polymers used for preparation, slightly increasing from 0.2 to 0.3 with increasing amount 
of cationic polymers. 
Additionally, cryoTEM measurements were performed to obtain information about the shape 
of the produced nanostructures (Figure 4.9B). Micelles that did not contain cationic 
copolymer were determined to be rod- or sheet-like, whereas darker rods are presumably 
sheets with a parallel orientation with respect to the electron beam. Previously, rod-like 
structures from ABA triblock copolymers with NonOx representing the hydrophobic inner 
and MeOx as the hydrophilic outer blocks have been reported.[60]  
Nanostructures consisting of the cationic block copolymer (P39) were found to be spherical. 
More interestingly, all mixed micelles showed a rod-like shape regarding the cryoTEM 
measurements. For this reason, it is quite likely that the prepared nanostructures are mixed 
micelles instead of two different species present. Furthermore, the shape was determined to by 
dependent on the polymer ratios within the nanostructures as shown in Figure 4.9C. 
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Figure 4.9. A: Z-average and PDI values of the prepared nanostructures (N01 to N06) in 0.9 wt% NaCl 
determined by DLS. B: Zoom-in cryoTEM images of N01 to N06 in 0.9 wt% NaCl. Ratios describe the mass 
ratios of P38 and P39 being used during nanostructure preparation. C: Schematic representation of the obtained 
shapes of the nanostructures dependent on the used block copolymers P38 and P39 in different ratios. Blue: 
EtOx. Grey: NonOx. Red: AmOx. 
Due to the fact that the stability of a polymeric micelle is dependent on its concentration 
within the aqueous medium, the critical micelle concentration (CMC) was determined using 
the pyrene method (Table 4.3).[108] Hereby, nanostructures with 60 to 100 wt% P(EtOx155-b-
NonOx76) (P38) (N01 to N03) revealed a CMC of 2 × 10-7 M, while it slightly increased for 
nanostructures of 0 to 40 wt% P38 (N04 to N06, 1 × 10-7 M). These values comply with 
similar systems consisting of block copolymers containing MeOx and NonOx, where CMCs 
between 10-6 M and 10-5 M have been reported.[58-59, 109] 
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Table 4.3. Key properties of nanostructures N01 to N06. CMC of the nanostructures N01 to N06 in 0.9 wt% 
NaCl determined by the pyrene method. For calibration of the CMC, the fluorescence intensity at λEm = 
390.0 nm while exciting at λEx = 338.0 nm was divided by the fluorescence intensity at λEm = 390.0 nm while 
exciting at λEx = 332.5 nm and is plotted against the log of the polymer concentration. aThe average molar mass 
of the polymers was calculated from the molar masses of P38 and P39. 
Nanostructure Wt% 
P(EtOx155-b-NonOx76) 
(P38) 
Wt% 
P(NonOx52-b-AmOx184) 
(P39) 
Ma 
[kg mol-1] 
CMC 
[µg mL-1] 
CMC 
[mol L-1] 
N01 100 0 30.3 8.3 2.7 × 10-7 
N02 80 20 31.5 7.3 2.3 × 10-7 
N03 60 40 32.7 6.8 2.2× 10-7 
N04 40 60 34.0 36.6 1.1 × 10-6 
N05 20 80 35.2 45.2 1.3 × 10-6 
N06 0 100 36.4 35.5 9.8 × 10-7 
In order to obtain information about the pH-responsiveness of the prepared nanostructures 
N01 to N06 DLS measurements at different pH values ranging from 4 to 8 were conducted 
and the change in the hydrodynamic diameter was calculated by division of the obtained size 
at a distinct pH value by either the size measured at pH = 4 (Figure 4.10B) or pH = 7 (Figure 
4.10C). As already assumed, an increasing pH value led to shrinkage of the hydrodynamic 
diameter, which is dependent on the amount of cationic P39 within the shell. Nanostructures 
consisting only of P38 were determined to be not pH responsive, as already supposed by the 
absence of amino groups in the shell (Figure 4.10B). In contrast, nanostructures containing 
100 wt% of the cationic P39 shrink to a hydrodynamic diameter of 80% at a pH value of 7 
compared to 4. Less pronounced shrinkages of the mixed micelles with a high amino content 
are attributed to the participation of the non pH-responsive units within the shell. For this 
reason, it is assumed that the cationic charges can be shielded by the EtOx units in 
physiological media, such as the blood stream. 
Calculations representing the endolysosomal acidification down to a pH value of 5 showed an 
increase of the hydrodynamic diameter up to 130%, possibly caused by the increased charge 
density of the AmOx units within the micellar shell, which further cause a stretching of the 
polymer chains and might help to force endosomal disruption as well as a release of 
micelleplexes. Stable PDI values verified the stability of the nanostructures at different pH 
values and, consequently, changes in die size are attributed to a collapsing, respectively 
stretching of the cationic blocks of the micellar shell.  
Due to the fact that the prepared nanostructures showed favorable characteristics for the 
complexation, transport and endosomal release of genetic material, they will be further 
evaluated regarding their biocompatibility, cellular uptake and transfection efficiency in 
Chapter 5. 
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Figure 4.10. A: Schematic representation of the changes in size of the mixed micelles induced by changes in the 
pH value. Grey represents NonOn, blue represents EtOx, and red represents the cationic AmOx block. B: Size 
ratios of the nanostructure dependency on the pH value (calculated by the division of the z-average at distinct pH 
values by the z-average at a pH value of 4). C: Size ratios at pH values of 5 and 7 (calculated by the division of 
the pH value of 5 by the pH value of 7). 
As shown the previous paragraph, self-assembled structures possess a CMC which might be 
disadvantageous for in vivo applications, i.e. in terms of drug delivery applications. For this 
reason, covalent core cross-linkage of assembled structures in combination with the covalent 
loading of an API might be useful. In order to prepare core-crosslinked nanostructures, water 
soluble block copolymers consisting of EtOx and AmOx (P24 and P25, Chapter 3.3) were 
utilized (Table 4.4). 
Table 4.4. Composition and analytical data of P24 and P25. a 1H-NMR in D2O.  
ID Pre Composition NMRa 
 
  DP Wt% (EtOx) Wt% (AmOx) Mn 
[kg mol-1] 
P24 P23 P(EtOx98-b-AmOx32) 130b 68b 32b 14.2b 
P25 P24 P(EtOx98-b-[AmOx31-stat-FOx1]) 130b 63b 37b 15.3b 
Nanogels of P24 and P25 were prepared by dissolving the block copolymers in chloroform, 
which is an inappropriate solvent for the cationic AmOx block and, consequently, induces 
self-assembly of the block copolymers caused by a phase segregation of the AmOx block. 
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Nanogels were subsequently core crosslinked by the addition of glutaraldehyde (GA),[57] 
leading to the formation of pH-responsive imine bonds.[110] Hereby, excessive aldehyde 
groups could be quenched by the addition of an amino group containing small molecule, such 
as 6-amino fluorescein (6AF) or Doxorubicin (DOX) (Scheme 4.1). 
 
Scheme 4.1. Schematic representation of the preparation of core crosslinked nanogels. A: P(EtOxn-b-AmOxn). 
B: Reversible self-assembly in CHCl3. C: Core crosslinking by the utilization of GA. D: Quenching of excessive 
aldehyde groups using 6AF or DOX. 
In this manner, a reversible covalent attachment of the dye, respectively drug to the micelle 
core could be accomplished. By variation of the GA amount added for crosslinking, the 
characteristics of the resulting nanostructures could be slightly altered (Table 4.5). Higher 
amounts of GA lead to nanostructures with an increased size as determined by DLS and 
cryoTEM as well as a lowered, however, positive zeta potential according to electrophoretic 
light scattering (ELS) measurements. The positive zeta potential might be beneficial for 
cellular uptake, caused by an enhanced interaction of the negatively charged cell membrane. 
Results of the uptake studies will be discussed in Chapter 6. The loading efficiency of the 
cargo could be determined using UV/via measurements and was found to be 17 to 24 wt% in 
the case of 6AF and 6 wt% in the case of DOX. Bioassays investigating the nanogels will be 
part of Chapter 6. 
The most important requirement for a drug carrier is the site specific release of the drug. As 
cargo molecules within the produced nanogels are attached via imine bonds, which are known 
to be reversible at pH values below 7, a release within endosomal or lysosomal cellular 
compartments is likely as previously shown by M. Hruby and co-workers.[35] In order to 
investigate the stability of the nanogels at 4 °C (storage temperature) and 37 °C (human body 
temperature) at a pH value of 7.4, the z-average and the PDI as well as the number mean size 
value of the DOX-nanogels (N12) was evaluated using DLS measurements (Figure 4.11A). 
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Table 4.5. Characterization of P(Ox) nanogels in an aqueous environment. 
ID Pre  DLS ELS UV/vis cryoTEM 
 
 Equiv. GA  
(per 2 NH2) 
Size 
[d, nm] 
ζ 
[mV] 
6AFa/DOXb 
[wt%] 
Size 
[d, nm] 
N07 P31 1 26 +28 17a 24 
N08 P31 1.5 34 +13 27a 26 
N09 P31 2 40 +10 20a 28 
N10 P31 2.5 44 +8 24a 30 
N11 P31 3 48 +8 17a 30 
N12 P32 3 30 +25 6b 30 
DOX-nanogels (N12) were determined to be stable during the entire measurement time of two 
weeks, revealing no significant changes in size or PDI. Furthermore, it was necessary to 
determine the possibility of a drug release at a lysosomal pH value of 5. J. S. Basuki et al. 
previously investigated iron oxide nanoparticles that were loaded with DOX via pH sensitive 
imine bonds via DLS measurements, revealing an increase in the particle size at a pH value of 
5, caused by drug release.[111] Since glycine was determined to be essential for cancer cell 
proliferation and, consequently, is present within tumorous compartments,[112] DLS 
investigations of the DOX-nanogels (N12) were conducted in phosphate buffered saline 
(PBS) and glycine was added representing a competitive amine to the imine bond 
(Figure 4.11B and C). While DOX-nanogels (N12) did not reveal significant changes in size 
or PDI at a pH value of 7.4, both increase at a pH value of 5.0. Herein, it is noteworthy that 
after a second addition of glycine, this trend further increases. This might be beneficial for 
triggering the endosomal burst, similarly to pH responsive P(Ox) micelles (N02 to N06), 
described previously within this chapter. In order to obtain additional qualitative information 
about the release of DOX from the DOX-nanogel (N12), diffusion order spectroscopy 
(DOSY) NMR measurements were also conducted (data not shown). Hereby, the diffusion 
coefficients of labeled DOX-nanogels in NaCl were compared to DOX-nanogels (N12) in 
150 mM PBS (pH = 5.0), which contained glycine. Pure DOX and glycine were evaluated for 
comparison. A stacking of the spectra suggests the release of DOX at pH 5.0, while no DOX 
release could be determined in NaCl. Unfortunately, a quantification of the DOX release from 
the labeled DOX-nanogels was not possible by the applied methods. 
Figure 4.11. Properties of labeled DOX-nanogels determined by DLS measurements. A: Nanogels were 
incubated in 150 mM PBS (pH = 7.4) at indicated temperatures for a certain time. The measurements were 
conducted at the indicated temperatures. PDI is derived from the z-average. B and C: Nanogels were incubated at 
37 °C in indicated buffers for a certain time. Measurements were conducted at 37 °C. Grey boxes indicate time 
points of the addition of 100 mmol Glycine. A: Actual values obtained by DLS measurements (n = 3, three 
measurements each). B: Size and PDI ratios calculated by division of the value obtained on a certain day by the 
initial value (day -1). 
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Within this chapter, the contribution of different P(Ox)s in terms of nanoparticle formation 
and self-assembly was presented (Scheme 4.2). Whereas water-soluble P(Ox)s can mediate 
the stabilization of hydrophobic nanoparticles, such as PLGA or poly(methacrylate)s 
(Chapter 4.1), amphiphilic block copolymers revealed spherical or worm-like micelle 
formation in aqueous media (Chapter 4.2). Furthermore, poly(urea) containing polymers 
formed hydrogen bond-stabilized nanostructures after assembly in water. Water-soluble 
cationic block copolymers were assembled in chloroform and could be successfully core 
crosslinked via pH-responsive Schiff-base chemistry. 
 
Scheme 4.2. Schematic representation of different P(Ox) containing nanostructures assembled in aqueous media 
or chloroform. Cyan: EtOx. Green: MeOx. Orange: Urea. Grey: NonOx/PLGA. Red: AmOx. 
Whereas this chapter was dedicated to die preparation and characterization of different P(Ox) 
bases nanostructures, within the following two chapters the application of selected 
nanoassemblies in terms of gene- and drug-delivery will be presented. Firstly, pH responsive 
micelles will be compared to water soluble cationic P(Ox) as vectors for gene-delivery 
applications. 
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5. Gene delivery systems 
Parts of this chapter have been published in: P3) M. N. Leiske, F. H. Sobotta, F. Richter. S. 
Hoeppener, J. C. Brendel, A. Traeger, U. S. Schubert, Biomacromolecules 2018, 19, 748-760. 
P5) D. Hertz‡, M. N. Leiske‡, T. Wloka, A. Traeger, M. Hartlieb, M. M. Kessels, S. Schubert, 
B. Qualmann, U. S. Schubert, J. Polym. Sci., Part A: Polym. Chem. 2018, in press. DOI: 
10.1002/pola.29000. ‡Equal contribution of both authors. 
Besides lipoplexes, also cationic polymers are used for gene delivery, since they are capable 
of forming polyplexes with the negatively charged phosphate backbone of nucleic acids. 
Poly(ethylene imine) (PEI) is one of the most commonly used materials for gene delivery 
applications and for a long time it was claimed to be the gold standard for the transfection of 
genetic material.[113] Its high charge density leads to the formation of physiological stable 
PEI-DNA polyplexes. Disadvantages of PEI-based systems are their high in vitro and in vivo 
toxicity and their resistance against biodegradation, leading to the accumulation of the 
polymer in the cells or tissue, which can elicit further toxicity effects.[114] Furthermore, the 
cytotoxicity has been shown to be dependent on the molar mass of the polymers,[115] but can 
be improved by the introduction of stealth units, i.e. EtOx, into the polymer chain.[74, 116] 
These drawbacks lead to a necessity to search for alternative polymer systems for gene-
delivery applications, which reveal high transfection efficiencies while expressing a low 
cytotoxicity. 
For this reason, cationic copolymers containing non-ionic comonomers with increasing 
hydrophobicity (MeOx < EtOx < NonOx) were prepared and compared regarding their 
transfection efficiency. Due to the fact that cytocompatibility as well as transfection efficiency 
of cationic polymers are dependent on the amount of cationic charges within the 
macromolecule, water soluble polymers containing 20% (P25 and P19), 40% (P40 and P43), 
60% (P41 and P44) or 80% (P44 and P45) AmOx were synthesized accordingly to Chapter 
3.3 (Table 5.1). The copolymers consisted of AmOx and either MeOx in order to form 
gradient copolymers (P25, P40 to P42) or EtOx forming random copolymers (P19, P43 to 
P45) Furthermore, P(EtOx3-b-AmOx157) (P46) was synthesized and is from now on denoted 
as P(AmOx). Cationic polymers were characterized by means of 1H-NMR and SEC (Table 
5.1). 1H-NMR measurements provided information about the DP of the polymers, which was 
determined to be between 130 and 190. SEC measurements confirmed the stability of the 
macromolecules during acidic deprotection. In addition to the water-soluble cationic 
copolymers, nanostructures (N01 to N06) consisting of amphiphilic block copolymers were 
investigated. The preparation and characterization of the pH-responsive nanostructures with 
varying AmOx content in the shell was already discussed in Chapter 4.2.  
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Table 5.1. Key properties of the synthesized P(Ox)s determined by either 1H-NMR or SEC measurements. a1H-
NMR spectroscopy (300 MHz) in CD3OD; bcalculated from Boc protected precursor; cSEC in 0.3% TFA + 
0.1 M NaCl, P2VP-cal.  
ID Composition NMRa SECc 
 
 DPb mol% 
MeOx/ 
EtOx 
mol% 
BocOx/ 
AmOx 
Mn 
[kg mol-1] 
Mn 
[kg mol-1] 
Ð 
P25 P(MeOx130-grad-AmOx31) 161 81 19 15.5 7.0 1.48 
P40 P(MeOx97-grad-AmOx55) 152 64 36 16.1 8.1 1.33 
P41 P(MeOx73-grad-AmOx89) 162 45 55 18.9 9.4 1.36 
P42 P(MeOx29-grad-AmOx166) 195 15 85 24.9 10.7 1.46 
P19 P(EtOx150-r-AmOx33) 183 82 18 19.6 8.0 1.41 
P43 P(EtOx77-r-AmOx55) 132 58 42 15.5 8.3 1.32 
P44 P(EtOx57-r-AmOx139) 196 29 71 25.4 10.7 1.39 
P45 P(EtOx31-r-AmOx163) 194 16 84 26.3 11.1 1.54 
P46 P(EtOx3-b-AmOx157) 160 2 98 22.6 13.5 1.56 
After polymer synthesis and self-assembly, the polyplex formation and dissociation abilities 
of the prepared polymers and nanostructures were evaluated. Herein, random (P19, P43 to 
P45) and gradient (P25, P40 to P42) copolymers as well as P(AmOx) (P46) were compared 
to the AmOx containing nanostructures (N02 to N06). Figures 5.1A to C show the decrease of 
the relative fluorescent units (RFU) of ethidium bromide (EtBr) in the ethidium bromide 
assay (EBA) after addition of the different cationic polymers. Herein, P(AmOx) (P46) 
exhibits a similar DNA binding ability as linear PEI (l-PEI). In the case of water soluble 
copolymers it was determined to be dependent on the amount of AmOx within the polymer, 
while the choice of the comonomer (EtOx vs. MeOx) and the resulting polymeric structure 
(random vs. gradient) does not have a significant influence on the DNA binding ability 
(Figure 5.1A and B). Copolymers with 20 mol% AmOx (P25 and P19) were not able to form 
polyplexes and, consequently, were excluded from further experiments. Interestingly, all other 
polymers reach a binding plateau at an amino group to phosphate (N*/P) ratio of about 10. 
However, the RFU values differ significantly in dependence on the AmOx amount within the 
polymer. Hence, it might be concluded that polymers with less cationic charges interact faster 
and cannot complex higher amounts of DNA due to lack of cationic charges. In addition to the 
polyplexes prepared with water soluble cationic copolymers, micelleplexes were prepared 
using pDNA and the cationic mixed micelles N02 to N06. Regarding EBA (Figure 5.1C), the 
DNA binding ability with respect to the N*/P ratio was similar for all investigated 
nanostructures and P(AmOx) (P46).  
For successful transfection of cells, the possibility of DNA release is also of significant 
importance. For this reason, DNA dissociation was investigated by the utilization of the 
heparin release assay (HRA, Figure 5.1D to F). All polyplexes prepared using water-soluble 
P(Ox)s (P40 to P46) could be dissociated after addition of 10 U mL-1 heparin (Figure 5.1D 
and E), while 20 U mL-1 were required for l-PEI and nanostructures (N02 to N06, Figure 
5.1F) independent on the amount of cationic polymer within the shell. 
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Figure 5.1. Comparison of polyplex formation and stability with pDNA using P(MeOxn-grad-AmOxm) (P25, 
P40 to P42) and P(EtOxn-r-AmOxm) (P19, P43 to P45), AmOx containing micelles (N02 to N06) as well as 
P(AmOx) (P46) and l-PEI. A to C: EBA. D to F: HRA of polyplexes formed at distinct N*/P ratios. D: N*/P = 
8.8 (P43); 12.4 (P44); 13.7 (P45); 14.9 (P46); 30 (l-PEI). E: N*/P = 8.0 (P40); 10.6 (P41); 13.8 (P42); 30 
(l-PEI). F: N*/P = 50. 
After preparation of the nanostructures (N01 to N06), their cytocompatibility was evaluated 
and compared to the water soluble cationic copolymers with either MeOx (P40 to P42) or 
EtOx (P43 to P45) and P(AmOx) (P46). Previous studies already demonstrated the cyto- and 
hemocompatibility of P(EtOx)[72] and P(MeOx).[73] Furthermore, cationic charges are known 
to force membrane disruption,[106] however, are indispensable for transfection of cells. 
Consequently, a reduction of the cell membrane disruption by shielding of the cationic 
charges was aimed.[107] Cytotoxicity measurements were performed using L929 mouse 
fibroblasts (Figure 5.2).  
 
Figure 5.2. Cytotoxicity of indicated polymers against L929 cells after 24 h determined by MTT (A and B) or 
AlamarBlue (C) assay. Values represent the relative cell viability after treatment with A: P(EtOxn-r-AmOxm) 
(P43 to P45) as well as P(AmOx) (P46) and l-PEI; B: P(MeOxn-grad-AmOxm) (P40 to P42) as well as l-PEI or 
or C: Nanostructures N01 to N06 in comparison to P46. Non-treated cells served as 100% relative viability. 
Values represent the mean ± S.D. (n = 3). 
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The cytotoxicity of the investigated substances was found to be dependent on the amount of 
cationic charges, however not on the comonomer or macromolecular structure. Furthermore, 
micelles with 100% AmOx within the shell (N06) were slightly less toxic than P(AmOx) 
(P46). Micelles (N01 to N06) and P(AmOx) (P46) were further investigated regarding their 
hemocompatibility (Figure 5.3). Herein, micelles induced less erythrocyte aggregation 
(Figure 5.3A) than P(AmOx) (P46), whereas the hemoglobin release was significantly 
increased (Figure 5.3B), which can be attributed to higher membrane interactions caused by 
the increased local charge density of the micelles.  
 
Figure 5.3. Hemocompatibility of indicated nanostructures (N01 to N06) and P(AmOx) (P47). A: Concentration 
dependent erythrocyte aggregation. Branched PEI represents the positive control (p.c.) and PBS the negative 
control (n.c.). Values represent the mean and S.D. (n = 3). B: Hemoglobin release assay of erythrocytes after 
incubation at indicated concentrations. A value of less than 2% hemoglobin release is classified as non-
hemolytic and more than 5% as hemolytic. Stars depict the position of non-hemolytic samples. Triton-X was 
used as the p.c. (100%) and PBS served as the n.c. and was subtracted from the values. Values represent the 
mean and S.D. (n = 3). Striped columns are below the CMC of the nanostructures in A and B.  
After successful DNA complexation and dissociation experiments as well as biocompatibility 
measurements, the polyplex uptake was investigated (Figure 5.4). Uptake experiments of 
EtOx and MeOx containing polyplexes (Figure 5.4A and B) were conducted in L929 mouse 
fibroblasts, while micelleplexes were investigated in HEK-293 cells (Figure 5.4C). l-PEI and 
P(AmOx) (P46) were elucidated within both cell-lines, leading to a better comparability of 
the results. According to flow cytometry measurements, the polyplex uptake is very efficient 
depending on the amount of cationic monomer within the polymers being used. No significant 
differences between EtOx and MeOx containing copolymers could be observed (Figure 5.4A 
and B). Copolymers containing 40% AmOx (P40 and P43) revealed the poorest cell 
internalization (70 to 80% after 4 h of incubation) combined with a very low mean 
fluorescence intensity (MFI) of 20. All other polymers showed a similar cell uptake (~100%), 
with an MFI between 60 and 90. Micelleplexes of N02 to N06 revealed a similar trend as 
water soluble polyplexes (Figure 5.4C). Herein, the MFI increased in dependency on the 
amount of cationic charges. Micelleplexes of N02 to N06 showed an increased amount of 
fluorescent cells (80 to 90%) compared to P(AmOx) (P46) and l-PEI (60%). 
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Figure 5.4. Cellular uptake studies of indicated polyplexes YOYO-1 labeled pDNA. L929 (A and B) or 
HEK-293 (C) cells were treated with polyplexes 4 h in medium with FCS and uptake efficiency as well as MFI 
were analyzed via flow cytometry. The amount of pDNA for cell treatment was kept constant. Graphs show the 
MFI of the cells in dependence on the amount of fluorescent. MFI values represent the mean ± S.D. (n=3). 
Values of fluorescent cells represent the mean (n = 3). A: P(EtOxn-r-AmOxm) (P43 to P45) and P(AmOx) (P46) 
as well as l-PEI. N*/P = 8.8 (P43); 12.4 (P44); 13.7 (P45); 14.9 (P46); 30 (l-PEI). P(MeOxn-grad-AmOxm) (P40 
to P42) as well as l-PEI. B: N*/P = 8.0 (P40); 10.6 (P41); 13.8 (P42); 30 (l-PEI). F: Nanostructures N02 to N06 
in comparison to P46 as well as l-PEI. N*/P = 50.  
Since all investigated polyplexes revealed good uptake efficiencies within the investigated 
cell lines, the transfection efficiency was analyzed. Hereby, polyplexes of MeOx and EtOx 
containing polyplexes were investigated within L929 mouse fibroblasts, while NonOx 
containing micelleplexes were elucidated in HEK-293 cells. With regard to flow cytometry 
measurements (Figure 5.5), none of the elucidated water soluble P(Ox)s (P40 to P46) caused 
any transfection in the cells after two days of incubation. In contrast to that, l-PEI transfected 
40% of the cells. 
A possible explanation for the lack in transfection might be attributed to a lack in endosomal 
release of the polyplexes. For this reason, the micelleplexes beforehand described might 
represent a suitable alternative to enhance the transfection efficiency of AmOx. 
 
Figure 5.5. Transfection efficiency of different polyplexes for L929 mouse fibroblasts in growth media at N/P = 
30 after 2 d analyzed via flow cytometry. Values represent the mean (n = 3). A: Relative MFI of all viable cells 
normalized by the negative control (YOYO-1, n.c.). 
HEK-293 cells were incubated with micelleplexes for 4 d and analyzed via flow cytometry 
(Figure 5.6). Hereby, the transfection efficiency as well as the MFI of cells by using 
5. Gene delivery systems 
51 

micelleplexes consisting of at least 40% AmOx within the micelle shell (N03 to N06) was 
enhanced compared to P(AmOx) (P46) (Figure 5.6A and B). Furthermore, the cell viability of 
all micelleplexes (80 to 95%) was superior to l-PEI and P(AmOx) (P46) (60%). For this 
reason, the transfection efficiency of all cells was also determined (Figure 5.6C), revealing a 
superiority of N05 and N06 compared to l-PEI. 
 
Figure 5.6. Transfection efficiency of different polyplexes for adherent HEK-293 cells in growth media at N*/P 
= 50 after 4 d analyzed via flow cytometry. Values represent the mean (n = 3). A: Relative MFI of all viable cells 
normalized by the negative control (n.c.). B: Transfection efficiency of all viable cells. C: Transfection 
efficiency of all cells. 
Within this chapter, water soluble cationic copolymers consisting of EtOx and AmOx 
(random) or MeOx and AmOx (gradient) as well as cationic nanostructures with EtOx and 
AmOx within the shell were compared to P(AmOx) and l-PEI regarding their potential as 
biocompatible non-viral vectors. Herein, the transfection efficiency of AmOx containing 
polyplexes could be enhanced by using copolymers with hydrophobic NonOx blocks that 
were self-assembled into micelles prior to complexation of the genetic material. It might be 
assumed that the endosomal release can be triggered by stretching of the cationic AmOx 
blocks during acidification of the endolysosomes (Scheme 5.1). Consequently, amphiphilic 
copolymers were determined to be more efficient than fully water soluble polymeric carrier 
systems.  
 
Scheme 5.1. Schematic presentation of the cellular uptake and endosomal release of different polyplexes. Left: 
water soluble polyplexes of random or gradient hydrophilic copolymers might not be able to be released from the 
endosomes and, consequently, lack in transfection efficiency. Right: Micelleplexes that were prepared by using 
amphiphilic polymeric micelles can trigger the endosomal burst by stretching of the cationic polymer blocks 
during acidification of the endolysosomes and, hence, successfully transfect cells. Cyan: EtOx. Green: MeOx. 
Red: AmOx. Grey: NonOx. Purple: pDNA. 
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Within the following chapter (Chapter 6), water soluble functional P(Ox)s will be applied in 
terms of drug-delivery systems by covalent conjugation of drugs to the hydrophilic polymers 
and their activity, respectively therapeutic efficiency will be elucidated and compared to the 
pure drugs. 
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6. Drug delivery systems 
Parts of this chapter have been published in: P4) D. Hoelzer‡, M. N. Leiske‡, M. Hartlieb, T. 
Bus, D. Pretzel, S. Hoeppener, K. Kempe, R. Thierbach, U. S. Schubert, Oncotarget 2018, in 
press. P7) T. Luehmann, M. Schmidt, M. N. Leiske, V. Spieler, T. C. Majdanski, M. Grube, 
M. Hartlieb, I. Nischang, S. Schubert, U.S. Schubert, L. Meinel, ACS Biomater. Sci. Eng. 
2017, 3, 304-312. P8) M. Hartlieb‡, T. Bus‡, J. Kübel, D. Pretzel, S. Hoeppener, M. N. 
Leiske, K. Kempe, B. Dietzek, U. S. Schubert, Bioconjugate Chem. 2017, 28, 1229-1235. 
‡Equal contribution of both authors. 
In addition to complexation of genetic material, functional groups of polymers can also be 
utilized for drug conjugation. As already mentioned in Chapter 2, many drugs (i.e. small 
molecules) are poorly water soluble. Conjugation to water soluble polymers can enhance the 
solubility significantly.[21-22] Furthermore, the blood circulation times can be increased[79] by 
preventing unspecific cellular uptake, immune response or renal excretion. 
Within this work, two different possibilities for the attachment of drugs to polymers were 
conducted. Firstly, single P(Ox) chains with a defined azide functionalized ω-end group were 
used for the POxylation of interleukin-4 (IL-4). Hereby, irreversible conjugation of polymers 
to proteins is mostly known from PEGylation, aiming longer blood circulation times and 
consequently altering the pharmacokinetics.[117-118] By further evaluating the PEGylation of 
proteins, some drawbacks are obvious by the nature of the unspecific reaction carried out: (i) 
Different protein molecules can be attacked at different positions, (ii) the active center of the 
protein can be blocked, (iii) mono-, di-, or multi-PEGylation occurs, and (iv) 25% of the 
human population already have PEG antibodies. These unwanted effects can lead to a 
significant change within the pharmacokinetics of the protein based pharmaceutical, since it 
cannot be determined precisely how much of the protein is still active or how significantly the 
blood circulation times are altered. For this reason, CuAAC might be used for the preparation 
of defined protein P(Ox) conjugates. 
 
 
6.1. POxylation of proteins 
In order to obtain mono-POxylated proteins, an alkyne modified amber codon was 
synthesized previously.[119] This amino acid can be inserted into the protein structure during 
protein biosynthesis and, hence, reveals a single, defined position within the protein. 
Consequently, the synthesis of mono azide functionalized P(Ox)s via ω-end 
functionalization[17-18] was conducted. In order to obtain conjugates of varying size, three 
different homopolymers of different molar mass were synthesized accordingly to Chapter 3.3 
and characterized using NMR as well as SEC (Table 6.1) to gain information about the size 
and dispersity of the polymers. Polymers P47 to P49 revealed a narrow dispersity (Ð ≤ 1.2) 
while having a molar mass of 2,600, 4,300 or 9,200 g mol-1. In addition to the P(MeOx) 
homopolymers, gradient copolymers of MeOx and AmOx (P50 to P52) were synthesized to 
enhance the cellular uptake mediated by the cationic charges. However, the amount of AmOx 
units was kept low to minimize cytotoxic effects caused by the cationic charges as reported 
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within Chapter 5. The polymers were end-functionalized accordingly to the homopolymers 
and analyzed by SEC and NMR measurements (Table 6.1). 
Table 6.1. Properties of azide terminated homo- and copolymers determined by either a 1H-NMR (300 MHz, 
CDCl3) or bSEC (DMAc + 0.21% LiCl, PS-cal.). c 1H-NMR (300 MHz, CD3OD). dCalculated from Boc 
protected precursor. 
ID Composition NMRa SECb 
 
 DP Mol% 
MeOx 
Mol% 
AmOx 
Mn 
[kg mol-1] 
Mn 
[kg mol-1] 
Ð 
P47 P(MeOx)30-N3 30 100 0 2.6 5.4 1.10 
P48 P(MeOx)50-N3 50 100 0 4.3 8.3 1.11 
P49 P(MeOx)108-N3 108 100 0 9.2 14.0 1.20 
P50 P(MeOx41-grad-AmOx2)-N3c 43d 95 5 3.8 5.8 1.20 
P51 P(MeOx38-grad-AmOx4)-N3c 42d 90 10 3.8 6.3 1.18 
P52 P(MeOx32-grad-AmOx8)-N3c 40d 80 12 3.9 6.4 1.19 
Utilizing the synthesized polymers, IL-4 was P(Ox)ylated via CuAAC to obtain conjugates 
(Figure 6.1A). The success of the conjugation was verified using SDS-PAGE gel 
chromatography (Figure 6.1B and C). By using homopolymers with different molar masses, it 
is obvious that the A-band within the gel shifts to higher molar masses (Figure 6.1B), while it 
is similar in case of the copolymers, which were prepared with a similar molar mass 
themselves (Figure 6.1C). Hereby, the successful conjugation of single ω-functional polymer 
chains to IL-4 by the highly selective CuAAC could be demonstrated. After the demonstration 
of the successful conjugation of single polymer chains to IL-4 via CuAAC, their activity was 
compared to the wild-type IL-4 in a proliferation as well as an enhanced yellow fluorescent 
protein (eYFP) reporter gene assay. 
Within this sub-chapter the utilization of ω-end functionalized P(Ox) for the mono-
POxylation of IL-4 was presented, possibly enabling the preparation of protein 
pharmaceuticals with defined blood circulation times. Another opportunity for drug 
conjugation is the reversible drug attachment of small molecules such as doxorubicin (DOX) 
to polymer carriers, e.g. by Schiff base chemistry, which will be discussed in the following 
paragraph. 
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Figure 6.1. P(Ox)ylation of IL-4. A: Schematic representation of the P(Ox)ylation of IL-4. Modified after T. 
Lühmann et al..[119] B: CuAAC reactions between Plk-IL-4 and P(MeOx)n-N3 polymers. C: CuAAC reactions 
between Plk-IL-4 and P(MeOxn-stat-AmOxm)-N3 polymers as analyzed by reduced SDS-PAGE. Plk-IL-4 is 
shown as control. Arrows indicate polymer conjugated IL-4 species. 
 
6.2. DOX conjugated P(Ox) nanogels 
DOX is a cytostatic agent known to cause severe side-effects. Hence, the reversible 
conjugation of the drug to a polymer might be a good opportunity to resolve this problem by 
minimization of unspecific uptake and, consequently, enhanced blood circulation times. The 
preparation and drug loading of the core cross-linked nanogels was described in Chapter 4.2. 
Furthermore, the stability at physiological pH values as well as the qualitative drug release of 
the DOX-nanogel (N12) was demonstrated (Figure 4.11, Chapter 4.2). Preliminary in vitro 
investigations regarding the cellular internalization of the 6AF loaded nanogels N07 to N11 
prepared in Chapter 4.2 were conducted, revealing a clear dependency of the cellular uptake 
of L929 mouse fibroblasts on the amount of GA utilized for cross-linking and, consequently, 
the zeta potential of the nanogels. Nanogel N07, which contains one equivalent GA per two 
amino groups within P31, showed the highest uptake, decreasing in order to a lowering zeta 
potential. Hence, N11 revealed the lowest, respectively slowest cellular internalization. Due to 
the fact that a system was aimed which is exclusively internalized into cancer cells, a low 
cellular uptake into L929 cells was favored and, consequently, N11 was used for further 
experiments and compared to DOX loaded nanogels (N12), which were prepared by using 
similar conditions (Table 4.5, Chapter 4.2). Nanogel stability and pH dependent DOX release 
were verified by DLS measurements conducted in Chapter 4.2. Firstly, cytotoxicity 
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experiments comparing the influence of the 6AF (N11) and the DOX (N12) loaded nanogels 
as well as pure DOX on the cell viability of L929 mouse fibroblasts, which are known to be 
sensitive to cytotoxic effects,[120] and HT-29 cells were conducted (Figure 6.2). Hereby N12 
was used at equal DOX concentrations as pure DOX and N11 was used at the same polymer 
concentration as N12. Independent on the concentration, 6AF loaded nanogels (N11) did 
not show any impairing effects on neither of the investigated cell lines after 72 h. 
Furthermore, L929 cells were more sensitive to DOX loaded nanogels (N12) that HT-
29 cells, indicated by a decreased cell viability (25%, Figure 6.2A) at a DOX 
concentration of 0.1 µg mL-1 compared to a cell viability of 80% in HT-29 cells 
(Figure 6.2B). Furthermore, in L929 cells, the nanogel N12 is more effective than pure 
DOX, which is less pronounced in HT-29 cells.  
 
 
Figure 6.2. Cytotoxicity of DOX-free nanogels (N11), labeled DOX-nanogels (N12) as well as free DOX were 
determined by XTT assay. L292 mouse fibroblasts (A) as well as HT-29 human colorectal carcinoma cells (B) 
were incubated for 72 h. Labeled DOX-nanogels (N12) were used at a concentration where the amount of loaded 
drug resembles the amount of DOX used per data point. DOX-free nanogels (N11) were used at the same 
polymer concentration as labeled DOX-nanogels (N12). Data are expressed as mean ± SD of six 
determinations.  
Further elucidation of the cellular uptake and endosomal release was investigated by the 
means of CLSM imaging (Figure 6.3). Hereby, the DOX loaded nanogel N12 was compared 
to pure DOX. Two sets of imaging were taken, i.e. after 6 h and after 24 h. 
After 6 h of incubation, the free DOX is mostly diffuse localized within the cytosol and 
nucleus. Previous studies already reported this phenomenon after 3 h.[121-122] N12, however, 
requires more time to enter the nucleus. After 6 h, mostly a colocalization of N12 and 
lysosomes could be obtained. Furthermore, the signals of DOX and the Alexafluor label are 
colocalized, indicating that the nanogels were not degraded up to that time point. After 24 h 
incubation time, the pure DOX was mostly localized in the nucleus. Furthermore, the DOX of 
N12 could also be found within the nucleus, whereas the polymer signal was localized outside 
the nucleus, indicating a successful degradation of the nanogel and, consequently, drug 
release.  
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Figure 6.3. CLSM images of free DOX as and labeled DOX-nanogels (N12) incubated with HT-29 colorectal 
carcinoma for 6 h or 24 h. Lysosomal cellular compartments were stained green using LysoTracker Green DND-
26 and the nucleus was labeled with Hoechst 33342 (blue). The fluorescence of DOX is depicted in red and the 
Alexafluor label of the polymer is shown in white.  
With regard to the in vitro results, an in vivo study using the xenograft mouse model was 
conducted using the DOX-loaded nanogel N12 in comparison to pure DOX. 6AF loaded 
nanogels (N11) as well as physiological sodium chloride solution represented the control 
groups. All substances were dissolved in sterile sodium chloride solution and mice were 
treated via tail vein injection. Preliminary experiments on the biocompatibility revealed no 
toxic effects of the nanogels at a DOX concentration of 1 mg kg-1. For this reason, this 
amount of DOX was used for the determination of the therapeutic efficiency in vivo. HT-29 
tumor cells were injected to male nude mice. After the tumor growth reached a certain level, 
therapy was conducted by the injection of six doses. Mice treated with DOX or N12 revealed 
a reduced tumor growth whereas N11 and NaCl did not have an influence. Interestingly, the 
DOX loaded nanogel N12 was slightly more efficient than the pure DOX (Figure 6.4A) and, 
furthermore, increased the median survival time significantly (N12: 73 d; DOX: 39 d; 
Figure 6.4B). 
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Figure 6.4. A: Development of absolute relative volume for animal groups illustrated over time after treatment 
(day 0). Male nude mice were subcutaneously injected with HT-29 cells. When tumors reached a volume of 100 
to 200 mm3, mice received six doses of 0.9 wt% NaCl, DOX (1 mg kg-1), DOX-free nanogel (N11) or labeled 
DOX-nanogel (N12) (corresponding to 1 mg kg-1 Dox) via tail vein injection from day 0 to day 15. Data 
represents the mean and S.D. B: Kaplan-Meier survival curve of mice bearing human HT-29 colorectal 
adenocarcinoma xenograft. Male nude mice received a subcutaneous injection of HT-29 cells into the flank. 
When tumors reached 100 to 200 mm3 mice received six doses of 0.9 wt% NaCl, DOX (1 mg kg-1), DOX-free 
nanogel (N11) or labeled DOX-nanogel (N12) (corresponding to 1 mg kg-1 DOX) via tail vein injection from day 
0 to day 15. The individual endpoint was achieved when the tumor volume reached 1500 mm3. Statistical 
differences are displayed as *p <0.05 and **p<0.01 according to the log-rank test. 
Within this chapter, two different strategies of drug conjugations were presented. Firstly, 
CuAAC was used for the irreversible conjugation of single P(Ox) chains to alkyne modified 
proteins. These proteins were afterwards determined to remain actively after P(Ox) 
conjugation. Furthermore, the reversible conjugation of multiple DOX molecules to the core 
of cross-linked P(Ox) nanogels was realized via Schiff base chemistry. The resulting drug 
carriers were shown to be more efficient than DOX in vitro and in vivo. 
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7. Summary 
Since their invention in the 1960s, research on the pseudopeptides poly(2-oxazoline)s 
(P(Ox)s) has risen significantly. Whereas initial investigations mainly concentrated on the 
synthesis of defined P(Ox)s with different substituents in 2-position and their chemical 
characterization, the field of biomedical applications has been focused increasingly during the 
last decade. Due to this broad scope in academic research on P(Ox)s, the aim of this thesis 
was to contribute to the understanding of the synthesis and polymerization, self-assembly 
behavior as well as biomedical applications of P(Ox)s (Figure 7.1).  
 
Figure 7.1. With the aid of detailed kinetic investigations, the CROP facilitates the synthesis of tailored 
polymers consisting of 2-oxazolines and/or urea (orange boxes). P(Ox)s can be utilized for stabilization of 
hydrophobic polymer particles as well as for direct self- and co-assembly (blue boxes). Functional P(Ox)s are 
used in a wide range of applications in drug as well as gene delivery (green boxes). 
By using distinct synthesis routes, different Boc protected amino-functionalized 2-oxazolines 
can be obtained. Firstly, the synthesis of 2-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxazoline 
(BocOx), which is already known from literature, is proceeded by using a three step synthesis 
utilizing 5-aminovaleric acid as starting material. The synthesis resulted in a Boc protected 2-
oxazoline, which can be polymerized using the cationic ring-opening polymerization (CROP). 
On the other hand, tert-butyl 2-iminooxazolidine-3-carboxylate (BocOI) can be synthesized from 
2-amino-2oxazoline in a single step reaction. Hereby, the endo-nitrogen of the molecule was found 
to be more reactive than the exo-nitrogen and, hence, leads to the formation of a Boc protected 2-
iminooxazolidine instead of a 2-oxazoline. BocOI was found to be polymerizable by CROP, 
resulting in Boc protected poly(urea) derivatives, which could be deprotected under acidic 
conditions to yield poly(urea). Thus, the synthesis of poly(urea) was proceeded in a controlled 
chain growth polymerization, yielding polymers with a narrow dispersity (Ð ≤ 1.3) instead of the 
less controllable step growth polymerization, invented by Otto von Bayer. Furthermore, by using 
the CROP for the preparation of poly(urea) it was possible to prepare copolymers of P(Ox)s and 
poly(urea) in a one-pot polymerization. Hereby, the polymerization constant of BocOI was found 
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to be more than ten times higher than 2-ethyl-2-oxazoline (EtOx), suggesting the formation of 
quasi block copolymers in a one-pot reaction.  
Furthermore, the copolymerization kinetics of the Boc protected 2-oxazoline BocOx and EtOx, 
respectively 2-methyl-2-oxazoline (MeOx) were evaluated. Here, BocOx was found to be as 
reactive as EtOx, leading to the formation of random copolymers, while MeOx was more reactive 
and, consequently, forms gradient copolymers with BocOx. Consequently, BocOI is much more 
reactive than BocOx, which might be caused by the monomer structure and the differences in the 
polymerization mechanism. Then, different functional copolymers were synthesized and 
characterized. The polymers were used for the preparation of colloidal structures and used for gene 
and drug delivery applications within this thesis. 
The second main objective of this thesis concentrated on the application of P(Ox)s for the 
preparation of nanostructures. Herein, water soluble homopolymers of P(EtOx) or P(MeOx) with 
different degrees of polymerization (DP; 25, 60, 100 and 200) were synthesized and investigated 
regarding their properties within the stabilization of hydrophobic nanoparticles during preparation, 
purification and lyophilization. In general, no significant differences between P(EtOx) and 
P(MeOx) could be observed. P(Ox)s with a DP of 25 were not suitable for neither of the aimed 
applications, possible caused by their low dynamic viscosity in aqueous solutions or their short 
chain length, which cannot stabilize the interphase between the hydrophobic nanoparticle and the 
aqueous solution in a satisfying manner. Though, P(Ox)s with a DP of 60, 100 or 200 were found 
to be suitable as stabilizers for nanoparticle preparation, purification and lyophilization at distinct 
concentrations. Consequently, it could be shown that non-ionic P(Ox)s can be utilized as an all-in-
one system to stabilize hydrophobic polymer nanoparticles.  
In terms of nano-assembly, the utilization of amphiphilic P(Ox)s for the preparation of pH-
responsive nanostructures was investigated. Herein, P(Ox) block copolymers were synthesized 
consisting of either 2-nonyl-2-oxazoline (NonOx) and EtOx or NonOx and 2-(4-aminobutyl)-2-
oxazoline) (AmOx) and self- as well as co-assembled in a simple mixed micelle approach. In both 
cases, NonOx served as the hydrophobic building block of the block copolymers, forming the 
micellar core during the assembly process. AmOx was chosen as the cationic core block to 
facilitate the complexation of genetic material for gene delivery applications. In contrast to that, 
EtOx served as the non-ionic building block suitable to enhance the biocompatibility of the 
nanostructures by shielding the cationic charges of AmOx. Nanostructures were prepared with 
different amino contents by simply mixing the two polymers in different weight ratios prior 
assembly. By this means, nanostructures with 0, 20, 40, 60, 80, or 100 wt% of the AmOx block 
copolymer could be prepared and elucidated regarding their size, morphology, critical micelle 
concentration (CMC), and pH responsiveness. All nanostructures containing the EtOx copolymer 
were found to be worm- or sheet-like with an average diameter of 100 nm, while the micelles 
consisting of 100 wt% of the AmOx copolymer where found to be slightly smaller (d ≈ 70 nm) and 
spherical. The CMC was very low (10-7 to 10-6 M) in all cases and the pH responsiveness increased 
with an increasing AmOx amount within the shell of the micelles. 
In addition to assembled micelles, also core cross-linked nanogels were prepared, utilizing 
AmOx and EtOx containing block copolymers. Hereby, block copolymers consisting of EtOx 
and AmOx were assembled in chloroform to form nanostructures with a cationic AmOx core. 
These nanostructures could be successfully prepared and reversible drug (6AF or DOX) 
conjugation was conducted using Schiff-base chemistry. The nanogels were found to be stable 
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at 4 °C and 37 °C at physiological pH values, while the DOX was shown to be successfully 
released at a pH value of 5.0 in the presence of the proteinogenic amino acid glycine. 
The transport of genetic material by cationic polymers into cells is one important topic of this 
thesis. For this reason, all AmOx containing nanostructures as well as a series of water soluble 
copolymers consisting of EtOx and AmOx (random copolymers), respectively MeOx and AmOx 
(gradient copolymers) was investigated. The cationic polymers were able to bind and release the 
genetic material. Complexes of plasmid DNA (pDNA) and AmOx containing micelles 
(micelleplexes) were evaluated regarding their transfection efficiency in vitro. Herein, micelles 
consisting of 80 or 100 wt% AmOx copolymer could cope with l-PEI when comparing the 
absolute transfection efficiency of the cell population. Hereby, also P(AmOx) was used for 
comparison, revealing no detectable transfection efficiency. As the transfection efficiency was 
proven to be enhanced for the amphiphilic micelleplexes in comparison to the AmOx 
homopolymers, also water-soluble copolymers of AmOx and EtOx (random) or AmOx and 
MeOx (gradient) were elucidated. Unfortunately, none of the investigated polyplexes were 
able to successfully transfect cells. For this reason, it was concluded that the hydrophobic 
NonOx block of the polymers enhances the transfection efficiency of AmOx. Furthermore, 
the assembled morphology could have an influence on the endosomal burst and the 
subsequent release of the micelleplexes from the endolysosomes.  
In addition to gene delivery systems, also drug delivery represents an important aspect for the 
application of P(Ox)s. In general, the encapsulation into or the conjugation to polymeric 
carrier systems aims an enhanced solubility of hydrophobic drugs, longer blood circulation 
times and reduced side-effects by targeted uptake. Since encapsulation of drugs might lead to 
unspecific diffusion within an organism, covalent conjugation might be more promising to 
fulfill these aims. Drugs can be conjugated irreversible or reversible to a polymer based 
carrier system. Within this thesis, irreversible conjugation was conducted using the copper 
catalyzed azide alkyne click reaction of the alkyne modified protein IL-4 and azide ω-end 
group functionalized water soluble P(Ox)s. Hereby, the conjugation of different P(Ox)s could 
be demonstrated in a very selective manner. SDS-PAGE analysis showed the specific 
attachment of single polymer chains to the proteins. Furthermore, the remaining activity of the 
protein was proven by the expression of eYFP. Furthermore, DOX containing nanogels were 
elucidated in terms of therapeutic efficiency in vitro and in vivo, revealing enhanced tumor 
suppression in combination with longer median survival times. 
In summary, within this thesis new P(Ox) and poly(urea) containing polymers could be 
synthesized from amino-functionalized 2-oxazolines and compared to amino-functionalized 
P(Ox) copolymers regarding their polymerization kinetics and reactivity ratios. The urea 
containing polymers could be characterized. Furthermore, water soluble P(Ox)s could be used 
as a suitable all-in-one system for the stabilization of hydrophobic polymer nanoparticles, 
while amphiphilic P(Ox)s could be self- and co-assembled and successfully applied as gene 
carriers. They were advantageous to water soluble gene vectors in terms of cell transfection. 
However, water soluble P(Ox)s could be applied as drug delivery systems by irreversible or 
reversible drug conjugation. 
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8. Zusammenfassung 
Seit der Entdeckung der Synthese der Poly(2-oxazolin)e (P(Ox)s) hat die Forschung rund um 
diese Polymerklasse stetig zugenommen. Ursprünglich lag der Forschungsfokus 
hauptsächlich auf der Synthese hochdefinierter P(Ox)s mit unterschiedlichen Substituenten in 
2-Position und deren Charakterisierung bezüglich des Löslichkeitsverhaltens oder der 
Glasübergangs-temperaturen. Während der letzten Jahre allerdings verschob sich der Fokus 
zunehmen in Richtung der biomedizinischen Anwendungen (Abbildung 8.1). 
Abbildung 8.1. Mithilfe detaillierter Kinetiken ermöglicht die kationische Rinöffnungspolymerisation (CROP) 
die Synthese maßgeschneiderter Polymere, welche aus 2-Oxazolinen und/oder Urea bestehen (orange Box). Die 
P(Ox)s können genutzt werden, um hydrophobe, polymerbasierte Partikel zu stabilisieren oder durch 
Selbstassemblierung Nanostrukturen aufzubauen (blaue Box). Funktionelle P(Ox)s können in einem breiten 
Spektrum des Gen- und Wirkstofftransports eingesetzt werden (grüne Box). 
Definierte synthetische Routen ermöglichen es, unterschiedliche Boc geschützte Amin-
funktionalisierte 2-Oxazoline herzustellen. In dieser Arbeit wurde die Herstellung des 
literaturbekannten 2-(4-((tert-Butoxycarbonyl)amino)butyl)-2-oxazolin (BocOx) in einer 
Dreistufensynthese, ausgehend von 5-Aminovaleriansäure, durchgeführt. Das Produkt dieser 
Synthese ist ein Boc geschütztes 2-Oxazolin, welches mithilfe der kationischen 
Ringöffnungspolymerisation (CROP) polymerisiert werden kann. Zusätzlich zu diesem 2-
Oxazolin wurde tert-Butyl-2-iminooxazolidin-3-carboxylat (BocOI) in einer Einstufensynthese, 
ausgehend von 2-Amino-2-oxazolin, synthetisiert. Da der endo Stickstoff des Ausgangsstoffes 
reaktiver ist als der exo Stickstoff, entsteht durch die Boc-Schützung das 2-Iminooxazolidin BocOI 
anstelle eines 2-Oxazolins. BocOI konnte mithilfe der CROP polymerisiert werden. Die 
resultierenden Polymere sind Poly(harnstoff)derivate mit einer engen Molmassenverteilung 
(Ð ≤1.3). Des Weiteren ermöglichte die CROP die Synthese von Copolymeren bestehend aus 
Poly(urea) und Poly(2-ethyl-2-oxazolin) (P(EtOx)). Copolymerisationskinetiken der Monomere 
zeigten, dass BocOI eine deutlich höhere Reaktionskonstante aufwies als 2-Ethyl-2-oxazolin 
(EtOx), was folglich die Synthese von blockähnlichen Copolymeren in einer einzigen 
Polymerisation ermöglicht. Weiterhin wurden Copolymerisationskinetiken des Amin-
funktionalisierten BocOx mit EtOx und MeOx durchgeführt. Hierbei zeigte sich eine zufällige 
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Monomerverteilung bei der Polymerisation von BocOx und EtOx, während Copolymere bestehend 
aus BocOx und 2-Methyl-2-oxazolin (MeOx) eine graduelle Monomerverteilung aufwiesen. 
Ausgehend von den durchgeführten Kinetiken konnten verschiedene Copolymere synthetisiert und 
charakterisiert werden.  
Ein zweiter Schwerpunkt dieser Arbeit bestand darin, P(Ox) enthaltende Nanostrukturen 
herzustellen und zu charakterisieren. Hierbei wurden zunächst wasserlösliche Homopolymere 
bestehend aus EtOx oder MeOx in Bezug auf ihre Fähigkeiten als Stabilisatoren für 
hydrophobe Nanopartikel untersucht. Homopolymere mit unterschiedlichem  
Polymerisationsgrad (DP; 25, 60, 100, 200) wurden synthetisiert und bezüglich ihrer Eignung 
als Emulgatoren für die Nanoemulsionsmethode mit den kommerziellen Emulgatoren 
Poly(vinylalkohol) und Pluronic F127 verglichen. Zusätzlich wurden diese Polymere als 
Kryoprotektoren eingesetzt und mit den standardmäßig genutzten Zuckern Glukose, 
Trehalose und Saccharose verglichen. Polymere mit einem DP von 60, 100 oder 200 erwiesen 
sich hierbei als sehr gute Stabilisatoren als „all-in-one“ System während der Präparation, 
Aufreinigung und Gefriertrocknung der Nanopartikel.  
Ein weiterer Schwerpunkt dieses Kapitels beschäftigte sich mit der Selbst- und Co-
Assemblierung von P(Ox)-basierten Copolymeren. Es konnte gezeigt werden, dass 
blockähnliche Copolymere bestehend aus P(EtOx) und Poly(harnstoff) in wässrigem Medium 
assembliert werden können und die resultierenden Nanostrukturen eine hohe Uniformität 
aufweisen. Diese Nanostrukturen werden vermutlich durch Wasserstoffbrückenbindungen 
stabilisiert.  
Weiterhin konnten amphiphile Block-Copolymere bestehend aus einem hydrophoben 2-
Nonyl-2-oxazolin (NonOx) Block sowie einem hydrophilen EtOx oder 2-(4-Aminobutyl)-2-
oxazolin (AmOx) Block selbst- und co-assembliert werden. Nanostrukturen, welche aus 
ausschließlich mit dem AmOx enthaltenden Copolymere präpariert wurden, waren hierbei 
sphärisch, während alle Co-Assemblierungen sowie die Selbst-Assemblierungen des EtOx 
enthaltenden Copolymers stäbchenförmig waren. Es konnte eine kritische 
Mizellenkonzentration von 10-7 bis 10-6 M bestimmt werden. Des Weiteren konnte mithilfe 
von dynamischer Lichtstreuung eine pH-responsive Größenänderung der Nanostrukturen 
abhängig von Anteil an AmOx bestimmt werden. Diese Nanostrukturen wurden in einem 
späteren Abschnitt dieser Arbeit für den Transport genetischen Materials genutzt.  
Nanostrukturen, genauer gesagt Nanogele, welche für den Transport von Wirkstoffen 
bestimmt waren, wurden aus wasserlöslichen Block-Copolymeren, bestehend aus AmOx und 
EtOx, hergestellt. Diese Copolymere wurden in Chloroform assembliert und anschließend 
über die Aminogruppen mittels einer Imin-Bindung quervernetzt, um definierte Nanogele zu 
erhalten. Des Weiteren wurde der Quervernetzungsprozess dazu genutzt einen Wirkstoff 
kovalent in den Kern des Nanogels zu binden. Mittels DLS Messungen konnten die 
Reversibilität dieser Nanogele nachgewiesen werden. Die Freigabe des Wirkstoffes ist 
deshalb wahrscheinlich, jedoch nicht quantifizierbar.  
Der Transport genetischen Materials in Zellen stellt ein wichtiges Themengebiet dieser Arbeit 
dar. Aus diesem Grund wurden die zuvor hergestellten pH responsiven Polymernano-
strukturen diesbezüglich untersucht. Zusätzlich zu den Nanostrukturen wurden hydrophile 
Copolymere bestehend aus AmOx und EtOx oder AmOx und MeOx untersucht. Es zeigte 
sich, dass die kationischen Copolymere das genetische Material reversibel binden konnten. 
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Zudem wurde eine erwartete Abhängigkeit der Zytotoxizität vom Amin-Gehalt der 
verwendeten Polymere bestätigt. Obwohl die wasserlöslichen Polymere und die 
Nanostrukturen ein ähnliches Verhalten bezüglich der zellulären Aufnahme zeigten, konnten 
nur Mizellen-basierte Systeme erfolgreich transfizieren. Diese Überlegenheit gegenüber den 
wasserlöslichen System kann sowohl auf dem hydrophoben Anteil der Polymere als auch der 
Anordnung zur Nanostruktur beruhen. 
Im letzten Kapitel dieser Arbeit, welches sich mit dem Transport von kovalent gebundenen 
Wirkstoffen befasste, wurden ebenfalls hydrophile Polymere genutzt. Hierbei konnte zum 
einen die gezielte Bindung Azid-endfunktionalisierter Polymere mittels Kupfer katalysierter 
Click-Chemie demonstriert werden. Zum anderen konnten die wasserlöslichen DOX 
enthaltenden Nanostrukturen in vitro und in vivo bezüglich ihrer zellulären Aufnahme und der 
therapeutischen Effizient untersucht werden. Es konnte festgestellt werden, dass unter in vitro 
Bedingungen eine verlangsamte zelluläre Aufnahme der Nanogele im Vergleich zum reinen 
Wirkstoff stattfindet. Des Weiteren konnte die Zytotoxizität in HT-29 Zell-Linien gesteigert 
werden. In vivo Experimente zeigten eine erhöhte Lebensdauer der mit DOX Nanogelen 
behandelten Tiere im Vergleich zu Tieren, welche mit DOX behandelt wurden. 
Zusammengefasst konnte in dieser Arbeit die Synthese neuer aus P(Ox) und Poly(urea) 
bestehenden Polymere gezeigt werden. Diese Polymere wurden ausgehend von Amin-
funktionalisierten 2-Oxazolinen hergestellt und bezüglich ihrer Syntheseroute als auch ihrer 
Polymerisationskinetiken mit Amin-funktionalisierten P(Ox) verglichen. Weiterhin konnten 
wasserlösliche P(Ox)-basierte Homopolymere als Nanopartikelstabilisatoren während der 
Herstellung, Aufreinigung und Lyophilisierung verwendet werden. Des Weiteren wurden 
Blockcopolymere assembliert und die Nanostrukturen charakterisiert. Diese Systeme konnten 
schließlich erfolgreich zum Transport von Wirkstoffen und genetischem Material verwendet 
werden. 
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Cationic ring-opening polymerization of protected
oxazolidine imines resulting in gradient
copolymers of poly(2-oxazoline) and poly(urea)†
Meike N. Leiske,a,b Matthias Hartlieb,‡a,b Fabian H. Sobotta,a,b Renzo M. Paulus,a,b
Helmar Görls,c Peter Bellstedta and Ulrich S. Schubert*a,b
Poly(urea)s are a polymer class widely used in industry. Their utilization in biomedical applications is
already described, however, the use of controlled polymerization methods instead of polycondensation
approaches would allow a better control over the degree of polymerization and the dispersity of the
resulting polymers, improving their suitability for this particular ﬁeld of application. Cationic ring-opening
polymerization (CROP) as a chain growth polymerization enables those requirements and, additionally,
allows the copolymerization with 2-oxazolines, which are generally known for their biocompatibility. In
this report, a Boc protected oxazolidine imine monomer is synthesized and polymerized in a homopoly-
merization, as well as in a copolymerization with 2-ethyl-2-oxazoline (EtOx) via CROP. The synthesized
polymers were analyzed regarding their chemical and physical properties, using NMR, GC, MALDI-MS,
SEC, TGA and DSC. Copolymerization kinetics revealed the formation of quasi-block copolymers, able to
self-assemble in aqueous solution as indicated by DLS.
Introduction
Poly(urea)s are commonly synthesized by polyaddition of di-
isocyanates and diamines, a method, which was first described
by Otto Bayer in 1947.1 Their major applications are in situ
formed foams,1 anti-fouling coatings,2 grease3 and anticorro-
sives.4 However, also biomedical applications such as siRNA
delivery are described.5–9
Modifications of the polymerization technique allow the
formation of nanocapsules by interfacial polyaddition in
inverse mini emulsion reactions9 or ring-opening polyaddi-
tion-condensations.10 One major advantage of these methods
is their insensitivity to moisture,1 however, the described reac-
tion times extend to several hours depending on their
functionalization,6,11,12 which can be significantly reduced to a
few minutes by using the microwave technique.13
Nevertheless, the step-growth polyaddition is not suited for
the synthesis of well-defined poly(urea)s with controlled
macromolecular architectures, molar mass as well as a head-
to-tail structure.
Living and controlled polymerization techniques like the
living anionic and cationic as well as controlled radical
polymerizations facilitate an improved control over the molar
masses and the use of functionalized monomers.14 The group
of Hedrick already described a method to synthesize well-
defined poly(carbonate)s via controlled ring-opening polymeriz-
ation instead of using polycondensation methods,15–17 leading
to materials which can be applied for biomedical applications.18
Moreover, the controlled cationic ring-opening polymerization
(CROP) of 1,3-oxazolidine-2-thione with methyl triflate was
already performed,19 yielding a sulfur analogue to poly(urea)s.
The focus of this report is the CROP of an oxazolidine-2-imine
and a possible copolymerization with 2-oxazolines to produce
poly(urea)s or copolymeric systems with poly(oxazoline)s (POx).
The polymerization of 2-oxazolines via CROP20 was first
described in the 1960s by four independent research
groups.21–24 The use of microwave technology allows a signifi-
†Electronic supplementary information (ESI) available: NMR, SEC, TGA, DSC,
HR-ESI-MS, ESI-MS, DLS and X-ray data, a detailed overview about all kinetic
studies. Crystallographic data (excluding structure factors) has been deposited
with the Cambridge Crystallographic Data Centre as supplementary publication.
CCDC 1477579 for 1b. For ESI and crystallographic data in CIF or other elec-
tronic format see DOI: 10.1039/c6py00785f
‡Current address: Department of Chemistry, University of Warwick, Gibbet Hill
Road, Coventry, CV4 7AL, UK.
aLaboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller
University Jena, Humboldtstraße 10, 07743 Jena, Germany.
E-mail: ulrich.schubert@uni-jena.de
bJena Center for Soft Matter (JCSM), Friedrich Schiller University Jena,
Philosophenweg 7, 07743 Jena, Germany
cInstitute of Inorganic and Analytical Chemistry, Friedrich Schiller University Jena,
Humboldtstraße 8, 07743 Jena, Germany
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cant reduction of the polymerization time by increasing the
reaction temperatures.25
By varying the initiator, moieties like alkyl chains26–29 or
unsaturated double and triple bonds30–32 can be introduced to
tune the solubility or to enable post-modification strategies of
the polymers. Furthermore, termination of the living chain
end using nucleophiles results in end-functionalized poly-
mers.33,34 The substituent in 2-position of the monomer can
be varied in order to alter the polymeric side group20 and
diﬀerent monomers can be combined to yield copolymeric
systems of various architectures.35
A further advantage of POx is their suitability as biomater-
ial, as derivatives with small substituents like 2-ethyl-2-oxazo-
line (EtOx) and 2-methyl-2-oxazoline (MeOx) are known to be
biocompatible and possess a stealth eﬀect similar to polyethyl-
ene glycol (PEG).36–39 In particular, EtOx is polymerizable with
a high degree of control40 and shows PEG-like characteristics
concerning biodistribution and excretion.41–43 During the last
years, polymers based on EtOx have been widely characterized
regarding toxicity and cellular uptake.37,39,44 Currently, the in
vivo behavior of POx is receiving an increasing attention45,46
due to their numerous previously described benefits in
vitro.47,48 The usage of POx in drug delivery systems by conju-
gation of low molar mass therapeutics49 and proteins50 are
promising for clinical studies. Additionally, the formation of
micelles as drug carriers,51 nanogels44 and surface coatings for
bio-analytics52 supports the increasing importance of POx.
The aim of this study is to combine the advantages of POx
and poly(urea)s by an easy CROP based copolymerization
process. The mechanism and kinetic behavior of the homo-
polymerization of a substituted oxazolidine imine, as well as the
copolymerization with EtOx are described. Homopolymers and
copolymers are characterized in detail regarding structure and
physical properties. Finally, the copolymer systems were investi-
gated in terms of reactivity ratios and their potential to form
nanostructures by hydrogen bond mediated self-assembly.
Results and discussion
Monomer synthesis
In order to synthesize a monomer, which can be polymerized
by CROP to yield a poly(urea) structure, the commercially avail-
able 2-amino-2-oxazoline hydrochloride was reacted with di-
tert-butyl dicarbonate (DiBoc) since the Boc protection group
is stable during CROP and can be removed under acidic con-
ditions.53 As the starting material is in a tautomeric equili-
brium, the molecule can react on two positions, at the endo-
and the exo-nitrogen (Fig. 1A).
It was already described in literature that the endo-nitrogen
of 2-amino-2-oxazoline, which is mainly present in solution,54
is more reactive as compared to the exo-nitrogen.55 The reacti-
vity was predicted by density functional theory (DFT) from the
molecule’s geometry derived by X-ray crystal analysis. Based on
the π-bond lengths, the electronegativity of the atoms could be
calculated (endo-nitrogen: −0.317, exo-nitrogen: −0.272),
explaining the diﬀerences in reactivity.
As a result, the monomer tert-butyl 2-iminooxazolidine-3-
carboxylate (1b, BocOI) can be synthesized from 2-amino-2-
oxazoline hydrochloride by reaction with DiBoc in the pres-
ence of triethyl amine (TEA). Since the tautomeric equilibrium
cannot be shifted completely to the 2-amino-2-oxazoline, the
crude product is a mixture of the two possible products tert-
butyl (4,5-dihydrooxazol-2-yl)carbamate (∼30%, 1a) and BocOI
(∼70%, 1b) (Fig. 1A) according to proton NMR experiments
(data not shown). The monomer was purified by recrystalliza-
tion and the structure was analyzed by 1H-NMR (Fig. S1A†),
13C-NMR (Fig. S1B†), Fourier transform infrared spectroscopy
(FTIR, Fig. S3†) and high-resolution electrospray ionization
mass spectrometry (HR-ESI-MS, Fig. S2†). HR-ESI-MS shows
the lability of the Boc protection group, as indicated by the
appearance of the dominant signal at m/z = 131.0 [M − Boc +
H+]. Information about the exact structure of the synthesized
monomer was obtained by X-ray structure analysis of a single
crystal (Fig. 1B, crystallographic data in Table S1†), proving the
identity of BocOI (1b).
Homopolymerization of BocOI (1b)
A kinetic study of the homopolymerization of BocOI (1b) was
performed by preparing a stock solution of BocOI (1b) and
methyl tosylate (MeTos) ([M]/[I] = 60) in dry dichloromethane
under a stream of argon and aliquoting the solution over
several microwave vials, which were heated in a microwave
synthesizer for various times. The conversion was determined
via gas chromatography (GC) by comparing the monomer con-
centration with the initial concentration in the stock solution.
Fig. 1 A: Schematic representation of the Boc protection of 2-amino-2-oxazoline hydrochloride using DiBoc resulting in two possible tautomeric
products (tert-butyl (4,5-dihydrooxazol-2-yl)carbamate (1a) and tert-butyl 2-iminooxazolidine-3-carboxylate (1b)), and B: Molecular structure of 1b
derived by X-ray crystal structure analysis; H-atoms are excluded.
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As the concentrations of BocOI (1b) and MeTos were equal in
all reaction vessels, dichloromethane could be used as an
internal standard. By plotting the natural logarithm of the
quotient of these amounts, the reaction constant (kp) could be
determined from the slope of the linear fit and the initial
initiator concentration (Fig. 2A).
Since the monomer should be copolymerized with EtOx,
140 °C was chosen as the reaction temperature being the
optimum for the synthesis of P(EtOx)s using the microwave
approach.25 However, at 140 °C the time dependence of kp is
not linear (Fig. S4A†). Possible explanations for this phenom-
enon might include the thermal deprotection of BocOI (1b), as
well as an increased reactivity of BocOI (1b), as compared to
EtOx. Hence, a reaction temperature of 100 °C was applied.
The time-dependent polymerization kinetics calculated by
the monomer conversion obtained from GC-analytics of BocOI
(1b) at 100 °C shows a nearly linear dependence of conversion
with time, however, side-reactions at higher molar masses are
still present as can be seen in the conversion dependent Mn
values and dispersities (Fig. 2B). The positive deviation of the
molar mass from linearity might be attributed to side reac-
tions, such as chain coupling at high conversions. Neverthe-
less, a pseudo-1st-order kinetics can be postulated for the
CROP of BocOI (1b, Fig. 2A), having a kp of 97.6 L mol
−1 s−1,
which is about 20 times higher than the kp of EtOx at this
temperature (kpEtOx = 4.6 L mol
−1 s−1, Fig. S6B†).
SEC measurements were performed to obtain information
about the increase in molar mass as well as the dispersity of
the resulting polymers (Fig. 2B and C), showing a linear
increase in molar mass and narrow dispersities below 1.3 and
mono-modal elution curves, indicating a living polymerization
at the given conditions. The increase in dispersity over time
could be explained on the same basis as the non-linearity of
the polymerization at 140 °C. The decrease in temperature,
however, lowers those unintended side-reactions.
NMR spectra of the purified polymer were collected to
obtain information about the polymeric structure (Fig. 3). In
the 1H-NMR spectrum, two signals for the backbone protons
are present at δ = 3.5 and 3.9 ppm, indicating diﬀerent substi-
tuted nitrogens in the polymer backbone as expected for
P(BocOI) (Scheme 1). Additionally, the peak at δ = 8.8 ppm is
typical for an amide group. Further information was obtained
from the 1H–1H-COSY-NMR spectrum, correlating protons on
neighboring carbon-atoms in the polymer. It is clearly visible
that the protons at δ = 3.5 and 3.9 ppm are coupling with each
other. Furthermore, the proton of the downfield shifted back-
bone signal couples with the amide group at δ = 8.8 ppm indi-
cating a poly(urea) like polymeric structure.
Since BocOI (1b) shows comparable structural character-
istics as 1,3-oxazolidine-2-thione,19 a plausible mechanism for
the CROP of this monomer can be postulated (Scheme 1). The
electrophilic methyl group of the initiator can be attacked by
the electron pair of the monomer’s imine functionality. This
results in a positively charged oxazolidinium ion as an inter-
mediate and a finally partial positively charged carbon atom in
5-position, that can be attacked by another imine group. This
leads to a ring-opening and the final poly(urea) like Boc pro-
tected backbone structure.
Fig. 2 Kinetic studies of BocOI ([M]/[I] = 60) in CH2Cl2 at 100 °C. A: Time-dependent polymerization kinetics calculated by the monomer conver-
sion obtained from GC-analytics. B: Molar mass and dispersity in dependence on the monomer conversion. C: SEC-traces (CHCl3-i-PrOH-TEA, PS-
cal.; 1st system peak after 12 min) of the reaction mixture after several polymerization times.
Fig. 3 1H–1H-COSY NMR spectrum (300 MHz, CDCl3) of P(BocOI)n.
Paper Polymer Chemistry
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The postulated mechanism of polymerization was further
analyzed by a polymerization of BocOI (1b) inside an NMR tube.
For practical reasons, deuterated chloroform was chosen as
solvent instead of dichloromethane. The reaction temperature
had to be lowered to 55 °C and was, therefore, slower than the
polymerization at 100 °C using the microwave. By comparing
the chemical shifts of the pure monomer with the reaction
mixture and the purified polymer (Fig. S7†), an assumption
about the active species can be made. The spectrum of the
monomer has two main triplets at δ = 3.86 and 4.22 ppm
belonging to BocOI (1b). In the reaction mixture, several new
signals appear. An individual integration was not possible due
to overlap of these signals, which are vanished after purification
of the polymer. However, the signals in this region match with
the chemical shift of protons of the active species during the
CROP of BocOI (1b) as predicted by increment analysis. The pro-
tonation of the exo-nitrogen leads to a shift of the protons next
to the endo-nitrogen (4-position). After methylation (B), a slight
high field shift (δ = 3.1 ppm) is also indicated by increment ana-
lysis. Furthermore, the electron rearrangement that leads to a
positively charged endo-nitrogen (C) and, therefore, to a stronger
shift to high fields (δ = 1.39 ppm) is observed. Additionally,
there are further signals between δ = 3.0 and 5.0 ppm matching
with the predicted intermediates. However, these signals cannot
be assigned certainly.
On the basis of the kinetic data, homopolymers of four
diﬀerent lengths (2a–d) were synthesized (2a–d). In order to
yield poly(urea)s, all purified homopolymers were deprotected
using TFA (3a–d, Scheme 2). The resulting poly(urea)s and the
Boc protected precursors were analyzed using 1H-NMR, SEC,
TGA and DSC (Table 1).
By 1H-NMR of the Boc protected homopolymers (Fig. S8†)
the degree of polymerization (DP) was determined directly
from the reaction mixture (data not shown) by comparing inte-
Scheme 1 Schematic representation of the postulated mechanism of the CROP of BocOI (1b) initiated with MeTos.
Scheme 2 Overview of the performed polymerization and deprotection reactions, showing the homopolymers P(BocOI)n (B)and P(OI)n (C) as well
as the copolymers P(BocOIn-co-EtOxm) (D) and P(OIn-co-EtOxm) (E) obtained by CROP of BocOI (1b, A) initiated with MeTos.
Table 1 Characterization data for P(BocOI)n
Polymer Composition [M]/[I] BocOI conversion [%] DP Mn
a [g mol−1] Mn
b [g mol−1] Đb Tg
c [°C] Td
d [°C]
2a P(BocOI)19 25 91.9 19
a 3500 3800 1.18 69.6 154.3
2b P(BocOI)54 50 86.9 55
a 10 300 4300 1.22 66.2 164.5
2c P(BocOI)73 75 85.0 73
a 13 600 4400 1.31 68.9 167.6
2d P(BocOI)112 100 87.2 112
a 20 900 4200 1.20 97.9 170.2
3a P(OI)19 n.a. n.a. 19 1600 n.d. n.d. 0.8 175.1
3b P(OI)54 n.a. n.a. 55 4700 n.d. n.d. — 218.2
3c P(OI)73 n.a. n.a. 73 6300 n.d. n.d. 7.6 136.3
3d P(OI)112 n.a. n.a. 112 9600 n.d. n.d. 2.4 179.5
a 1H-NMR (300 MHz) in CDCl3.
b SEC (PS-calibration) in CHCl3-i-PrOH-TEA.
cDSC. d TGA; n.d.: not determinable due to insolubility; n.a. not
applicable. DP and Mn of 3a–d were calculated from
1H-NMR results of 2a–d.
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grals of the aromatic protons of the MeTos initiator (δ = 7.15
and 7.67 ppm) with one of the polymer backbone peaks (δ =
3.5 ppm). As a consequence, DP values of 19, 54, 73 and 112
could be obtained, respectively. A polymerization at [M]/[I] =
300 was attempted, however resulted in increased dipseristies,
which is a result of the longer reaction times required leading
to more side reactions (ESI Fig. S31†) According to the 1H-NMR
investigations, the monomer consumption was between 85
and 90% (Table 1). Therefore, the positive deviation of the
obtained DP from the aimed [M]/[I] can most probably be
explained by inaccuracies while weighting the solid monomer.
Additionally, 13C-NMR spectra of all Boc protected homopoly-
mers were recorded (Fig. S10†). These spectra provide qualita-
tive information about the polymeric structure. At δ =
28.0 ppm, the peak of the Boc protection group is visible.
Moreover, the methyl group of the initiator results in a peak at
δ = 30.9 ppm. The two diﬀerent methylene carbons of the poly-
meric backbone split into two peaks at δ = 39.9 and 43.3 ppm.
At δ = 126.0 and 128.6 ppm, the carbonyl carbons can be
identified. Furthermore, SEC measurements of the Boc pro-
tected polymers (Fig. S13†) were performed to gain infor-
mation about their dispersity, revealing narrow values
(Table 1). The molar mass does not vary markedly with respect
to the DP, which might be due to column interactions.
Although it is not obvious from the kinetic studies (Fig. 2), the
maximum molar mass for kinetic samples was Mn = 2700 g
mol−1 and, therefore, is significantly lower than the length of
the herein synthesized homopolymers. Additionally, an
ESI-MS spectrum (Fig. S14†) of P(BocOI)19 (2a) was recorded to
verify the mass of the repeating unit. The spectrum shows
specific peaks for P(BocOI) as well as partially and fully de-
protected poly(urea).
FTIR measurements provided further information about
the Boc protected (Fig. S11†) and deprotected (Fig. S12†)
homopolymers. The spectra of the protected polymers show
specific bands at λ = 1533 and 3336 cm−1, representing the NH
oscillations of the polymers. At λ = 2937 to 3009 cm−1, the CH2
vibrations of the polymeric backbone are visible as three
diﬀerent peaks. Furthermore, the Boc protection group shows
oscillations at λ = 754, 852 and 1371 cm−1, respectively. Carbo-
nyl vibrations in the FTIR spectrum are visible at λ = 1157,
1231, 1681 and 1719 cm−1, respectively.
The spectra of the deprotected polymers lack specific bands
at λ = 1371 and 852 cm−1 verifying the deprotection. Further-
more, the carbonyl band at λ = 1719 cm−1 shift to a lower value
around λ = 1681 cm−1, overlapping with the previous amide
band, after deprotection.
1H-NMR measurements of the deprotected homopolymers
were performed in deuterated hydrochloric acid and verified
the success of the deprotection by disappearance of the Boc
peak in the spectrum (Fig. S9†) while keeping the backbone
signals at δ = 3.4 to 3.8 ppm. The peaks at high ppm values
(δ = 7.15 and 7.67 ppm) could be attributed to a degradation of
the polymer in the presence of high DCl concentrations. SEC
and MS measurements of deprotected polymers could not be
performed due to the insolubility in the available solvents.
To elucidate the thermal properties of the polymers, TGA
and DSC measurements were performed. The TGA results
revealed a Td of 150 to 170 °C for the protected homopolymers
(2a–d) that increases slightly with the polymer length
(Table 1). Since this temperature does not change significantly
with the polymer length and the graph (Fig. S26A†) only shows
a partial decomposition (∼50%), a thermal deprotection of the
polymers can be assumed. Issues regarding this phenomenon
have already been reported56 and might also be the trigger of
the lack in controllability while polymerizing BocOI at 140 °C.
After this first mass loss, all polymers show a comparable
decomposition behavior with a second Td around 200 °C. Like-
wise, this is roughly the Td of the deprotected polymers (3a–d)
(Fig. S27A†), verifying the hypothesis of a thermal de-
protection. The lack of a clear trend of the Td of 3a–d might be
caused by intra- and intermolecular stabilization of the poly-
mers due to hydrogen-bond formation during the heating
process, which is also explaining the higher degradation temp-
eratures of the polymers.
According to the DSC measurements (Fig. S28A†), the Boc
protected homopolymers (2a–d) show a Tg between 65 and
70 °C, except polymer 2d which shows a significantly increased
Tg of 98 °C (Table 1). The reason for this sudden increase in Tg
is not understood jet. The deprotected homopolymers (3a–d)
have a glass-transition temperature between 0 and 10 °C
(Fig. S29A†), again showing no dependency of the chain length
of the polymers. This sharp decrease in the Tg is caused by
intra- and intermolecular interactions of the urea structure.
Copolymerization of BocOI and EtOx
After the successful homopolymerization of BocOI (1b) via
CROP, the copolymerization with EtOx was investigated. The
formation of gradient or quasi-block structured polymers was
assumed to be likely due to the high diﬀerence in the reaction
constants between the two monomers based on the homopoly-
merization kinetics. To confirm this assumption, the reactivity
ratios were assessed by determination of velocity constants of
both monomers while copolymerizing at diﬀerent monomer
ratios. The general reaction conditions were kept equal to the
homopolymerization. Four stock solutions bearing diﬀerent
monomer ratios were prepared under a stream of argon, divided
over several reaction vessels and heated to 100 °C in a microwave
synthesizer for predetermined times. After the reaction times,
the kp values for both monomers were calculated from the linear
fit of the monomer conversion determined by GC measurements
(Fig. 4). BocOI shows slight deviation from ideal linear behavior,
which could be assigned to interactions with EtOx, as linearity
increases at higher BocOI contents. The resulting averaged con-
stant for BocOI (kp = 58.0 ± 5.6 L mol
−1 s−1) is about ten times
higher than for EtOx (kp = 5.2 ± 1.4 L mol
−1 s−1).
The formation of gradient copolymers from 2-oxazoline
monomers having diﬀerent kp values is described in literature
for several monomer pairs like 2-nonyl-2-oxazoline and
2-phenyl-2-oxazoline (PhOx),51 as well as MeOx and 2-(3-
butenyl)-2-oxazoline.57,58 However, it should be pointed out
that the diﬀerence between EtOx and BocOI is significantly
Paper Polymer Chemistry
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larger, leading to the assumption of a quasi-block polymeric
structure. Using the data from the kinetic studies, the reactivity
ratios (r) were calculated by non-linear least square fitting
(Fig. 5A).59 For these calculations, the kinetic plots were used
to determine the ratio of consumed monomers at 30% of con-
version of the faster monomer (BocOI, 1b) to ensure that
monomer feed ratios are unaﬀected by the polymerization,
excluding a falsification of the calculation by changing
monomer ratios at high conversions. Subsequently, the conver-
sion of EtOx as the less reactive monomer is calculated at this
time. By plotting the incorporated EtOx fraction (F1) against
the theoretical EtOx fraction in the monomer feed ( f1), a non-
linear dependence is obtained. The reactivity ratios were calcu-
lated using eqn (3) as adapted from literature,60 excluding
negative values. A similar behavior was already reported by
Hoogenboom et al.61 and Kagiya et al.62 for MeOx and PhOx,
respectively.
The calculations resulted in rBocOI = 28.72 ± 10.07 ≫ 1 ≫
rEtOx = 0.000 ± 0.002. The very large diﬀerence between the two
monomers as well as the fact that the reactivity ratio of EtOx is
close to zero, while BocOI monomers are present in the reac-
tion mixture, leads to the conclusion of a very narrow gradient
area in the polymer chain. To illustrate this fact, the monomer
distribution over the polymer chain (Fig. 5B) was calculated
based on the kinetic plots (Fig. 4). Symbols represent the
actual values of the EtOx fraction in the polymer chain. These
values were fitted by a non-linear Boltzmann fitting (lines) to
obtain information about the monomer distribution in the
polymer from initiation to termination, showing that most
BocOI (1b) is polymerized prior to the EtOx incorporation.
Based on the information obtained by the kinetic data, a
series of copolymers with diﬀerent monomer ratios was syn-
thesized and deprotected with TFA. Polymerizations were
carried out under microwave irradiation at 100 °C under argon
atmosphere. Aiming for a DP of 100, polymers with 20%, 40%,
60% and 80% BocOI (1b) content were synthesized. The
analytical details for all copolymers can be found in Table 2.
The DP was determined by 1H-NMR directly from the reaction
Fig. 4 Time-dependent polymerization kinetics calculated by the monomer conversion obtained from GC-analytics for BocOI (1b) and EtOx at four
monomer compositions, namely 20, 40, 60 and 80 mol% BocOI (1b), performed in dichloromethane at 100 °C with [M]/[I] = 100 and methyl tosylate
as initiator.
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mixture (data not shown), comparing the aromatic protons of
the MeTos initiator (δ = 7.15 and 7.67 ppm) with the backbone
protons of BocOI (δ = 3.5 and 3.9 ppm) and EtOx (δ =
3.44 ppm). It should be noted that the polymer peaks overlap
with the oxazolidine monomer peaks of BocOI (δ = 3.88 and
4.31 ppm) and, therefore, the isolated monomer integral at δ =
4.31 ppm needs to be subtracted from the calculated backbone
integral to obtain the value of the averaged DP. The monomer
composition was calculated from 1H-NMR of the purified pro-
tected polymers (Fig. S20†) by determination of the BocOI (1b)
content using the Boc-peak at δ = 1.48 ppm. Moreover,
13C NMR spectra of all Boc protected copolymers (Fig. S21†)
were recorded to gain information about the polymeric struc-
ture. These spectra showed additional signals compared to the
13C NMR spectra of the homopolymers. The peaks at δ = 9.3
and 26.0 ppm can be allocated to EtOx. Additionally, the back-
bone signals at δ = 39.9 to 47.1 ppm further split, reflecting
the two diﬀerent backbone types of the urea and the 2-oxazo-
line part of the polymer.
In addition, FTIR spectra of all Boc protected (Fig. S24†)
and deprotected (Fig. S25†) copolymers were recorded. The
main diﬀerence to the spectra of the homopolymers is shown
in a band at λ = 3422 cm−1, which is, compared to the homo-
polymers, much broader. This is caused by the presence of
EtOx in the copolymers. Furthermore, the carbonyl peak at λ =
1620 cm−1, specific for EtOx, varies within the polymer compo-
sition. With an increasing BocOI amount, a slight shift to λ =
1650 cm−1, characteristic for the urea, can be observed. More-
over, the amide band at λ = 1480 cm−1 specific for EtOx, while
a band at λ = 1460 cm−1 is characteristic for the urea
derivative.
Furthermore, 1H-NMR spectra of all deprotected copoly-
mers and P(EtOx)116 (Fig. S22†) were recorded to gain further
information about the success of the deprotection. The spectra
do not show a signal of the Boc protection group, verifying the
deprotection of the polymers. Additionally, the spectra provide
information about the stability of the polymer backbone
against acidic degradation. After deprotection, two diﬀerent
backbone signals are visible in the 1H-NMR spectrum.
Between δ = 3.09 and 4.32 ppm, diﬀerent overlapping peaks
represent the polymer backbone protons of the EtOx and the
OI part.
Fig. 5 A: Relation between the fraction of EtOx in the monomer feed ( f1) and the incorporated fraction of EtOx in the copolymerization (F1) deter-
mined via GC-measurements at ∼30% BocOI (1b) conversion (ln(M0/Mt) = 0.36). B: Monomer distribution calculated from the kinetic plot of the
copolymerization (Fig. 4). Symbols show the experimental values, the lines show the non-linear Boltzmann ﬁtting of the values.
Table 2 Characterization data for P(BocOIn-co-EtOxm)
Polymer Composition [M]/[I] DP Mn
a [g mol−1] Mn
b [g mol−1] Đb BocOI [%] Tg
d [°C] Td
e [°C]
4a P(BocOI16-co-EtOx84) 100 95
a 11300 6100 1.27 16a 53.2 89.2
4b P(BocOI36-co-EtOx64) 100 96
a 13 000 5300 1.36 36a 51.5 155.6
4c P(BocOI52-co-EtOx48) 100 100
a 14 400 5900 1.34 52a 56.7 120.0
4d P(BocOI84-co-EtOx16) 100 100
a 17 200 7400 1.26 84a 54.2 168.7
5a P(OI16-co-EtOx84) n.a. 95 9700 n.d. n.d. 18
c 65.8 203.3
5b P(OI36-co-EtOx64) n.a. 96 9400 n.d. n.d. 27
c 10.6 136.1
5c P(OI52-co-EtOx48) n.a. 100 9200 n.d. n.d. 47
c 5.9 137.3
5d P(OI84-co-EtOx16) n.a. 100 8800 n.d. n.d. 76
c
−4.9 168.1
6 P(EtOx)116 100 116
a 11 500a 6800b 1.16b 0a 62.7 353.8
a 1H-NMR (300 MHz) in CDCl3.
b SEC (PS-calibration) in CHCl3-i-PrOH-TEA.
c 1H-NMR (300 MHz) in 35% DCl in D2O, CDCl3-standard.
dDSC.
e TGA. n.d.: not determinable due to insolubility. n.a.: not applicable. DP and Mn of 5a–d were calculated from
1H-NMR results of 4a–d.
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The molar masses, as determined by SEC (Fig. S23†) are
almost constant for all protected polymers, whereas the diﬀer-
ences might originate from changes in monomer compo-
sitions and the associated diﬀerences in molar mass as well as
interactions of the column material with P(BocOI). SEC investi-
gations of the deprotected P(OI) copolymers were not possible
since the polymers assembled in the SEC eluent.
TGA and DSC measurements of all copolymers and
P(EtOx)116 (6) were performed to obtain information about the
thermal properties. TGA analysis of the protected copolymers
(4a–d) shows varying Td values, however, no apparent relation
between the BocOI (1b) amount and the temperature can be
observed. Nevertheless, all Boc protected copolymers reveal the
same sharp decrease in mass as the homopolymers below
200 °C, caused by thermal deprotection. Further decompo-
sition follows the behavior of P(BocOI) and P(EtOx)
(Fig. S26B†). The deprotected copolymers (5a–d) show a
similar degradation behavior as the homopolymers
(Fig. S27B†). The low Td observed for protected polymers is
attributed to thermal deprotection, which is not possible for
deprotected polymers. It should be noted that Td is defined as
the temperature at which 5% of mass loss is observed and
does not necessarily mean a full decomposition. According to
the OI amount in the polymers, no obvious trend is observed.
However, the Td of copolymers (100 to 200 °C) is in the same
range as observed for the homopolymers.
The Boc protected copolymers (4a–d) reveal a Tg around 50
to 55 °C (Fig. S28B†), independent on the monomer ratio, as
determined by DSC measurements.
After deprotection, a significant influence of the polymer
composition on the Tg values is visible, caused most probably
by intermolecular interactions of the macromolecules.
P(BocOI) precursors (2a–d) as well as P(EtOx)116 (6) possess Tg
values around 60 °C, resulting in an overall Tg between 50 and
55 °C. Until now, we do not have an explanation for this
decrease in Tg of the copolymers compared to the homopoly-
mers. The deprotected macromolecules (5a–d), however, show
a distinct decrease in the Tg with increasing OI amount
(Fig. S29B†). As the Tg of the P(OI) homopolymers is signifi-
cantly lower than the Tg of P(EtOx)116, this could as well be the
result of a homogenious mixture of both blocks in bulk. Pre-
vious investigations on POx also described a decrease in Tg
associated with the decreasing length of the EtOx block.63
Self-assembly
The results of the copolymerization studies from BocOI and
EtOx show the formation of quasi-block copolymers with
narrow dispersity. As the P(OI) homopolymers are not water
soluble, block-like copolymers of P(OI) and P(EtOx) are
expected to self-assemble or aggregate in aqueous solution. To
evaluate the formation of such hydrogen bond stabilized64,65
nano-assemblies, the polymers were dissolved in TFA, which is
known to break hydrogen bonds, and MilliQ water was added
slowly under stirring to induce phase segregation. The resul-
ting solution was dialyzed to remove the acid and to obtain
nanostructures in solution. Larger aggregates were removed by
syringe filtration (0.45 μm) and the size distribution was deter-
mined by DLS measurements (Table 3, Fig. S30†).
P(EtOx)116 (6) and copolymers with a low OI content (∼20 to
30%, 5a,b) have a z-average around 4 nm in diameter, indica-
ting unimers or small aggregates. In contrast, copolymers with
a high OI amount (5c,d) form nanostructures in aqueous solu-
tion, having diameters of 55.3 ± 13.4 and 107.7 ± 53.4 with
increasing co-monomer content. Furthermore, the zeta poten-
tial of the aggregates was investigated. As shown in Table 3,
P(EtOx)116 (6) shows a slightly negative zeta potential. The
copolymers, on the other hand, show a positive zeta potential,
which could be attributed to a partial degradation of PEtOx
resulting in a minor amount of poly(ethylene imine) units in
the PEtOx segment, caused by the acidic conditions of de-
Table 3 Characterization of the formed nanostructures after precipitation of the copolymers in MilliQ water by DLS
Polymer Composition Concentrationa [mg mL−1] Sizeb [d, nm] ζ [mV]
5a P(OI16-co-EtOx84) 1 4.7 ± 0.1 18.6 ± 15.7
5b P(OI36-co-EtOx64) 1 5.1 ± 0.6 8.2 ± 0.5
5c P(OI52-co-EtOx48) 1 55.3 ± 13.4 9.1 ± 3.3
5d P(OI84-co-EtOx16) 0.1 107.7 ± 53.4 1.3 ± 1.8
6 P(EtOx)116 10 4.3 ± 0.7 −5.0 ± 0.4
aDetermined after freeze-drying of the dialyzed solutions. bNumber PSD.
Scheme 3 Schematic representation of the possible macrostructures derived from P(OIn-co-EtOxm) bearing diﬀerent co-monomer ratios in water.
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protection and a self assembly process (the P(EtOx) homopoly-
mer was not treated with TFA prior to DLS measurements).
Due to the low solubility of the polymers and the resulting low
resolution of the 1H NMR spectra it was not possible to prove
this hypothesis.
It should be noted that the results on the self-assembly be-
havior are preliminary and the optimization of copolymer com-
position regarding aggregation and possibly micelle
formation, as well as the investigation on the self-assembling
process and the resulting nanostructures will be the subject of
subsequent studies (Scheme 3).
Conclusion
A Boc protected oxazolidine imine was synthesized, polymer-
ized via CROP and deprotected to form poly(urea)s with a low
dispersity. Homopolymers of diﬀerent lengths were syn-
thesized and characterized via NMR, SEC, MALDI-MS, TGA
and DSC. A copolymerization kinetic with EtOx was performed
and the resulting reactivity ratios of the two monomers
suggest the formation of quasi-block copolymers. Copolymers
with diﬀerent monomer ratios were synthesized and character-
ized regarding their composition and thermal properties. Self-
assembly of those polymers in aqueous solution resulted in
nano-assemblies as detected by DLS measurements. These
structures are believed to be a result of hydrogen bond for-
mation between the P(OI) segments. The presented copolymer
system oﬀers an easy access to quasi-block systems with the
potential to self-assemble in solution.
Further research will focus on the self-assembly process
and the nature of the resulting nano-structures, as well as the
assessment of their suitability for biomedical applications.
Experimental part
Material and instrumentation
All chemicals were purchased from Sigma-Aldrich, Merck, TCI
and Synthon-Chemicals. Triethylamine (TEA), 2-ethyl-2-oxazo-
line (EtOx) and methyl tosylate (MeTos) were distilled to
dryness under argon atmosphere prior to usage. Dichloro-
methane was obtained from a solvent purification system
(MB-SPS-800 by MBraun) and stored under argon.
Polymerization reactions were performed under microwave
irradiation, using an Initiator Sixty single-mode microwave
synthesizer from Biotage, equipped with a noninvasive IR
sensor (accuracy: 2%). Microwave vials were heated overnight
at 100 °C under vacuum and allowed to cool to RT under
argon before usage. Polymerizations were performed using
temperature control.
Size-exclusion chromatography (SEC) of the protected
homo- and copolymers was performed on a Shimadzu system
equipped with a SCL-10A system controller, a LC-10AD pump,
a RID-10A refractive index detector and a PSS SDV column
with chloroform-TEA-2-propanol (94 : 4 : 2) as eluent. The
column oven was set to 50 °C and a polystyrene (PS) standard
was used for calibration.
Proton NMR spectroscopy (1H-NMR) was performed at RT
using a Bruker Avance I 300 MHz spectrometer, utilizing either
CDCl3 or 35% DCl in D2O as solvent. The chemical shifts are
given in ppm relative to the signal from the residual non-
deuterated chloroform. Measurements in DCl were performed
with an additional CDCl3 standard.
1H–1H-COSY NMR and 1H-NMR experiments of the
polymerization inside the NMR tube were performed at RT or
55 °C on a Bruker Avance II 400 MHz, using CDCl3 as solvent.
IR spectra were recorded using an Aﬃnity-1 FT-IR from Shi-
madzu, utilizing the reflection technique.
High resolution electrospray ionization (HR-ESI) mass spec-
trometry (MS) was performed on a micrOTOF Q-II (Bruker Dal-
tonics) mass spectrometer equipped with an automatic syringe
pump from KD Scientific for sample injection at 4.5 kV at a
desolvation temperature of 180 C. The mass spectrometer was
operating in the positive ion mode.
Batch dynamic light scattering (DLS) was performed on a
Zetasizer Nano ZS (Malvern Instruments, Herrenberg,
Germany). All measurements were performed in folded capil-
lary cells (DTS1071, Malvern Instruments, Herrenberg,
Germany). After an equilibration time of 180 s, 3 × 30 s runs
were carried out at 25 °C (λ = 633 nm). Scattered light was
detected at an angle of 173°. Each measurement was per-
formed in triplicates. Apparent hydrodynamic radii, Rh, were
calculated according to the Stokes–Einstein equation.
Diﬀerential scanning calorimetry (DSC) experiments were
performed on a Netzsch DSC 204 F1 Phoenix under a nitrogen
atmosphere with a heating rate of 20 K min−1 from −20 to
140 °C, if not indicated diﬀerently. Three cycles were recorded
for each sample. The glass transition temperature (Tg) values
are reported for the second heating run. Thermo-gravimetric
analysis (TGA) was performed under a nitrogen atmosphere on
a Netzsch TG 209 F1 Iris in the range from room temperature
to 800 °C with a heating rate of 10 K min−1.
For crystal structure determination, the intensity data were
collected on a Nonius KappaCCD diﬀractometer, using graph-
ite-monochromated Mo-Kα radiation. Data were corrected for
Lorentz and polarization eﬀects; absorption was taken into
account on a semi-empirical basis using multiple-scans.66–68
The structure was solved by direct methods (SHELXS69) and
refined by full-matrix least squares techniques against Fo
2
(SHELXL-97 69). All hydrogen atoms were located by diﬀerence
Fourier synthesis and refined isotropically. All non-hydrogen
atoms were refined anisotropically. MERCURY70 was used for
structure representations.
tert-Butyl 2-iminooxazolidine-3-carboxylate (BocOI) (1b)
2-Amino-2-oxazoline hydrochloride (20 g, 163 mmol) was dis-
solved in a mixture of 1,4-dioxane (300 mL) and aqueous
sodium hydroxide (3 wt%, 300 mL). Dry TEA (16.5 g,
163 mmol) was added to this mixture to remove hydrochloric
acid. DiBoc, (35 g, 163 mmol) was dissolved in 1,4-dioxane
(150 mL) and added dropwise to the solution of 2-amino-2-oxa-
Paper Polymer Chemistry
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zoline The reaction mixture was stirred at RT for 24 h and, sub-
sequently, extracted with dichloromethane (3 × 200 mL). The
organic phase was dried over sodium sulfate before evapor-
ation of the solvent under reduced pressure. The crude
product was further purified via recrystallization from cyclo-
hexanes to give the final product as a white crystalline solid
(24.0 g, 87.2%).
1H-NMR (CDCl3, 300 MHz): δ = 7.38 (1H, s, NH), 4.23 (2H, t,
CH2-oxazolidine), 3.86 (2H, t, CH2-oxazolidine), 1.51 (9H, s,
CH3) ppm.
13C-NMR (CDCl3, 300 MHz): δ = 154.89 (O–CNH–N), 151.37
(N–CO–O), 83.57 (O–C–(CH3)3), 62.21 (CH2-oxazolidine), 44.39
(CH2-oxazolidine), 28.06 (CH3) ppm.
HR-ESI: m/z calc. for C8H14N2O3H [M + H]: 187.1007, found:
187.1081 (error: 1.9 ppm).
FTIR: λ [cm−1] = 3422 (w, carbonyl), 3336 (m, NH), 2939 (s,
CH2 CH3), 1620, 1570 (s, amide), 1165 (m, CH3).
Crystal data for 1b. C8H14N2O3, Mr = 186.21 g mol
−1, colour-
less prism, size 0.098 × 0.088 × 0.068 mm3, monoclinic, space
group P21/n, a = 9.7713(7), b = 9.5154(7), c = 11.5372(9) Å, β =
113.738(4)°, V = 981.95(13) Å3, T = −140 °C, Z = 4, ρcalcd =
1.260 g cm−3, µ (Mo-Kα) = 0.97 cm
−1, multi-scan, transmin:
0.6395, transmax: 0.7456, F(000) = 400, 6408 reflections in
h(−12/12), k(−11/11), l(−14/14), measured in the range 2.32° ≤
Θ ≤ 26.37°, completeness Θmax = 99.9%, 2004 independent
reflections, Rint = 0.0448, 1736 reflections with Fo > 4σ(Fo), 174
parameters, 0 restraints, R1obs = 0.0682, wR
2
obs = 0.1284, R1all =
0.0802, wR2all = 0.1320, GOOF = 1.307, largest diﬀerence peak
and hole: 0.237/−0.213 e Å−3.
Kinetic studies
For kinetic investigations a stock solution of BocOI, (and EtOx
for copolymerizations), MeTos and CH2Cl2 ([M] = 1 mol
−1,
[M]/[I] = 60) was prepared, aliquoted into microwave vials
(1 mL per vial) and heated in a microwave synthesizer (100 °C,
varying reaction times). After polymerization, the conversions
of the monomers were determined using GC using the solvent
as an internal standard. The reaction rate constants kp of the
monomers were determined using eqn (1) and (2) assuming
that the slope of the linear fit of ln([M]0/[M]t) = f (t ) complies
with keﬀ.
ln M0  ln Mt ¼ keff t ð1Þ
keff ¼ kp½I ð2Þ
Reactivity ratios of both monomers were calculated for four
diﬀerent monomer ratios at 30% BocOI conversion (deter-
mined by GC) using non-linear least square fitting60 (eqn (3)):
F1 ¼
ðr1  1Þf12 þ f1
ðr1 þ r2  2Þf12 þ 2ð1 r2Þf1þr2
; r1  0 ð3Þ
F1 = instantaneous mole fraction; f1 = mole fraction of
monomer EtOx; f2 = mole fraction of monomer BocOI; r1 =
reactivity ratio of EtOx; r2 = reactivity ratio of BocOI.
Homopolymerization inside an NMR tube
In an NMR tube BocOI (112 mg, 0.6 mmol), MeTos (0.8 µL,
0.024 mmol) and CDCl3 (550 µL) were mixed under inert con-
ditions and the reaction mixture was heated to 55 °C for a pre-
determined time. 1H-NMR spectra at RT were recorded at
specific points of time to determine the reactive species
during polymerization.
Homopolymerization of BocOI (2a–d)
The experimental procedure for homopolymerizations is exem-
plarily described on polymers with [M]/[I] = 25 (2a).
In a microwave vial BocOI (2793 mg, 15.0 mmol), MeTos
(19.8 µL, 0.6 mmol) and dichloromethane (14.9 mL) were
mixed under inert conditions and the reaction mixture was
heated to 100 °C for a predetermined time. The resulting solu-
tion was purified via BioBeads SX-1 column using CH2Cl2 as
eluent. After combining the polymer fractions, the solvent was
evaporated under reduced pressure to obtain the product as a
white crystalline solid.
1H-NMR (CDCl3, 300 MHz): δ = 8.70 (0.8H, s, NH-back-
bone), 3.87 (2H, m, backbone), 3.41 (2H, m, backbone), 2.80
(0.06H, d, CH3), 1.46 (9H, m, CH3) ppm.
SEC (eluent: CHCl3-i-propanol-TEA, PS-standard): Mn =
3700 g mol−1, Mw = 4700 g mol
−1, Đ = 1.18.
FTIR: λ [cm−1] = 3336 (m, NH (backbone)), 3009, 2978, 2937
(s, CH2 (backbone), CH3 (Boc)). 1719, 1681 (s, carbonyl), 1533
(s, NH (backbone)), 1371 (s, CH3 (Boc)), 1231 (s, carbonyl),
1157 (s, carbonyl), 852 (m, CH3 (Boc)), 754 (m, CH2
(backbone)).
Deprotection of P(BocOI) (3a–d)
The experimental procedure for deprotection is exemplarily
described for the polymers with a [M]/[I] = 25 (3a).
10 mL of TFA were added to the polymer and the solution
was stirred at RT overnight. Subsequently, the reaction mixture
was diluted with methanol and precipitated from ice-cold
diethyl ether (300 mL). The polymer was filtered oﬀ and dried
in a high vacuum to obtain the product as a white crystalline
solid.
FTIR: λ [cm−1] = 3333 (s, NH (backbone)), 2939 (s, CH2
(backbone)), 1620, 1570 (s, amide (backbone)), 1446 (CH2
(backbone)), 1141 (s, carbonyl).
Copolymerization of BocOI and EtOx (4a–d)
The experimental procedure for copolymerizations is exempla-
rily described for the polymers with a [M]/[I] = 100 aiming a
BocOI amount of 20% (4a).
In a microwave vial BocOI (745 mg, 4.0 mmol), EtOx
(1586 µL, 16.0 mmol), MeTos (30.3 µL, 0.2 mmol) and di-
chloromethane (8.35 mL) were mixed under inert conditions
and the reaction mixture was heated to 100 °C for 15 h. The
resulting solution was purified by precipitation into ice cold
diethyl ether. The white solid was filtered oﬀ and re-dissolved
in CH2Cl2 and the solvent was evaporated under reduced
pressure to obtain the product as a white crystalline solid.
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1H-NMR (CDCl3, 300 MHz): δ = 8.73 (0.1H, s, NH-back-
bone), 3.90 (0.3H, m, backbone), 3.45 (3.6H, s, backbone), 2.40
(1.7H, s, CH2 (EtOx)), 1.51 (1.3H, d, CH3 (BocOI)), 1.12 (2.5H,
s, CH3 (EtOx)) ppm.
SEC (eluent: CHCl3-i-propanol-TEA, PS-standard): Mn =
6100 g mol−1, Mw = 7700 g mol
−1, Đ = 1.27.
FTIR: λ [cm−1] = 3422 (w, carbonyl), 3336 (m, NH (back-
bone)), 2939 (s, CH2 (backbone), CH3 (Boc)), 1720 (s, carbonyl),
1632 (m, amide), 1431 (m, CH3 (Boc), CH2 (backbone)), 1373
(m, CH3 (Boc)), 1141 (s, carbonyl), 754 (m, CH2 (backbone)).
Deprotection of P(BocOI-co-EtOx) (5a–d)
The experimental procedure for deprotection is exemplarily
described for the polymers with a [M]/[I] = 100 aiming a BocOI
amount of 20% (5a).
10 mL of TFA were added to P(BocOI-co-EtOx) and stirred at
RT overnight. Subsequently, the solution was diluted with
methanol and purified by precipitation into ice cold diethyl
ether (300 mL). The white solid was filtered oﬀ and dried in a
high vacuum to obtain the product as a white crystalline solid.
1H-NMR (35% DCl in D2O, CDCl3-standard, 300 MHz):
3.09–4.32 (4H, m, backbone), 2.63 (1.7H, s, CH2 (EtOx)), 1.11
(2.4H, s, CH3 (EtOx)) ppm.
FTIR: λ [cm−1] = 3422 (w, carbonyl), 3336 (m, NH (back-
bone)), 2939 (s, CH2 (backbone), CH3 (Boc)), 1616 (s, amide
(BocOI)), 1580, 1562 (s, amide (EtOx)), 1138 (m, CH2, CH3
(EtOx)). 813 (m, CH2, CH3 (EtOx), CH3 (EtOx)).
Homopolymerization of EtOx (6)
In a microwave vial, EtOx (8076 µL, 80.0 mmol), MeTos
(121.1 µL, 0.8 mmol) and acetonitrile (11.8 mL) were mixed
under inert condition and the reaction mixture was heated to
140 °C for a predetermined time and subsequently quenched
by the addition of 500 µL of deionized H2O. The resulting solu-
tion was purified via precipitation into ice cold diethyl ether.
The polymer was filtered oﬀ and re-dissolved in CH2Cl2 and
the solvent was evaporated under reduced pressure to obtain
the product as a white crystalline solid.
1H-NMR (CDCl3, 300 MHz): δ = 4.34 (0.1H, s, backbone-
OH), 3.44 (4.0H, s, backbone), 3.02 (0.3H, s, CH3-backbone),
2.4 (1.7H, m, CH2 (EtOx)), 1.11 (2.5H, s, CH3 (EtOx)) ppm.
1H-NMR (35% DCl in D2O, CDCl3-standard, 400 MHz): 4.08
(4H, s, backbone), 2.55 (2.4H, d, CH2 (EtOx)),1.10 (2.8H, s, CH3
(EtOx)) ppm.
SEC (eluent: CHCl3-i-propanol-TEA, PS-standard): Mn =
6800 g mol−1, Mw = 7900 g mol
−1, Đ = 1.16.
FTIR: λ [cm−1] = 3422 (w, carbonyl), 2939 (s, CH2, CH3),
1620, 1570 (s, amide (backbone)), 1427 (s, CH2, CH3), 1160
(m, CH2, CH3).
Self-assembly of P(OI-co-EtOx)
30 mg of deprotected copolymer (5a–d) were dissolved in TFA
(600 µL). 3.0 mL of MilliQ water were added via syringe pump
(10 mL h−1) while stirring (1400 rpm). Directly after the
addition, the solution was dialyzed against deionized H2O
(MWCO 3500 g mol−1) for 72 h. The final concentration of the
solution was provided by lyophilization and determined as
1 mg mL−1 for 5a–c, 0.1 mg mL for 5d and 10 mg mL−1.
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Mission ImPOxable – or the unknown utilization
of non-toxic poly(2-oxazoline)s as cryoprotectants
and surfactants at the same time†
Meike N. Leiske,ab Anne-Kristin Tru¨tzschler,ab Sabine Armoneit,c Pelin Sungur,ab
Stephanie Hoeppener,ab Marc Lehmann,c Anja Traeger*abc and
Ulrich S. Schubert *abd
Polymer based nanoparticles offer great opportunities for diverse applications, i.e. their drug delivery
potential is promising. However, their major drawback is identified in preparation via the nanoemulsion
technique, which is needed for the encapsulation of hydrophilic drugs and whereby the utilization of
surfactants, e.g. poly(vinyl alcohol) (PVA), is mandatory. Furthermore, the preparation of nanoparticles is
critical due to the need of lyophilization for storage. For this reason it is common to use cryoprotectants,
which are usually sugar based. In the current study, we present the use of non-toxic, water-soluble poly-
(2-oxazoline)s (P(Ox)s) in terms of polymeric nanoparticle stabilizers for preparation, purification, and
lyophilization. The nanoparticles were characterized via dynamic light scattering (DLS) and cryo-transmission
electron microscopy (cryoTEM). The use of hydrophilic P(Ox)s with a degree of polymerization of about
60 yielded stable nanoparticles. For the preparation via nanoemulsion a PDI below 0.2 could be obtained
after adjustment of the surfactant concentration. All nanoparticles were in the size range of 100 to 200 nm
according to DLS. Furthermore, the addition of P(Ox) was beneficial during particle purification via
centrifugation and filtration as well as lyophilization, yielding nanoparticles with a PDI below 0.3 as
determined via DLS and confirmed via cryoTEM measurements. Cytotoxicity, hemolysis and erythrocyte
aggregation measurements of these P(Ox)s did not show any harmful effect on the treated cells.
1. Introduction
The design and preparation of potent drug carriers play a pivotal
role in pharmaceutical, biomedical, and chemical research,
since carriers offer possibilities for targeted drug release by the
introduction of targeting moieties, reduction of side effects, or
protection of active pharmaceutical ingredients (APIs). Nano-
particles based on polymers can be tuned in a tailor-made
fashion regarding their size, charge, loading, release, and
functionality.1 Water-insoluble polyesters, such as Food and
Drug Administration (FDA) approved poly(lactic-co-glycolic acid)
(PLGA), are commonly used in a number of preclinical trials at
the moment.2 PLGA is a biodegradable polymer that can be
degraded by esterases, which can be found inside the endosomal
compartments of cells, under acidic conditions within minutes
into its natural degradation products.3
Lipid-based carriers, i.e., liposomes, which are already used
in therapeutics, also show high efficiencies, a high cargo
capacity and a wide range of design opportunities. Nevertheless,
liposomes also feature potential immune response activation,
expensive fabrication, and complex pharmacodynamics.4 Polymer
systems, on the other hand, are affordable, easily storable as
powder and highly designable. In comparison to viral vectors or
lipid based systems, concerns about immunogenicity or expensive
and difficult up-scaling are limited. The benefits of polymeric
nanoparticles seem to make them ideal drug carriers; however,
there are limitations regarding their efficiency. One possible
obstacle is originated in the particle preparation. Particles are
commonly prepared via solvent-evaporation methods using nano-
precipitation with water-miscible organic solvents or emulsions
with water-immiscible solvents.5–7 The resulting suspension
might not be stable for an unlimited time as the precipitants
tend to aggregate during preparation, purification or evaporation
and subsequent storage. Furthermore, the possible diffusion of
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hydrophilic drugs in water-based particle suspension might
reduce the drug loading in a time dependent manner. To avoid
these limitations, the particles can be lyophilized using cryopro-
tectants, which are necessary due to the difficult resuspension of
pure particles. Saccharides, such as trehalose, sucrose, and
glucose, are the most commonly used cryoprotectants.8 In the
literature, the common amount of sugar used is 5.0 wt% or even
higher.9,10 Unfortunately sugars are hygroscopic, which can be a
disadvantage for long-term storage. Furthermore, many saccharides
themselves already owe biochemical activity by specific uptake
mechanisms via GLUT transporters.11 For this reason, research on
finding alternatives for these cryoprotectants was already started by
some groups.12,13
The second issue regarding nanoparticles is related to their
preparation for encapsulation of hydrophilic drugs, e.g. siRNA.
These drugs cannot be easily incorporated by nanoprecipitation
methods, but require double emulsion techniques instead.7 As
this preparation method uses a solvent, which is not miscible
with water, the emulsion has to be further stabilized by using a
surfactant. The most common surfactant in this context is the
water-soluble poly(vinyl alcohol) (PVA).8,14 In nanoscience it is
well-known that the utilization of amphiphilic particle stabilizers,
such as PVA, is beneficial and can reduce the surface tension of the
nanoparticles. The resulting nanoparticles are uniform with a
narrow size distribution but, however, PVA influences the physical
properties and the cellular uptake of nanoparticles.15 Furthermore,
it is declared to be possibly carcinogenic and might influence the
cellular uptake of the nanoparticles.15–17 As a consequence, the use
of PVA leads to the necessity of excessive purification of the
nanoparticle formulations before administration.
Usually in terms of purification, crude particles are centri-
fuged, filtered, or dialyzed.3 In particular during centrifugation,
immense forces operate on the particles and potentially influence
the particle characteristics.
Taking all these facts into account, the research for new,
biocompatible surfactants and cryoprotectants is indispensable.
Biocompatible poly(2-oxazoline) (P(Ox)) polymers might be
interesting candidates to address this issue. Since their inven-
tion in the 1960s by four different research groups,18–21 the
interest in this polymer class has risen exponentially. Fundamen-
tal studies mainly included monomer synthesis and polymeriza-
tion parameter optimization as well as the characterization of the
resulting polymers.22–26 As the polymerization process of the
cationic ring-opening polymerization (CROP) of 2-oxazolines is
slow, it requires high temperatures in order to reach useful
reaction times. The usage of the microwave technique (poly-
merization under pressure) since 2004 has decreased the
synthesis time from several days to only a few minutes.27
Since this circumstance makes P(Ox)s affordable, biocompat-
ibility and pharmaceutical studies have come to the fore.28
FDA approved polymers consisting of the water-soluble
monomer 2-ethyl-2-oxazoline (EtOx)29 as well as 2-methyl-2-
oxazoline (MeOx) are of major interest in this context.
Their biocompatibility and biodistribution mechanisms have
already been tested in vitro30 and in vivo,31 and at the moment
the first clinical trial is running.32
P(Ox)s have already been studied in terms of surfactant
abilities, e.g., by investigations on the surface activity of different
block copolymer compositions.33–35 Kobayashi et al. additionally
studied hydrophilic P(Ox) homopolymers providing a hydrophobic
end-group.36 Furthermore, P(Ox)s were investigated as stabilizers
for hydroxyapatite37 and metal-based nanoparticles.38
The aim of this study is to use purely hydrophilic P(Ox)
homopolymers as an all-in-one-system for polymeric nano-
particles to replace both the surfactant necessary for particle
preparation and the cryoprotectant required for particle storage. A
series of poly(2-ethyl-2-oxazoline)s (P(EtOx)) and poly(2-methyl-2-
oxazoline)s (P(MeOx)) with varying degree of polymerization (DP)
were synthesized. In detail, P(EtOx)61 was used as a surfactant for
PLGA nanoparticle preparation in comparison with commercial
PVA and Pluronics F127. Furthermore, P(EtOx)61 was compared
with P(EO)57 and saccharides regarding its cryoprotectant proper-
ties for PLGA nanoparticles. After optimizing the conditions
regarding stabilizer concentration, P(Ox)s of varying DPs were
compared in terms of surfactant and cryoprotectant abilities.
Additionally, the purification techniques (centrifugation and
filtration) were evaluated. Their potential as additives in the
encapsulation of hydrophilic drugs was exemplarily shown for
Nile red and PKC 412, a kinase inhibitor, e.g. for protein kinase
C. The nanoparticles were analyzed using DLS and cryoTEM.
2. Results and discussion
2.1. Surfactant abilities
2.1.1. Comparison of P(Ox)s and commercial surfactants.
Since nanoparticles for drug delivery are often prepared via
nanoemulsion, which requires the use of surfactants, whose
absolute removal is nearly impossible, investigations regarding
in vitro cytotoxicity (AlamarBlues) and hemolysis behavior
(hemoglobin release) of potential candidates were conducted
(Fig. 1). Therefore the potential surfactants were tested in a
range of 0.0003 to 5.0 wt%. Due to difficulties with their
solubility, PVA and Pluronics F127 could not be tested at
5.0 wt%. Even at a high polymer concentration of 5.0 wt%
none of the tested surfactants is cytotoxic as revealed by the
AlamarBlues assay (Fig. 1A); however, hemolysis experiments
showed an enhanced hemolytic activity of PVA and Pluronics
F127 at concentrations of 1.0 wt% and higher, while the
investigated P(Ox)s are not hemolytic even at a concentration
of 5.0 wt%, proving their good biocompatibility (Fig. 1B).
Biotests regarding the erythrocyte aggregation (Fig. S1, ESI†)
and an LDH-assay (Fig. S2, ESI†) showed no significant differences
between the tested surfactants PVA, Pluronics F127, P(EtOx)61 and
P(MeOx)57.
Initial particle preparation experiments were performed
using the nanoprecipitation method (Fig. S3A, ESI†) for PVA,
Pluronics F127 and P(EtOx)61 as nanoparticle stabilizers using
concentrations of 0.3, 0.5 and 1.0 wt%. In fact, the precipitation
method results in good PLGA nanoparticles without using
surfactants. However, PLGA nanoparticles, which are used for
therapeutical purposes, often carry drugs and therefore need to
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be prepared using surfactants. For this reason, first particle
preparation experiments were performed via nanoprecipitation
of solely PLGA to provide information about a possible disturbance
introduced by non-suitable additives. The resulting nanoparticles
were compared regarding z-average and PDI values (Fig. S3B and
Table S3, ESI†). Nanoparticles prepared using Pluronics F127 and
P(EtOx)61 were rather small (dPluronicsF127 E 120 nm; dP(EtOx) E
115–135 nm), while the usage of the more hydrophilic PVA and
P(MeOx)57 produces larger nanoparticles (dPVA E 150 nm;
dP(EtOx)E 195 nm).
We assume that these differences are caused by hydrophili-
city of the surfactants. The PDI of the nanoparticles was below
0.160 in all cases, indicating the formation of well-shaped
particles.
Furthermore, the more sophisticated emulsion technique
was investigated (Scheme 1) concerning a comparison of
common and new potential surfactants.39
Since this method uses an organic solvent, which is not
water-miscible, representing the hydrophobic phase, a surfactant
is generally necessary to avoid subsequent phase separation and
particle aggregation.
PVA, as a commonly used surfactant, P(EtOx)61, as repre-
sentative of the P(Ox)s, and Pluronics F127, a surfactant and
shearforce protecting agent, were evaluated for this method by
comparing the z-average and PDI value of the resulting nano-
particles (Fig. 2 and Table S4, ESI†).
In the range of 0 to 1.0 wt% polymer the optimum surfactant
concentration was evaluated for each surfactant tested. Particles
prepared using PVA or Pluronics F127 tend to be very small
(dE 100 nm) and show PDI valueso 0.2 at low concentrations
(0.3 to 0.5 wt%). P(EtOx)61 leads to small particles (dE 110 nm)
with low PDI values (PDI o 0.2) at concentrations of about
1.0 wt%. The preparation of nanoparticles utilizing lower P(EtOx)61
concentrations was not possible. Nevertheless, by using 1.0 wt% of
P(EtOx)61 particles of equal quality as PVA stabilized particles could
be produced. Furthermore, it is obvious that particle preparation
without a surfactant leads to poor PDI values of about 0.4 and is,
therefore, not appropriate. After pre-evaluation of P(EtOx)61 the
more hydrophilic P(MeOx)57 was examined only at the most
convenient concentration of P(EtOx)61 and led to similar PDI
values. For this reason, the preparation of block-copolymers, which
consist for example of the monomers MeOx and 2-butyl-2-
oxazoline (BuOx), leads to amphiphilicity and, consequently, good
stabilization abilities in aqueous solution.40
It can be assumed that the ability of the homopolymers to
stabilize the emulsion is caused by their solubility in water as
well as in the organic solvents used for preparation (Scheme 1).41
This phenomenon was already evaluated for PVA by S. Galindo-
Rodriguez et al.,42 who declared that the polymer chains can be
solubilized by the aqueous phase as well as the interphase and
Fig. 1 Concentration dependent biocompatibility of different surfactants.
(A) Cytotoxicity of indicated polymers using AlamarBlues assay. Non-
treated cells were set to 1 for relative viability. L929 cells were treated
for 24 h with the indicated concentrations of the polymers. Values
represent the mean  S.D. (n = 3). (B) Hemoglobin release of erythrocytes
after incubation for 60 min at 37 1C with polymers at indicated concen-
trations. A value of less than 2% hemoglobin release is classified as non-
hemolytic and45% as hemolytic. Values represent the mean  S.D. (n = 3).
Scheme 1 Schematic representation of the nanoparticle preparation via
the nanoemulsion technique. A hydrophobic drug and the polymer are
dissolved in a not miscible organic solvent and water. Surfactants are
added and the solution is emulsified by sonication. After evaporation of the
organic solvent, nanoparticles are obtained. Magnification of the nano-
particle–aqueous phase boundary layer is presented, showing the potential
behavior of polymer surfactants in the nanoemulsion process.
Fig. 2 Properties of PLGA nanoparticles prepared via the nanoemulsion
technique (water and ethyl acetate), using different surfactants as deter-
mined by DLS measurements (n = 3, 5 measurements each). Values
colored in white were not investigated. See values in Table S4 (ESI†).
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the organic phase. Inter- and intrachain interactions of the
surfactant polymer lead to repulsion and steric effects that might
stabilize the droplet. Furthermore, a reduction of the interfacial
tension is beneficial for the stabilization of an emulsion as
known from the literature. This explanation could also fit to
the 2-oxazoline homopolymers used in this study. For this
reason, the surface tension of surfactant containing water dro-
plets was measured for all the surfactants used (Fig. S4, ESI†).
From the comparison of results, all surfactants were found to
reduce the surface tension of water at least slightly. However, the
comparison of the different P(Ox) solutions does not show any
dependence of the surface tension on the concentration or the
molar mass of the polymer (gP(EtOx)n E 60 N m
1, gP(MeOx)n E
70 N m1), while PVA and Pluronics F127 do (gPVAn E 55 to
45 N m1, gPluronicsF127 E 45 to 40 N m
1). Therefore, the
concentration dependent surfactant ability might be mainly
caused by the viscosity of the solutions (Fig. 4A). It is already
known from the literature that the viscosity of the aqueous P(Ox)
solution can be influenced by the molar mass as well as the
polymer concentration.43 As shown in Fig. 4A, the dynamic
viscosity of the used PVA solution (3 wt%) is between 4.5 and
5.0 mPA s, whereas the utilized P(EtOx)60 and P(MeOx)60 solu-
tions have much lower viscosities. At a concentration of 10 wt%
the P(Ox) solutions have a dynamic viscosity of B3.0 mPA s,
which seems to be an applicable value for the stabilization of the
emulsion. Even though PVA has great surfactant abilities at the
determined values of surface tension and viscosity, P(Ox)s also
work at significantly lower viscosities and reduced surface ten-
sion. Since Pluronics F127 has very good potential to reduce the
surface tension of water, the lower viscosity of the solution might
not be disadvantageous. These findings support the hypothesis
that the stabilization of the particles is influenced by the surface
tension and the viscosity of the used surfactant.
2.1.2. Influence of the molar mass of the surfactant. To
prove whether the success of surfactant ability of the different
polymers depends on the polymer size, hydrophilic P(Ox)s
with a varying DP (B25, B60, B100, B200) were tested and
characterized regarding the z-average and PDI values of the
resulting particles using DLS (Fig. 3 and Fig. S5, ESI†).
While using the nanoprecipitation technique, the resulting
nanoparticles are of comparable z-average (d E 160 nm) and
have a narrow dispersity (PDI o 0.1) (Fig. S5 and Table S5,
ESI†). By using the more sophisticated nanoemulsion tech-
nique (Fig. 3 and Table S5, ESI†), P(Ox)s with a DP of 60, 100
and 200 produce larger nanoparticles (d E 200 nm) with a
moderate dispersity (PDI o 0.2), while the P(Ox)s with a DP of
25 cannot be used for the production of stable, narrow disperse
nanoparticles (d E 800 nm, PDI Z 0.3). These results indicate
the dependence of the surfactant ability on the DP of the used
polymers for the nanoemulsion technique. A possible explana-
tion for this phenomenon might be given by the viscosity of the
polymer solutions. Fig. 4B shows the strong dependence of the
viscosity on the DP of the used P(Ox)s. T. X. Viegas et al. have
already investigated this using a different molar mass range of
P(EtOx)n.
43 If we consider these results, a DP of 60 is the
minimum possible for successful particle stabilization within
the tested range. Low molar mass polymers with a DP below 60
are not capable of stabilizing the PLGA nanoparticles. However,
after crossing a certain point, which was a DP of 60 in the
current study, an increase of the molar mass seems to be
neither beneficial nor disadvantageous for the stabilization of
the nanoparticles.
2.2. Lyophilization experiments
2.2.1. Comparison of P(Ox)s and commercial cryoprotec-
tants. Successful nanoparticle lyophilization and resuspension
are crucial elements for particle preparation and storage
(Fig. 5A). Usually, polymeric nanoparticles show difficulties in
resuspension after lyophilization and lack in quality. Therefore,
first experiments concentrated on the possible capability of
P(Ox)s to act as a stabilizing agent during lyophilization of
nanoparticles after successful preparation.
P(EtOx)61 was used for initial lyophilization experiments to
determine the polymer amount necessary for particle stabili-
zation. PLGA nanoparticles were prepared via the nanoprecipi-
tation technique without using any stabilizers. Their z-average
and PDI values were determined by DLS measurements. Sub-
sequently, different amounts of the cryoprotectants ranging
from 0.05 to 10 wt% were added to the crude nanoparticle
suspension, which was lyophilized afterwards and tested
regarding the z-average and PDI values of the particles and
Fig. 3 Properties of PLGA nanoparticles prepared by nanoemulsion
(water and ethyl acetate), using hydrophilic P(Ox)s with varying DP as
surfactants (1.0 wt%). z-Average and PDI values were determined via DLS
investigations (n = 3, 5 measurements each). See values in Table S5 (ESI†).
Fig. 4 Dynamic viscosity of different polymer solutions. (A) Dynamic
viscosity dependent on the polymer concentration. (B) Dynamic viscosity
of P(Ox) solutions with different DP.
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compared to the previous results (Fig. 5B and Table S3, ESI†).
z-Average and PDI ratios of 1.0 are favorable in this context. In
Fig. 5B the results of the dynamic light scattering of the
particles after lyophilization are summarized compared to the
particle properties before. Thereby the ratios of the z-average
and the PDI were calculated as shown in eqn (1) and (2).
z-average ratio ¼
z-average after lyophilization
z-average after preparation
(1)
PDI ratio ¼
PDI after lyophilization
PDI after preparation
(2)
In this experimental setup, saccharose showed the best
performance (z-average ratio = 1.0; PDI ratio = 1.8) at a used
sugar concentration of 10 wt%. Glucose (z-average ratio = 1.0;
PDI ratio = 2.1) and trehalose (z-average ratio = 1.4; PDI ratio = 2.7)
were slightly more unfavorable at concentrations of 10 and 5 wt%,
respectively. In contrast, at a low cryoprotectant concentration of
about 0.5 wt% P(EtOx)61, the z-average (ratio = 1.5) and PDI
(ratio = 2.0) mostly remain constant, while increasing signifi-
cantly by the utilization of other cryoprotectants. Even though
saccharose shows a better performance at a high concentration
of 5.0 wt%, P(Ox)s at low concentrations offer better stabili-
zation. Using P(Ox)s, the increase in the size can be explained
by the cryoprotectant addition. P(EtOx)61 chains themselves
seem to assemble on the PLGA particle surface, whereby the
size of the particle increases. It should be noted that a PDI ratio
of two, which means a doubling in the actual values, results in
PDI values of around 0.2, which still represents a very good value.
For comparison, also poly(ethylene oxide) (P(EO)), i.e. P(EO)57,
was tested regarding its cryoprotectant abilities, since P(Ox) and
P(EO) are often claimed to show comparable characteristics.
Nanoparticles that were stabilized using P(EO)57 showed a
huge increase in z-average (ratio4 2.5) and PDI (ratio4 4.5) in
all tested concentrations ranging from 0.05 to 5 wt%. For this
reason, P(EO)57 does not seem to be suitable for PLGA
nanoparticle stabilization, while P(EtOx)61 is superior to commonly
used cryoprotectants when used at low concentrations. The tested
sugars show their best cryoprotective ability at a concentration of
10.0 wt%, which is twenty times higher than the investigated
P(EtOx)61. Since sugars are known to be hygroscopic, the use of
P(Ox)s, which can be used at much lower amounts, represents a
possible alternative for the common cryoprotectants.
2.2.2. Influence of the molar mass of the cryoprotectant.
After initial experiments using P(EtOx)61, P(Ox)s with varying
molar masses were investigated. Herein, P(EtOx)n and the more
hydrophilic P(MeOx)n were used for the surfactant experiments
(DP E 25, 60, 100, 200). As an all-in-one system was targeted,
nanoparticle samples prepared with those polymers acting as
surfactants were directly lyophilized and re-suspended in dou-
ble deionized water. The resulting size and PDI values were
compared to the values that were determined directly after
preparation and are plotted in Fig. 6.
By using the P(Ox)s with a DP of 60, 100 and 200 the
characteristics of the PLGA nanoparticles can be maintained
during lyophilization (size ratioE 1, PDI ratio: 1 to 2), while the
Fig. 5 (A) Schematic representation of the lyophilization and resuspension of polymeric nanoparticles using P(Ox)s as suitable particle stabilizers
(cryoprotectants). (B) Properties of the lyophilized PLGA nanoparticles using different cryoprotectants at various concentrations. Diameter size ratios of
the z-average and PDI ratios of the nanoparticles were determined by DLS investigations (n = 3, 5 measurements each). Ratios were calculated using
eqn (1) and (2). Values colored in white were not investigated. See values in Table S3 (ESI†).
Fig. 6 z-Average and PDI ratios of PLGA nanoparticles prepared by the
nanoprecipitation technique using 0.3 wt% P(Ox). The particles were
lyophilized without further purification and the ratios were calculated
using eqn (1) and (2) (n = 3, 5 measurements each). See values in
Table S6 (ESI†).
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usage of P(Ox)s with a DP of 25 does not seem to be beneficial
(size ratio E 2, PDI ratio: 4 to 6).
According to the determined ratios, a P(Ox) based all-in-one
system is possible. Direct lyophilization of the PLGA nano-
particles after preparation leads to nanoparticles of defined size
and PDI values which seem to be improved by using P(Ox)s with
higher molar masses. However, drug encapsulation usually
leads to the necessity of particle purification to eliminate free drug
from the particle suspension. Furthermore, P(Ox)s with lower
molar masses are known to undergo faster renal excretion44 and
are, therefore, further examined in the current study.
2.3. Particle purification
After successful investigation of P(Ox)s as surfactants, the
influence of particle purification (centrifugation or filtration)
on their size and PDI values was elucidated. For this reason
PLGA nanoparticles were produced by nanoprecipitation using
0.3 wt% P(Ox) as the surfactant. The resulting nanoparticles
were either centrifuged for 45 min at 11 000 rpm and 4 1C or
filtered using a 0.45 mm nylon filter before lyophilization. To
see whether it is necessary to use an additional amount of P(Ox)
solution for good resuspension, the same amounts of P(Ox)
solutions were added before lyophilization to either centrifuged
or filtered nanoparticles. For comparison, nanoparticle suspen-
sions which have not been purified before were lyophilized as
well (Fig. 7A and Table S7, ESI†). The z-average distribution
values of the particles before and after purification were investi-
gated via DLS and cryoTEM measurements and are summarized
in Fig. 7B.
After preparation, the nanoparticles are of comparable size
(d E 190 nm) and dispersity (PDI o 0.1) and, furthermore,
suitable for syringe filtration as well as centrifugation. The
particles moreover feature a perfect spherical shape. Syringe
filtration was conducted using a 0.45 mm nylon syringe filter.
Standard sterile filtration would be usually performed using a
0.2 mm syringe filter but to be sure not to filter out possible
aggregation of particles a larger filter was used.
DLS measurements provided initial information about
the stability of the nanoparticles. Nanoparticles prepared with
P(MeOx)57 resulted in a diameter of about 200 nm and the PDI
wasE 0.1, while for nanoparticles prepared by using P(EtOx)61
the addition of a P(Ox) solution was necessary (d = 165.1 
1.0 nm; PDI = 0.172  0.044) after purification to avoid particle
aggregation (d = 1075  112 nm; PDI = 0.948  1). However, by
having a close look at the particle morphology via cryoTEM, it is
also visible that most of the nanoparticles are still well defined
and only a few aggregates are present. Nanoparticle sizes
obtained by DLS measurements could mostly be confirmed by
cryoTEM measurements. Regarding the DLS and cryoTEM results,
this purification has no influence on the particle morphology and
is, therefore, a suitable purification method that can be used, e.g.,
to separate the particles from larger aggregates.
Centrifugation of nanoparticles is a common purification
method for their separation from small and dissolved mole-
cules. This technique potentially has stronger forces which are
exerted onto the nanoparticles; hence, the stability of the
Fig. 7 (A) Schematic representation of nanoparticle purification by either syr-
inge filtration or centrifugation using P(Ox) as the particle stabilizer. (B) Influence
of various purification techniques on the size distribution and morphology of
PLGAnanoparticles thatwere prepared by nanoprecipitation, determined byDLS
(green columns, n= 3, 5measurements each) and cryoTEMmeasurements. See
values in Table S7 (ESI†). See raw cryoTEM images in Fig. S6 (ESI†).
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particle solutions was also tested under these conditions.
Therefore, the raw particle suspensions were centrifuged for a
predetermined time, decanted and afterwards resuspended in
either ultra-pure water or a 0.5 wt% P(Ox) solution. Unfortunately,
the nanoparticles, which were resuspended in ultra-pure water,
formed large aggregates and were, therefore, excluded from further
studies. On the other hand, the resuspension in a 0.5 wt% P(Ox)
solution resulted in well-defined nanoparticles. For this reason, we
conclude that a certain amount of the surfactant is washed out by
centrifugation and has to be added afterwards to reach the amount
necessary for particle stabilization.
With the aid of rhodamine B labeled P(Ox)s, which were
used for nanoparticle preparation via nanoprecipitation (water
and acetone), we could obtain further information regarding
the interaction of P(Ox)s and particles. The raw nanoparticles
were subsequently centrifuged and the particle pellet was
resuspended in either ultra-pure water or in a 0.5 wt% solution
of rhodamine B labeled P(Ox)s. The resulting nanoparticles
were then lyophilized and resuspended in ultra-pure water.
A control batch, which was lyophilized without further purifica-
tion, was also prepared. The final particles were characterized
using DLS and UV/Vis measurements (Table 1) to determine the
P(Ox) amount within the polymer particle by using rhodamine
B calibration. Nanoparticles that were centrifuged and resus-
pended in ultra-pure water aggregate after lyophilization as
revealed by the DLS results (dP(MeOx): particle aggregation;
dP(EtOx) not available because of particle aggregation). UV/Vis
measurements resulted in less than 1 mg P(Ox)s per mg PLGA
within the purified nanoparticles. For comparison, nano-
particles which were resuspended in a 0.5 wt% P(Ox) solution
possessed a P(Ox) amount of more than 4 mg P(Ox)s per mg
PLGA.
The nanoparticles are of smaller size (dP(MeOx) = 182.7 
21.7 nm; dP(EtOx) = 175.4  4.5 nm) and with lower PDI
(PDIP(MeOx) = 0.192  0.062 nm; PDI P(EtOx)(MeOx) = 0.273 
0.019 nm) than the nanoparticles which were purified without
a surfactant.
By comparing the DLS and the UV/Vis results of the nano-
particles, it is clearly visible that the z-average as well as the PDI
value depends on the P(Ox) amount of the particles. Therefore,
a resuspension in 0.5 wt% P(Ox) solutions is defined to be
beneficial for the nanoparticle uniformity.
These findings could also be confirmed via CLSM measure-
ments. For this purpose, microparticles were produced using
the microemulsion technique (water and dichloromethane)
and rhodamine B labeled P(MeOx)57 as the surfactant. After
evaporation of the solvent, the PLGA microparticles were char-
acterized. The particles have a clear pink corona (Fig. 8), indicat-
ing a surfactant layer, which is visible even after centrifugation.
2.4. Variation of hydrophobic particle forming polymers
It is of fundamental interest to verify that the introduced
method is also applicable to other polymer systems. Therefore,
the effect of P(Ox) surfactants on PCL and methacrylate based
particles was also evaluated. Regarding the previous experiments,
the hydrophilic P(Ox)s P(EtOx)61 and P(MeOx)57 are suitable
cryoprotectants and surfactants for PLGA nanoparticles. In addi-
tion to PLGA, also the nanoparticle formation of the polymers
poly(caprolactone) (P(CL)), Eudragit RS100, and P(MMA97-co-
MAEMA32) via nanoemulsion was tested (Table S8, ESI†).
Unfortunately, preparation of nanoparticles consisting of
PCL was not possible using P(Ox)s as a surfactant, since the
particles were not stable in aqueous solution. Nevertheless,
excellent particles could be prepared from Eudragit RS100 and
P(MMA97-co-MAEMA32) methacrylate based copolymers (Fig. 9).
Eudragit RS100 forms large particles (dP(EtOx) = 214.0  0.7 nm;
dP(MeOx) = 244.3  2.5 nm; dultra-purewater = 101.6  0.5 nm),
when using P(Ox)s as a surfactant. Furthermore, well-defined
Table 1 Characteristics of PLGA nanoparticles prepared by nanoprecipitation (water and acetone) using rhodamine B labeled P(EtOx)61 as the surfactant.
z-Average and PDI values were determined via DLS measurements
P(EtOx)61-rhodamine
After preparation via nanoprecipitation
z-Average [d, nm] 132.1  0.4 134.0  1.3
PDI 0.096  0.002 0.093  0.017
Lyophilized
Centrifugation + ultra-pure water Centrifugation + 0.5 wt% P(Ox)
z-Average [d, nm] n.a. 175.5  4.5
PDI n.a. 0.273  0.019
P(Ox)a [mg] 0.7 4.6
P(MeOx)57-rhodamine
After preparation via nanoprecipitation
z-Average [d, nm] 193.8  2.0 190.6  2.3
PDI 0.090  0.038 0.072  0.021
Lyophilized
Centrifugation + ultra-pure water Centrifugation + 0.5 wt% P(Ox)
z-Average [d, nm] Particle aggregation 182.7  21.7
PDI Particle aggregation 0.192  0.062
P(Ox)a [mg] 0.0 4.0
a Calculated from UV/Vis absorption measurements at lEx = 630 nm. n.a.: not available because of particle aggregation. For absorbance and
emission spectra of the labelled P(Ox)s, see Fig. S7 (ESI).
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nanoparticles can only be achieved by utilization of P(Ox)
surfactants (PDIP(EtOx) = 0.063  0.018; PDIP(MeOx) = 0.081 
0.012; PDIultra-purewater = 0.246  0.020).
When using P(MMA97-co-MAEMA32), the more hydrophilic
surfactant P(MeOx)57 leads to less disperse (PDIP(MeOx) =
0.087  0.023; PDIP(EtOx) = 0.147  0.030) nanoparticles. How-
ever, at this point, it should also be pointed out that the PDI
values of the nanoparticles prepared using P(EtOx)61 are still
very good. However, the prepared particles are only slightly less
disperse than particles prepared without using a surfactant
(PDIultra-purewater = 0.191  0.012). Therefore, at first glance, the
particles do not seem to benefit the usage of P(Ox)s as a surfactant.
Since the non-ionic P(Ox)s have a neutral zeta potential, the zeta
potential of the nanoparticles (zP(MeOx)4 30 mV; zP(EtOx)4 30 mV;
zMilliQ4 40 mV) is more or less unaffected by the surfactant as it
remains being strongly positive.
More interestingly, for P(MMA97-co-MAEMA32) both P(Ox)s
seem to have a comparable ability of being a surfactant
agent; however, the prepared particles are only slightly less
disperse than particles prepared without using a surfactant
(PDIultra-pure water = 0.191  0.012). Therefore, at first glance,
the particles do not seem to benefit the usage of P(Ox)s as a
surfactant. In both cases the particle size is dependent on the
surfactant as well as on the type of hydrophibic polymer being
used. As this study mainly concentrates on the investigation
of P(Ox)s as suitable surfactants for all tested polymers,
the particles consisting of different types of polymers are not
compared with each other directly. However, the influence of
P(Ox) based surfactants on the nanoparticle size and PDI value
was examined. Purification via centrifugation and filtration as
well as lyophilization experiments with these nanoparticles
were also investigated (Fig. 10 and Tables S9, S10, ESI†).
The purification of Eudragit RS100 yielded stable nanoparticles
when prepared using P(Ox) based surfactants (size ratio o 1.3;
PDI ratio:o 1.7 (except centrifugation and resuspension in ultra-
pure water)), while nanoparticles without surfactants aggregated
after lyophilization (Fig. 10A). While purifying P(MMA97-co-
MAEMA32) filtration did not work in any case. However, the
addition of a P(Ox) solution after filtration was beneficial even
for P(MMA97-co-MAEMA32) nanoparticles prepared without a sur-
factant. Centrifugation and resuspension in ultra-pure water
before lyophilization also yielded stable nanoparticles with respect
to their size and PDI ratios, which are below a value of two.
Fig. 8 CLSM (lEx = 514 nm, lEm = 531 to 704 nm) of PLGA microparticles
prepared by microemulsion (water and dichloromethane) using P(MeOx)57-
rhodamine as a surfactant. For absorbance and emission spectra of the
labelled P(Ox)s, see Fig. S7 (ESI†).
Fig. 9 Properties of the nanoparticles prepared by nanoemulsion (water
and ethyl acetate), using P(Ox)s as surfactants. z-Average and PDI values
were determined via DLS (n = 3, 5 measurements each). See values in
Table S8 (ESI†).
Fig. 10 Dependence of z-average and PDI ratios of (A) Eudragit RS100
and (B) P(MMA97-co-MAEMA32) nanoparticles on the purification method
by either direct lyophilization of the particle suspension (None), centri-
fugation at 11 000 rpm for 45 min and resuspension in ultra-pure water (A),
centrifugation at 11 000 rpm for 45 min and resuspension in a 0.5% P(Ox)
solution (B) or syringe filtration using a 0.45 mm nylon filter (C). Nano-
particles were prepared via nanoprecipitation (water and acetone). See
values in Tables S9 and S10 (ESI†).
Paper Journal of Materials Chemistry B
Pu
bl
ish
ed
 o
n 
01
 N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
by
 T
hu
er
in
ge
r U
ni
ve
rs
ita
ts 
La
nd
es
bi
bl
io
th
ek
 Je
na
 o
n 
02
/0
2/
20
18
 0
8:
35
:4
7.
 
View Article Online
9110 | J. Mater. Chem. B, 2017, 5, 9102--9113 This journal is©The Royal Society of Chemistry 2017
2.5. Drug encapsulation
2.5.1. Encapsulation of Nile red. After the successful inves-
tigation of P(Ox)s for combined cryoprotection and stabilization,
the influence of drug encapsulation was examined. For this
purpose, the model drug Nile red was tested. Nile red containing
PLGA nanoparticles were prepared with both nanoprecipitation
(water and acetone) and nanoemulsion (water and ethyl acetate)
technique with either P(EtOx)61 or P(MeOx)57 as the surfactant
under previously determined optimum conditions. Nile red could
be dissolved in the same organic solvent as the PLGA in both
cases. 10 mg Nile red per 1 mg PLGA was used. For comparison
particles without a surfactant were prepared. All the resulting
particles were compared with regard to the z-average and PDI
values (Fig. 11 and Table S11, ESI†).
The particle preparation using Nile red as a model drug resulted
in well-defined nanoparticles in all cases. Similar to the preparation
of nanoparticles without drug, the preparation of nanoparticles with
Nile red using the nanoprecipitation method is possible without
using surfactants (d = 145.2  2.5 nm; PDI = 0.075  0.018);
however, the utilization of P(Ox)s leads to slightly larger particles
(dP(EtOx) = 160.8 1.5 nm; dP(MeOx) = 151.2 0.8 nm), which are still
well-defined (PDIP(EtOx) = 0.053  0.028; PDIP(MeOx) = 0.065  0.021).
More interestingly, the particle preparation via nanoemulsion
techniques also results in nanoparticles with low PDI values
(PDIP(EtOx) = 0.124  0.013; PDIP(MeOx) = 0.099  0.014), while a
stable particle formation without an additional surfactant is
impossible (Table S11, ESI†). The nanoparticles prepared using
P(EtOx)61 as a surfactant are about 10 nm larger than the
particles prepared with P(MeOx)57. This phenomenon correlates
well with the steric properties resulting from the longer side-
chains of the polymers. Again, different purification techniques
were examined on the nanoparticles prepared via nanoprecipita-
tion (Fig. 11 and Tables S12, S13, ESI†) to complete the investi-
gation on encapsulated particles as done before for particles
without the model drug. Nile red could be dissolved in the same
organic solvent as the PLGA in both cases. 10 mg Nile red and
3 mg P(Ox)s per 1 mg PLGA were used. Consequently, encapsula-
tion efficiency (EE) of approximately 2.5 mg Nile red per 1 mg
nanoparticle corresponds to 100% EE. P. Pietzonka et al. have
already encapsulated 0.1 mg per 1mg PLGA nanoparticle (0.1 wt%)
by using PVA as a suitable surfactant.45
Interestingly, direct lyophilization of the raw nanoparticles
resulted in aggregation only when prepared with P(MeOx)57;
however, nanoparticles prepared with P(EtOx)61 remained
stable (d = 168.0  1.6; PDI = 0.087  0.031). The same
observations were made for nanoparticles that were purified
via syringe filtration. While nanoparticles that were prepared
using P(MeOx)57 aggregated after purification, P(EtOx)61 is
beneficial (d = 161.7  3.4; PDI = 0.157  0.011). This dis-
advantage of P(MeOx)57 compared to P(EtOx)61 can be explained
by its enhanced hydrophilicity, caused by the shorter side
chains. Since it is uncertain whether the particle shell of PLGA
is probably permeated by the surfactant, we guess that the more
hydrophobic P(EtOx)61 interacts with the hydrophobic drug in a
more stabilizing manner than P(MeOx)57 leading to more stable
nanoparticles.
At this point it should also be noted that nanoparticles that
were purified using centrifugation and resuspended in a
0.5 wt% solution of the corresponding P(Ox), as shown before
for particles without the model drug, are stable and well-defined
in both cases (dP(EtOx) = 184.3  1.6 nm; dP(MeOx) = 187.4 
3.2 nm; PDIP(EtOx) = 0.145  0.028; PDIP(MeOx) = 0.123  0.052),
whereas the nanoparticles that were prepared without a surfac-
tant were not resuspendable. Particles prepared with a surfactant
and resuspended in ultra-pure water have not been under
investigation due to the unpleasant results without the model
drug. The encapsulation efficiency was moderate in all cases,
ranging from 0.21 to 0.52 mg Nile red per mg nanoparticle, which
corresponds to 10 to 20%. We could not define any dependency
on the surfactant or purification technique.
In order to obtain information about the influence of the
P(Ox) surfactants on cellular uptake of drug loaded nano-
particles, CLSM measurements were performed (Fig. 12).
CLSM images show an uptake of all nanoparticles. Even
though the fluorescence intensity of Nile red was slightly
weaker when using P(MeOx)57, quantification via CLSM is
difficult. However, intense cellular uptake studies, e.g. via flow
cytometry, were not part of the current study and have to be
investigated in an additional project.
Cells that were treated with Nile red solutions, which do not
contain PLGA, were not fluorescent. This finding supports the
Fig. 11 (A) z-Average and PDI of PLGA nanoparticles encapsulating the
model drug Nile red, prepared by either nanoprecipitation (water and
acetone) or nanoemulsion (water and ethyl acetate) determined using DLS
measurements (n = 3, 5 measurements each). See values in Table S11
(ESI†). (B–D) z-Average and PDI ratios as well as encapsulation efficiency
(EE) of PLGA nanoparticles using Nile red as a model drug depending on
the purification method by either direct lyophilization of the particle
suspension (none), centrifugation at 11 000 rpm for 45 min and resuspen-
sion in 0.5 wt% P(Ox) solution (‘‘A’’), syringe filtration using a 0.45 mm nylon
filter and addition of 1 mL of 0.5 wt% P(Ox) solution (‘‘B’’) or syringe
filtration using a 0.45 mm nylon filter (‘‘C’’). EE (mg Nile red per mg nano-
particle, 2.5 mg mg1 corresponds to 100%) is calculated from UV/vis
absorption measurements at lEx = 630 nm, mean value of n = 3. Values
colored in white were not investigated. Nanoparticles were prepared by
nanoprecipitation (water and acetone). See values in Tables S12 and S13
(ESI†).
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fact that the P(Ox) surfactants do not encapsulate Nile red,
which is beneficial for the removal of not encapsulated drug
after preparation. An in vitro or in vivo influence of not
encapsulated drug can consequently be reduced.
2.5.2. Encapsulation of PKC 412. Since Nile red is only a
model drug for the encapsulation of a drug into nanoparticles,
additional studies on the encapsulation of the application-
related drug PKC 412 into PLGA nanoparticles were conducted
(Fig. 13 and Table S14, ESI†) using P(EtOx)61 or P(MeOx)57 as a
surfactant. In general, the preparation of nanoparticles via
nanoprecipitation is possible by using either no surfactant
(none), P(EtOx)61 or P(MeOx)57 as a surfactant. However, PKC
412 is only soluble in dimethyl sulfoxide, which was mixed with
the polymer–acetone solution, leading to the necessity of
further purification after preparation. For this reason, the
usage of P(Ox) based surfactants was investigated. 30 mg PKC
412 and 3 mg P(Ox)s per 1 mg PLGA were used. Consequently,
encapsulation efficiency (EE) of approximately 7.5 mg PKC
412 per 1 mg nanoparticle corresponds to 100% EE.
After preparation, all the resulting nanoparticles revealed
good properties regarding size (dPEtOx = 168.6  2.4 nm;
dPMeOx = 184.6  1.1 nm; dultra-pure water = 156.1  0.9 nm) and
PDI characteristics (PDIPEtOx = 0.061  0.019; PDIPMeOx =
0.063  0.034; PDIultra-pure water = 0.077  0.024).
In preliminary experiments, the preparation of PKC 412
loaded nanoparticles using PVA resulted in much larger particles
(d = 276 nm, data not shown). As the drug has enhanced solubility
in DMSO, the nanoparticles were purified using centrifugation to
remove the solvent and avoid the drug diffusing out. The nano-
particles were resuspended in either ultra-pure water or a 0.5 wt%
P(Ox) solution of the polymer that was used for preparation.
Fig. 12 Cellular uptake study of different Nile red formulations. HEK-293
cells were treated with formulations for 30 min in growth media and
analyzed via CLSM (red: Nile red). See Fig. S8 (ESI†) for zoom-in images and
control.
Fig. 13 Characteristics of PLGA nanoparticles using PKC 412 as drug.
(A) z-Average and PDI value after preparation determined by DLS inves-
tigations. Data represent the mean of 3 samples and 5 measurements
each. (B) z-Average and PDI ratios after lyophilization of the nanoparticles
calculated using eqn (1) and (2). Data represent the mean of three samples
and five measurements each. EE (mg PKC 412 per mg PLGA; 7.5 mg PKC 412
per 1 mg nanoparticle corresponds to 100% EE) determined by UV/Vis
(lEx = 293 nm). Nanoparticles were prepared by nanoprecipitation (water
and acetone/dimethyl sulfoxide). Ratios larger than two (no surfactant) are
excluded. See values in Tables S14 and S15 (ESI†).
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As expected, nanoparticles prepared without any additives
aggregate when resuspended after lyophilization. In contrast, the
nanoparticles prepared using P(Ox)s are well resuspendable and
maintain their size (dP(EtOx) = 178.9  2.0 nm; dP(MeOx) = 190.4 
2.4 nm) and PDI characteristics (PDIP(EtOx) = 0.058  0.025;
PDIP(MeOx) = 0.086  0.022). Surprisingly, nanoparticles prepared
by using P(EtOx)61 do not show any drug encapsulation, while
the encapsulation efficiency for nanoparticles prepared with
P(MeOx)57 is around 0.92  0.08 mg mg
1 nanoparticle, corres-
ponding to 12% EE. Regarding these characteristics, the encap-
sulation of PKC 412 is possible by using P(MeOx)57. Preliminary
experiments using PVA as a stabilizer showed much lower
encapsulation efficiencies (B1%, data not shown).
3. Conclusion
In the presented study, we demonstrated the ability of water
soluble and biocompatible P(Ox)s to act as stabilizing agents
for polymer based nanoparticles. First, we showed their ability
to replace the commonly used sugar based cryoprotectants and
result in resuspendable particles with constant properties. After
successful lyophilization experiments, we also used the poly-
mers as biocompatible surfactants. By adjusting the optimum
P(Ox) concentration, PLGA nanoparticles could be prepared via
nanoprecipitation and nanoemulsion techniques omitting the
use of PVA, which allows the preparation of well-defined
nanoparticles at the expense of cytotoxicity and additionally
required purification steps. Furthermore, we demonstrated the
possibility to use P(Ox)s as an all-in-one system for the stabili-
zation of polymeric nanoparticles during preparation, purifica-
tion and lyophilization. After a proof of concept using PLGA
serving as the shell-polymer for the nanoparticles, some other
polymers were investigated including PCL and methacrylate
based copolymers, i.e. Eudragit RS100. Finally, the P(Ox) based
nanoparticle surfactants were used to stabilize nanoparticles
while encapsulating the model drug Nile red or the application-
relevant drug PKC 412. Thereby, the properties, especially the
stability in purification processes, of the nanoparticles could be
improved as well. Since these non-toxic polymers are not
known to mediate cellular responses like P(EO) or specific
uptake mechanisms like sugars, they could be used as promis-
ing stabilizing agents for nanoparticles that are supposed to be
used in biomedical applications. Further experiments will
concentrate on the preparation of micro- and nanoparticles,
using labeled polymers as suitable surfactants for cell-specific
targeting.
We are confident that it will be possible to improve the
performance of P(Ox)s for use in drug encapsulation and with
this their application in biomedical treatment will be of high
interest to the pharmaceutical community.
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ABSTRACT: Despite their promising potential in gene transfection, the toxicity and
limited eﬃciency of cationic polymers as nonviral vectors are major obstacles for their
broader application. The large amount of cationic charges, for example, in poly(ethylene
imine) (PEI) is known to be advantageous in terms of their transfection eﬃciency but
goes hand-in-hand with a high toxicity. Consequently, an eﬃcient shielding of the
charges is required to minimize toxic eﬀects. In this study, we use a simple mixed-micelle
approach to optimize the required charge density for eﬃcient DNA complex formation
and to minimize toxicity by using a biocompatible polymer. In detail, we coassembled
mixed poly(2-oxazoline) nanostructures (d ≈ 100 nm) consisting of a hydrophobic-
cationic block copolymer (P(NonOx52-b-AmOx184)) and a hydrophobic−hydrophilic
stealth block copolymer (P(EtOx155-b-NonOx76) in ratios of 0, 20, 40, 60, 80, and 100
wt % P(NonOx52-b-AmOx184). All micelles with cationic polymers exhibited a very good
DNA binding eﬃciency and dissociation ability, while the bio- and hemocompatibility
improved with increasing EtOx content. Analytics via confocal laser scanning
microscopy and ﬂow cytometry showed an enhanced cellular uptake, transfection ability, and biocompatibility of all prepared
micelleplexes compared to AmOx homopolymers. Micelleplexes with 80 or 100 wt % revealed a similar transfection eﬃciency as
PEI, while the cell viability was signiﬁcantly higher (80 to 90% compared to 60% for PEI).
■ INTRODUCTION
Modern gene therapy uses two diﬀerent types of gene carriers,
namely viral and nonviral systems. Because of their high
transfection eﬃciency and approval in clinical trials, virus-based
systems are more common in recent gene therapy approaches.1
Although viruses are predestinated for gene delivery, caused by
their evolutionary optimization, there are some disadvantages,
which hamper the use of viruses in gene therapy. One major
drawback of viral vectors is the occurring immunogenicity,
which may cause an activation of inﬂammatory cells leading to
the degeneration of treated tissue. Moreover, toxin production
and insertional mutagenesis were observed in some cases.
Because of their size, viral vectors are limited by the transgenic
capacity; furthermore, the upscaling of these systems is
challenging.2
Thus, even if the eﬃciency of nonviral systems is lower
compared to viral systems, there are signiﬁcant advantages,
which constitute nonviral systems as relevant alternatives in the
area of gene delivery. In general, nonviral vectors show
relatively low host immunogenicity; moreover, they allow an
almost unlimited transgene size and provide the ability of
repeated application.3 Additionally, compared to viruses,
nonviral systems beneﬁt from low-cost production and their
ability for an easy upscaling. Most commonly, cationic polymers
are used for gene delivery since they are capable of forming
polyplexes with the negatively charged phosphate backbone of
nucleic acids. Because of the positive charges of the polymer,
the polyplex can interact with the negatively charged cell
membrane and is consequently internalized via endocytosis.
Subsequently, the complexes need to undergo endosomal
escape into the cytoplasm, resulting in the release of the
polyplexes.4 P. Stayton et al. demonstrated that pH-dependent
amphiphilic nanocarriers are capable to trigger an enhanced
endosomal release by interaction with the endosomal
membrane.5 Thus, changes in the pH value and protein
interactions trigger the dissociation of the polyplex, and thus,
the genetic material can enter the nucleus to transfect the cells.
Poly(ethylene imine) (PEI) is one of the most commonly used
materials for gene delivery applications and for a long time it
was claimed to be the gold standard for the transfection of
genetic material.6 Its high charge density leads to the formation
of physiological stable PEI−DNA polyplexes. In general, the
high eﬃciency of PEI is based on the ability of the amine
groups to buﬀer the pH value over a wide range, causing an
eﬃcient endosomal escape (proton sponge eﬀect).7 Disadvan-
tages of PEI-based systems are their high in vitro and in vivo
toxicity and their resistance against biodegradation, leading to
the accumulation of the polymer in the cells or tissue, which
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can elicit further toxicity eﬀects.8 Furthermore, the cytotoxicity
has been shown to be dependent on the molar mass of the
polymers9 but can be improved by the introduction of stealth
units, that is, EtOx, into the polymer chain.10,11 These
drawbacks lead to a necessity to search for alternative polymer
systems for gene delivery applications, which reveal high
transfection eﬃciencies while expressing a low cytotoxicity. K.
Miyata et al. introduced primary and secondary amines into the
side chains of poly(aspartamide) to induce pH-sensitive
membrane destabilization at an endosomal pH value of 5,
resulting in enhanced cytocompatibility at physiological pH
values of 7.12 Another possibility to fulﬁll this aim was shown to
be the introduction of hydrophobic units, such as cholesterol13
or stearic acid,14 to the cationic polymer chains. The
hydrophobic units could be shown to increase the cellular
uptake as well as the transfection eﬃciency, however, not the
cytotoxicity.
The aim of this study was the development of a micellar
polymeric gene delivery system with low cytotoxicity combined
with enhanced cellular uptake and transfection eﬃciency by
adjusting the ratio of stealth and cationic units. Poly(2-
oxazoline)s (P(Ox)s) are a class of polymers that were
intensively studied during the past years in the context of
several potential applications.15−17 In the ﬁeld of nanomedicine,
the combination of enhanced biocompatibility and structure
variability has been shown to be an essential beneﬁt of this
polymer class.17−19 The synthesis of P(Ox)s by the living
cationic ring-opening polymerization (CROP) provides even
access to sophisticated polymer architectures such as block
copolymers20 and star-shaped,21,22 hyperbranched,23 and cross-
linked networks.24,25 The combination of monomer units
bearing side-chains with diﬀerent hydrophilicities leads to
amphiphilic copolymers, which can self-assemble into diﬀerent
nanostructures.25 Block copolymers of two or more chemically
diﬀerent polymer chains,26 which potentially phase separate in
bulk or selective solvents, provide access to several deﬁned self-
assembled structures. Furthermore, cationic P(Ox)s have
already shown their potential in gene delivery applications.27,28
For these reasons, we synthesized two diﬀerent amphiphilic
block copolymers. The ﬁrst copolymer consisted of NonOx for
the formation of a hydrophobic core and the amino-
functionalized AmOx to facilitate polyplex formation with the
genetic material. The second copolymer consisted of the same
hydrophobic unit; however, EtOx served as the hydrophilic
block since it is known for its stealth properties.29 Finally,
mixed nanostructures with diﬀerent weight ratios of these two
block copolymers were prepared and characterized regarding
the micelle size, PDI value, pH-responsiveness, CMC, toxicity,
polyplex formation, and dissociation as well as their cellular
uptake and transfection eﬃciency.
■ MATERIALS AND METHODS
Materials and Instrumentation. Triethylamine (TEA, Sigma-
Aldrich), butyronitrile (VWR), 2-ethyl-2-oxazoline (EtOx, Sigma-
Aldrich), 2-nonyl-2-oxazoline (NonOx, Henkel), and methyl tosylate
(MeTos, Sigma-Aldrich) were distilled to dryness over calcium
hydride (VWR) under argon atmosphere prior to usage. Ethyl acetate
(EtOAc) and acetone, hydrochloric acid, N,N-dimethylformamide
(DMF), and tetrahydrofuran (THF) were purchased from VWR
Chemicals. Acetonitrile was obtained from a solvent puriﬁcation
system (MB-SPS-800 by MBraun) and stored under argon. All other
solvents used were obtained from standard suppliers. Ethidium
bromide solution (1%, 10 mg mL−1) was purchased from Carl Roth
(Karlsruhe, Germany). AlamarBlue YOYO-1 iodide and Hoechst
33342 trihydrochloride as well as all other indicated CLSM dyes were
obtained from Life Technologies (Thermo Fisher Scientiﬁc,
Germany). If not stated otherwise, cell culture media and solutions
(L-glutamine, antibiotics) were obtained from Biochrom (Berlin,
Germany). Plasmid eGFP (pEGFP-N1, 4.7 kb, Clontech, USA)
enhanced green ﬂuorescent protein (eGFP) was isolated with the Giga
Plasmid Kit provided by Qiagen (Hilden, Germany). Plasmid pCMV-
GFP was obtained from PlasmidFactory (Bielefeld, Germany).
The synthesis of 2-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxazo-
line (BocOx) was described previously in our research group.24
Cryo transmission electron microscopy (cryoTEM) investigations
were conducted with a FEI Tecnai G2 20 at 200 kV acceleration
voltage. Specimens were vitriﬁed by a Vitrobot Mark V system on
Quantifoil grids (R2/2). The blotting time was 1 s with an amount of
solution of 8.5 μL. Samples were plunge frozen in liquid ethane and
stored under liquid nitrogen until transfer to the Gatan cryo-holder
and brought into the microscope. Images were acquired with an
Olympus Mega View camera (Olympus Soft Imaging Solutions; 1376
× 1032 pixels) or an Eagle 4 × 4 k CCD camera system.
Proton NMR spectroscopy (1H NMR) was performed at room
temperature using a Bruker Avance I 300 MHz spectrometer, utilizing
either CDCl3, CD3OD, or D2O as solvent. The chemical shifts were
given in ppm relative to the signal from the residual nondeuterated
solvent.
Size exclusion chromatography (SEC) of the copolymers was
performed on an Agilent 1200 series system, equipped with a PSS
degasser, G1329A pump, a PSS GRAM guard/30/1000 Å with 10 μm
particle size, and a G1362 refractive index (RI) detector. DMAc
containing 0.21% LiCl served as eluent. The column oven was set to
40 °C at a ﬂow rate of 1 mL min−1 and polystyrene (PS, 400−
1 000 000 g mol−1) served as the calibration.
SEC of the Boc-protected P(EtOx3-b-BocOx157) was performed on
a Shimadzu system equipped with a CBM-20A controller, GDU-14A
degasser and a LC-10AD VP pump, a PSS SDV guard/linear S column
with 5 μm particle size, and a RID-10A RI detector. CHCl3-iso-
propanol (i-PrOH)-NEt3 (94:2:4) served as eluent. The column oven
was set to 40 °C using a ﬂow rate of 1 mL min−1. PS (400−100 000 g
mol−1) served as the calibration.
SEC of the P(EtOx3-b-AmOx157) was conducted using a Jasco
system equipped with a DG-980−50 degasser and a PU-980 pump,
PSS SUPREMA-MAX guard/300 Å column with 10 μm particle size,
and a RI-930 RI detector. 0.3% (v/v) TFA containing 0.1 M NaCl
served as aqueous eluent. The column oven was set to 30 °C utlizining
a ﬂow rate of 1 mL min−1. Poly(2-vinylpyridine) (P2VP, 1 300−
81 000 g mol−1) served as the calibration.
Lyophilization of the nanostructure suspensions was conducted
using an Alpha 1−2 LDplus freeze-dryer from Martin Christ
Gefriertrocknungsanlagen GmbH (Germany). Absorbance and ﬂuo-
rescence measurements of the bioassays were performed at RT using a
TECAN Inﬁnite M200 PRO.
Confocal laser scanning microscopy (CLSM) was performed with
an LSM880 ELYRA PS.1 system (Zeiss, Oberkochen, Germany)
applying a 63 × 1.4 NA plan apochromat oil objective.
Batch dynamic light scattering (DLS) was performed on a Zetasizer
Nano ZS (Malvern Instruments, Herrenberg, Germany). All measure-
ments were performed in standard polypropylene semi micro cuvettes,
Malvern Instruments, Herrenberg, Germany). After an equilibration
time of 180 s, 3 × 300 s runs were carried out at 25 °C (λ = 633 nm).
Scattered light was detected at an angle of 173°. Each measurement
was performed in triplicates (three measurements consisting of three
runs each per sample). Apparent hydrodynamic radii, Rh, were
calculated according to the Stokes−Einstein eq 1:
πη
=R
kT
D6
h
(1)
Synthesis of P(Ox)s. All polymerization solutions were prepared
within a glovebox under nitrogen atmosphere.
Polymerization reactions of 2-oxazolines were performed under
microwave irradiation using an Initiator Sixty single-mode microwave
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synthesizer from Biotage, equipped with a noninvasive IR sensor
(accuracy: 2%). Microwave vials were heated overnight at 100 °C
under vacuum and allowed to cool to room temperature under argon
before usage. Polymerizations were performed under temperature
control. According to the polymer characteristics, SEC of the polymers
was performed on diﬀerent systems and noted in the respective part.
The synthesis of P(Ox)s was described previously.30
P(EtOx3-b-BocOx157). In a microwave vial, MeTos (1.9 mg, 0.01
mmol), EtOx (3.0 mg, 0.03 mmol), and acetonitrile (392.6 mg) were
mixed under inert conditions and heated in the microwave to 140 °C
for 63.5 min. Subsequently the vial was opened under an inert
atmosphere, and BocOx (477.4 mg, 1.97 mmol) was added. The
reaction mixture was heated in the microwave at 140 °C for additional
18.0 min. The resulting polymer diluted with chloroform and
precipitated in ice-cold diethyl ether. The precipitate was ﬁltered oﬀ
and redissolved in chloroform. The solvent was evaporated under
reduced pressure to obtain the product as a white solid (391 mg, 82%).
Deprotection of P(EtOx3-b-BocOx157) Yielding P(EtOx3-b-
AmOx157). P(EtOx3-b-BocOx157) (390 mg, 10.2 mmol) was dissolved
in 10 mL of MeOH, and 2 mL of concentrated hydrochloric acid was
added. The reaction mixture was stirred at room temperature for 24 h.
Subsequently, the solvent was evaporated under reduced pressure, and
the crude product was redissolved in 10 mL of MeOH and
precipitated in ice cold diethyl ether. Then the precipitate was ﬁltered
oﬀ and redissolved in 100 mL of MeOH. Amberlyst A21 was added
and the mixture was stirred slowly (100 rpm) overnight at room
temperature. Then the Amberlyst A21 was ﬁltered oﬀ and the organic
solvent was evaporated under reduced pressure. The polymer was
redissolved in 10 mL of deionized water and lyophilized to obtain the
product as a white powder (186 mg, 81%).
P(EtOx155-b-NonOx76). In a microwave vial, MeTos (24.8 mg, 0.13
mmol), EtOx (1.98 g, 20.0 mmol), and butyronitrile (13.0 g) were
mixed under inert conditions and heated in the microwave to 140 °C
for 130 min. Subsequently, the vial was opened under an inert
atmosphere, a sample of 100 μL was taken, and NonOx (1.58 g, 8.0
mmol) was added. The reaction mixture was heated in the microwave
at 140 °C for another 120 min. The resulting polymer was precipitated
in ice-cold diethyl ether and centrifuged at 11 000 rpm for 5 min. The
supernatant was discarded, and the solid was redissolved in CH2Cl2.
The solvent was evaporated under reduced pressure to obtain the
product as a white solid (1.7 g, 86%).
P(NonOx52-b-BocOx184). In a microwave vial, MeTos (7.8 mg,
0.04 mmol), NonOx (493 mg, 2.5 mmol), and butyronitrile (6.1 g)
were mixed under inert conditions and heated in the microwave to 140
°C for 120 min. Subsequently, the vial was opened under an inert
atmosphere, a sample of 100 μL was taken, and BocOx (1.75 g, 7.2
mmol) was added. The reaction mixture was heated in the microwave
at 140 °C for another 90 min. The resulting polymer was precipitated
in ice-cold diethyl ether, and the solid was resuspended in deionized
water and centrifuged at 11 000 rpm for 5 min. The supernatant was
discarded, and the solid was suspended in deionized water. The
solvent was lyophilized under reduced pressure to obtain the product
as a white powder (740 mg, 33%).
Deprotection of P(NonOx52-b-BocOx184) Yielding P-
(NonOx52-b-AmOx184). P(NonOx52-b-BocOx184) (700 mg, 12.8
mmol) was dissolved in 5 mL of TFA and stirred at room temperature
overnight. Subsequently, 5 mL of MeOH was added, and the polymer
was precipitated in ice-cold diethyl ether. The precipitate was
redissolved in MeOH, Amberlyst A21 was added, and the solution
was stirred slowly at room temperature for 72 h. Afterward, Amberlyst
A21 was ﬁltered oﬀ, and the solvent was evaporated under reduced
pressure. The polymer was resuspended in deionized water, and the
solvent was lyophilized under reduced pressure to obtain the product
as a white powder (457 mg, 98%).
Self-Assembly. Fifty milligrams of polymer was dissolved in 10
mL of DMAc by vortexing and ultrasoniﬁcation. Subsequently, 10 mL
of ultrapure water was added slowly using a syringe pump (5 mL h−1)
under continuous stirring (1000 rpm). After that, the resulting
solution was transferred to a dialysis tube (cellulose, MWCO 3.5 kDa)
and dialyzed against distilled water for 4 days by daily water exchange.
Subsequently, it was diluted using a 1.8 wt % aqueous NaCl solution to
adjust the salt concentration to 0.9 wt % (pH = 6). The resulting
nanostructures were ﬁltered using a 0.2 μm syringe ﬁlter and
characterized by DLS measurements.
The concentration of the polymer in the resulting solution was
determined gravimetrically (n = 3) after lyophilization of the samples.
For this reason, also a 0.9 wt % aq. NaCl solution was lyophilized (n =
3). The mean of the mass of the NaCl samples was subtracted from
each polymer containing sample to obtain the absolute polymer mass.
The average molar mass of the micelles was calculated by using eq
2:
=
× ‐ ‐ + × ‐ ‐
M
M Wt b M Wt b%(P(NonOx AmOx ) %(P(EtOx NonOx )
100
n 52 184 n 155 76
(2)
pH Responsive Behavior. The pH-responsiveness of the
nanostructures was determined by mixing 1 mL of a 1.0 mg mL−1
solution with 1 mL of the following buﬀers (Table S1).
The solutions were incubated at room temperature overnight at 200
rpm (BioShake iQ, Qantifoil Intruments GmbH, Jena, Germany).
Afterward the pH value was checked and the Z-average and PDI were
determined by DLS measurements.
Determination of Critical Micelle Concentration (CMC). The
determination of the CMC via pyrene method was described
previously.31 Fluorescence was recorded with a Jasco FP 6500. A
serial dilution of the nanostructure suspension in 0.9 wt % aq. NaCl
was prepared.
A saturated pyrene solution in 0.9 wt % aq. NaCl was prepared as
follows. Pyrene was dissolved in acetone (1 mg mL−1) and added
dropwise to a solution of 0.9 wt % in ultrapure water until a slight
precipitation (visible turbidity) occurred. The solution was stirred for
48 h at room temperature (1000 rpm) to evaporate the acetone. Then
the solution was ﬁltered using a pleated ﬁltered to remove any
precipitate. Subsequently, the same volume of the saturated solution of
pyrene in 0.9 wt % aq. NaCl was added to each dilution of the micelles
to obtain a total volume of 2 mL. The mixtures were incubated
overnight at room temperature at 200 rpm (BioShake iQ, Qantifoil
Intruments GmbH, Jena, Germany). Excitation spectra were collected
at λEm = 390 nm and λEx = 300−380 nm. The pyrene stock solution
served as the calibration sample and was subtracted from all spectra
prior to calculations to remove any ﬂuorescence artifacts. For
calculation of the CMC, the resulting spectra were used. The
ﬂuorescence intensity at λEm = 390.0 nm while exciting at λEx2 = 338.0
nm was divided by the ﬂuorescence intensity at λEm = 390.0 nm while
exciting at λEx2 = 332.5 nm and plotted against the log of the polymer
concentration. A nonlinear Boltzmann ﬁtting and a subsequent linear
ﬁtting were conducted using OriginPro 2015G. Hereby, the
Boltzmann ﬁtting was used to visualize visible areas, while the linear
ﬁt was utilized to obtain the cross-point of two diﬀerent linear areas,
which corresponds to the CMC of the nanostructures.
Cell Culture. HEK-293 cells (CRL-1573) were cultured in DMEM
medium with L-glutamine (Biochrom, Berlin, Germany) supplemented
with 1 g L−1 glucose, 10% fetal calf serum (FCS, v/v), 100 μg mL−1
streptomycin and 100 IU mL−1 penicillin at 37 °C in a humidiﬁed 5%
CO2 atmosphere.
Cytotoxicity. The cytotoxicity was tested with L929 cells, as this
cell line is recommended by ISO10993−5. In detail, cells were seeded
at 104 cells per well in a 96-well plate and incubated for 24 h. No cells
were seeded in the outer wells. After exchanging the media with fresh
one and 30 min incubation, polymers at the indicated end
concentrations were added, and the cells were incubated at 37 °C
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for additional 24 h. Subsequently, the medium was replaced by fresh
media and AlamarBlue (Life Technologies, Darmstadt, Germany) as
recommended by the supplier. After incubation for 4 h, the
ﬂuorescence was measured at λEx = 570 nm, λEm = 610 nm, with
untreated cells on the same well plate serving as controls. The
experiments were performed independently three times on three
diﬀerent well-plates.
Hemolysis Assay and Erythrocyte Aggregation. All animal
husbandry is performed in compliance with the relevant European and
German laws, institutional guidelines, and to state the institutional
animal committee. The sheep blood was taken for general veterinary
management of the animal health.
To assess the hemolytic activity of the polymer solutions, blood
from sheep, collected in heparinized-tubes (Institut für Versuch-
stierkunde and Tierschutz/Laboratory of Animal Science and Animal
Welfare, Friedrich Schiller University Jena), was centrifuged at 4500 ×
g for 5 min, and the pellet was washed three times with cold 1.5 mmol
L−1 phosphate buﬀered saline (PBS, pH = 7.4). After dilution with
PBS in a ratio of 1:7, aliquots of erythrocyte suspension were mixed
1:1 with the polymer solution and incubated in a water bath at 37 °C
for 60 min. After centrifugation at 2400 × g for 5 min, the hemoglobin
release into the supernatant was determined spectrophotometrically
using a microplate reader at λEx = 544 nm wavelength. Complete
hemolysis (100%) was achieved using 1% Triton X-100 serving as
positive control. Thereby, PBS served as negative control (0%). A
value less than 2% hemolysis rate was taken as nonhemolytic.
Experiments were run in triplicates and were performed with three
diﬀerent blood donors. The hemolytic activity of the polycations was
calculated by eq 3:
= ×
−A A
A
% Hemolysis 100
( )sample negative control
positive control (3)
For the examination of the erythrocyte aggregation, erythrocytes were
isolated as described above. An erythrocytes suspension was mixed
with the same volume of polymeric micelle solution in a clear ﬂat
bottomed 96-well plate. The cells were incubated at 37 °C for 2 h, and
the absorbance was measured at λEx = 645 nm in a microplate reader.
b-PEI (25 kDa, 50 μg mL−1) was used as positive control and PBS-
treated cells served as the negative control. Absorbance values of the
test solutions lower than the negative control were regarded as
aggregation. Experiments are the result of triplicates and were
performed with three diﬀerent donor blood batches.
Polyplex Formation. Polyplexes of pDNA and polymeric micelles
were prepared by mixing stock solutions of 1.5 μL pDNA (1 mg
mL−1) and diﬀerent amounts of polymeric micelle solutions (1 mg
mL−1) to obtain various N*/P ratios (amines of polymer to phosphate
of pDNA) 150 mM aq. NaCl solution. 150 mM aq. NaCl was used to
equalize the volumina of the diﬀerent solutions. The solutions were
vortexed for 10 s at maximal speed (2700 min−1) and incubated at
room temperature for 20 min to ensure complex formation.
Ethidium Bromide Quenching Assay (EBA). Brieﬂy, a master
mix containing 69 μg mL−1 pDNA and 4.6 μg mL−1 ethidium bromide
was prepared in 150 mM NaCl and incubated in the dark for 10 min at
room temperature. Subsequently, polyplexes were prepared in black
96-well plates (Nunc Thermo Fisher) by adding diﬀerent amounts of
polymeric micelles (various N*/P ratios) to 20 μL of master mix per
well. The diﬀerences in the ﬁnal volume of polymer were equalized by
ﬁlling up with 150 mM NaCl to 230 μL per well (for exact amounts,
see also Table S2; for ﬁnal polymer concentrations, see Table S3).
The samples were incubated in the dark at room temperature for 5
min. The ﬂuorescence of the samples was measured at λEx = 525 nm
and λEm = 605 nm using a microplate reader. A sample containing the
same amount of pDNA and ethidium bromide diluted using 150 mM
NaCl was used as a reference for 100% ﬂuorescence to calculate the
percentage of dye displaced upon polyplex formation (eq 4):
= ×
F
F
RFU [%] 100
sample
pDNA (4)
Here, RFU is the relative ﬂuorescence, and Fsample and FpDNA are the
ﬂuorescence intensities of a given sample and the ethidium bromide
intercalated into pDNA alone.
Heparin Dissociation Assay. To investigate the release of pDNA
from polyplexes, the heparin dissociation assay was performed.
Polyplexes with an N*/P ratio of 50 were prepared as described
above in a total volume of 115 μL of 150 mM NaCl containing
ethidium bromide (0.4 μg mL−1) (for exact amounts, see also Table
S2). After incubation in the dark at room temperature for 10 min, the
master mix was transferred into 1.5 mL reaction tubes (one per
polymer) and polymers were added. Subsequently, the polyplexes were
transferred into a black 96-well plate, and heparin of indicated
concentrations was added. The solution was mixed and incubated for
further 15 min at 37 °C in the dark.
Flow Cytometry. For transfection and uptake studies, HEK-293
cells were used. In detail, 5 × 104 cells were seeded in each well of a
24-well plate and cultured for 24 h. One hour prior to the addition of
the polyplexes, the medium was changed to 0.5 mL of fresh culture
media. For kinetic studies, pDNA was labeled with YOYO-1 iodide
(YOYO-1) prior to the polyplex preparation. For labeling of 1 μg of
pDNA, 0.026 μL of 1 M YOYO-1 solution was mixed with pDNA and
incubated for 20 min at 4 °C protected from light. The polyplexes
were prepared as described above, and at least 50 μL was added to the
cells (dependent on the N*/P ratio of the polymers, for the exact
Scheme 1. Schematic Representation of Block Copolymerization of 2-Oxazolines via CROPa
a(A) P(EtOx155-b-NonOx72) was synthesized using the sequential monomer addition of EtOx and NonOx. (B) P(NonOx52-b-AmOx184) was
synthesized via the sequential monomer addition of NonOx and BocOx. The resulting block copolymers were deprotected using TFA and
neutralized with Amberlyst A21. Blue: EtOx. Grey: NonOx. Red: BocOx/AmOx.
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amounts see also Table S4). The amount of pDNA added to the cells
was kept constant (0.75 μg pDNA). The plates were incubated for the
indicated time point at 37 °C, 5% CO2. Afterward, the cells were
harvested by trypsinization and were resuspended in PBS
supplemented with 1% FCS. To determine the transfection eﬃciency
or polyplex uptake of the polyplexes, 10 000 cells were measured by
ﬂow cytometry using a Cytomics FC 500 (Beckman Coulter). The
amount of viable cells showing YOYO-1 or eGFP signals were gated
and the mean ﬂuorescence intensity (MFI) of all viable cells were
compared. To quench the outer ﬂuorescence of YOYO-1 labeled
polyplexes, 10% trypan blue was added prior to the measurement.
Dead cells were identiﬁed via shift in the side and forward scatter of
cells.32 The experiments were performed at least three times.
Confocal Microscopy. For CLSM studies, 5 × 104 cells were
seeded on glass-bottomed dishes (CellView cell culture dishes with
four compartments, Greiner bio-one) and cultivated for 24 h. One
hour prior to the polymer addition, the medium was changed to 0.5
mL of fresh growth media. The polyplexes were formed using YOYO-
labeled pDNA as described above, added to the cells, and incubated
for additional 4 h. Subsequently, medium was replaced by fresh culture
medium supplemented with Hoechst 33342 for nucleus staining,
LysoTracker Red DND-99 (all from Thermo Fisher Scientiﬁc) for
lysosome staining respecting the instructions given by the Supplier.
Prior to imaging, 10% trypan blue was added to quench the outer
ﬂuorescence of YOYO-1 labeled pDNA.
Live-cell imaging was performed on an LSM880, Elyra PS.1 system
(Zeiss, Oberkochen, Germany). Three color channels were recorded:
blue (nucleus, Hoechst 33342, λEx = 405 nm,), green (pDNA, YOYO-
1 Iodide, λEx = 488 nm), and red (lysosome, LysoTracker Red DND-
99, λEx = 561 nm). To avoid possible cellular motions in the time
frame of the experiment, a quick measurement was warranted by the
simultaneous acquisition of all three color channels.
■ RESULTS AND DISCUSSION
Polymer Synthesis. The aim of this study was to obtain
mixed polymeric micelles, with a cationic and a stealth polymer
within the shell for eﬃcient cellular uptake, transfection, and
reduced cyto- and hemotoxicity. For this purpose, two diﬀerent
block copolymers were synthesized via the sequential monomer
addition method (Scheme 1). By using this preparation
method, the order of the block sequence is of signiﬁcance
importance for the dispersity of the resulting block copolymers.
Utilizing the less reactive monomer ﬁrst might lead to slower
initiation speeds during the polymerization of the second block,
and, consequently a loss of the living/controlled character of
the polymerization. For this reason, the nonionic copolymer
was polymerized with EtOx representing the ﬁrst and NonOx
as the second block (Scheme 1A). For a successful preparation
of the cationic block copolymer, on the other hand, it was
necessary to use NonOx as the ﬁrst block since the
polymerization of Boc-protected primary amine functionalized
2-oxazolines with common initiators leads to side-reactions
during polymerization.33
NonOx served as the hydrophobic block in both copolymers,
while the hydrophilic block either contained AmOx, to obtain
good DNA binding capabilities, or EtOx to enhance the
biocompatibility of the micelles due to its stealth properties.
The polymers were analyzed using 1H NMR and SEC
measurements (Table 1, Figures S1−S5). In both polymers,
the degree of polymerization (DP) of the NonOx block was
kept similar, resulting in diﬀerent weight ratios of the
hydrophobic and the hydrophilic blocks, namely 55% to 45%
in case of P(EtOx155-b-NonOx76) and 28% to 72% in case of
P(NonOx52-b-AmOx184), respectively. The DP of the AmOx
block was adjusted higher than the EtOx block to facilitate the
endosomal release of the micelle−DNA complexes (micelle-
plexes) and, consequently, of the genetic material by stretching
of the cationic blocks within the endolysosome (fusion of and
endosome and a lysosome) caused by a decrease of the pH
value from 7.4 to 5. Prelimary polymerizations in acetonitrile
(data not shown) lead to the precipitation of NonOx
containing polymers. For this reason, butyronitrile was chosen
as a suitable solvent for block copolymerization, even though
the obtained dispersity of polymers is in general increased
compared to polymers synthesized in acetonitrile. Nevertheless,
both block copolymers also showed a comparable total DP as
well as a narrow dispersity (Đ < 1.2) regarding SEC
measurements in DMAc (Figure S4). In addition to that, an
entirely hydrophilic polymer, mainly consisting of AmOx
(P(EtOx3-b-AmOx157)), was synthesized using an oligo(EtOx)
initiator and characterized for comparison. Since the controll-
ability of the polymer dispersity was determined to be
enhanced by using acetonitrile as the solvent for polymerization
compared to butyronitrile, this polymer was prepared in
acetonitrile. Because of its high AmOx content, it is entitled as
AmOx homopolymer in the following discussion.
Table 1. Key Properties of Synthesized Polymers
ID SECa 1H NMRb
Mn Mw Đ DP DP mol % mol % wt % wt %
[kDa] [kDa] hydrophilic NonOx hydrophilic NonOx hydrophilic NonOx
block block block block block block
P(EtOx)155 22.6 25.0 1.11 155 n.a.
f 100 n.a. 100 n.a.
7.6d 9.4d 1.24d
P(EtOx155-b-NonOx76) 38.3 43.6 1.14 155 76 67 33 45 55
17.2d 18.4d 1.07d
P(NonOx)52 12.4 13.0 1.04 n.a. 52 n.a. 100 n.a. 100
9.0d 9.7d 1.08d
P(NonOx52-b-BocOx184) 32.2 38.3 1.19 184 52 78 22 81 19
22.1d 22.9d 1.29d
P(NonOx52-b-AmOx184) 24.3 30.5 1.26 184
c 52c 78c 22c 72c 28c
P(EtOx3-b-BocOx157) 15.3
d 16.8d 1.10d 160 0 100 0 100 0
P(EtOx3-b-AmOx157) 13.5
e 21.0e 1.56e 160c 0c 100c 0c 100c 0c
aSEC (eluent: DMAc, 0.21% LiCl; PS-standard). b1H NMR (300 MHz). cCalculated from Boc-protected precursor polymer. dSEC (eluent: CHCl3-
i-PrOH-NEt3 94:2:4; PS-standard).
eSEC (eluent: 0.1 M NaCl(aq) + 0.3% TFA; P2VP-standard).
fn.a., not available.
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Self-Assembly. For self-assembly, the polymers were mixed
in diﬀerent weight ratios and dissolved in DMAc serving as the
nonselective solvent. Subsequently, an equal amount of
ultrapure water serving as the selective solvent was added
very slowly (1 mL h−1) to induce micelle formation.
Subsequently, the solution was dialyzed against deionized
water to allow a slow increase of the total water content while
the organic solvent diﬀuses out. The stability of the
nanostructures in physiological medial, for example, NaCl
solution, represents an important criterion for further in vivo
applications. For this reason, the nanostructures were mixed
with aq. NaCl to obtain a total NaCl amount of 0.9 wt % in
solution. All micelles were characterized regarding their size and
PDI value by DLS measurements (Figure 1A and S6, Tables S5
and S6). All nanostructures containing P(EtOx155-b-NonOx76)
formed nanostructures with an average diameter of about 80 to
100 nm, while the self-assembly of P(NonOx52-b-AmOx184)
resulted in signiﬁcantly smaller structures with a diameter of 60
nm. Furthermore, all micelles with P(EtOx155-b-NonOx76)
exhibited a PDI below 0.2 while micelles, which consist only of
P(NonOx52-b-AmOx184), showed a PDI of 0.25.
The size diﬀerences of the self-assembled micelles of either
P(EtOx155-b-NonOx76) or P(NonOx52-b-AmOx184) are distinct
and all measured DLS curves were monomodal in terms of
intensity, volume, and number PSD (Figures 1A and S6, Table
S2).
After size determination via DLS, cryoTEM measurements
were used to obtain further information about the shape and
uniformity of the nanostructures (Figure 1B, Figure S8).
Micelles consisting of only of P(EtOx155-b-NonOx76) formed
rod-like structures, while those prepared from pure
P(NonOx52-b-AmOx184) were predominantly spherical. Next
to the rod-like structures formed exclusively by P(EtOx155-b-
NonOx76) also sheet-like structures were observable. Darker
rods are presumably sheets with a parallel orientation with
respect to the electron beam. More interestingly, by mixing the
two polymers P(EtOx155-b-NonOx76) and P(NonOx52-b-
AmOx184) using ratios of 20, 40, 60, or even 80% of
P(NonOx52-b-AmOx184), the micelles were still rod-like with
respect to the cryoTEM measurements. Furthermore, in
cryoTEM, all samples feature the same mixture of similar
structures that indicates the formation of mixed micelles rather
than the formation of two species consisting of the two polymer
components. Moreover, already the 100:0 sample featured the
coexistance of rod-like structures and sheet-like aggregates.
Recently, S. Jaksch et al. reported on the formation of worm-
like micelles using triblock (ABA) copolymers with NonOx as
the hydrophobic block (B) and MeOx as the hydrophilic blocks
(A).34 Hereby, it was also possible to observe changes in the
nanostructure by the encapsulation of hydrophobic drugs such
as paclitaxel.
After characterization of the micelles via DLS and cryoTEM,
the critical micelle concentration (CMC) in physiological
sodium chloride solution was determined by the pyrene
method. After incubation overnight, excitation measurements
at λEm = 390.0 nm were conducted. The peak intensities at λEx1
= 332.5 nm and λEx2 = 338.0 nm were compared to calculate
the CMC (Table 2, Figure S9). The nanostructures consisting
of 100, 80, and 60 wt % P(EtOx155-b-NonOx76)) exhibited a
CMC of around 2 × 10−7 M, those with 40, 20, and 0 wt %
P(EtOx-155-b-NonOx76)) showed a CMC of about 1 × 10
−6 M.
These values are expected since nanostructures from P(MeOxn-
Figure 1. (A) Z-average and PDI values of the prepared nanostructures in 0.9 wt % aq. NaCl determined by DLS. (B) Zoom-in cryoTEM images of
the prepared nanostructures in 0.9 wt % aq. NaCl. Ratios describe the mass ratios of P(EtOx155-b-NonOx76) to P(NonOx52-b-AmOx184) being used
during nanostructure preparation. Full pictures can be found in the Supporting Information. (C) Schematic representation of the obtained shapes of
the nanostructures dependent on the used block copolymers in diﬀerent ratios. Blue represents EtOx, gray represents NonOx, and red represents the
cationic AmOx block.
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b-NonOxm) are reported to have a CMC between 10
−6 and
10−5 M.35−37
pH Responsiveness. The transport of the genetic material
is presumably realized by endosomal pathways. Hereby, the
decrease in the pH values inside the endolysosomes leads to an
endosomal burst and the subsequent release of the polyplex.
Cationic charges are known to force this membrane
disruption.38 This side eﬀect should be reduced outside the
cell but be active inside the endolysosomes. Consequently, a
pH-dependent shielding of the cationic charges is a favorable
polymer design strategy.39 By the preparation of mixed
micelles, we aim to obtain a system that is composed of the
pH dependent AmOx shell that expands upon reduction of the
surrounding pH value, mixed with EtOx units, which should
provide stealth properties and do not show pH-responsiveness
(Figure 2A).
To prove our assumption, we diluted the nanostructures in
aqueous buﬀers of diﬀerent pH values (pH = 4.10, 5.04, 6.17,
7.04, 7.58, 8.00, Table S1) and determined the changes in Z-
average and PDI value by DLS measurements (Figure S9).
Control measurements, diluting the nanostructures with an
equal volume of 0.9 wt % NaCl did not reveal any signiﬁcant
changes regarding size or PDI (Table S7). Furthermore, the
PDI values of the nanostructures at diﬀerent pH values
remained constant, verifying the stability of the nanostructures.
Furthermore, with regard cryoTEM measurements, no
morphological changes could be observed by increasing the
pH value to 8 (Figure S11). Figure 2B and C show a
dependence of the pH responsiveness on the amount of
P(NonOx52-b-AmOx184). While nanostructures with 100 wt %
P(EtOx155-b-NonOx76) maintained a similar size at any tested
pH value, nanostructures of 100 wt % P(NonOx52-b-AmOx184)
increased in size up to 130% when changing the pH value from
7 to 5. This increased size at acidic conditions is related to an
increased charge density on the AmOx block, which causes the
stretching of the polymer chains in the shell. The increased
charge density might help to force an enhanced endosomal
Table 2. CMC of Nanostructures in 0.9 wt % aq. NaCl by the
Pyrene Methoda
wt %
P(EtOx155-b-
NonOx76)
wt %
P(NonOx52-b-
AmOx184)
Mb
[kg mol−1]
CMC
[μg mL−1]
CMC
[mol L−1]
100 0 30.3 8.3 2.7 × 10−7
80 20 31.5 7.3 2.3 × 10−7
60 40 32.7 6.8 2.2 × 10−7
40 60 34.0 36.6 1.1 × 10−6
20 80 35.2 45.2 1.3 × 10−6
0 100 36.4 35.5 9.8 × 10−7
aFor calculation of the CMC, the ﬂuorescence intensity at λEm = 390.0
nm while exciting at λEx2 = 338.0 nm was divided by the ﬂuorescence
intensity at λEm = 390.0 nm while exciting at λEx2 = 332.5 nm and is
plotted against the log of the polymer concentration. bMolar mass was
calculated by using eq 2 (see Figure S8 for original plots).
Figure 2. (A) Schematic representation of the changes in size of the mixed micelles induced by changes in the pH value. Gray represents NonOx,
blue represents EtOx, and red represents the cationic AmOx block. (B) Size ratios of the nanostructure dependency on the pH value (calculated by
division of the Z-average at distinct pH values by the Z-average at a pH value of 4). (C) Size ratios of the nanostructures at pH values of 5 and 7
(calculated by division of the Z-average at distinct pH values by the Z-average at a pH value of 7). For values, see Figure S10.
Biomacromolecules Article
DOI: 10.1021/acs.biomac.7b01535
Biomacromolecules 2018, 19, 748−760
754
release, one major bottleneck during the transfection process.
By reducing the content of the AmOx polymer, the change in
size with decreasing pH value becomes less pronounced, which
correlates well with the assumption of mixed micelles, as only
the responsive AmOx in the shell will react on the change in
pH value and become more stretched at low pH values, but not
the EtOx polymer. For this reason, the measurability of the
changes in size of the mixed nanostructures might be diﬃcult
since the hydrodynamic radius is inﬂuenced by both blocks in
the shell, EtOx or AmOx. This might explain the rather low
changes of nanostructures containing 60 or 80% AmOx.
Additionally, all intensity weighted size distributions revealed a
monomodal distribution, further proving the assumption of
mixed micelles instead of two species.
Cytotoxicity, Hemolysis, and Erythrocyte Aggrega-
tion. Enhanced cyto- and hemocompatibility of polymeric gene
carriers represents an important criterion for in vivo
investigations. Unfortunately, PEI, the gold standard in terms
of transfection abilities, is very cytotoxic and leads to high
hemoglobin release and erythrocyte aggregation,40,41 which
might cause severe side-eﬀects.
For this reason, subsequently to the characterization of the
physical properties of the prepared micelles, they were also
investigated regarding their cytotoxicity, hemolysis, and
erythrocyte aggregation (Figure 3). The cytotoxicity measure-
ments (AlamarBlue assay) demonstrated that the micelles are
not toxic up to a concentration of 50 μg mL−1 (rel. cell viability
≥80%). As expected, an increase of the cytotoxicity with the
AmOx content in the micelle shell was observed (Figure 3A),
that is, all micelles with EtOx in the shell, are nontoxic at 100
μg mL−1. These data support our assumption that the toxicity
can be reduced by introduction of a neutral, biocompatible
polymer such as EtOx into the micellar shell. These results
comply with previous studies conducted on copolymers of
P(EtOx) and PEI.10,11 By preparing statistically distributed
copolymers, the cytotoxicity could be decreased signiﬁcantly at
concentrations of 5 mg mL−1 when reducing the PEI content
from 100 to 59% (24 h incubation).11 Block copolymers of
P(EtOx) and PEI also reduced the cytotoxicity;10 however, the
cell viability was lower (40 to 60% in HeLa cells) compared to
the statistic copolymers (80% in 3T3 ﬁbroblasts) with a similar
PEI amount (∼60%). These diﬀerences might be caused by the
charge density within the polymers. Presumably, the shielding
of the cytotoxic cationic charges is enhanced by a random
distribution of the stealth units compared to the block
structures, when assuming the polymers to coil in aqueous
solution. Within the current study, the cationic blocks consisted
of more repeating units than the stealth block to enhance the
endosomal release of the polyplexes caused by a possible
stretching of the cationic arms. This circumstance might also
explain the lack in terms of cytocompatibility and could be
further evaluated by preparing nanostructures with longer
stealth blocks. However, this was not part of the current study.
Interestingly, the P(AmOx) homopolymers revealed a reduced
viability to approximately 50% even at concentrations of 50 μg
mL−1, whereas our group previously showed that l-PEI575
reveals a similar eﬀect on diﬀerent cell lines after treatment
with a 3.5 μg mL−1 solution.41 B. D. Monnery et al. recently
published results on the dependency of the cytotoxicity of
polycations on their molar mass.9 Even though both polymers
have a similar molar mass (Mn ≈ 24 kDa), their cytotoxicity
diﬀers signiﬁcantly. Consequently, we attribute these diﬀer-
ences to the amount of cationic charges, respectively the charge
Figure 3. Concentration dependent cyto- and hemocompatibility of
nanostructures. (A) Cytotoxicity assay of indicated polymers using
AlamarBlue. Nontreated cells served as 100% relative viability. L929
cells were treated 24 h with the indicated concentrations of the
polymer micelle solutions. Values represent the mean ± SD (n = 3).
(B) Concentration dependent erythrocyte aggregation of nanostruc-
tures. b-PEI represents the positive control (p.c.) and PBS the negative
control (n.c.). Values represent the mean ± SD (n = 3). For
microscopy images, see Figure S12. (C) Hemolysis assay of
erythrocytes after incubation with nanostructures at indicated
concentrations. A value of less than 2% hemoglobin release is
classiﬁed as nonhemolytic and more than 5% as hemolytic. Stars depict
the position of nonhemolytic samples. Triton X was used as the p.c.
(100%) and PBS served as the n.c. and was subtracted from the values.
Values represent the mean (n = 3). Striped columns are below the
CMC of the nanostructures.
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density within the diﬀerent polymers, which is 3.5-times higher
in the utilized l-PEI.
In addition to the AlamarBlue cytotoxicity assay, the
hemolysis of the nanostructures at varying polymer concen-
trations was measured (Figure 3C). Using these measurements,
a hemoglobin release below 2% is considered to be not
hemolytic, while 2 to 5% is slightly hemolytic and a rate above
5% is hemolytic. At low polymer concentration of 10 μg mL−1,
none of the tested nanostructures was hemolytic; however, it
should be mentioned that this concentration was already below
the CMC of nanostructures with 60, 80, and 100 wt %
P(NonOx52-b-AmOx184), which were hemolytic at concen-
trations of 50 μg mL−1. In contrast to that, micelles with 0 or 20
wt % P(NonOx52-b-AmOx184) as well as the homopolymers
were not hemolytic even at polymer concentrations of 100 μg
mL−1, while those with 40 wt % P(NonOx52-b-AmOx184) were
not hemolytic up to 50 μg mL−1. l-PEI was only slightly
hemolytic at concentrations of 100 μg mL−1.40 By comparing
these results, it is obvious that the hemolytic activity of the
polymeric micelles depends on the amount of AmOx within the
shell and that the micellar structure enhances the membrane
disruption. It should be mentioned that the hemolytic activity
was tested in PBS as buﬀer system without any proteins to
further protect the cells, meaning that the critical concen-
trations might be diﬀerent in in vivo or even in vitro situations.
However, the erythrocyte aggregation represents also a method
to measure the membrane interactions of polymers (Figure
3B).42,43 Again, the aggregation rate of cells was clearly
dependent on the ratio of cationic to stealth units within the
micellar shell. In particular, the homopolymers of AmOx
showed membrane aggregation comparable to the ISO-
standard b-PEI even at the lowest concentration, whereas the
micelles revealed no erythrocyte aggregation except the 100
wt % P(NonOx52-b-AmOx184) at 100 μg mL
−1. Interestingly,
P(EtOx3-b-AmOx157) did not show hemolytic activity but a
high membrane aggregation potential. Micelles, on the other
hand, were more hemolytic, however, had a lower membrane
aggregation potential. This indicates that the micelles forces a
membrane hole formation in contrast to the homopolymers,
which is beneﬁcial for the endosomal release of these
nanostructures.
DNA Binding and Dissociation Capabilities. As the
prepared nanostructures are supposed to act as transfection
vectors, investigations on the DNA binding and dissociation
capabilities of nanostructures with 20 to 100 wt % P(NonOx52-
b-AmOx184) were conducted. The DNA binding ability was
determined by the ethidium bromide assay (EBA) and was
evaluated with respect to the nitrogen atoms bearing the
Figure 4.Micelleplex formation with pDNA and stability test using the polymer P(EtOx3-b-AmOx157) and micelles with 20 to 100 wt % P(NonOx52-
b-AmOx184). (A) EBA of all polymers at the indicated N*/P (amino groups in the polymers per phosphate groups in the DNA) ratios utilizing a
pCMV-GFP plasmid for polyplex formation in HBG buﬀer. Values represent the mean ± SD (n = 3). (B) Heparin dissociation assay of polyplexes
formed at N*/P 50 using heparin as polyanion. Values represent the mean ± SD (n = 3). (C, D) DLS determination of size (diameter) and size
distribution of polyplexes (N*/P = 50) formed with pCMV-GFP plasmid and homopolymers as well as polyplex forming micelles. Values represent
the mean and SD (n = 3). (C) One representative DLS curve and possible micelleplexe structures are shown. (D) As two populations were found,
the intensity as well as the size of the two populations was plotted.
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potential for DNA binding (amino group in the polymer side
chain) (N*/P, Figure 4A).
By comparing the nanostructures of diﬀerent AmOx content
in the micelle shell with respect to the DNA complexation, the
N*/P ratios are similar for all nanostructures. Interestingly, the
same plateau at approximately 60% ﬂuorescence intensity was
reached, even if only 20% of the shell contains DNA binding
amines. It leads to the conclusion that all nanostructures are of
the same quality for polyplex formation and the EtOx units do
not interfere with the DNA interaction, demonstrating the
potential of the block copolymers. Subsequently, the DNA
dissociation of the polyplexes was investigated by the heparin
assay (Figure 4B). A release of the DNA from micelles and
homopolymers was possible using 20 U mg−1 heparin, a
representative polyanion commonly used for DNA release.44,45
In the case of the micelles, a release was even observed at 10 U
mL−1 heparin. This result supported the assumption that the
self-assembly has an inﬂuence on the critical gene carrier
parameters, for example, caused by sterically phenomena of the
charging density. A release of the genetic material is desired to
enable transfer to the nucleus or transcription. Polyplexes were
further evaluated via DLS measurements, showing a main peak
distribution with a diameter of 100 nm and some larger
aggregates (Figure 4C,D). Even though a quantiﬁcation and
discussion of the DLS results are diﬃcult, the micelleplexes
containing 60 to 100 wt % of P(NonOx52-b-AmOx184) seem to
form less aggregates than micelleplexes with 20 or 40 wt %
P(NonOx52-b-AmOx184), possibly due to higher local charge
densities. For this reason, it is likely that micelles with more
cationic charges tend to bind one molecule of pDNA per
micelle, while micelles with less density of cationic charges
might be bound to the pDNA in groups (Figure 4C). Since the
polyplexes are prepared by aiming an N*/P ratio of 50, we
observe an excess of polymeric micelles in all cases; however,
the amount of polymers increases with a decreasing amount of
P(NonOx52-b-AmOx184), which makes the formation of such
larger micelleplexes quite likely.
Cellular Uptake. To prove whether the micelles are able to
transport the genetic material into cells, the pDNA was stained
with the intercalating dye YOYO-1 that is also not released by
the cationic polymers. Diﬀerent amounts of micelleplex
solution were added to the cells according to their N*/P
ratio. The amount of pDNA added was kept constant. After 30
min and 4 h of incubation, the cells were analyzed via ﬂow
Figure 5. Cellular uptake study of diﬀerent polyplexes (N*/P 50) using YOYO-1 labeled pDNA. (A) HEK-293 cells were treated with micelleplexes
for 30 min and 4 h in growth media and uptake was analyzed via ﬂow cytometry (MFI, mean ﬂuorescence intensity). Values represent the mean and
SD (n = 3). (B) MFI of the cells in dependence on the amount of ﬂuorescent cells after 4 h of incubation. (C) CLSM images of micelleplexes (N*/P
50) after 4 h of incubation. The cell nucleus is stained with Hoechst (blue), endosomes are stained with LysoTracker (red), and pDNA with YOYO-
1 (green). Yellow dots indicate a colocalization of green and red ﬂuorescence. Dead cells and outer ﬂuorescence of noninternalized micelleplexes
were quenched by the addition of trypan blue.
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cytometry using trypan blue to quench ﬂuorescent polyplexes
outside the cells. All polymers revealed a time-dependent
uptake in the mean ﬂuorescence intensity (MFI) as well as the
amount of cells, which internalized the micelleplexes (Figure
5A).
The transport of the genetic material of the micelles was
enhanced with increasing AmOx amount in the shell and the
micelle with 100% AmOx in the shell showed an enhanced
transfer capacity compared to the AmOx homopolymer. If
these structures are compared with the gold standard PEI it is
obvious that more cells take up polyplexes; in particular the
amount of cells is increased for all tested micelles. However, the
MFI of PEI exceeded the micelles after 4 h of incubation,
showing the better transport potential of PEI, although less
cells take up the polyplexes. This can be also observed by
CLSM investigations, where the green signal (YOYO-1) was
more intensive for the homopolymers compared to the micelles
(Figure 5C). For a better comparison of the polymers and to
obtain insight into a structure−property-relationship, the MFI
was plotted against the amount of cells (Figure 5B). Here, two
trends are visible. (i) The MFI increased with increasing
amount of AmOx in the micellar shell. The amount of cells was
constant throughout the diﬀerent compositions except for the
micelles with the lowest AmOx content (20 wt % P(NonOx52-
b-AmOx184)), which showed a slightly reduced percentage.
These facts indicate an uptake independent of the cationic
charge density in the micellar shell. In particular, the micelles
with lower AmOx content can therefore be considered as a
potential gene carrier with high bio- and hemocompatibility,
which still can transfect a high percentage of the desired cells.
(ii) The micellar structure enhances the performance of AmOx
in terms of MFI and the amount of cells taking up the genetic
material. These results underline the favorable uptake and
transport capabilities of micellar structures compared to
homopolymers.
Transfection Eﬃciency. Finally, the transfection eﬃcien-
cies of the polymers were investigated using an eGFP
expressing plasmid and the analysis via ﬂow cytometry. Again,
the amount of cells expressing eGFP as well the MFI of all
viable cells was detected. Moreover, the viability of each
measurement was analyzed and plotted against the transfection
eﬃciency (Figure 6). The polymers can be categorized into two
classes, where the ﬁrst showed only marginal transfection
eﬃciency, namely P(EtOx3-b-AmOx157), and the nanostruc-
tures that are composed of 20 or 40 wt % P(NonOx52-b-
AmOx184), respectively. The second class revealed acceptable to
high transfection eﬃciencies in the following order: 60 wt %
P(NonOx52-b-AmOx184) < 80 wt % P(NonOx52-b-AmOx184) <
100 wt % P(NonOx52-b-AmOx184) < l-PEI. In parallel to the
uptake eﬃciency of the polymers, the performance of the
micelles increased with increasing P(NonOx52-b-AmOx184)
content from 40 to 100 wt %. Micelles with 100 and 80 wt
% P(NonOx52-b-AmOx184) showed transfection eﬃciencies
similar to PEI with a distinct reduction in cytotoxicity (micelles
>80% viability, PEI 60% viability). It is noteworthy that
architecture or the assembly of the materials, respectively, has a
tremendous inﬂuence on the transfection eﬃciency. Although
P(EtOx3-b-AmOx157) revealed the smallest transfection eﬃ-
ciency, the micelle of 100 wt % P(NonOx52-b-AmOx184)
showed a performance similar to PEI, although applying the
same N*/P ratio (same amount of protonable nitrogen atoms).
This result demonstrates the potential of the micellar structure
for the development of more eﬃcient polymeric materials for
transfection.
■ CONCLUSIONS
In the current study, we synthesized two diﬀerent amphiphilic
block copolymers, namely P(NonOx52-b-AmOx184), to induce
cationic charges and P(EtOx155-b-NonOx75) for the introduc-
tion of stealth units. The two P(Ox)s were coassembled in
aqueous physiological NaCl solution and subsequently
characterized via DLS and cryoTEM. All nanostructures that
contained at least a maximum P(NonOx52-b-AmOx184) content
Figure 6. Transfection eﬃciency of diﬀerent polyplexes for adherent
HEK-293 cells in growth media at N*/P = 50 after 4 d analyzed via
ﬂow cytometry. Values represent the mean. (n = 3). (A) Relative MFI
of all viable cells normalized by the negative control (n.c.). (B)
Transfection eﬃciency of all viable cells. (C) Transfection eﬃciency of
all cells. For values, see Table S8.
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of 80 wt % resulted in rod-like micelles with an apparent
average diameter of 100 nm (assuming spheres by DLS
measurements), whereas pure P(NonOx52-b-AmOx184) micelles
were spherical. DLS measurements of the nanostructures in
buﬀers of distinct pH values resulted in a pH-dependent
alteration of the size with respect to the pH value and the
amount of P(NonOx52-b-AmOx184). A reversible polyplex
formation was possible with all amino group containing
nanostructures. We observed that the cytotoxicity, erythrocyte
aggregation, and hemolytic activity were dependent on the
polymer composition within the nanostructures. The high
charge density of the micelles led to an enhanced hemoglobin
release compared to the P(AmOx) homopolymer. Examina-
tions on the cellular uptake showed that the number of
ﬂuorescent cells is similar for all nanostructures (∼80%), while
the MFI increases applying micelles with more cationic charges.
In comparison, we observed 60% ﬂuorescent cells using l-PEI
or AmOx homopolymers and the MFI of P(AmOx) was
considerably lower than for l-PEI. Flow cytometry analysis of
the transfection eﬃciency revealed an enhanced viability of the
cells when treated with micelleplexes (80−90%) compared to
polyplexes of P(AmOx) or l-PEI (60%). The transfection
eﬃciency was strongly dependent on the amount of cationic
polymer within the micelles and ranged from less than 5% (20
wt % P(NonOx52-b-AmOx184)) to more than 60% (100 wt %
P(NonOx52-b-AmOx184)). Micelleplexes with 80 or 100 wt %
P(NonOx52-b-AmOx184) showed a better allover performance
in terms of transfection eﬃciency than l-PEI, while P(AmOx)
was worse than the micelleplexes with 20 wt % P(NonOx52-b-
AmOx184). We attribute these advantages to the architecture of
the micelles and the following accumulation of cationic charges
on their surface due to the cationic blocks. On the basis of these
ﬁndings, we were able to improve the performance of a toxic,
poorly transfecting polymer by appropriate self- and
coassembly process to obtain nanostructures with a decreased
cytotoxicity and improved transfection eﬃciency compared to l-
PEI and the AmOx homopolymer.
Further studies might concentrate on the utilization of
cationic block copolymers with diﬀerent lengths to obtain
nanostructures, which have an optimum balance between
shielding by the EtOx blocks and eﬃcient endosomal release by
the stretching of the cationic blocks within the endolysosomes.
These experiments might help to ﬁnd biocompatible and
eﬃcient gene carrier systems.
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
        
    








      


       








   


        


     
      
     


  


         
        
       

       
 
       
     
at λnanogels the absorbance was detected at λ       
      
    

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



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
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
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      
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
     
        

 L292 mouse fibroblasts (

             






     
        





        

        

       
      

        
     




      
       

       
     





      
      
       

      




its fluorescence between λ  
λ      


   

          












      
         




 



     




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33342 (blue). The fluorescence of DOX is depicted in red and the Alexafluor label of the polymer is shown in white. 
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Figure 5: Confocal fluorescence images of histological samples derived from organs of mice that were treated with 
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

       

     





(λ = 633 nm). 

      
     



 
      


in triplicate at 25° C. The zeta potential (ζ) was calculated 
from the electrophoretic mobility (μ) according to the 







        




        
  





      







20 min). The solution was precipitated in cold (−80° C, 


, 300 MHz) (6): δ = 7.66, (d, 8.1 Hz, 






mL methanol and precipitated in 400 mL of cold (−80° C) 

         

dissolved in de-ionized water and freeze dried (−80° C, 


, 300 MHz) (2): δ = 4.9 (s, 2.3 H,    



      
          
     
      
   
    






   
UV/Vis: λ = 660 nm, λ

     
  

        
         






cold diethyl ether (−80° C). To purify the self-assembled 
      
  

      





    




        


was detected at an excitation wavelength of λ = 450 nm. 

emission maximum at λ = 510 nm. 

         
 
  





     











       


     

      
      






    
        
       

     

a wavelength of λ = 450 nm and a reference wavelength 
of λ = 630 nm with untreated cells on the same well 

       



    

       




         


       




λ = 

    




      



was measured at λ = 645 nm in a microplate reader 

        

      




        
    
  
       
       

      
      
       


    



       


    


      
       



 





          



 





   
       












         






         
     








    
      

        

 


     


         

       

   
        

 
     
        
   
  




       
   
      
     









       




  




      

    


   





      




  
       
    

         

    

      


  



     
     

  



        

  


  



  


  


         



          
       

 


13. Kronek J, Kroneková Z, Lustoň J, Paulovičová E, 
Paulovičová L, Mendrek B.   


 

      
    


          


           
   
     

 
   



  
      



 

     
     

         




 
   
   

  



 


      

24. Kronek J, Paulovičová E, Paulovičová L, Kroneková 
Z, Lustoň J. Immunomodulatory efficiency of poly(2-

 
       

 
   
  

        
Stroobants S, Hoogenboom R, Staelens S. μPET imaging 


      

       

R. The Label Matters: μPET Imaging of the Biodistribution 


          
      


       
    
      

 




 

    

 

      
     

   

   
      


        



        
    
      
  

 




       
     

 



    
  

 

      
 

 


 
         



        
      
      

        
     

 
       


     
        
    



          





       
       

 



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INTRODUCTION 
For the introduction of regulative RNAs such as 
small interfering RNA (siRNA) or short hairpin 
RNA (shRNA) into cells, delivery vectors 
represent attractive strategies enabling the 
treatment of e.g. cancer using gene therapy.1-3 
Since free genetic material is rapidly degraded 
in vivo,4-7 efficient carriers preventing the 
degradation of nucleic acids are indispensable. 
These carriers require properties for the 
association with the plasma membrane of 
target cells and for internalization into the 
cytosol.8 Beyond these requirements there are 
further intracellular hurdles, such as the escape 
from the endosomal pathway, trafficking 
through the cytosol, and, in the case of shRNA 
delivery, entry into the nucleus.2, 9 
In general, carriers for nucleic acids 
complexation and transport are subdivided into 
viral and non-viral carriers.10, 11 In contrast to 
viral carriers, which are highly efficient, but 
induce mutagenic and immunogenic 
responses,12, 13 non-viral carriers, in particular 
cationic polymers, are safer, cheaper and 
simpler in production and storage.14, 15 
Furthermore, polymers can be easily modified 
and exhibit a high loading capacity of genetic 
material. One of the main disadvantages of 
polymers is the lower efficiency of transfection 
in comparison to viral carriers.16 A reason for 
this problem is the disability of some polyplexes 
to escape from endosomal vesicles leading to a 
degradation of nucleic acids by lysosomal 
enzymes.17 Polymers with efficient release from 
endosomes possess a pKa value in the 
ABSTRACT 
Poly(ethylene imine) can be considered as the gold standard for DNA delivery into cells in vitro, but 
severe cytotoxic side-effects and inapplicability for targeted approaches in vivo urgently call for the 
design of new gene carriers. Since poly(2-oxazoline)s (P(Ox)s) can be easily synthesized and modified, 
this polymer class might be ideal for the optimization of polymeric transfection processes. The 
utilization of 2-methyl-2-oxazoline (MeOx) and 2-ethyl-2-oxazoline (EtOx) is also known to be 
beneficial because these monomers were suggested to overcome solubility issues, mediate stealth 
behavior and, consequently, facilitate a reduction of cytotoxicity. A series of amino (AmOx) 
functionalized P(Ox) copolymers with either MeOx (gradient copolymers) or EtOx (random 
copolymers) was synthesized, deprotected and biochemically characterized regarding cytotoxicity, 
polyplex formation ability, cellular uptake and transfection efficiency. 
Polymers with percentages of AmOx higher than 35 mol% showed stable polyplex formation but also 
an increase in cytotoxicity. All elucidated P(Ox)s revealed a poor transfection efficiency in both L929 
and Hepa1-6 cell lines. However, the investigations contribute to the understanding of the influence 
of stealth units (MeOx and EtOx) and their distribution within the polymer chain on selected 
properties of polyplexes and describe characteristics of amino functionalized P(Ox)s in different cell 
lines. 
KEYWORDS: Poly(2-oxazoline); DNA interaction; cell uptake; random and gradient copolymers; flow 
cytometry 
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physiological pH range showing buffer 
properties for acidic endosomal vesicles.18 
Additionally, a high transfection efficiency of 
polymeric vectors usually goes hand-in-hand 
with pronounced cytotoxicity.19, 20 
Consequently, the previously mentioned 
aspects are the major targets of research to 
improve non-viral carriers. Besides polyamides 
like poly(L-lysine) or poly(methacrylate)s21, 22, 
PEI can be considered as the polymeric gold 
standard for DNA delivery into cells.23 Both 
types of PEI, namely the linear (l-PEI) and the 
branched (b-PEI) form, possess high 
transfection efficiencies in various cell lines, but 
also severe cytotoxic effects and undesired non-
specific interactions in vitro and in vivo.19, 20 To 
reduce the cytotoxicity and enhance the 
delivery capacity, new carriers have to be 
designed. Since the well-defined l-PEI is 
synthesized by acidic or basic hydrolysis of 
(P(Ox)s),24 commercially available l-PEI usually 
contain 5 to 10 mol% non-hydrolyzed P(EtOx) 
units.25 P(EtOx) and P(MeOx) of various molar 
masses were already investigated in vitro in 
terms of biocompatibility, showing no harmful 
effects on cells in cytotoxicity assays or 
hemolysis.26, 27 For this reason, it might be 
interesting to elucidate amino functionalized 
P(Ox)s with EtOx or MeOx in terms of 
transfection abilities and biocompatibility. 
P(Ox)s can be produced via the cationic ring-
opening polymerization (CROP) of 2-oxazolines, 
whiĐh was first desĐriďed iŶ the ϭ9ϲϬ’s ďǇ four 
independent research groups.28-31 The 
introduction of the microwave technique in 
2004 reduced the reaction times from several 
days to minutes, by keeping the controlled 
character of the CROP and resulting in well-
defined polymers.32 The application of 
functional initiators or terminating agents 
results iŶ α- aŶd ω-functionalized P(Ox)s.33-35 
Furthermore, 2-oxazolines can be easily 
modified in the 2-position, leading to a high 
chemical versatility for structural modification 
through copolymerization. The utilization of the 
hydrophilic monomers MeOx and EtOx results 
in water-soluble polymers, which also mediate 
stealth behavior and facilitate the reduction of 
cytotoxicity.33, 36 In 2015, our group showed 
advantages of amino functionalized P(Ox)s 
towards l-PEI, by using a library approach.34 
They synthesized allyl functionalized P(Ox) 
precursors, which were amino modified via 
thiol-ene click-reactions, to obtain different 
amino functionalized P(Ox)s. Some of the 
resulting polymers showed very good 
transfection efficiencies while maintaining a 
good biocompatibility. However, the use of 
proper protection groups enables the possibility 
to directly polymerize different monomers with 
a high variety of functional groups, such as 
aldehydes,37, 38 carboxylic acids39 and amino 
groups.40, 41 The dependence of the 
polymerization constant (kp) of 2-oxazolines on 
the substituent in 2-position has been recently 
summarized.42 Due to the different kp values 
reported, copolymerization of EtOx with the 
amino functionalized monomer 2-(4-((tert-
butoxycarbonyl)amino)butyl)-2-oxazoline 
(BocOx) might result in another monomer 
distribution than a copolymerization of MeOx 
and BocOx. 
Comparison of random and gradient 
copolymers regarding DNA complexation and 
cellular interaction are still largely unexplored. 
However, S. Filippov et al. could show that 
block and gradient copoly(2-oxazoline) micelles 
show a different behavior with a uniform 
density profile of the core in block copolymers 
and a higher density in the outer part of the 
core for gradient copolymers.43 This could have 
a significant influence on polyplex formation 
and cell interaction, in particular with immune 
cells, regarding a higher shielding capacity in 
block copolymers in comparison with gradient 
polymers. 
In the present study, a series of amino 
functionalized P(Ox) copolymers with either 
MeOx or EtOx representing the stealth unit and 
different amounts of the Boc-protected amino 
functionalized comonomer BocOx was 
synthesized, deprotected and fully 
characterized. Polyplex formation using plasmid 
DNA (pDNA) in a wide range of nitrogen-to-
phosphate group (N/P) ratios as well as the 
structure, stability, and cytotoxicity of 
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polyplexes were studied. In addition, polyplex 
uptake and transfection efficiency were 
determined by flow cytometry and confocal 
laser scanning microscopy (CLSM). 
EXPERIMENTAL  
Materials and Instrumentation 
EtOx, MeOx and methyl tosylate (MeTos) were 
purchased from Sigma-Aldrich and were 
distilled to dryness over calcium hydride (VWR) 
under argon atmosphere prior to usage. 
Triethylamine (TEA, Sigma-Aldrich) was distilled 
under argon atmosphere prior to usage. 
Acetonitrile was obtained from a solvent 
purification system (MB-SPS-800, MBraun) and 
stored under argon. All other solvents used 
were obtained from standard suppliers. 
Trifluoroacetic acid (TFA, Sigma-Aldrich), 
Amberlyst® A21 (Sigma-Aldrich), ethidium 
bromide (EtBr) solution (10 mg mL-1, Carl Roth), 
YOYO-1 iodide (Thermo Fisher), LysoTracker 
Red DND-99 (Thermo Fisher) and 
Hoechst 33342 trihydrochloride (Thermo Fisher) 
were used as obtained. Cell culture media and 
antibiotics were obtained from Biochrom. 
Plasmid pRNAT-H1.1 (Genscript) was isolated 
with the Midi Plasmid Kit (Qiagen). Cell 
Proliferation Kit I (MTT), heparin sodium salt 
and trypan blue solution (0.4%) were purchased 
from Sigma-Aldrich. 
l-PEI and BocOx were synthesized according to 
literature procedures.25, 33, 44  
For the general characterization of l-PEI, please 
refer to T. Bus et al..33 
Polymerization reactions of 2-oxazolines were 
performed under microwave irradiation, using 
an Initiator Sixty single-mode microwave 
synthesizer from Biotage, equipped with a 
noninvasive IR sensor (accuracy: 2%). 
Microwave vials were stored overnight at 
100 °C under vacuum and allowed to cool to 
room temperature (RT) under argon before 
usage. Polymerizations were performed under 
temperature control. According to the polymer 
characteristics, size exclusion chromatography 
(SEC) measurements of the polymers were 
performed on different systems and noted in 
the respective part. 
SEC measurements of the polymerization 
kinetics were performed on an Agilent 1200 
series system, equipped with a PSS degasser, a 
G1329A pump, a PSS GRAM guard/30/1000 Å 
with 10 µm particle size and a G1362 refractive 
index (RI) detector. Dimethylacetamide (DMAc) 
containing 0.21% LiCl served as eluent. The 
column oven was set to 40 °C at a flow rate of 
1 mL min-1 and poly(styrene) (PS, 400 to 
1,000,000 g mol-1) served as the calibration. 
SEC of the Boc-protected copolymer precursors 
was conducted on a Shimadzu system equipped 
with a SCL-10A VP controller, GDU-14A 
degasser and a LC-10AD VP pump, a PSS GRAM 
guard/30/1000 Å with 10 µm particle size and a 
RID-10A RI detector. DMAc containing 0.21% 
LiCl served as eluent. The column oven was set 
to 40 °C using a flow rate of 1 mL min-1 and PS 
(400 to 1,000,000 g mol-1) served as the 
calibration. 
SEC of the Boc-protected P(EtOx3-b-BocOx157) 
was performed on a Shimadzu system equipped 
with a CBM-20A controller, GDU-14A degasser 
and a LC-10AD VP pump, a PSS SDV guard/linear 
S column with 5 µm particle size and a RID-10A 
RI detector. CHCl3-iso-propanol (i-PrOH)-NEt3 
(94:2:4) served as eluent. The column oven was 
set to 40 °C using a flow rate of 1 mL min-1. PS 
(400 to 100,000 g mol-1) served as the 
calibration. 
SEC of the deprotected, amino functionalized 
polymers was conducted on a Jasco system 
equipped with a DG-980-50 degasser and a PU-
980 pump, PSS SUPREMA-MAX guard/300 Å 
column with 10 µm particle size and a RI-930 RI 
detector. 0.3% (v/v) TFA containing 0.1 M NaCl 
served as aqueous eluent. The column oven was 
set to 30 °C using a flow rate of 1 mL min-1. 
Poly(2-vinylpyridine) (P2VP, 1,300 to 
81,000 g mol-1) served as the calibration. 
Proton NMR spectroscopy (1H-NMR) was 
performed at RT using a Bruker Avance I 
300 MHz spectrometer, utilizing either CDCl3 or 
D2O as solvent. The chemical shifts are given in 
ppm relative to the signal from the residual 
non-deuterated solvent. 
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Gas chromatography (GC) was performed on a 
Shimadzu system (GC-2010 plus) equipped with 
a flame ionization detector, AOC-20s 
autosampler, AOC-20i injector and a 
PerkinElmer Elite-5MS column using helium as 
carrier gas. The stationary phase consists of 5% 
diphenyl and 95% dimethyl polysiloxane. 
Lyophilization of the polymers was conducted 
using an Alpha 1-2 LDplus freeze dryer from 
Martin Christ Gefriertrocknungsanlagen GmbH. 
For the characterization of polyplexes and 
biocompatibility assays, a SpectraMax 
microplate reader (Molecular Devices) was 
used. 
Flow cytometry was conducted on a Cytomics 
FC 500 (Beckman Coulter). 
CLSM was performed with a LSM880, Elyra PS.1 
system (Zeiss) using the following excitation 
wavelengths/laser lines 405 nm (for 
Hoechst 33342), 488 nm (for YOYO-1) and 
561 nm (for LysoTracker Red DND-99). 
Batch dynamic light scattering (DLS) was 
performed on a Zetasizer Nano ZS (Malvern 
Instruments). All measurements were 
performed in folded capillary cells (DTS1070 
Malvern Instruments). After an equilibration 
time of 180 s, 3 × 30 s runs were carried out at 
25 °C ;ʄEx = 633 nm). Scattered light was 
detected at an angle of 173°. The mean particle 
size was approximated as the effective (z-
average) diameter and the width of the 
distribution as the polydispersity index of the 
particles (PDI) obtained by the cumulants 
method assuming a spherical shape. Each 
measurement was performed in triplicates.  
Electrophoretic light scattering (ELS) was used 
to ŵeasure the zeta poteŶtial ;ζͿ. The 
measurement was also performed on the 
Zetasizer Nano ZS by applying laser Doppler 
velocimetry. For each measurement, 20 runs 
were carried out using the slow-field reversal 
and the fast-field reversal mode at 150 V. Each 
experiment was performed in triplicates at 
25 °C. The zeta potential was calculated from 
the electrophoretic mobilitǇ ;ʅͿ aĐĐordiŶg to 
the Henry equation. Henry coefficient f(ka) was 
calculated according to Ohshima.45 
For the acid/base titration, the copolymers 
were dissolved in deionized water, reaching a 
final concentration of 10 mg mL-1 and 10 µL 
concentrated HCl (12 M) were added. The 
titration was performed against 0.1 M NaOH 
using a 765 Dosimat (Metrohm), a digital 
pH/mV-thermometer GMH 3530 (Greisinger 
electronic), and the EBS9 M Recorder software. 
Recorded curves were smoothed using 5-point 
FFT-fitting in OriginPro 2015G. The resulting 
curve was derivated two times to determine the 
pKa value of the copolymers. 
Synthesis and Characterization 
Kinetic Studies of Copolymerizations 
The general procedure for all kinetic 
investigations is as follows: 
Under inert conditions, a solution of MeTos and 
MeOx (respectively EtOx) in acetonitrile 
(cMeTos = 0.013 mol L-1, [M]/[I] = 3) was prepared 
in a microwave vial and heated in a microwave 
synthesizer (140 °C, 102 min, absorption level 
high). Subsequently, distinct ratios of BocOx 
and MeOx or EtOx (nMeOx/EtOx:nBocOx; 80:20, 
60:40, 40:60, 20:80, [M]/[I] = 147) were added 
and the solution was aliquoted into microwave 
vials and heated in a microwave synthesizer 
(140 °C, varying reaction times, absorption level 
very high). After polymerization, the 
conversions of the monomers were determined 
utilizing GC measurements, using the solvent as 
an internal standard. The polymerization 
constants (kp) of the monomers were 
determined using equations (1) and (2) 
assuming that the slope of the linear fit of 
ln([M]0/[M]t) = f(t) complies with keff. lnM଴ − lnMt = kୣ୤୤ ∙ t   (1) 
kୣ୤୤ = kp[I]    (2) 
The reactivity ratios of both monomers were 
calculated for four different monomer ratios at 
30 mol% BocOx (for the EtOx kinetics) 
respectively 30 mol% MeOx (for the MeOx 
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kinetics) conversion (determined by GC) using 
non-linear least square fitting46 (equation (3)): Fଵ =  ሺrభ−ଵሻ୤భమ+୤భሺrభ+rమ−ଶሻ୤భమ+ଶሺଵ−rమሻ୤భ+rమ   (3) 
F1 = instantaneous mole fraction; f1 = mole 
fraction of monomer EtOx/MeOx; f2 = mole 
fraction of monomer BocOx; r1 = reactivity ratio 
of MeOx/EtOx; r2 = reactivity ratio of BocOx. 
Synthesis of Boc-protected P(Ox)s 
The synthesis of P(Ox)s was accomplished as 
previously described.44 
Briefly, it is explained for P(EtOx150-r-BocOx33) 
(P(E150B33)). In a microwave vial, MeTos (9.3 mg, 
0.05 mmol), EtOx (15.1 mg, 0.15 mmol) and 
acetonitrile (2.87 g) were mixed under inert 
conditions and heated in the microwave to 
140 °C for 93 min. Subsequently, the vial was 
opened under an inert atmosphere, and EtOx 
(778.2 mg, 7.85 mmol) and BocOx (484.6 mg, 
2.00 mmol) were added. In the case of the 
homopolymers, only BocOx was added. The 
reaction mixture was heated in the microwave 
at 140 °C for another 44 min. The resulting 
polymer was precipitated in ice-cold diethyl 
ether and the solid was re-dissolved in CH2Cl2. 
The solvent was evaporated under reduced 
pressure to obtain the product as a white solid. 
1H-NMR (CDCl3, 300 MHz): δ = 3.48 (s, 4 H, 
backbone), 3.12 (m, 0.5 H, CH2-CH2-NH 
(BocOx)), 2.38 (m, 1.91 H, CH2 (EtOx)), 1.43 – 
1.65 (m, 2.4 H, CH2-CH2-CO (BocOx) + CH2-CH2-
CH2-CH2 (BocOx)), 1.37 (s, 2.4 H, CH3 (EtOx)) 
ppm. 
SEC (eluent: DMAc, 0.21% LiCl, PS-cal.): 
Mn = 19,100 g mol-1; Mw = 22,200 g mol-1; 
Ð = 1.16. 
Deprotection of Boc-protected P(Ox)s to Yield 
Primary Amino Functionalized P(Ox)s 
The deprotection of P(E150B33) to yield P(EtOx150-
r-AmOx33) (P(E150A33)) is exemplarily described. 
P(E150B33) (1.0 g) was dissolved in 5 mL TFA and 
stirred at RT overnight. Subsequently, it was 
diluted using 10 mL methanol and precipitated 
in ice-cold diethyl ether. The resulting solid was 
filtered off and re-dissolved in methanol. 
Amberlyst® A21 was added and the polymer 
solution was stirred at 100 rpm at RT overnight. 
Then, the Amberlyst® A21 was filtered off and 
the solvent was evaporated under reduced 
pressure. The polymer was re-dissolved in 
deionized water and lyophilized to obtain the 
product as a white powder. 
1H-NMR (D2O, 300 MHz): δ = 3.39 (s, 4 H, 
backbone), 2.87 (0.4 H, CH2-CH2-NH2 (AmOx)), 
2.23 (s, 2 H, CH2 (EtOx) + CH2-CH2-CO (EtOx + 
AmOx)), 1.50 (s, 0.8 H, CH2-CH2-CH2-CH2 
(AmOx)), 0.92 (s, 2.4 H, CH3 (EtOx)) ppm. 
SEC (eluent: 0.3% TFA + 0.1 M NaCl, P2VP-cal.): 
Mn = 8,000 g mol-1; Mw = 11,200 g mol-1; 
Ð = 1.41. 
Polyplex Formation 
Polyplexes were prepared by mixing stock 
solutions of 15 µg mL-1 pDNA and different 
amounts of polymers to obtain various N/P 
ratios in HBG buffer (20 mM 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES) and 5% (w/v) glucose, pH 7.2). The 
solutions were vortexed for 10 sec at maximum 
speed (2800 rpm) and incubated at RT for 
15 min to ensure complex formation. 
EtBr Quenching Assay (EBA) 
Formation of polyplexes with pDNA was 
investigated by quenching of EtBr fluorescence 
as described previously.47 Briefly, pDNA 
(15 µg mL-1) in a total volume of 100 µL HBG 
buffer was incubated with EtBr (10 µg mL-1) for 
10 min at RT. Subsequently, polyplexes with 
increasing concentrations of each polymer 
(calculated to N/P ratios) were formed in black 
96-well plates (Nunc, Thermo Fisher) and 
incubated at RT for 15 min. The fluorescence of 
the samples was measured at 
ʄEx = 525 Ŷŵ/ʄEm = 605 nm using a microplate 
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reader. A sample containing only pDNA and 
EtBr was used to calibrate the device to 100% 
fluorescence against a background of 10 µg mL-1 
of EtBr in HBG solution. The percentage of dye 
displaced upon polyplex formation was 
calculated using equation (4). RFU [%] = F౩aౣ౦ౢe−FబF౦ీNA−Fబ ∙ ͳͲͲ  (4) 
Here, RFU is the relative fluorescence units and 
Fsample, F0, and FpDNA are the fluorescence 
intensities of a given sample, EtBr in HBG alone, 
and EtBr intercalated into pDNA alone. 
Experiments were conducted in triplicates. 
Heparin Dissociation Assay 
To investigate the release of pDNA from 
polyplexes, the heparin dissociation assay was 
performed. Polyplexes with an N/P ratio of 30 
were formed as described above in a total 
volume of 100 µL HBG buffer containing EtBr 
(10 µg mL-1). After incubation in the dark at RT 
for 15 min, the polyplexes were transferred into 
a black 96-well plate containing heparin in 
increasing concentrations. The solution was 
mixed and incubated for further 30 min at 37 °C 
in the dark. The fluorescence of EtBr was 
ŵeasured at ʄEx = 525 Ŷŵ/ʄEm = 605 nm utilizing 
a microplate reader. The percentage of 
intercalated EtBr was calculated as described 
before. The experiments were conducted in 
triplicates. 
Cell Culture 
Mouse liver cell line Hepa1-6 (CRL-1830TM, 
ATCC) and mouse fibroblast cell line L929 
(CCL-1TM, ATCC) were cultured in growth 
medium containing DulbeĐĐo’s ŵodified eagle’s 
medium (DMEM, Lonza) supplemented with 
10% fetal calf serum (FCS), 100 U mL-1 penicillin 
and 100 µg mL-1 streptomycin at 37 °C in a 
humidified 5% (v/v) CO2 atmosphere. 
 
 
Cytotoxicity MTT Assay 
The cytotoxicity of the investigated polymers 
was measured by MTT assay using the cell lines 
Hepa1-6 and L929. Cells were cultured in a 96-
well plate for 24 h as described above. The 
polymers to be tested were added to the cells in 
a concentration range of 1 to 500 µg mL-1 for 
24 h. Subsequently, 10 µL aliquots of the MTT 
solution were added to each well and the plates 
were further incubated for 4 h at 37 °C in a 
humidified 5% (v/v) CO2 atmosphere. The 
formed formazan crystals were solubilized by 
addition of 10% sodium dodecyl sulfate (SDS) in 
0.01 M HCl. The solubilized formazan product 
was spectro-photometrically quantified using a 
ŵiĐroplate reader at ʄEx1 = 550 nm and the 
refereŶĐe at ʄEx2 = 690 nm. The relative cell 
viability was calculated using equation (5): Rel. cell viab. [%] = ሺλుxభ−λుxమሻ౩aౣ౦ౢeሺλుxభ−λుxమሻc౥౤౪౨౥ౢ ∙ ͳͲͲ (5) 
Data are expressed as mean and standard 
deviation (S.D.) of three measurements. 
Furthermore, the 50% cytotoxic concentration 
(CC50) was determined for comparison of the 
gradient and random polymers in both cell 
lines. 
Polyplex Uptake 
For uptake studies, cells were seeded at a 
density of 2 × 105 cells mL-1 in 24-well plates 
(500 µl) and cultured for 24 h. One hour prior to 
the addition of the polyplexes at concentrations 
described in Table 1, the medium was changed 
to DMEM with or without FCS.  
The polyplexes were formed and 50 µL 
polyplexes in HBG buffer were added to the 
cells. The plates were incubated for 2 or 4 h at 
37 °C in a humidified 5% (v/v) CO2 atmosphere. 
For kinetic studies of polyplex uptake, pDNA 
was labeled with YOYO-1 prior to polyplex 
preparation. For this reason, 0.02 µL of 1 M 
YOYO-1 solution was mixed with 1 µg pDNA in 
HBG buffer and incubated for 20 min at 4 °C 
protected from light. 
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TABLE 1 Corresponding concentrations of all 
tested polymers with an N/P ratio of 30. 
Polymer system Concentration [µg mL-1] 
P(M97A55) 9.79 
P(M73A89) 9.47 
P(M29A166) 9.10 
P(E77A55) 10.41 
P(E57A139) 9.56 
P(E31A163) 9.27 
P(E3A157) 8.99 
l-PEI 5.43 
Subsequently, polymers were added at an N/P 
ratio of 30 and the polyplexes were formed as 
described before (Table 1). After 2 or 4 h of 
polyplex incubation the cells were washed to 
remove extracellular polyplexes. 
To determine the relative uptake of the 
polyplexes, 10,000 cells were measured by flow 
cytometry and the amounts of viable cells 
showing YOYO-1 signal were gated. Uptake of 
pDNA with YOYO-1 alone was used as control to 
define the gate. Dead cells were identified via 
SSC/FSC signal. The experiments were 
performed at least three times independently. 
For live cell imaging, Hepa1-6 cells 
(5 × 105 cells mL-1) were seeded in glass-
bottomed, 4-chamber dishes (CELLviewTM, 
Greiner Bio One) and cultured for 24 h. One 
hour prior to polymer addition, the cells were 
rinsed with PBS and the media were changed to 
DMEM without FCS. Polyplexes were prepared 
with an N/P ratio of 30 as described above 
(Table 1) and added to the cells (50 ʅL per wellͿ 
for 4 h. Subsequently, the cells were washed 
with PBS and incubated for 5 min with a 
mixture of DMEM and PBS supplemented with 
LysoTracker Red DND-99 (1:1000) and 
Hoechst 33342 (1:1000; 10 mg mL-1) for 
lysosomes as well as nucleus staining, 
respectively. A 1:10 diluted trypan blue solution 
was added to the medium immediately before 
imaging to quench polyplexes not taken up by 
the cells. The living cells were imaged with a 
LSM880, Elyra PS.1 system. For the 
quantification of the amount of YOYO-1 and/or 
LysoTracker Red DND-99 positive organelles per 
cell the software ImageJ and the plugin Coloc2 
(version 3.0.0) were used. Since cell borders 
could not be defined due to overlap of the cells, 
the average numbers of YOYO-1 and 
LysoTracker Red DND-99 positive organelles per 
cell (defined by the number of Hoechst 33342 
positive nuclei) per area of 112.5 ʅm × 
112.5 ʅm were determined. Cut-off was set to 5 
to 1000 pixel units for all organelles. 
Transfection Efficiencies in Adherent Cells 
Hepa1-6 and L929 cells were cultured as 
described above. For transfection, the cells 
were seeded at a density of 105 cells mL−1 in 24-
well plates (500 µl) and incubated for 24 h. One 
hour prior to transfection, the cells were 
washed with phosphate buffer saline (PBS) and 
supplemented with DMEM with or without FCS. 
Polyplexes with an N/P ratio of 30 were 
prepared as described above and were added 
to the cells (50 ʅL per wellͿ. The ĐorrespoŶdiŶg 
concentrations for all tested polymers with an 
N/P ratio of 30 are shown in Table 1. 
After an incubation time of 4 h at 37 °C, the 
supernatant was replaced by fresh medium, and 
the cells were further incubated for 44 h. For 
analysis via flow cytometry, the cells were 
harvested by trypsinization and 10,000 cells 
were analyzed by flow cytometry. For 
determination of the viability, dead cells were 
identified via side scatter/forward scatter 
(SSC/FSC) signal as described previously.48 
Viable cells expressing GFP were gated for 
analysis of the transfection efficiency. 
Transfection with pDNA alone was used as 
control to define the gate. The experiments 
were performed at least three times 
independently. 
Statistical Analysis 
The quantification of YOYO-1 and LysoTracker 
Red DND-99 positive organelles was performed 
for normal distribution by Shapiro-Wilk 
normality test. As the values did not follow 
normal distributions, data were analyzed by 
non-parametric Kruskal-Wallis test with DuŶŶ’s 
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

       
–
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TABLE 2 Key properties of the synthesized P(Ox)s determined by 1H-NMR spectroscopy (300 MHz) in 
indicated solvents. 
Sample Polymer DP mol% 
MeOx or  
EtOx 
mol% 
BocOx or  
AmOx 
Mn 
[g mol-1] 
P(M130B31) P(MeOx130-grad-BocOx31)a 161 81d 19d 18,600 
P(M97B55) P(MeOx97-grad-BocOx55)a 152 64d 36d 21,600 
P(M73B89) P(MeOx73-grad-BocOx89)a 162 45d 55d 27,700 
P(M29B166) P(MeOx29-grad-BocOx166)a 195 15d 85d 41,400 
P(M130A31) P(MeOx130-grad-AmOx31)b 161c 81 19 15,500 
P(M97A55) P(MeOx97-grad-AmOx55)b 152c 64 36 16,100 
P(M73A89) P(MeOx73-grad-AmOx89)b 162c 45 55 18,900 
P(M29A166) P(MeOx29-grad-AmOx166)b 195c 15 85 24,900 
P(E150B33) P(EtOx150-r-BocOx33)a 183 82d 18d 22,800 
P(E77B55) P(EtOx77-r-BocOx55)a 132 58d 42d 20,900 
P(E57B139) P(EtOx57-r-BocOx139)a 196 29d 71d 39,300 
P(E31B163) P(EtOx31-r-BocOx163)a 194 16d 84d 42,500 
P(E150A33) P(EtOx150-r-AmOx33)b 183c 82 18 19,600 
P(E77A55) P(EtOx77-r-AmOx55)b 132c 58 42 15,500 
P(E57A139) P(EtOx57-r-AmOx139)b 196c 29 71 25,400 
P(E31A163) P(EtOx31-r-AmOx163)b 194c 16 84 26,300 
P(E3B157) P(EtOx3-b-BocOx157)a 160 2d 98d 38,300 
P(E3A157) P(EtOx3-b-AmOx157)b 160c 2 98 22,600 
aCDCl3; bCD3OD; ccalculated from Boc-protected precursor; dcalculated from deprotected copolymer. 
Within the investigated monomer ratios, EtOx 
and BocOx exhibited similar kp values 
(kp(EtOx) = 47.2 ± 11.0 L mol-1 s-1; kp(BocOx) = 44.0 ± 
13.3 L mol-1 s-1), while MeOx polymerized faster 
than BocOx (kp(MeOx) = 75.4 ± 2.8 L mol-1 s-1; 
kp(BocOx) = 50.7 ± 4.0 L mol-1 s-1).  
This complies with previously published kp 
values of the homopolymerizations of the 
investigated monomers.42 To gain an insight 
into the monomer distribution within the 
polymer chain, the calculation of the reactivity 
ratios is indispensable and was performed using 
equation (3).46, 49, 50 The reactivity ratios of EtOx 
and BocOx were found to be similar 
(rBocOx = 1.02 ≈ 1 ≈ rEtOx = 0.98), suggesting the 
formation of random copolymers.51 On the 
other hand, copolymerization of MeOx and 
BocOx resulted in slight gradient copolymers 
(rMeOx = 1.50 > 1 > rBocOx = 0.67).  
Regarding the SEC measurements, the polymers 
showed a linear increase in the molar mass and 
low dispersities (Ð ≤ 1.2) up to high conversions. 
Only polymers with high BocOx amounts 
revealed small high molar mass shoulders, 
suggesting side reactions at high BocOx 
conversions of more than 90 mol%, which are 
probably caused by the amino side chain. 
However, these side reactions can be minimized 
by aiming for a slightly lower conversion during 
the preparation of copolymers. 
The investigations of cytotoxicity, polyplex 
stability and cellular uptake efficiency within 
this study enable a comparison of gradient 
(MeOx) and random (EtOx) copolymers by 
variation of the non-charged comonomers. 
Differences regarding the polyplex performance 
might be found in terms of cytotoxicity 
provoked by an enhanced shielding by gradient 
copolymers compared to random polymers. 
Furthermore, differences in the cellular uptake 
could also be caused by the shielding of the 
non-ionic comonomer. These two crucial factors 
might be important for a successful transfection 
efficiency of the investigated polyplexes. 
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TABLE 3 Size aŶd surfaĐe Đharge ;zeta poteŶtial, ζͿ of polǇpleǆes at aŶ N/P ratio of ϭϱ ŵeasured iŶ HBG 
or 150 mM NaCl determined by DLS and ELS (n=3).  
 HBG NaCl 
Polymer system z-average [d, nm] PDI 
ζ  
[mV] 
z-average 
[d, nm] PDI 
P(M97A55) 209 ± 17 0.396 ± 0.063 29.2 ± 6.0 210 ± 10 0.107 ± 0.025 
P(M73A89) 164 ± 6 0.356 ± 0.076 27.6 ± 2.2 138 ± 6 0.060 ± 0.031 
P(M29A166) 194 ± 12 0.527 ± 0.117 34.2 ± 6.3 n.d. n.d. 
P(E77A55) 158 ± 8 0.342 ± 0.069 26.9 ± 1.6 1,360 ± 167 0.532 ± 0.123 
P(E57A139) 210 ± 58 0.468 ± 0.139 33.7 ± 2.8 730 ± 243 0.336 ± 0.074 
P(E31A163) 207 ± 37 0.581 ± 0.143 27.5 ± 3.8 n.d. n.d. 
P(E3A157) 187 ± 41 0.546 ± 0.164 36.4 ± 4.2 1,443 ± 171 0.316 ± 0.074 
l-PEI 306 ± 126 0.528 ± 0.078 37.1 ± 1.9 1,310 ± 174 0.285 ± 0.025 
n.d.: not determined
All Boc-protected polymeric precursors were 
analyzed using 1H-NMR spectroscopy to obtain 
information about the DP and the monomer 
ratios (Table 2, Figures S9 to S13) as well as by 
SEC to gain an insight about the dispersity of 
the polymers (Table S1, Figures S14 to S16).  
The total DP of the Boc-protected P(Ox) 
precursors was between 150 and 200 for all 
polymers while the BocOx content was 
approximately 20, 40, 60 or 80 mol% (Table 2, 
column 5). All copolymers were deprotected 
under acidic conditions to yield the final amino 
functionalized copolymers with either MeOx 
(P(MnAm)) or EtOx (P(EnAm)) to evaluate the 
influence of the neutral comonomer on 
transfection as well as cytotoxicity. After 
deprotection, SEC measurements under 
aqueous conditions were performed to validate 
the absence of degradation (Table S1, 
Figures S14 to S16). 
Characterization of the Polyplexes 
After successful synthesis and characterization 
of a series of cationic P(Ox)s, they were 
investigated regarding their polyplex formation 
and dissociation abilities. For the 
characterization of all indicated polyplexes, EBA 
at different N/P ratios and heparin dissociation 
assays at an N/P of 30 were performed. These 
assays are based on the ability of EtBr to 
intercalate into DNA leading to an increase in 
fluorescence. A displacement of EtBr by 
interaction of polymers with DNA reduces the 
fluorescence indicating polyplex formation.52 
As expected, the complexation of the tested 
polymers with pDNA was stronger with 
increasing percentages of AmOx (Figures 2A and 
2B). To form stable polyplexes, polymers 
needed AmOx percentages higher than 
35 mol%. Polymers with less than 35 mol% 
AmOx (P(M130A31) and P(E150A33)) did not form 
stable polyplexes and were, therefore, excluded 
from further investigations. The pDNA 
complexation ability of the polymer consisting 
of 98 mol% AmOx (P(E3A157)) was comparable to 
l-PEI (Figure 2B), which is commonly used within 
our group as an internal reference.33, 53 This 
supports the assumption that the investigated 
P(Ox)s with primary amines contribute in a 
similar way to the polyplex formation like l-PEI 
does. The polyplex formation was found to be 
dependent on the AmOx amount within the 
polymers, however, not on the utilized non-
ionic monomers MeOx or EtOx (Figure 2C). 
For most of the investigated polymers, an N/P 
ratio of 30 was required to reach a plateau, 
where no further decrease of the RFU was seen. 
For this reason, heparin dissociation assays 
were performed at an N/P ratio of 30.  
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
      

     
     
       
      
    
       
     
    
        
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    
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    

    


        
      
 
       

     
     
     


     
      

       
     
    
     
       


    
 
     

 
      
     
     
 
    

    
      

        


     








      
      


     

      

    
 
  
      

 
     
    
     
      
    
     
        

       

    



               


               

 15 
Possible explanations for the observed cell type 
dependency of the uptake and transfection 
efficiency are different membrane 
characteristics, intracellular transport 
mechanisms and DNA-degrading enzymes due 
to discriminative expression patterns.59 
Polyplexes with AmOx amounts of 35 mol% 
were internalized less well in both cell lines due 
to the presence of fewer cationic charges.60 
Having a closer look at the cells, which were 
cultivated in serum free medium, L929 cells 
revealed an uptake efficiency of nearly 100% 
even after 2 h of incubation, while efficiency 
was slightly less (80 to 90%) for Hepa1-6 cells 
(Figure 4A). 
After 4 h incubation exclusively the MFI per cell 
in both cell lines further increased suggesting an 
increased polyplex uptake by several cells, 
which could have a positive effect on 
transfection efficiency (Figure S18B). No 
differences between the P(Ox)s and l-PEI were 
observed. 
Interestingly, the uptake efficiency significantly 
decreased when using 10% FCS containing 
(complete) medium in combination with Hepa1-
6 cells. While the differences between the two 
media were negligible within the L929 cell line, 
in Hepa1-6 cells, we observed an uptake 
efficiency in complete medium of only 50% 
after 2 h (Figure 4C) and 50 to 70% after 4 h 
(Figure S18C). This phenomenon might be 
explained by the interaction of the polyplexes 
with serum proteins.61 It is noteworthy that 
similar results were obtained for l-PEI, possibly 
due to high charge densities within all 
polyplexes. As there were no difference 
between the investigated polymers and l-PEI 
the influence of P(MeOx) and P(EtOx) on 
polyplex uptake is only of minor importance. 
Transfection Efficiency 
The previous results indicated that the tested 
polymers fulfill the prerequisites to be 
investigated as non-viral gene-delivery agents. 
As a consequence, they were analyzed 
regarding transfection efficiency using Hepa1-6 
and L929 cells and pDNA encoding green 
fluorescent protein (GFP) as visual reporter. The 
transfection efficiency was analyzed by flow 
cytometry counting all viable cells (SSC/FSC), 
which successfully expressed GFP (Figures 5 and 
S18). For all tested polymers, an N/P ratio of 30 
was used to form stable polyplexes. In a first 
step, we determined the optimal time point for 
the detection of the GFP expression using l-PEI. 
After 48 h of transfection in both cell lines 
(Hepa1-6 and L929) the number of GFP 
expressing cells doubled, and an increase of the 
MFI was detected compared to measurements 
after 24 h (Figure S19). In comparison to L929 
cells, Hepa1-6 cells revealed a lower GFP 
expression. It is well-known that various 
transfection reagents show different 
transfection efficiencies in various cell lines and 
especially L929 cells display high uptake and 
transfection efficiencies.57, 58, 62 Similar to 
differences in the uptake efficiency also the 
transfection efficiency is dependent on the 
discriminative expression pattern leading to 
variations in membrane topology, intracellular 
transport and enzymes for DNA degradation.59 
Furthermore, as serum proteins influenced the 
uptake efficiency, we also investigated the 
transfection efficiency of l-PEI based polyplexes 
in growth media supplemented with 10% FCS in 
comparison to media without serum. In L929 
cells, serum containing medium decreased the 
transfection efficiency by 50% after 24 h and 
48 h. Nevertheless, GFP expression was 
detectable after 48 h in 40% of all cells. Hepa1-6 
cells showed a stronger impact upon presence 
of serum with no transfection efficiencies 
higher than 5%, neither after 24 h nor 48 h 
(Figure S19). 
Based on these results and with the knowledge 
that stealth moieties are able to reduce the 
interaction with serum proteins, we 
investigated transfection after 48 h in medium 
with (complete) or without serum (serum free). 
Figure 5 shows the results of the transfection 
efficiencies of all investigated P(Ox)s comparing 
Hepa1-6 and L929 cells in medium with 
(complete, Figure 5A and B) or without FCS 
(serum free, Figure 5C and D). None of the 
elucidated P(Ox)s was able to transfect Hepa1-6 
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TABLE 4 pKa values of different P(Ox)s 
determined by titration of acidified solutions 
with 0.1 M NaOH. pKa values were calculated 
from 1st derivation (Figures S20 to S24). 
Polymer pKa value 
P(M97A55) 9.9 
P(M73A89) 9.6 
P(E77A55) 9.5 
P(E57A139) 9.4 
P(E3A157) 9.5 
PEI 7.9 to 9.664 
Since polyplexes have to escape the 
endolysosomal system for transfection, a strong 
colocalization with the specific lysosomal 
marker LysoTracker Red DND-99 indicates a 
prevention of mentioned release. As shown in 
Figure 7, polymers containing EtOx as the non-
ionic comonomer possessed a significant 
increase in YOYO-1 and LysoTracker Red DND-
99 positive organelles per cell in comparison to 
l-PEI (Figure 7A). In contrast to that, the MeOx 
based copolymer did not show a significant 
increase of dye positive organelles. A closer 
look further revealed an increased amount of 
YOYO-1 positive organelles for P(Ox)s analyzed 
in comparison to l-PEI (Figure 7B). For this 
reason, it is assumed that MeOx containing 
copolymers were partially retained in other 
vesicular organelles of the endolysosomal 
system, which were not acidified after 4 h of 
incubation. The significant increase in these 
YOYO-1 positive organelles suggests strong 
defects in polyplex release into the cytosol, 
consequently a prevention of transfection. 
Previous investigations on amino functionalized 
P(Ox)s revealed significantly higher transfection 
efficiencies.33, 34, 41, 53 We could show that the 
transfection efficiency of AmOx can be 
enhanced by the preparation and self-assembly 
of amphiphilic 2-nonyl-2-oxazoline containing 
block copolymers.53 Hereby, the hydrophobicity 
could increase the interaction of the polyplexes 
with the lysosomal membrane, or the assembly 
of the polymers might trigger the endosomal 
release. In addition to the investigated micelles, 
MeOx or EtOx containing, hydrophilic 
copolymers exhibited an enhanced transfection 
efficiency compared to the herein investigated 
system.33, 34 However, the amino functionalities 
were introduced via thiol-ene reaction after the 
polymerization, resulting in copolymers with a 
thio-ether containing spacer within the amino 
functional side chain.  
 
 
FIGURE 6 CLSM images of Hepa1-6 cells. Cells were incubated with l-PEI, P(M73A89), P(E57A139), or 
P(E3A157) based polyplexes at an N/P of 30 in medium without FCS at 37 °C for 4 h. The cell nucleus is 
stained with Hoechst 33342 (blue), lysosomes are stained with LysoTracker Red DND-99 (red) and pDNA 
with YOYO-1 (green). Trypan blue was used to quench extracellular polyplexes. While only few YOYO-1 
(green dots, highlighted by white arrows) or YOYO-1 and LysoTracker Red DND-99 positive organelles 
(yellow dots, highlighted by white arrowheads) were detected after incubation with l-PEI based 
polyplexes, incubation with polyplexes of P(M73A89), P(E57A139) and P(E3A157) resulted in an increase in 
YOYO-1 positive organelles indicating defects in the endolysosomal release of the polyplexes. 
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

      
     
      
     
   
     
    


      


    
      
      
      
     
     

      
      
     
      
       
  
      
       
       
  
      
     
    




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gene delivery by using the investigated 
conditions. Future studies might concentrate on 
alternative copolymers with differences in the 
hydrophobicity and buffer capacity to identify 
ideal carriers for genetic material, which can 
ensure biocompatibility while expressing higher 
transfection efficiencies. 
Based on the different uptake efficiencies in the 
investigated cell lines targeting moieties can 
also increase the uptake and possibly 
transfection efficiency. Since gradient polymers 
show higher polyplex stability in physiological 
sodium chloride solution we would recommend 
to prefer this polymer structure over random 
polymers. 
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c.
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Geesthacht, Kantstr. 55, 14513 Teltow, Germany. 
Research on poly(2-oxazoline)s (P(Ox)s) has significantly evolved over the 
last decades. Whereas mainly synthesis and characterization were studied 
first, focus is increasingly shifting towrads biomedical applications of the 
polymer class, also catalyzed by the drawbacks of commonly used polymers, 
such as poly(ethylene glycol) (PEG). The cationic ring-opening 
polymerization enables the copolymerization of various functional 
monomers, as well as modifications at the α- and ω-terminus. This variety of 
functional groups is supposed to be beneficial for self-assembly processes, 
drug conjugation or polyplex formation. Copolymers with 2-ethyl-2-
oxazoline (EtOx) or 2-methyl-2-oxazoline (MeOx) repeating units were found 
to show stealth ability and, consequently, provide an enhanced 
biocompatibility and elongated blood circulation times. For these reasons, 
P(Ox)s are progressively used for in vivo studies and clinical trials to find safe 
pharmaceuticals. Hence, the synthetic approaches leading to biomedical 
relevant P(Ox)s, their biocompatiblity, as well as findings from in vivo studies 
using P(Ox)s is summarized and evaluated within this review. 
Key learning points 
• P(Ox) synthesis and important polymer characteristics for in vivo studies  
• Important P(Ox) architectures for in vivo studies 
• Influence of P(Ox)s on the blood circulation time and the biodistribution 
of drugs 
• Controlled drug release by P(Ox) conjugates 
• Developments in cancer therapy 
Introduction 
The first synthetic polymer-based medicines in clinical practice 
were developed only three decades ago and the first product 
approval occurred in 1990.1 In the 1990s, R. Duncan coined the 
term “polymer therapeutics”, which means that the polymer 
can either act as the bioactive itself or as a part of the covalent 
conjugate, e.g. polymer-drug conjugates and polymer-protein 
conjugates.2 Furthermore, self-assembled systems, such as 
polymeric micelles and multi-component polyplexes, which are 
known as non-viral vectors, are of great importance.1 In 
general, biodegradable structures are preferred since the body 
needs to be able to deal with the polymers after they fulfilled 
their purpose; however, none of them should lead to 
undesired toxicity or an immunogenic response before and 
after biodegradation.3, 4  
The currently most prominent example in this context is 
poly(ethylene glycol) (PEG), which is already in use for several 
applications against various diseases, e.g. multiple sclerosis 
(Copaxone®), hepatitis C (PEGIntron®) or anaemia (Macugen®, 
Puricase®).5 However, many advantages and disadvantages of 
       
        
      


      
          

         

      
       
     
        
          

     
     
     
   
         

     


          

        

       

        
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
        
        
        
       
      
        
         
 
        

          

        



defined P(Ox)s (Ð ≤ 1.1) in a 
         

       
 
    
         


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   μ                 

       
       
        
       
      

        
       
        
        
        
        
        


         
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       
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     
APIs to the α or ω     

      

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Table 1. Overview of publications using P(Ox)s in terms of biocompatibility and pharmacokinetics. 
Author Year Polymer Purpose Drug Nanostructure 
Goddard et 
al.3 
1989 
 
Biodistribution an
d blood clearance 
None None 
Zalipsky et 
al.23 
1996 
 
Blood clearance None Liposome 
Gaertner et 
al.46 
2007 
 
Biodistribution None None 
Mero et al.47 2012 
 
Physicochemical 
properties and 
aggregation 
potential 
Granulocyte  
colony 
stimulating  
factor 
Conjugate 
Tong et al.32 2013 
 
Crossing the BBB, 
Enhancement of 
blood circulation 
times 
Superoxide 
dismutase I 
Conjugate 
Eskow 
Jaunarajs et 
al.25 
2013 
 
Parkinson’s 
Disease 
Rotigotine Conjugate 
Wyffels et al.4 2016 
 
None None None 
Glassner et 
al.36 
2017 
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         
        

       


        
       
        


        

        
       
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       

       
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      
       
       




 

        
         
      

       
         

      
     
        



    
         


       
        

         
        
       
      

      
          
     
      
       
       

       
introduction of functional α or ω   

       





      

              

    

        
       
      


   
       
         
       
        
          
       
      
         
         
       

      

       
       


1,1′3,3,3′,3′
         
        
      

      
       
         
        
        

        
 

        
     

    
    
     
    

       
      























    
 

 
 

 
 

 
 

 
 

 
 

 

 





 





 

 
 

 
 

 

N
O
N
O
N
N
O
37 23 37
N
O
O
O
O H
n m
N
O
O
O
O HN
H
O
HN
O
OH
O
HN N
N
NH
H
NHO NH2
n m
N
O
O O
O
n
N
O
O
O
N
O
O
O
n
O
O H
m
N
N
H
O
N
O
OH
n
N
O
O
O
O
O
O
O
O
O
N
O
n nmm
N
O
N
O
N
N
O
NH33 26 45
N∗
O
N
∗
O
O
NH
Dox
n m

                                             
  
        
   
  
     
        
      




       
       

        
        


        
     
         
      
         
       
         





      
    




                       
  


 
    

           

            

 
 

  

              

             

  

 
12. H. Schlaad, C. Diehl, A. Gress, M. Meyer, A. L. Demirel, Y. Nur and A. Bertin, 
Macromol. Rapid Commun., 2010, 31, 511-525. 
13. M. Hartlieb, K. Kempe and U. S. Schubert, J. Mat. Chem. B, 2015, 3, 526-538. 
14. P. Wilson, P. C. Ke, T. P. Davis and K. Kempe, Eur. Polym. J., 2016, 88, 486-515. 
15. K. Lava, B. Verbraeken and R. Hoogenboom, Eur. Polym. J., 2015, 65, 98-111. 
16. L.-Y. Qiu, L. Yan, L. Zhang, Y.-M. Jin and Q.-H. Zhao, Int. J. Pharm., 2013, 456, 
315-324. 
17. Y. Gao, Y. Li, Y. Li, L. Yuan, Y. Zhou, J. Li, L. Zhao, C. Zhang, X. Li and Y. Liu, 
Nanoscale, 2015, 7, 597-612. 
18. J. Li, Y. Zhou, C. Li, D. Wang, Y. Gao, C. Zhang, L. Zhao, Y. Li, Y. Liu and X. Li, 
Bioconjugate Chem., 2015, 26, 110-119. 
19. P. H. Kierstead, H. Okochi, V. J. Venditto, T. C. Chuong, S. Kivimae, J. M. J. 
Fréchet and F. C. Szoka, J. Controlled Release, 2015, 213, 1-9. 
20. Y. Zhao, Y. Zhou, D. Wang, Y. Gao, J. Li, S. Ma, L. Zhao, C. Zhang, Y. Liu and X. Li, 
Acta Biomater., 2015, 17, 182-192. 
21. Z. He, A. Schulz, X. Wan, J. Seitz, H. Bludau, D. Y. Alakhova, D. B. Darr, C. M. 
Perou, R. Jordan, I. Ojima, A. V. Kabanov and R. Luxenhofer, J. Controlled 
Release, 2015, 208, 67-75. 
22. Z. He, X. Wan, A. Schulz, H. Bludau, M. A. Dobrovolskaia, S. T. Stern, S. A. 
Montgomery, H. Yuan, Z. Li, D. Alakhova, M. Sokolsky, D. B. Darr, C. M. Perou, 
R. Jordan, R. Luxenhofer and A. V. Kabanov, Biomaterials, 2016, 101, 296-309. 
23. S. Zalipsky, C. B. Hansen, J. M. Oaks and T. M. Allen, J. Pharm. Sci., 1996, 85, 
133-137. 
24. H. Xu, W. Zhang, Y. Li, F. F. Ye, P. P. Yin, X. Yu, M. N. Hu, Y. S. Fu, C. Wang and 
D. J. Shang, Pharm. Res., 2014, 31, 3038-3050. 
25. K. L. Eskow Jaunarajs, D. G. Standaert, T. X. Viegas, M. D. Bentley, Z. Fang, B. 
Dizman, K. Yoon, R. Weimer, P. Ravenscroft, T. H. Johnston, M. P. Hill, J. M. 
Brotchie and R. W. Moreadith, Mov. Disord., 2013, 28, 1675-1682. 
26. O. Sedlacek, B. D. Monnery, J. Mattova, J. Kucka, J. Panek, O. Janouskova, A. 
Hocherl, B. Verbraeken, M. Vergaelen, M. Zadinova, R. Hoogenboom and M. 
Hruby, Biomaterials, 2017, 146, 1-12. 
27. C. Legros, M.-C. De Pauw-Gillet, K. C. Tam, S. Lecommandoux and D. Taton, 
Eur. Polym. J., 2015, 62, 322-330. 
28. Z. He, L. Miao, R. Jordan, D. S-Manickam, R. Luxenhofer and A. V. Kabanov, 
Macromol. Biosci., 2015, 15, 1004-1020. 
29. M. N. Leiske, M. Hartlieb, C. Paulenz, D. Pretzel, M. Hentschel, C. Englert, M. 
Gottschaldt and U. S. Schubert, Adv. Funct. Mater., 2015, 25, 2458-2466. 
30. M. Hartlieb, T. Bus, J. Kübel, D. Pretzel, S. Hoeppener, M. N. Leiske, K. Kempe, 
B. Dietzek and U. S. Schubert, Bioconjugate Chem., 2017, 28, 1229-1235. 
31. R. W. Moreadith, T. X. Viegas, M. D. Bentley, J. M. Harris, Z. Fang, K. Yoon, B. 
izman, R. Weimer, B. P. Rae, X. Li, C. Rader, D. Standaert and W. Olanow, Eur. 
Polym. J., 2016. 
32. J. Tong, X. Yi, R. Luxenhofer, W. A. Banks, R. Jordan, M. C. Zimmerman and A. 
V. Kabanov, Mol. Pharm., 2013, 10, 360-377. 
33. R. Luxenhofer, A. Schulz, C. Roques, S. Li, T. K. Bronich, E. V. Batrakova, R. 
Jordan and A. V. Kabanov, Biomaterials, 2010, 31, 4972-4979. 
34. Y. Seo, A. Schulz, Y. Han, Z. He, H. Bludau, X. Wan, J. Tong, T. K. Bronich, M. 
Sokolsky, R. Luxenhofer, R. Jordan and A. V. Kabanov, Polym. Adv. Technol., 
2015, 26, 837-850. 
35. M. C. Woodle, C. M. Engbers and S. Zalipsky, Bioconjugate Chem., 1994, 5, 
493-496. 
36. M. Glassner, L. Palmieri, B. D. Monnery, T. Verbrugghen, S. Deleye, S. 
Stroobants, S. Staelens, L. wyffels and R. Hoogenboom, Biomacromolecules, 
2017, 18, 96-102. 
37. K. Kempe, S. L. Ng, K. F. Noi, M. Müllner, S. T. Gunawan and F. Caruso, ACS 
Macro Lett., 2013, 2, 1069-1072. 
38. T. R. Dargaville, B. G. Hollier, A. Shokoohmand and R. Hoogenboom, Cell Adh. 
Migr., 2014, 8, 88-93. 
39. Y. Liu, Y. Wang, Y. Wang, J. Lu, V. Piñón and M. Weck, J. Am. Chem. Soc., 2011, 
133, 14260-14263. 
40. L. Tauhardt, K. Kempe, M. Gottschaldt and U. S. Schubert, Chem. Soc. Rev., 
2013, 42, 7998-8011. 
41. M. Bauer, C. Lautenschlaeger, K. Kempe, L. Tauhardt, U. S. Schubert and D. 
Fischer, Macromol. Biosci., 2012, 12, 986-998. 
42. M. Bauer, S. Schroeder, L. Tauhardt, K. Kempe, U. S. Schubert and D. Fischer, J. 
Polym. Sci. A: Polym. Chem., 2013, 51, 1816-1821. 
43. Y. Gao, Y. Zhou, L. Zhao, C. Zhang, Y. Li, J. Li, X. Li and Y. Liu, Acta Biomater., 
2015, 23, 127-135. 
44. R. Shah, Z. Kronekova, A. Zahoranová, L. Roller, N. Saha, P. Saha and J. Kronek, 
J. Mater. Sci. Mater. Med., 2015, 26, 157. 
45. M.-J. Shieh, C.-L. Peng, W.-L. Chiang, C.-H. Wang, C.-Y. Hsu, S.-J. J. Wang and 
P.-S. Lai, Mol. Pharm., 2010, 7, 1244-1253. 
46. F. C. Gaertner, R. Luxenhofer, B. Blechert, R. Jordan and M. Essler, J. Controlled 
Release, 2007, 119, 291-300. 
47. A. Mero, Z. Fang, G. Pasut, F. M. Veronese and T. X. Viegas, J. Controlled 
Release, 2012, 159, 353-361. 
48. D. Hoelzer, M. N. Leiske, M. Hartlieb, T. Bus, D. Pretzel, S. Hoeppener, K. 
Kempe, R. Thierbach and U. S. Schubert, Oncotarget, 2018, Submitted. 
49. H. Xu, M. Hu, X. Yu, Y. Li, Y. Fu, X. Zhou, D. Zhang and J. Li, Eur. J. Pharm. 
Biopharm., 2015, 91, 66-74. 
50. P. Zhang, X. Qian, Z. Zhang, C. Li, C. Xie, W. Wu and X. Jiang, ACS Appl. Mater. 
Interfaces, 2017, 9, 5768-5777. 
 
 
Publications P1 to P8 
 
 
Publication P7 
Site-specific POxylation of interleukin-4 
 
T. Luehmann, M. Schmidt, M. N. Leiske, V. Spieler, T. C. Majdanski, M. Grube, M. Hartlieb, 
I. Nischang, S. Schubert, U.S. Schubert, L. Meinel,  
ACS Biomater. Sci. Eng. 2017, 3, 304 - 312. 
 
Reproduced by permission of The American Chemical Society. Copyright © 2017. 
The paper as well as the supporting information (free of charge) is available online: 
doi.org/10.1021/acsbiomaterials.6b00578. 
 
 
 
Site-Speciﬁc POxylation of Interleukin‑4
Tessa Lühmann,† Marcel Schmidt,† Meike N. Leiske,‡,§ Valerie Spieler,† Tobias C. Majdanski,‡,§
Mandy Grube,‡,§ Matthias Hartlieb,‡,§,# Ivo Nischang,‡,§ Stephanie Schubert,§,∥ Ulrich S. Schubert,‡,§
and Lorenz Meinel*,†
†Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, DE-97074 Würzburg, Germany
‡Institute of Organic and Macromolecular Chemistry [IOMC], Friedrich Schiller University Jena, Humboldtstrasse 10, DE-07743
Jena, Germany
§Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
∥Department of Pharmaceutical Technology, Friedrich Schiller University Jena, Otto-Schott-Strasse 41, DE-07747 Jena, Germany
*S Supporting Information
ABSTRACT: Polymer conjugated biologics form a multibillion
dollar market, dominated by poly(ethylene glycol) (PEG).
Recent reports linked PEGs to immunological concerns, fueling
the need for alternative polymers. Therefore, we are presenting a
strategy replacing PEG by poly(2-oxazoline) (POx) polymers
using genetically engineered interleukin-4 (IL-4) featuring an
unnatural amino acid for site-speciﬁc conjugation through
bioorthogonal copper-catalyzed azide alkyne cycloaddition
(CuAAC). Conjugation yields of IL-4-PEG were poor and did
not respond to an increase in the copper catalyst. In contrast,
POxylated IL-4 conjugates resulted in homogeneous conjugate
outcome, as demonstrated electrophoretically by size exclusion
chromatography and analytical ultracentrifugation. Furthermore,
POxylation did not impair thermal and chemical stability, and
preserved wild-type IL-4 activity for the conjugates as demonstrated by TF-1 cell proliferation and STAT-6 phosphorylation in
HEK293T cells, respectively. In conclusion, POxylation provides an interesting alternative to PEGylation with superior outcome
for the synthesis yield by CuAAC and resulting in conjugates with excellent thermal and chemical stress proﬁles as well as
biological performances.
KEYWORDS: cytokine engineering, 2-methyl-2-oxazoline, genetic code expansion,
CuAAC (copper(I) catalyzed azide alkyne cycloaddition), bioconjugation
■ INTRODUCTION
Many low-molar-mass biologics (5−50 kDa), including enzymes,
growth factors and cytokines are eﬃciently excreted via the
kidney and sinusoidal lining cells. Protein conjugation using
hydrophilic polymers increases the circulation half-life,
dominated by poly(ethylene glycols) (PEGs).1 The PEGylated
biologic conjugates are hydrophilic, thereby decreasing inter-
action with blood and cellular components while increasing
biocompatibility through the “stealth eﬀect”.2,3 However, in
spite of these stealth properties, recent reports linked com-
plement activation to PEG attached to liposomes, leading
to accelerated blood clearance after the second injection, which
was ﬁnally assigned to anti-PEG neutralizing antibodies.4−8
Additionally, PEGylation may reduce receptor aﬃnities which is
through PEG binding of water introducing steric hindrance for
interaction with cell surfaces.9 As a promising alternative to
PEG, poly(2-oxazoline)s (POx) have attained increasing atten-
tion and are intensively studied for biomedical applications
ranging from antifouling polymer coatings10,11 to the delivery
of hydrophobic drugs, proteins, and genetic materials.12−17
Small side chain derivatives of POx are known to be bio-
compatible18 and possess a stealth eﬀect similar to PEG.19,20
Moreover, a recent clinical study detailed the potential of site-
directed modiﬁcation of rotigotine with POx, establishing
successful “ﬁrst in man” use of POx−drug conjugates.21
Conjugation of POx to proteins has been performed with
unspeciﬁc coupling chemistries, for example linking the POx to
amino- or carboxyl-groups of the biologic through (1-ethyl-3-
(3-(dimethylamino)propyl)carbodiimide) (EDC)/N-hydroxy-
succinimide (NHS) synthesis or, more selectively, enzymati-
cally to glutamine residues15,22−24,16 and by thiol reactive
iodacetamide.21 Unspeciﬁc coupling leads into product hetero-
geneity introducing challenges to pharmaceutical development
including, for example, yield or analytical characterization.25,26
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Furthermore, unspeciﬁc chemistries, leading to heterogeneous
product outcome, drive another challenge−immunogenicity.27
Through heterogeneity, more species (thereby more conforma-
tional variants) are presented to the patient’s immune system
thereby exposing the immune system to a number of altered
epitopes as compared to the wild type, arguably more eﬀec-
tively supporting antibody formation against the biologic.
These considerations fuel the need for alternatives, leading to
homogeneous product outcome. We are approaching this by
genetically introducing unnatural groups into the biologics̀
backbone at one predeﬁned site, providing a distinctive
functional group. Only at that introduced group will decoration
occur, removing the heterogeneity of the majority of coupling
strategies pursued today.26,28−30 To this end, we recently
reported on genetic code expansion integrating pyrrolysine
derivatives, e.g., N-propargyl-L-lysine (Plk), through recombi-
nant protein expression for site-speciﬁc modiﬁcation of growth
factors,31 ﬂuorescent proteins,32 as well as for cytokines33 and
use for the surface decoration of glyco-engineered cells34 or
bioresponsive drug delivery35 through bio-orthogonal copper
catalyzed azide alkyne cycloaddition (CuAAC). In this
study, we pursue the production of site-speciﬁcally decorated
polymer-interleukin-4 (IL-4) conjugates with the ultimate goal
for unprecedented homogeneity in IL-4 conjugate out-
come and maintained potency as compared to the wild type
(wt) IL-4. IL-4 is a small and (at physiological conditions)
positively charged 15 kDa-cytokine, triggering macrophage
(Mφ) polarization along the M2 lineage with possible appli-
cation in Mφ associated diseases.36 In light of the favor-
able protein-repellent property and good biocompatibility,
hydrophilic POx-based polymers of diﬀerent molar masses
(2.5, 4, 10 kDa) and architecture, including an azide group for
cycloaddition, were synthesized to approach site-speciﬁc
conjugation of Plk-IL-4 with the polymer. Conjugation with
PEG resulted in poor yield, whereas POx polymers were
eﬀectively conjugated as a function of the polymers’ weight-
average molar mass MW. The IL-4 conjugate products were
detailed with respect to bioactivity, secondary structure, as well
as thermal and chemical stability.
2. MATERIALS AND METHODS
DMEM, RPMI-1640 medium, L-glutamine, L-alanyl-L-glutamine, sodium
pyruvate, bovine serum albumin solution 7.5%, lipid medium supple-
ment, copper(II) sulfate, sodium L-ascorbate, and tris(3-hydroxypropyl-
triazolylmethyl) amine (THPTA) were purchased from Sigma-Aldrich
(Schnelldorf, Germany). Penicillin G and streptomycin solution (Pen/
Strep) were purchased from Biochrom AG (Berlin, Germany). Fetal
bovine serum (FBS) was from GIBCO life technologies (Carlsbad,
USA). HiTrap SP XL and HiTrap SP HP ÄKTA columns were from
GE Healthcare (Buckinghamshire, GB). Vivaspin centrifugal concen-
trators were from Sartorius AG (Göttingen, Germany) and HyperSep
C18 desalting columns were from Thermo Scientiﬁc (Waltham, USA).
WST-1 was purchased from Roche (Basel, Switzerland). All other
chemicals used were at least of pharmaceutical grade and were purchased
from Sigma-Aldrich and Merck (unless noted otherwise). Solvents were
obtained by Sigma-Aldrich, VWR, Linde, and Arcos Organics.
2.1. Polymer Synthesis and Characterization. A detailed
overview about synthetic procedures and characterization is given in
the Supporting Information.
2.2. Chemical Synthesis of Propargyl-L-lysine (Plk). Propargyl-
L-lysine (Plk) was prepared as HCl-salt following procedures described
by Milles et al.37 1H NMR spectra were acquired on a Bruker Advance
400 MHz spectrometer for conﬁrmation of the product.31
2.3. Expression of Plk-IL-4 and wt-IL-4. Plk-IL-4 and wt-IL-4
were expressed as described previously.33 Brieﬂy, E.coli BL21 DE3,
encoding for TAG(42)-IL-4 and for the PylRS/tRNACUA pair, were
cultured at 37 °C and the Plk substrate was added at a ﬁnal
concentration of 2 mM at OD600 = 0.3 in standard TB (Terriﬁc Broth)
medium. For wt-IL-4 expression, BL21 (DE3) cells, encoding for
wt-IL-4, were used. Protein expression was subsequently induced with
1 mM IPTG at OD600 = 0.6 at 37 °C. After 6 h, the bacterial cells were
harvested and the pellet was solubilized after soniﬁcation and
centrifugation with lysis buﬀer, containing 5 M guanidine-HCl and
2 mM reduced and 0.2 mM oxidized glutathione. This solution was
subsequently refolded using a glutathione redox buﬀer system as
described.38 After centrifugation, the supernatant containing Plk-IL-4
was puriﬁed by ion exchange aﬃnity chromatography using a FPLC
system (GE Healthcare Äkta Puriﬁer, Life sciences, Freiburg,
Germany). After puriﬁcation, fractions containing IL-4 proteins were
extensively dialyzed against PBS and stored at −80 °C. Wt-IL-4 and
Plk-IL-4 concentrations were determined by UV-absorbance at
280 nm, using a molar extinction coeﬃcient of 8860 M−1 cm−1.39
2.4. Copper-Catalyzed Azide−Alkyne Huisgen Cycloaddi-
tion (CuAAC). Twenty-ﬁve μM Plk-IL-4 and a 50-fold molar excess of
each polymer was used. The click reaction was performed in the
presence of 2.5 mM L-ascorbic acid, 500 μM THPTA, and 100 μM
CuSO4 or in the presence of 2.5 mM L-ascorbic acid, 1 mM THPTA,
and 1 mM CuSO4 in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4,1.47 mM KH2PO4, pH 7.4). CuSO4 and THPTA was
premixed and incubated with L-ascorbic acid under air exclusion for
10 min to quench occurring reactive oxygene species (ROS) as
detailed before.34 The click reaction was performed at room temper-
ature overnight and the reaction was stopped by the addition of 5 mM
EDTA. The proteins and conjugates were subsequently analyzed by
SDS-PAGE and MALDI-MS analysis or used for further puriﬁcation.
2.5. MALDI-MS. The samples were desalted using ZipTipC18-tips
following the manufacturer’s instructions. Matrix-assisted laser desorp-
tion ionization (MALDI-MS) spectra were acquired in the linear
positive mode by using an Autoﬂex II LRF instrument (Billerica, USA).
Mass spectra were calibrated externally with a protein standard I from
Bruker Daltonics Inc. (Billerica, USA), containing insulin, ubiquitin,
myoglobin, and cytochrome C.
2.6. SDS-PAGE. Expressed proteins and proteins used in click
reactions were analyzed by standard Tris-glycine SDS-PAGE as out-
lined before.40 Gels were stained with Coomassie Brilliant Blue G250
and photographed using a FluorChem FC2 imaging system (Protein
Simple, Santa Clara, CA).
2.7. RP-HPLC and SEC Analysis. Protein purity was assessed on a
RP-HPLC system using a VWR Hitachi LaChrom HPLC system
(Darmstadt, Germany). Protein samples and polymers were applied to
a ZORBAX Eclipse XDB-C18 column (150 mm * 4.6 mm, particle
size = 5 μm (Agilent, Santa Clara, CA)), equilibrated by water
containing 0.1% TFA and acetonitrile (ACN) containing 0.1% TFA
(90:10 v/v). Polymers, wt-IL-4 and IL-4 conjugates were eluted by a
linear gradient of 10−60% ACN containing 0.1% TFA with a gradient
of 1% ACN/min and a ﬂow rate of 1 mL/min. Column temperature
was kept at 24 °C and UV-absorbance was monitored at λ = 214 nm
and λ = 280 nm, respectively.
After desalting using HyperSep C18 columns, IL-4-conjugates were
eluated with 45% MeCN, containing 0.1% TFA (v/v). For SEC analysis,
approximately 10 μg protein sample was applied to an equilibrated
BioSep-SEC s2000 column (300 * 4.6 mm, particle size = 5 μm, pore
size = 145 Å (Phenomenex, Torrance, USA)). Polymers, wt-IL-4 and
IL-4 conjugates were analyzed in 45% MeCN, containing 0.1% TFA
(v/v) at a ﬂow rate of 1 mL/min according to the manufacturer’s
instructions for small peptides and proteins. UV-absorbance was
monitored at λ = 220 nm. Data analysis, including nonlinear curve
ﬁtting and parameter determination (EC50-value range within the 95%
conﬁdence interval), was performed with the software GraphPad
Prism 7 (San Diego, California, USA).
2.8. Analytical Ultracentrifugation (AUC). Sedimentation
velocity experiments were performed using a ProteomeLab XL-I
analytical ultracentrifuge (Beckman Coulter Instruments, Brea, CA)
with an An-60Ti four-hole rotor using double-sector aluminum center-
pieces with a 12 mm optical path length. Interference optics detection
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was used for observation of the sedimentation boundary in respect to
time. All experiments were performed at a rotor speed of 50.000 rpm
for 24 h and at a temperature of 20 °C. The cells were ﬁlled with
410 μL of the sample in PBS and with 440 μL of the solvent PBS as
the reference. Sedimentation velocity data were analyzed with SEDFIT
(version 15.01b) and the c(s) model with a maximum entropy regulari-
zation procedure. This model accounts for a numerical solution of the
sedimentation velocity proﬁles and provides respective distributions of
sedimentation coeﬃcients. Density and viscosity of the solvent used
for the modeling procedure were estimated as follows. The density of
PBS was determined to 1.0056 g cm−3 at a temperature of 20 °C with
a density meter DMA 4100 (Anton Paar, Graz, Austria). The dynamic
viscosity of PBS was measured as 1.03 mPas with an AMVn Auto-
mated Micro Viscometer also from Anton Paar. The value of the partial
speciﬁc volume (0.73 cm3 g−1) of the polymer−protein conjugate could
only be assumed from typical values of proteins41 and the literature
concerning a related protein.42 For the polymer, an average value based
on previous measurements of P(MeOx) (0.8 cm3 g−1) was used.
2.9. Cell Culture. TF-1 cells (ATCC-Number CRL-2003, ATCC,
and Manassas, VA) were harvested from exponentially growing
suspensions. The cells were maintained in 75 cm2 culture ﬂasks in
growth medium (RPMI-1640 medium, supplemented with 10% heat-
inactivated FBS, 1% Pen/Strep solution, 4.5 g/L D-glucose, 2 mM
L-glutamine, 2 mM L-alanyl-L-glutamine, 1 mM sodium pyruvate, and
2 ng/mL human GM-CSF) at 37 °C and 5% CO2. HEK 293T cells
(ATCC-Number CRL-1573, ATCC, Manassas, VA) were harvested from
exponentially growing subconﬂuent monolayers in growth medium
(DMEM containing 10% heat-inactivated FBS and 1% Pen/Strep
solution) at 37 °C and 5% CO2.
2.10. WST-Proliferation Assay. TF-1 cells were seeded in a
96-well plate format (50 000 cells/well) in WST-1 assay medium
(RPMI-1640 medium, supplemented with 10% FBS, 1% Pen/Strep,
0.5% BSA), supplemented with dilution series of wt-IL-4, Plk-IL-4 and
polymer conjugated IL-4 variants ranging from 0.001 to 2 nM. After
stimulation for 48 h, the cells were incubated with WST-1 for 4 h at
37 °C according to the manufacturer’s instructions. The absorbance of
the soluble formazan product was determined at λ = 450 nm using a
Spectramax 250 microplate reader (Molecular Devices, Sunnyvale).
2.11. Enhanced Yellow Fluorescent Protein and Secreted
Alkaline Phosphatase Reporter Gene Assays in HEK293T cells.
For the enhanced yellow ﬂuorescent protein (eYFP) reporter gene
assay, 15.000 HEK 293T cells were cotransfected in 24 well plates with
1 μg of the plasmids pHW0040 (PSTAT6−eYFP) and 1 μg of the
constitutive STAT6 expression vector pSTAT6 (Genebank accession
N-BC075852.1) as described before.33 After exchange of the trans-
fection medium against growth medium, supplemented with 1.3 nM of
wt-IL-4, Plk-IL-4, and polymer-conjugated IL-4 variants, respectively,
HEK 293T cells were stimulated for 48 h at 37 °C and 5% CO2. eYFP
expression was detected with an Axiovert 200 M inverted microscope
(Zeiss, Oberkochen, Germany). For the secreted alkaline phosphatase
(SEAP) reporter gene assay 4000 HEK 293T cells were cotransfected
in 96 well plates with 0.2 μg of the plasmid pHW003 (PSTAT6−SEAP)
and 0.2 μg of the constitutive STAT6 expression plasmid pSTAT6
(Genebank accession N- BC075852.1). After exchange of the trans-
fection against growth medium supplemented with 1.3 nM wt-IL-4 or
polymer-conjugated-IL-4, respectively, the cells were stimulated for
48 h at 37 °C and 5% CO2. Twenty microliters of the medium super-
natant was then incubated with 200 μL of Quanti-BlueTM alkaline
phosphatase detection medium and SEAP activity was monitored at
650 nm using a Spectramax 250 microplate reader (Molecular Devices,
Sunnyvale, CA). Detailed information about STAT-6 gene reporter
plasmids is given elsewhere.43
2.12. Chemical Unfolding and Fluorescence Emission
Spectroscopy. Unfolding of Plk-IL- 4, wt-IL- 4 ,and polymer-IL-4
conjugates in dependency to the denaturant urea was analyzed as
previously described.44 A stock solution of IL-4 variants was diluted to
a ﬁnal concentration of 10 μM in the presence of increasing concen-
trations of urea, ranging from 0−9 M, in 20 mM phosphate buﬀer,
pH 7.4. Fresh stock solutions of urea were prepared gravimetrically in
20 mM phosphate buﬀer and its ﬁnal concentration were as described
before.45 Samples of Plk-IL- 4, wt-IL-4, and polymer-IL-4 conjugates
were incubated at room temperature for 20 h before analysis on a LS
50 B ﬂuorescence spectrophotometer (PerkinElmer, Waltham, USA).
Fluorescence emission spectra were obtained using at λ = 280 nm as
excitation wavelength and λ = 380 nm as emission wavelength and a
scan speed of 240 nm/min in a quartz cuvette. All obtained spectra were
baseline corrected against urea containing buﬀer ﬂuorescence intensities.
2.13. Circular Dichroism Spectroscopy. IL-4 samples were
dialyzed against 20 mM sodium phosphate buﬀer with a pH of 7.0,
with the identical buﬀer serving as a blank. Circular dichroism (CD)
spectra were recorded at diﬀerent temperatures or during increasing
temperature with a J715 spectropolarimeter (JASCO Labor- and
Figure 1. (A) Structure of polymers and copolymers. (B) Crystal structure of IL-4. Pdb =2B8U1. The introduction site of the uAA (cyan) is
highlighted. Structure of the uAA propargyl-L-lysine (Plk) (4).
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Datentechnik GmbH, Groß-Umstadt, Germany) with protein solu-
tions with a ﬁnal concentration of 0.2 mg mL−1 in a 2 mm path length
cell with the following scan parameters: 100 mdeg sensitivity, 0.1 nm
step resolution, 50 nm min−1 scan speed, 2 s time constant. Three
accumulations per scan were averaged. Thermal unfolding curves of
IL-4 samples were similarly performed by monitoring the change in
ellipticity at λ = 222 nm. Data processing included solvent background
correction and adjustment for path length and concentration.
2.14. Statistics. Data were analyzed using ANOVA with the
Tukey-Kramer test for post hoc comparison. Results were considered
statistically signiﬁcant at p ≤ 0.05(*) and are displayed as mean with
standard deviation (SD).
3. RESULTS AND DISCUSSION
3.1. Polymer Synthesis and Characterization. Azide
functionalized hydrophilic polymers composed of 2-methyl-2-
oxazoline (MeOx) were produced by cationic ring-opening poly-
merization as previously described46,47 (Figure 1A, 1). Addition-
ally, statistical copolymers composed of MeOx in combination
with aminobutyl-2-oxazoline (AmOx)48free primary amine
groups at the polymer side chains that can be used for addi-
tional decoration purposes including the coupling of targeting
motifswere synthesized with a terminally located azide group
(for CuAAC with Plk-IL-4) (Figure 1A, 2). PEG polymers were
functionalized with azide groups following polymerization
(Figure 1A, 3).
The composition of the used polymers is described (Table 1)
and polymerization procedures and characterization including 1H
NMR, MALDI-MS and SEC data are provided in Figures S1− S11.
Table 1. List of Polymers with n and m = Number of
Repeating Monomer Units (see Figure 1)
molar mass (g mol−1)
polymer ∼2500 ∼4000 ∼10 000
1, P(MeOx)n-N3 n = 30 n = 50 n = 108
2, P(MeOxn-stat-AmOxm)-N3 n = 41; m = 2
n = 38; m = 4
n = 32; m = 8
3, PEGn-N3 n = 57 n = 91
Figure 2. (A) CuAAC reactions between Plk-IL-4 and P(MeOx)n-N3
polymers. (B) CuAAC reactions between Plk-IL-4 and P(MeOxn-stat-
AmOxm) -N3 polymers. (C) CuAAC reactions between Plk-IL-4 and
P(EG)n-N3 polymers as analyzed by reduced SDS-PAGE. Plk-IL-4 is
shown as control. Arrows indicate polymer conjugated IL-4 species.
Figure 3. (A) RP-HPLC analysis of Plk-IL-4 and puriﬁed P(MeOx)50-
IL-4 and puriﬁed P(MeOx38-stat-AmOx4)-IL-4. (B) Reducing SDS-
PAGE of P(MeOx)50-IL-4 in comparison to Plk-IL-4. (C) Reducing
SDS-PAGE of P(MeOx38-stat-AmOx4)-IL-4 in comparison to Plk-IL-4.
(D) SEC analysis of IL-4 polymer conjugates in comparison to Plk-IL-4
and unconjugated polymers.
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3.2. Expression and Chemical Functionalization of
Plk-IL-4 with P(MeOx)n-N3, P(MeOxn -stat-AmOxm)-N3,
and PEGn-N3 by CuAAC. IL-4 with an unnatural amino acid
(uAA) Plk (4) integrated at position #42 (K42/Plk42) was
engineered in E. coli by amber codon suppression31 (Figure 1B;
IL-4 receptor signaling tolerates K42/Plk exchange33). At ﬁrst,
we studied the eﬃciency of the click reaction chemistry of
Plk-IL-4 and the azide functionalized polymers on small scale
using copper(II) sulfate with sodium L-ascorbate and the
water-soluble base tris(3-hydroxypropyltriazolyl-methyl) amine
(THPTA).31,34,49 Two diﬀerent copper(II) sulfate concen-
tration were compared (100 μM and 1 mM). The electro-
phoretic mobility of unconjugated Plk-IL-4 (15 kDa) and
conjugated Plk-IL-4 was qualitatively assessed by gel electro-
phoresis followed by Coomassie staining (Figure 2).
Qualitatively, the conjugation yield was highest with the low
molecular weight P(MeOx)30-N3 (Figure 2A, lanes 1 and 2),
followed by the higher molar mass P(MeOx)50-N3 and
P(MeOx)108-N3 (Figure 2A, lanes 3−7), respectively. The
copper(II) sulfate concentration (100 μM versus 1 mM) had
no impact on the unconjugated Plk-IL-4 (e.g., aggregation
could have been expected) or conjugation outcome. Con-
jugation of Plk-IL-4 with P(MeOxn-stat-AmOxm)-N3-polymers
bearing diﬀerent amino group contents resulted in broader
bands as compared to the amine-free polymers reﬂecting that
additional charges might inﬂuence SDS complexation50 and gel
migration behavior51 of the P(MeOxn-stat-AmOxm)-IL-4
conjugates (Figure 2 B). Contrasting the excellent reaction
with MeOx homopolymers, conjugation eﬃciencies of Plk-IL4
with P(EG)n-N3 were poor, resulting in small amounts of the
conjugated species running at ∼20 kDa (Figure 2C). We
speculate that polyethers, in spite of the fact that this chemistry
is frequently used for similar conjugation purposes,49 interact
noncovalently with the copper(I) catalyst, reducing the con-
jugation yield and in analogy to previous reports, linking impaired
copper electrodeposition to the presence of PEG during elec-
troplating.52 The unsuccessful conjugation of PEG-N3 could
also be related to its hydrophobic end-group, possibly leading
into polymer aggregation53 or nonspeciﬁc interactions54 with
the Plk-IL-4. We could not overcome this limitation even when
providing the catalyst at 10-fold concentration (from 100 μM
to 1 mM; Figure 2). Therefore, copper-free bioorthogonal
chemistries should be preferred for site-speciﬁc PEGylation of
proteins.55
MeOx based polymers with similar molar masses (∼4 kDa)
but diﬀerent architecture, namely, P(MeOx)50-N3 and P(MeOx38-
stat-AmOx4)-N3 but not PEG, were selected for bioconjugation to
Plk-IL-4 on a larger scale. Large-scale production was followed
by cationic ion exchange chromatography for puriﬁcation and
further characterization of the conjugates.
3.3. Characterization of IL-4 Conjugates. Following up-
scaling, IL-4 bioconjugates P(MeOx)50-IL-4 and P(MeOx38-stat-
AmOx4)-IL-4 were puriﬁed from unreacted educts (Figure 3).
The conjugates eluted at 30.6 and 30.8 min, respectively
(Figure 3A). This result was conﬁrmed by gel electrophoresis,
with unconjugated IL-4 (15 kDa) being absent (Figure 3B, C)
and new bands at approximately 20 kDa for (P(MeOx)50-IL-4
(Figure 3B) and for P(MeOx38-stat-AmOx4)-IL-4 (Figure 3C),
corresponding to the monoconjugated IL-4 species, respec-
tively. We deployed MALDI-MS analysis, which corroborated
Figure 4. Results from analytical ultracentrifugation showing (A) the sedimentation fronts of the polymer P(MeOx)50-N3 (c = 0.1% (w/w)), (B) the
conjugate P(MeOx)50-IL-4 (c = 0.04% (w/w)), and (C) the normalized diﬀerential distribution of sedimentation coeﬃcients c(s) of the polymer
P(MeOx)50-N3 in gray and of the P(MeOx)50-IL-4 in black.
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these ﬁndings. (P(MeOx)50-IL-4 revealed an average centered
mass of 20 000 Da (Figure S12).
Conjugation of the statistical copolymer P(MeOx38-stat-
AmOx4)−N3 resulted in an average centered mass of 19.1 kDa
and a broad peak reﬂecting the statistical mass distribution of
the P(MeOx38-stat-AmOx4) conjugated to IL-4 (Figure S13).
The homogeneity of the IL-4-conjugates was further corro-
borated by SEC and AUC experiments. Both bioconjugates
(P(MeOx)50-IL-4 and the statistical copolymer P(MeOx38-stat-
AmOx4)-IL-4) were indistinguishable by SEC (r.t.: P(MeOx)50-
IL-4 = 2.90 min; r.t.: P(MeOx38-stat-AmOx4)-IL-4 = 2.88 min)
and similar to unmodiﬁed Plk-IL-4 (r.t. = 2.96 min; Figure 3D),
whereas the (unreacted) polymers eluted at later retention
times (r.t.: P(MeOx)50-N3 = 3.67 min; r.t.: P(MeOx38-stat-
AmOx4)-N3 = 3.42 min) reﬂecting their lower molar mass as
compared to the conjugates. The presence of one single peak
for both IL-4 bioconjugates suggested homogeneous product
outcome through CuAAC coupling without detectable oligomers.
The SEC ﬁndings were further detailed by AUC and the
monodisperse P(MeOx)50-N3. P(MeOx)50-N3 had an approx-
imate molar mass of 3700 g mol−1 with a diﬀuse sedimentation
proﬁle and signiﬁcant back-diﬀusion (Figure 4A). The resulting
distribution of the sedimentation coeﬃcient (Figure 4C, gray
line) was narrow and indicated one single population of species,
i.e. homogeneity of the polymer’s molar mass. P(MeOx)50-IL-4
conjugates had less diﬀuse sedimentation proﬁles as compared
to the unconjugated P(MeOx)50-N3 polymer, reﬂecting the con-
jugate’s higher molar mass (Figure 4B). However, P(MeOx)50-
IL-4 conjugates sedimented with a single population of species,
indicating the absence of the unconjugated P(MeOx)50 on the
one hand or higher oligomeric species on the other hand
(Figure 4C, black line). Therefore, these conjugation protocols
lead to homogeneous conjugation outcome.
3.4. In Vitro Activity of IL-4 Conjugates. IL-4 signals
through two diﬀerent receptor complexes both of which com-
prising IL-4Rα and γc (type I receptor; preferentially expressed
on cells of hematopoietic origin) or IL13Rα1 (type II receptor;
preferentially on nonhematopoietic cells). Interaction of IL-4
with the IL-4Rα subunit has picomolar aﬃnity (KD = 100 pM)
56
(step 1) followed by ligand-mediated receptor heterodimeriza-
tion (step 2) to recruit the low aﬃnity receptors γc (type I
receptor) or IL13Rα1 (type II receptor). Proliferation of TF-1
suspension cells (hematopoietic cells expressing both the type I
and the type II IL-4 receptor) was detailed in response to IL-4
concentration (Figure 5A).
Bioactivity of IL-4 conjugates was alike the wt-IL-4,
indicating fully retained IL-4 bioactivity following POxylation.
A weak reduction in bioactivity was observed for P(MeOx)50-
IL-4 in contrast to Plk-IL-4 (but not wt-IL-4). This data set was
corroborated by analyzing STAT-6 phosphorylation, thereby
reporting on IL-4 receptor activation (Figure 5B, C). Kidney
derived HEK293T cells (nonhematopoietic and expressing the
type II receptor) were cotransfected with a STAT-6 expression
vector reporting either for eYFP or for SEAP expression as
previously described.57 Treatment with both IL-4 conjugates
resulted in similarly strong STAT-6 phosphorylation as com-
pared to wt-IL-4 and signiﬁcant weaker responses in unstimulated
but transfected control cells (Figure 5C). These results sug-
gested that both chemically modiﬁed IL-4 conjugates conserved
wt-IL-4-activity in cells of hematopoietic and nonhematopoietic
origin.
3.5. Stability of IL-4 Conjugates. The stability of IL-4 was
studied through ﬂuorescence emission taking advantage of a
single tryptophan (W91) buried within the correctly folded
IL-4 (not ﬂuorescent) and being surface exposed after unfolding
(ﬂuorescent; Figure 6A).
Chemically induced IL-4 unfolding was studied with
increasing urea concentrations. Identical curves were recorded
for P(MeOx) 50-IL-4 and of P(MeOx38-stat-AmOx4)-IL-4 as
compared to unconjugated wt-IL-4 and Plk-IL-4, respectively.
Both IL-4 conjugates maintained their structural integrity after
stressing with up to 6 M of the denaturant urea, highlighting
their excellent chemical stability. This data was corroborated by
exposing the groups to thermal stress tying to previous reports
Figure 5. (A) TF-1 proliferation assay of wt-IL-4, Plk-IL-4, and polymer
conjugated IL-4 derivatives (mean ± standard deviation, n = 3). R2
values of the nonlinear ﬁtting as well as the 95% conﬁdence intervals of
the estimated EC50 values are given. (B) eYFP reporter gene assay of
HEK 293 T cells transfected with pSTAT6−eYFP and pSTAT6 after
stimulation with 1.3 nM wt-IL-4, Plk-IL-4, and polymer conjugated IL-4
species. The control shows transfected but unstimulated cells. (C) SEAP
reporter gene assay of HEK293 T cells transfected with pSTAT6-SEAP
and pSTAT6 after stimulation with 1.3 nM wt-IL-4, Plk-IL-4 and
polymer conjugated IL-4 species. Asterisks indicate statistically
signiﬁcant diﬀerences among groups (p ≤ 0.05 (*), n = 5).
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on the thermal stability of POxylated virus particles.58 Moreover,
other hydrophilic polymers such as trehalose side chain polymers
induced enhanced stability of lysozyme conjugates to environ-
mental stress factors compared to unconjugated polymers added
to the enzyme,59 providing insights into an superior eﬀect of
covalent conjugation for protein stabilization.
Unfolding with temperature was recorded through variable
temperature circular dichroism (CD; Figure 6B). CD pattern of
IL-4 conjugates and Plk-IL-4 were recorded at temperature of
maximal stability (Ts = 20.8 °C)
44 before, during, and after
thermal stressing (100 °C; Figure S14A, B). The IL-4
conjugates had equal helicity (minima at λ = 208 nm and
λ = 222 nm; maximum at λ = 193 nm) as unconjugated
Plk-IL-4 at 20 °C, indicating that the polymer modiﬁcation on
the IL-4 surface did not interfere with IL-4 folding. Under
thermal stress (100 °C), the overall levels of helical content
were reduced in all groups (Figure S14B). Following cooling
to 20 °C of these samples (Figures S14C), refolding of
P(MeOx)50-IL-4 and of P(MeOx38-stat-AmOx4)-IL-4 resulted
in 50.8% ± 1.2 and 50.9% ± 1.3 of recovered helical content,
respectively (with respect to the molar ellipticity (at λ = 222 nm)
of untreated IL-4 samples set as 100%; Figure 6B). In contrast,
unconjugated, thermally stressed Plk-IL-4 attained at signiﬁcantly
reduced helical content of 45.4% ± 1.9 at 20 °C, reﬂecting faci-
litated refolding upon thermal stress for the conjugated variants
as compared to unconjugated IL-4.
We than recorded thermal unfolding proﬁles of P(MeOx)50-
IL-4, of P(MeOx38-stat-AmOx4)-IL-4 and of Plk-IL-4 from
45 to 100 °C as a function of the CD signal at λ = 222 nm
(Figure S15).
The transition temperatures of unfolding (Tm) were calculated
from the inﬂection points of the nonlinear ﬁtted curves with
Plk-IL-4 unfolding at 83.2 °C (in line with previously reported
83.8 °C44), and P(MeOx)50-IL-4 and P(MeOx38-stat-AmOx4)-
IL-4 at 83.4 and 83.9 °C, respectively. These studies demon-
strated the excellent stability properties of POxylated IL-4 with
respect to both chemical and thermal stresses.
■ CONCLUSIONS
In summary, we presented a modular design strategy for
polymer conjugation of the immune modulating cytokine IL-4
by using bio-orthogonal copper-catalyzed click chemistry.
Hydrophilic poly-2-oxazolines were eﬀectively coupled to Plk-
IL-4, contrasting the unsatisfying outcome when using PEG
instead. Future work is required addressing the in vivo poten-
tial of POxylated IL-4-conjugates in terms of pharmacokinetic,
safety, and pharmacodynamic performances, respectively.
Promising outcome on conjugate stability following chemical
and thermal stresses, suggests interesting features in terms of
storage stability of future conjugates, potentially facilitating
manufacture and shipment of future drug products formats.
Further stability studies with other biologics are required
before ﬁnal conclusions can be drawn on this potential advantage
of POxylated conjugates. In the light of the need for PEG-
alternatives as of observed immunological challenges in some
but not all patients, the developed P(MeOx)n-IL-4 conjugates
are interesting images for future (pre)-clinical testing, with
fully retained stability and in vitro biological performances as
compared to wt-IL-4. Furthermore, the demonstrated successes
with conjugates holding an additional amine functional group
provide further handle for future conjugates, e.g., the facilitated
decoration with targeting motifs or other ligands at the polymer.
From a developmental perspective this would provide various
advantages, particularly the separate production of a target
motif-decorated polymer, which in return is site-speciﬁcally
clicked to the Plk-biologic. These approaches using copper-
catalyzed synthesis for protein−polymer conjugation provide a
blue print leading to homogeneous, high-quality polymer−
conjugate outcome.
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ABSTRACT: Controlling the size and charge of nanometer-
sized objects is of upmost importance for their interactions
with cells. We herein present the synthesis of poly(2-
oxazoline) based nanogels comprising a hydrophilic shell and
an amine containing core compartment. Amine groups were
cross-linked using glutaraldehyde resulting in imine based
nanogels. As a drug model, amino ﬂuorescein was covalently
immobilized within the core, quenching excessive aldehyde
functions. By varying the amount of cross-linker, the zeta
potential and, hence, the cellular uptake could be adjusted.
The ﬂuorescence of the nanogels was found to be dependent
on the cross-linking density. Finally, the hemocompatibility of
the described systems was studied by hemolysis and erythrocyte aggregation assays. While cellular uptake was shown to be
dependent on the zeta potential of the nanogel, no harmful eﬀects to red blood cells was observed, rendering the present system
as an interesting toolbox for the production of nanomaterials with a deﬁned biological interaction proﬁle.
■ INTRODUCTION
Nanomedicine, the use of nanoscopic objects for biomedical
applications such as diagnostics or treatment of diseases, has
attracted increasing interest in recent years.1,2 By using
(polymeric) carriers, it is possible to solubilize, protect, and
deliver drug molecules to the desired site of action in the body.
Nanogels, such as (reversibly) cross-linked polymer micelles,3
are particularly valuable in this context as, if the chemistry is
chosen appropriately, premature drug release or disassembly
can be reduced.4 In the nanomedicine based treatment of
cancer, the enhanced permeability and retention (EPR) eﬀect is
used to generate a tumor speciﬁc accumulation of the drug.5
The concept exploits the leaky nature of tumor tissue and the
passive accumulation of nanosized objects within those cavities.
However, in order to take advantage of the EPR eﬀect, a drug
carrier has to exhibit long blood circulation times and a low
level of unspeciﬁc cellular interactions. Many parameters such
as size, shape, hydrophilicity or charge inﬂuence the cellular
uptake,6,7 and with regard to new nanomedicines, the ability to
tailor the cellular interaction in an easy way is highly beneﬁcial.
It was shown that a positively charged surface signiﬁcantly
increases the uptake of nanoparticles.6,8−12 This eﬀect is also
used in gene therapy approaches in terms of a complexation of
negatively charged genetic material by positively charged
polymers in order to penetrate cellular membranes.13 However,
a positively charged surface usually also increases the
cytotoxicity induced by the system.14,15 In addition, in the
context of the EPR eﬀect, a hydrophilic, low fouling surface is
indispensable to maintain low protein adsorption levels. Poly(2-
oxazoline)s (POx) display a promising material in a biomedical
context, as certain derivatives bearing small side chains, like
poly(2-methyl-2-oxazoline) (PMeOx) or poly(2-ethyl-2-oxazo-
line) (PEtOx), show excellent biocompatibility.16−18 Indeed,
their performance in biological applications is often compared
to poly(ethylene glycol) (PEG), since they also show a stealth
eﬀect.19,20 Recent studies show that in terms of circulation time
in the bloodstream and unspeciﬁc accumulation in the body,
PEtOx is even more advantageous than PEG.21 Their versatile
functionalization chemistry displays another advantage.22 There
are sparse examples of POx based nanogels using PEtOx or
PMeOx as a polymer shell23,24 and only a few were utilized for
biomedical applications.25,26
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Recently, we reported the synthesis of nanogels based on the
self-assembly of POx block copolymers consisting of an amine-
containing, cationic block (poly(4-amino-butyl-2-oxazoline
(PAmOx))27 and a hydrophilic PEtOx segment.26 The
nanogels maintained low toxicity levels while possessing a
positive zeta potential. Within the present contribution, the
inﬂuence of the cross-linking process on the properties of
nanogels, in particular, on the cellular uptake, is investigated.
■ RESULTS AND DISCUSSION
A highly deﬁned POx-based diblock copolymer P(EtOx98-b-
BocOx32), 1, Đ = 1.07, Table 1, was synthesized via cationic
ring opening polymerization by sequential monomer addition.
The Boc-group was abstracted using triﬂuoroacetic acid to yield
P(EtOx98-b-AmOx32), 2 with a dispersity of 1.07. To produce
nanogels this polymer was dissolved in chloroform, which leads
to the formation of micellar structures comprising an PAmOx
core. The charged nature of the amine groups leads to a phase
segregation of the PAmOx block while PEtOx is readily soluble
in chloroform, stabilizing the micelle.
Cross-linking was applied using glutaraldehyde (GA)
resulting in the formation of nanogels cross-linked by imine
bonds, which are pH responsive.28 To quench the gelation and
to obtain systems that are stable within an aqueous environ-
ment, 6-amino ﬂuorescein (6AF) was used. The free amino
group of 6AF reacts with residual aldehyde groups of the cross-
linker resulting in a reversible covalent attachment to the
nanogel (Scheme 1). In order to use these systems in drug
delivery applications, the interaction of the produced nanogels
with cells is of utmost importance. Therefore, the content of
cross-linker was varied to alter the charge of the resulting
nanogels (3 to 7). A higher degree of cross-linking and,
consequently, a lower amount of free amine groups should
result in a reduced zeta potential and, henceforth, in a reduction
of the cellular uptake. The content of GA was varied between 1
and 3 equiv. (per 2 amine groups) (Table 2).
As displayed in Figure 1, an increase of GA leads to a
reduction of the zeta potential from ζ = 28 mV for equimolar
cross-linking to ζ = 7 mV for a 3-fold excess of GA. Moreover,
an increase in size, as detected by DLS, can be observed for
compounds 3 to 7. These ﬁndings seem best explained by
increased amounts of water present during gelation. GA was
applied in a 70 wt % aqueous solution and during the cross-
linking reaction water is produced as a byproduct. The
additional water will accumulate within the hydrophilic core
compartment of the micelle and swell the nanostructure prior
to or during cross-linking resulting in larger nanogel sizes. This
assumption is supported by cryoTEM measurements showing
an increase in size with an increasing cross-linking density
(Figure 2).
The obtained values are, however, smaller compared to DLS
data indicating a falsiﬁcation of the DLS derived values possibly
caused by the presence of a small fraction of agglomerates. A
third parameter investigated, depending on the cross-linking
density, was the dye-loading of the resulting systems by
evaluating their absorption and ﬂuorescence. Based on its
absorbance, the amount of 6AF conjugated to the nanogels can
be estimated to values between 17 and 27 wt %, without an
obvious dependence on the degree of cross-linking. However,
determined by ﬂuorescence intensity, a steady increase in the
amount of dye could be monitored up to values which would
correspond to a loading eﬃciency above 100 wt % when
Table 1. Composition and Analytical Data of the POx Block
Copolymers
NMR SEC
sample composition (NMR) Mn (g mol
−1) Mn (g mol
−1) Đ
1a P(EtOx98-b-BocOx32) 17 500 8 200 1.07
2b P(EtOx98-b-AmOx32) 14 200 13 900 1.11
aSEC measurement in CHCl3.
bSEC Measurement in DMAc.
Scheme 1. Schematic Representation of the Synthesis and Self-Assembly of P(EtOx-b-AmOx) in Chloroform to Form Micelles
with a Cationic Core and a PEtOx Shell, as Well as the Subsequent Cross-Linking and 6AF Conjugation to Obtain Dye-Loaded
Nanogels
Table 2. Characterization of POx Nanogels in an Aqueous
Environment
sample
cross-linker (equiv
per 2 NH2)
sizea
(nm, r) ζ (mV)
content of
6AF (wt %)
sizeb
(r, nm)
3 1 13 28 17 12
4 1.5 17 13 27 13
5 2 20 10 20 14
6 2.5 22 8 24 15
7 3 24 7 17 15
aDetermined by DLS. bdetermined by cryo-TEM.
Figure 1. Dependency of zeta potential, as well as size by DLS on the
cross-linking density of POx nanogels.
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compared to a calibration of free 6AF, indicating a boost in
ﬂuorescence intensity by varying the core composition (Figure
S1). To study this eﬀect in detail, ﬂuorescence lifetime
measurements were conducted (Figure 3).
The investigations revealed an increase in ﬂuorescence
lifetime with increasing degree of cross-linking except for 2.5
equiv. of GA. Also, the integrals of the decay curves, which
serve as a measure of the ﬂuorescence quantum yield, increase
within the series. As depicted in Figure S1, the absolute amount
of dye within the nanogels is relatively constant between 17 and
27 wt %. It is described for ﬂuorescein and its derivatives that
electrostatic interactions between the dye and a cationic
(surfactant) micelle are able to stabilize the anionic form of
the molecule which leads to an increase in ﬂuorescence lifetime
and quantum yield.29 However, the cationic character decreases
with a higher degree of cross-linking and can, therefore, be held
responsible for a general boost of ﬂuorescence compared to
pure 6AF, but not for the increasing lifetimes within the series.
Also, the dye−dye distance can be estimated as roughly
constant. Therefore, dye−dye interactions such as excimer
formation are unlikely to be responsible for the observed
eﬀects. Presumably, increasing the amount of cross-linker will
increase the stiﬀness of the core. Thus, the increases in
quantum yield and emission lifetime could be explained by
frozen degrees of freedom, resulting in a reduced rate constant
for nonradiative decay processes.30,31 This is supported by
proton NMR measurements of the nanogels (Figure S2). In
contrast to the precursor polymer, only signals of the PEtOx
constituting the shell are visible, while PAmOx signals are
absent. This indicates a restriction of degrees of freedom of the
block forming the core compartment of the micellar structure
and supports the hypothetic cause for the increase in quantum
yield.
In order to determine the inﬂuence of the varying cross-
linking density on the cellular uptake, ﬂow cytometry
investigations were performed using L929 mouse ﬁbroblasts
(Figure 4). The decrease in mean ﬂuorescence with an
increasing cross-linking degree within the series of nanogels
demonstrates the inﬂuence of the zeta potential on the
internalization for all concentrations investigated. Moreover,
time dependent uptake experiments visualize this behavior. The
Figure 2. CryoTEM images of nanogels (3 to 7) in water. Scale bars represent 100 nm.
Figure 3. Fluorescence lifetime measurements of POx nanogels with varying degrees of cross-linking. (A) Fluorescence decay curves. (B)
Fluorescence life times and decay integrals of nanogels 3 to 7.
Figure 4. Cellular internalization of nanogels 3 to 7 dependent on the
concentration (A) after 24 h incubation at 37 °C or at varying
incubation times (B) at a concentration of 0.5 mg mL−1 at 37 °C.
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diﬀerence in the ﬂuorescence intensity between the nanogels
was considered by referencing to the absolute ﬂuorescence
intensity of the measurement. This ﬁnding is in agreement with
literature reports where objects having a positive net charge are
described to be taken up more eﬃciently as compared to
neutral or anionic structures.32 The reported investigation
shows that the cellular uptake, which displays a crucial factor for
the utilization as a drug delivery agent, can be ﬁne-tuned for the
presented nanogel systems.
In order to investigate the nature of the cellular internal-
ization, uptake studies at 4 °C were performed (Figure S3).
The diminished uptake at low temperatures suggests an energy
dependent internalization via endocytosis as expected for
objects in such a size range.7,33
Besides cellular uptake, the biocompatibility of the drug
carriers represents an essential parameter. It was reported that
an increase in zeta potential of nanoparticles negatively aﬀects
the cell viability.14,15 Nanogel 3, investigated in a previous
study, possesses the highest zeta potential (ζ = +28 mV) within
the series and is, therefore, expected to induce the highest
toxicity, although the system did not interfere with the
metabolism of L929 mouse ﬁbroblasts in a negative way up
to a concentration of 5 mg mL−1.26 While this is a promising
indication regarding the biocompatibility of the material, the
most important environment a drug delivery system is facing is
the bloodstream. Long circulation times, leading to a passive
targeting, require a low level of interaction with the
components of the blood. An interaction with erythrocytes
resulting in clotting or disruption is highly undesired. The
hemolytic activity of 6AF loaded nanogels was studied
depending on the applied concentration (Figure 5A). All
nanogels in a concentration range between 10 and 100 μg mL−1
resulted in hemolytic activity values well below 2%, which is
deﬁned as the threshold for a hemolysis (according to the
ASTM F756−00 standard).
Furthermore, the erythrocyte aggregation was investigated
and found to be negligible in the given concentration range
with absorbance values comparable with the negative control
(Figure 5B, Figure S4).
These ﬁndings are remarkable, since positively charged
nanomaterials are expected to feature a decreased blood
compatibility. In contrast to nanoparticle systems with an
altered surface chemistry, the charge of the nanogels presented
herein results from amine groups within the core of the micellar
structure, whereas the periphery is covered with noncharged
PEtOx chains. While this setup enables tailoring of the cellular
interaction, as shown by the cellular uptake studies, the
biocompatibility of the nanogels is maintained in all cases.
■ CONCLUSION
Within this contribution, we present a straightforward synthetic
route to poly(2-oxazoline)-based polymeric nanogels with a
tailored cellular uptake. The gels are produced by phase
segregation of a diblock copolymer, containing a cationic and a
neutral block forming micellar structures in chloroform. Cross-
linking is conducted using glutaraldehyde and the ﬂuorescent
dye 6-amino ﬂuorescein is loaded covalently. By changing the
cross-linking density, it is possible to alter the properties of the
nanogels in terms of ﬂuorescence intensity and zeta potential.
Hence, it is possible to adjust their cellular uptake as shown by
ﬂow cytometry measurements. Due to the unique nature of the
nanogels, which carry the charged units within the core of the
micellar structure, the biocompatibility is not aﬀected by the
variation in charge as demonstrated by hemocompatibility
experiments. Therefore, the herein presented material displays
a versatile toolbox for the production of drug delivery vehicles.
Further studies will focus on the extension of the concept to in
vivo investigations as well as on the loading of anticancer drugs
such as doxorubicin, and the utilization of drug loaded nanogels
in vitro and in vivo.
■ EXPERIMENTAL SECTION
Material and Instrumentation. Chemicals and solvents
were purchased from Sigma-Aldrich, Merck, Fluka, and Acros.
2-Ethyl-2-oxazoline (EtOx) and methyl tosylate (MeOTos)
were distilled to dryness prior to use. EtOx was dried using
barium oxide before distillation. 2-(4-((tert-Butoxycarbonyl)-
amino)butyl)-2-oxazoline (BocOx) was synthesized as de-
scribed in a previous publication.27 If not stated otherwise,
cell culture media and supplements (L-Glutamin, antibiotics)
were obtained from Biochrom (Merck Millipore, Germany).
The Initiator Sixty single-mode microwave synthesizer from
Biotage, equipped with a noninvasive IR sensor (accuracy: 2%),
was used for polymerizations under microwave irradiation.
Microwave vials were heated overnight to 110 °C and allowed
to cool to room temperature under an argon atmosphere before
use. All polymerizations were carried out under temperature
control. Size-exclusion chromatography (SEC) measurements
of the protected polymers were performed on a Shimadzu
system equipped with a SCL-10A system controller, a LC-
10AD pump, a RID-10A refractive index detector, and a PSS
SDV column with chloroform/triethylamine (NEt3)/iso-prop-
anol (94:4:2) as eluent. The column oven was set to 50 °C.
SEC of the deprotected statistical copolymers was performed
on a Shimadzu system with a LC-10AD pump, a RID-10A
refractive index detector, a system controller SCL-10A, a
degasser DGU-14A, and a CTO-10A column oven using N,N-
Figure 5. Induction of hemolysis (A) as well as erythrocyte aggregation (B) by 6AF loaded nanogels (3 to 7) in a concentration range between 10
and 100 μg mL−1 using sheep blood of three diﬀerent donor batches.
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dimethylacetamide (DMAc) with 2.1 g L−1 LiCl as the eluent
and the column oven set to 50 °C. Poly(styrene) (PS) samples
were used as calibration standards for both solvent systems.
Proton NMR spectroscopy (1H NMR) measurements were
performed at room temperature on a Bruker AC 300 and 400
MHz spectrometer, using CDCl3 or N,N-dimethylformamide
(DMF)-D7 as solvents. The chemical shifts are given in ppm
relative to the signal of the residual nondeuterated solvent.
Batch dynamic light scattering (DLS) was performed on a
Zetasizer Nano ZS (Malvern Instruments, Herrenberg,
Germany). All measurements were performed in folded
capillary cells (DTS1071, Malvern Instruments, Herrenberg,
Germany). After an equilibration time of 180 s, 3 × 30 s runs
were carried out at 25 °C (λ = 633 nm). The counts were
detected at an angle of 173°. Each measurement was performed
in triplicate. Apparent hydrodynamic radii, Rh, were calculated
according to the Stokes−Einstein equation.
Laser Doppler velocimetry was used to measure the
electrokinetic potential, also known as zeta potential. The
measurements were performed on a Zetasizer Nano ZS
(Malvern Instruments, Herrenberg, Germany) in folded
capillary cells (DTS1071). For each measurement, 15 runs
were carried out using the fast-ﬁeld and slow-ﬁeld reversal
mode at 150 V. Each experiment was performed in triplicate at
25 °C. The zeta potential (ζ) was calculated from the
electrophoretic mobility (μ) according to the Henry equation.34
The Henry coeﬃcient, f(ka), was calculated according to
Ohshima.35
CryoTEM investigations were conducted utilizing a FEI
Tecnai G2 20 at 200 kV acceleration voltage. Specisms were
vitriﬁed by a Vitrobot Mark V system on Quantifoil grids (R2/
2). The blotting time was 1 s with blotting force oﬀset of 0. The
amount of solution was 7 μL. Samples were plunge frozen in
liquid ethane and stored under liquid nitrogen until transferred
to the Gatan cryo-holder and brought into the microscope.
Images were acquired with a 4k × 4k CCD Eagle camera.
Absorbance and ﬂuorescence spectra as well as hemolysis and
erythrocyte aggregation assays were recorded using a Tecan
M200 Pro ﬂuorescence microplate reader (Crailsheim,
Germany) by the use of black well plates with a ﬂat and
transparent bottom.
The cellular uptake studies of nanogels were performed with
a Beckmann Coulter Cytomics FC-500 equipped with a
Uniphase Argon ion laser (488 nm, 20 mW output) and
analyzed with the Cytomics CXP software.
Block Copolymer of 2-Ethyl-2-oxazoline (EtOx) and 2-
(4-((tert-Butoxycarbonyl)amino)butyl)-2-oxazoline
(BocOx) (P(EtOx-b-BocOx)), (1). In a microwave vial, EtOx
(757 μL, 7.5 mmol), MeOTos (16.2 μL, 0.107 mmol) and
acetonitrile (3.4 mL) were mixed under inert conditions. After
heating in the microwave synthesizer at 140 °C for 25 min the
vial was introduced into a glovebox with nitrogen atmosphere
and BocOx (803 μL, 3.2 mmol) was added. The closed vial was
heated again in the microwave synthesizer (140 °C, 20 min).
The solution was precipitated in cold (−80 °C, 300 mL)
diethyl ether. The white precipitate was ﬁltered and dried in
high vacuum (1.4 g, 92%).
1H NMR (CDCl3, 300 MHz): δ = 7.66, (d, 8.1 Hz, 0.019 H,
tosylate), 7.14 (d, 8.21 Hz, 0.019 H, tosylate), 3.45 (s, 4 H,
backbone), 3.10 (s, 0.58 H, CH2−CH2−NH (BocOx)), 2.50−
2.15 (m, 1.96 H, CH2 (EtOx)/CH2−CH2−NHBoc), 1.62 (s,
0.52 H, CH2−CH2−CH2 (BocOx)), 1.52 (s, 0.52 H, CH2−
CH2−CH2 (BocOx)), 1.42 (s, 2.3 H, CH3 (BocOx)), 1.21
(s, 2.1 H, CH3 (EtOx)) ppm.
SEC (eluent: CHCl3/iso-propanol/NEt3, PS-standard):
Mn = 8200 g mol
−1, Đ = 1.07.
Deprotection of P(EtOx-b-BocOx) (1) to yield (P(EtOx-
b-AmOx), (2). P(EtOx-b-BocOx) (1, 1.3 g) was dissolved in
TFA (5 mL) and heated to 60 °C for 1 h. After stirring for 12 h
at room temperature, the mixture was diluted with 10 mL
methanol and precipitated in 400 mL of cold (−80 °C) diethyl
ether. The precipitate was redissolved in methanol (100 mL)
and stirred with Amberlyst A21 for 48 h. Subsequently, the
solvent was removed, the polymer was dissolved in deionized
water and freeze-dried (−80 °C, 0.003 mbar). The polymer was
obtained as white powder (1.2 g, 92%).
1H NMR (DMF-D7, 300 MHz): δ = 4.9 (s, 2.3 H, NH2),
3.51 (s, 4 H, backbone), 3.07 (s, 0.49 H, CH2−CH2−NH2),
2.44 (m, 2.1 H, CH2 (EtOx)/CH2−CH2−CO (AmOx)), 1.9−
1.54 (m, 0.96 H, CH2−CH2−CH2−CH2 (AmOx)), 1.2 (s, 2,3
H, CH3 (EtOx)) ppm.
SEC (eluent: DMAc/LiCl, PS-standard): Mn = 13 900 g
mol−1, Đ = 1.11.
General Procedure for Self-Assembly and Cross-
Linking (3−7). To create nanostructures, block copolymer
(2, 90 mg, 0.006 mmol) was dissolved in CHCl3, (5 mg mL
−1)
and stirred for 3 h. Subsequently, glutaraldehyde (30 mg,
0.3 mmol, 1.5 equiv per amine (4)) was added and the solution
was stirred another 3 h. With proceeding reaction time the
color of the solution changed from colorless to yellow. To
quench the excess of aldehyde functionalities, 6-amino
ﬂuorescein (50 mg) was added and the mixture was stirred
for 12 h. Subsequently, the amount of solvent was reduced
under an argon stream and the residual was precipitated in 100
mL cold diethyl ether (−80 °C). To purify the self-assembled
structures from residual capping agent and cross-linker, dialysis
in MeOH/water (1:4) was applied using a membrane with a
molar mass cut oﬀ of 3500 g mol−1 (Roth Zellutrans). After the
extraction was ﬁnished, the dialysis medium was changed to
pure water and the aqueous solution was freeze-dried to yield
an orange powder.
Determination of Dye Loading Content by Absorb-
ance/Fluorescence. The absorbance/ﬂuorescence of 6AF
loaded nanostructures was investigated under alkaline con-
ditions (1 mol L−1 NaOH in water) in diluted solution (0.1 mg
mL−1). The absorbance was determined at a wavelength of
490 nm and compared to a sequential dilution series of 6AF in
the same aqueous NaOH solution. A 100-fold excess of
glutaraldehyde was added to the control to ensure that only the
imine species of 6AF is present. Emission was detected at an
excitation wavelength of 450 nm. Nanogels as well as 6AF
calibration exhibit an emission maximum at 510 nm. The
readout was accomplished using a Tecan M200 Pro
ﬂuorescence microplate reader (Crailsheim, Germany).
Fluorescence Lifetime Measurements. The emission
decay curves were obtained by time-correlated-single-photon-
counting. After excitation with a frequency-doubled Ti-sapphire
laser adjusted to 870 nm (Tsunami, Newport Spectra-Physics
GmbH, pulse-to-pulse repetition rate 400 kHz after passing a
pulse selector, model 3980, Newport Spectra-Physics GmbH),
i.e., at λex = 435 nm, the luminescence of the sample was
collected in a 90°-geometry and detected with a Becker & Hickl
PMC-100-4 photon-counting module. A long-pass ﬁlter
(455 nm) is inserted in the detection beam path. The samples
were adjusted to yield optical densities <0.03 at the excitation
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wavelength in aqueous NaOH (0.1 mol L−1). The measure-
ments were accumulated at count rates <3% of the rep.-rate
until 15 000 counts in the maximum were reached.
Blood Compatibility Measurements. To assess the
hemolytic activity of the polymer solutions, blood from sheep
collected in heparinized tubes (Institute of Laboratory Animal
Science and Animal Welfare, Friedrich Schiller University Jena)
was centrifuged at 4500 × g for 5 min, and the pellet was
washed three times with cold 1.5 mmol L−1 phosphate buﬀered
saline (PBS, pH 7.4). After dilution with PBS in a ratio of 1:7,
aliquots of erythrocyte suspension were mixed 1:1 with the
polymer solution and incubated in a water bath at 37 °C for 60
min. After centrifugation at 2400 × g for 5 min the hemoglobin
release was determined by measuring the absorbance of the
supernatant with a microplate reader at 544 nm wavelength.
Complete hemolysis (100%) was achieved using 1% Triton X-
100 serving as positive control. Thereby, PBS served as negative
control (0%). A value less than 2% hemolysis rate was taken as
nonhemolytic. Experiments were run in triplicate and were
performed with three diﬀerent batches of donor blood.
The hemolytic activity of the polycations was calculated as
follows (eq 1):
= ×
−A A
A
%Hemolysis 100
( )Sample Negative control
Positive control (1)
For the examination of the erythrocyte aggregation, the
erythrocyte suspension was mixed with the same volume of
polymer solution in a clear ﬂat-bottomed 96-well plate. The
cells were incubated at 37 °C for 2 h, and the absorbance was
measured at 645 nm in a microplate reader. 25 kDa bPEI (50
μg mL−1) was used as positive control, and as negative control,
cells were treated with PBS. Absorbance values of the test
solutions lower than negative control were regarded as
aggregation. Experiments are the result of triplicates and were
performed with three diﬀerent donor blood batches.
Investigation of the Cellular Uptake. The evaluation of
the nanogel uptake was performed with the cell line L929
(CCL-1, ATCC). In general, the cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS), 100 U mL−1 penicillin and
100 μg mL−1 streptomycin at 37 °C in a humidiﬁed 5% CO2
atmosphere. For the uptake studies, cells were seeded at
105 cells per mL in a 24-well plate and incubated for 24 h.
For the time-dependent uptake studies, cells were incubated
with nanogels at a concentration of 0.5 mg mL−1 for 30 min to
24 h, whereas the concentration-dependent uptake was
investigated over an incubation time of 24 h using nanogel
concentrations in the range between 0.1 and 1 mg mL−1. Cells
incubated with culture medium only served as control. For
uptake studies at low temperature, the cells were incubated with
nanogels (0.5 mg mL−1) for 4 h at 4 and 37 °C, respectively,
and the internalization was monitored using FC analysis as
described above.
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